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Abstract 
Despite the huge range of neurobiological targets within the appetite system, the 
development of pharmacological anti-obesity agents is making slow progress as a 
result of limitations on maximal weight loss, adverse side-effects, and/or long-term 
resistance. However, in principle, the use of drug polytherapy allows for the use of 
lower doses, possible synergistic/additive weight loss, fewer and less serious side-
effects and reduced potential for counter-regulation. Although food intake and/or 
bodyweight have been and are being researched following co-treatment with a 
range of agents, there is a distinct gap in the literature regarding the behavioural 
specificity of the anorectic effects for recently approved and upcoming anti-obesity 
therapies. The present thesis therefore characterised the acute effects of individual 
systemic (i.p.) treatment with the general opioid receptor antagonist naltrexone (0.1, 
1.0 and 3.0mg/kg), the noradrenaline and dopamine reuptake inhibitor bupropion 
(10, 20 and 40mg/kg), the serotonin 5-HT1B/2C receptor agonist mCPP (0.1, 1.0 and 
3.0mg/kg), and the GLP-1R mimetic exendin-4 (0.025, 0.25, and 2.5µg/kg), on food 
intake, feeding and non-feeding behaviour, the behavioural satiety sequence (BSS), 
and weight gain. In addition, the acute anorectic response to co-treatment with sub-
maximal doses of each non-opioid compound plus an opioid antagonist (naloxone 
or naltrexone) was assessed. The results suggested that, while the anorectic 
effects of naloxone and naltrexone were behaviourally-selective, those of 
rimonabant, bupropion, mCPP and exendin-4 may have largely resulted from 
competing behaviour. The co-treatment studies highlighted concurrent anorexia and 
an undesirable behaviour for rimonabant, bupropion and, potentially, mCPP. 
However, the anorectic action of mCPP and exendin-4 may have largely resulted 
from malaise. The results further showed that, while only the combination of 
bupropion and naltrexone produced an additive effect on food intake, co-treatment 
with an opioid antagonist reduced/eliminated unwanted effects normally associated 
with higher doses of rimonabant, bupropion and, potentially, mCPP. The search for 
efficacious and safe anti-obesity agents should therefore focus, to an even greater 
extent than at present, on the therapeutic potential of targeting multiple systems 
(polytherapy). Overall, current findings have emphasised the value of detailed 
behavioural analysis of drug effects on appetite. As such, novel treatment 
combinations may well produce a successful anti-obesity agent, if clinical trials are 
prefaced by adequate preclinical testing.  
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Chapter 1 Neurobiology of Appetite 
Feeding is vital for survival, and its regulation depends upon numerous 
physiological, behavioural, social, psychological and environmental influences 
(Figure 1-1). Thus, while the present thesis concerns the behavioural pharmacology 
of appetite, it is important to emphasise that neurobiology is just one aspect of 
appetite regulation. 
 
Figure 1-1: The Obesity System Atlas 
The obesity system is pragmatically defined here as the sum of all the relevant factors and their 
interdependencies that determine the condition of obesity for an individual or a group of people. 
The obesity system, as defined, has been visualised as a causal loop model. (Vandenbroeck., 
2007). Yellow, Social Psychology; Orange, Individual Psychology; Red, Physical Activity 
Environment; Brown, Individual Physical Activity; Blue, Physiology; Light Green, Food 
Consumption; Dark Green, Food Production 
The neurobiological regulation of appetite involves a complex interaction between 
central and peripheral signals interacting in numerous positive and negative 
feedback loops to create an intricate mechanism determining calorific intake. The 
aim of Chapter 1 is to provide an overview of the current understanding of the 
mechanisms that regulate appetite. This will be done from a historical perspective 
i.e how our knowledge about key systems has developed over time.  
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1.1 Historical Overview of Theories and Models of Appetite 
Regulation 
The original “one nutrient hypothesis” was based upon the belief, 2000 years ago, 
that food provided us with a universal nutrient. Digestion was the mechanism for the 
extraction of this nutrient and, as a result, growth and development occurred. Prout 
(1845; cited in Geiger, 1933) then proposed not one but three primary nutrients; 
saccharine (carbohydrate), oleosa (triglyceride), and albuminosa (protein). Around 
the same time, Mulder (1839; cited in Geiger, 1933) coined the term “protein”; a 
nitrogen-containing substance essential for life. Leibig (1843; cited in Geiger, 1933) 
then suggested two roles of protein; the formation of blood and use in metabolism. 
He additionally separated food into two distinct groups; ‘‘proteinaceous” (or foods 
containing nitrogen) and those not. These early concepts introduced nutrient-
regulated theories of appetite i.e. that feeding is initiated by a nutrient deficit and 
terminated by nutrient replenishment.  
In the 20th Century, theories of appetite regulation were still highly simplistic but 
focused instead on the gastrointestinal tract (GIT). In 1912, Cannon and Washburn 
proposed that gastric contractions were the main influencing factor in food intake 
(Cannon & Washburn, 1912). Based upon studies whereby balloons were inserted 
into the stomach to induce extension, an association was identified between 
contractions and subjective feelings of hunger. More recently, Koopmans et al., 
(1981) transplanted an extra stomach and intestines into rats and established that 
food injected into the transplanted stomach decreased eating in proportion to its 
volume and caloric content. The transplanted stomachs had no nerves, but did 
have a blood supply, thus allowing the conclusion that some blood-borne chemical 
was released from the stomach in response to the caloric value and volume of food.  
1.1.1 Set-point theories 
The next significant advance was the development of set-point theories, based 
upon the idea that we eat in the presence of an energy deficit to return our energy 
resources to an optimal level. Set-point systems have three key components: a set-
point mechanism (defines the set-point), a detector mechanism (detects deviations) 
and an effector mechanism (acts to eliminate deviations). Based upon the 
assumptions of negative feedback systems, whereby feedback from changes in one 
direction elicits compensatory effects in the opposite direction, these theories saw 
behavioural changes in feeding as an inevitable outcome of changes in 
physiological signalling. Grounded in this theory, a range of feedback models was 
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subsequently developed throughout the mid-1940s to the mid-1950s, each based 
on a different biochemical signal. 
Thermostatic theory (Brobeck, 1946) proposed that food intake could be 
increased or decreased in direct relation to the thermoregulatory demands on the 
organism. The basic argument was that heat loss generates heat production, 
causing the thermosensitive hypothalamus to influence feeding behaviour (Hamilton 
& Ciaccia, 1971).  
The adipostatic model (a.k.a. lipostatic model), introduced by Kennedy (1953), 
proposed that the amount of energy stored in adipose tissue represents the balance 
between calorific intake and energy expenditure. He further suggested that, in order 
to maintain an adipose set-point, homeostatic mechanisms monitor changes in 
adipose tissue to elicit increases/decreases in intake (coined “indirect calorimetry”). 
This model implies that the central nervous system (CNS) is sensitive to 
concentrations of circulating metabolites, a mechanism for which was later 
suggested by Hervey (1969). It was proposed that a fat-soluble hormone acted as a 
tracer substance to monitor fat tissue mass via the dilution principle. This proposal 
was supported empirically and subsequently led to the identification of the protein 
leptin (Zhang et al., 1994; see Section 1.2.2). 
The glucostatic model (Mayer, 1955) argued that the CNS monitors blood glucose 
levels to control nutrient intake and maintains a glucose concentration set-point. 
Meal initiation was thought to be determined by “metabolic hypoglycaemia”, i.e. 
when peripheral concentration differences in blood glucose became too small, 
glucose no longer entered metabolizing cells (Van Itallie, 1990). Mayer (1955) also 
argued that set-point theories were complementary rather than mutually exclusive, 
in that glucostatic theory could account for short-term aspects of feeding (such as 
meal initiation and termination) while lipostatic theory could account for the long-
term regulation of feeding. Bray (1996) later suggested a glucodynamic model, 
whereby food intake is determined not by the actual level of circulating glucose but 
rather the rate of glucose utilization, i.e. the changes in glucose concentrations are 
the triggers that initiate or terminate feeding, known as the “pattern of dynamic 
change in glucose” (Bray, 2000).  
The aminostatic model (Mellinkoff et al., 1956) proposed that amino-acid 
metabolism predicts hunger, a suggestion supported by the finding of a reciprocal 
relationship between amino-acid levels and appetite. Increased amino-acid 
concentrations reduce subjective appetite while increased appetite is accompanied 
by reduced amino-acid concentrations (Mellinkoff et al., 1956). 
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Although these set-point theories were supported by experimental validation of 
blood glucose/adipose/amino-acid concentrations, such manipulations were 
generally effective only at high magnitudes (Keesey, 1986). In fact, it was found that 
beliefs about the calorific content of a liquid preload have more influence on the 
size of a subsequent meal than does actual calorific content (Shide & Rolls, 1995). 
Furthermore, these set-point theories were inconsistent with eating-related 
evolutionary pressures, as animals would need to avoid a deficit rather than 
respond to it (Magdalena Farias et al., 2011). Such theories also failed to recognise 
major influences such as taste, learning, social and environmental factors.  
1.1.2 The dual centre model 
In parallel to the set-point theories of appetite control by peripheral signals, brain 
lesion research strongly suggested that eating behaviour is centrally regulated by 
two different regions of the hypothalamus: Ventromedial hypothalamus (VMH) and 
Lateral hypothalamus (LH; Stellar, 1954; see Figure 1-2). 
  
Figure 1-2: Hypothalamus 
A coronal section of rat brain showing the positions of the lateral and ventromedial nuclei of the 
hypothalamus (Bear, 2006). 
Classical lesion studies carried out in the 1940s found that large bilateral electrolytic 
lesions of the VMH in rats produced symptoms of excessive overeating 
(Hetherington & Ranson, 1940). The VMH Syndrome, characterised by 
hyperphagia, obesity and finikiness (Graff & Stellar, 1962; Hetherington & Ranson, 
1940), has two phases; dynamic and static. The dynamic phase is characterised by 
several weeks of excessive eating and weight gain, whereas the static phase is 
characterised by a gradual reduction in consumption to a level sufficient to maintain 
obesity. The initial experiments demonstrated that VMH lesions typically increase 
feeding bouts, suggesting an impairment in the termination of feeding, and hence 
this nucleus became known as the “satiety mechanism” (Brooks et al., 1946). Later 
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however, Miller et al. (1950) found evidence of a paradoxical dissociation with VMH 
lesions whereby rats appeared less “hungry” i.e. although the consumption of food 
increased, the animals were less willing to “work for it” (Teitelbaum, 1957) or to 
consume unpalatable foods (Miller et al., 1950). Using un-lesioned rats with 
matched obesity Weingarten et al. (1983) suggested that the latter findings were a 
consequence of obesity rather of the VMH lesion. Other theories suggested that 
bilateral VMH lesions increased blood insulin levels which in turn increased 
lipogenesis (production of body fat) and decrease lipolysis (breakdown of body fat; 
Powley & Plocher, 1980). The rat is therefore considered to be converting its 
energy into stores and so must consume more food in order to ensure enough 
calories for immediate energy requirements (Hustvedt & Lovo, 1972). 
In contrast to the developing VMH story, bilateral electrolytic lesions of the LH 
produced extreme aphagia, a failure to eat resulting in death (Anand & Brobeck, 
1951). In LH syndrome, aphagia is also accompanied by adipsia, a failure to drink 
(Teitelbaum & Stellar, 1954). The converse findings can be elicited through 
electrical stimulation of these brain areas. That is to say that, VMH stimulation 
decreases food intake, whereas LH stimulation increases food intake (Wyrwicka & 
Dobrzecka, 1960). 
These early findings led to the development of the dual centre model (Stellar, 
1954), whereby it was proposed that termination of eating is controlled by the VMH 
or “satiety centre”, whereas the LH or “feeding centre” controlled active feeding 
behaviours. Later, Teitelbaum and Epstein (1962) found that when LH lesioned rats 
were kept alive via tube-feeding, they were able to recover food and water intake. 
However, feeding motivation remained impaired, thereby implicating the LH in 
feeding motivation. The dual centre model was linked to adipostatic theory by 
Hervey (1969) who, using evidence that lesions to the VMH prevented a “satiety 
factor” from eliciting behavioural changes, argued that a hormone must relay 
information about fat tissue mass via the VMH. 
Although helpful in the development of our understanding of appetite regulation, 
there are many limitations to lesion studies. For example, the LH syndrome also 
produced a wide range of severe motor disturbances and a lack of responsiveness 
to sensory input; thus deficits in feeding and drinking were just two symptoms of a 
more general disorder. Furthermore, the effective locus of the LH lesion required to 
produce aphagia and adipsia overlapped with the nigrostriatal dopamine pathway 
(Ungerstedt, 1970). Additionally, when the paraventricular nuclei (PVN) of the 
hypothalamus are damaged (e.g. by bilateral lesions of the noradrenergic bundle or 
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the PVN), this produces hyperphagia and obesity similar to that produced by VMH 
lesions. Thus, lesions studies are often unable to target one system independently 
and findings derived from this methodology alone may be unreliable (Kapatos & 
Gold, 1973; Leibowitz et al., 1981). 
It is now believed that the primary role of the hypothalamus is in the regulation of 
energy metabolism, and not just eating per se.  
1.1.3 The Hypothalamus Revisited 
Since the original dual centre model of appetite regulation, and as a result of 
technological developments, many more hypothalamic nuclei (as well as extra-
hypothalamic structures) have been implicated in the control of hunger and satiety.  
The identification of numerous orexigenic and anorectic mechanisms and their 
morphological relationships support the role of distinct interconnected circuitry 
operating within the hypothalamus (see reviews: Broberger, 2005; Broberger & 
Hokfelt, 2001; Grossman, 1975; Hillebrand et al., 2002; Kalra et al., 1999; Mercer & 
Speakman, 2001; Schwartz et al., 2000; Williams et al., 2001)  
The primary regions of hypothalamus currently identified include, but are not limited 
to: the arcuate nucleus, the paraventricular nucleus, the dorsomedial hypothalamic 
area, and the lateral hypothalamic area (see Figure 1-3). Other key structures in the 
regulation of food intake include the amygdala and the brain stem (Arora & 
Anubhuti, 2006).  
The arcuate nucleus (ARC) lies adjacent to the third ventricle and above the 
median eminence. The ARC-median eminence area has a modified blood-brain-
barrier (BBB) to allow entry of peripheral peptides and proteins (Friedman & 
Halaas, 1998). Multiple projections from the ARC to other hypothalamic and extra-
hypothalamic nuclei support the key role of this nucleus as a hub in the integration 
of hormonal signals that regulate feeding (Cone et al., 2001).  
The paraventricular nucleus (PVN), adjacent to the superior part of third ventricle in 
the anterior hypothalamus, plays a large role in integrating nutritional signals with 
the hypothalamic-pituitary-thyroid (HPT) axis (Zoeller et al., 2007). In addition to the 
localisation of orexigenic producing neurons, it is thought that the PVN has a high 
concentration of receptor sites for all the main orexigenic signals. 
The ventromedial nucleus of the hypothalamus (VMH) is thought to act primarily as 
a satiety centre, as discussed earlier. Research is progressively supporting its role 
as a receptive field, whereby feeding is mediated via the convergence of multiple  
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Figure 1-3: Human Hypothalamus (detailed) 
Abbreviations: Arc, arcuate nucleus, DHA, dorsal hypothalamic area, DMN, dorsomedial 
nucleus, LHA, lateral hypothalamic area, PeVN, periventricular nucleus), PFA, parafornicular 
nucleus, PVN, paraventricular nucleus, VMN, ventromedial nucleus, SO, supraoptic nucleus, 
SC, surprachiasmatic nucleus. Arc and PeVN are drawn transparently in the sagittal section in 
order to show the underlying nuclei. (Netterimages.com, 2010) 
synaptic inputs, as characterised by extensive links to other hypothalamus sites 
(Morton et al., 2006).  
The lateral hypothalamus (LH), as discussed earlier, acts primarily as a feeding 
centre. It has glucose sensitive neurons, allowing it to mediate the hyperphagia 
associated with hypoglycemia (Bernardis & Bellinger, 1996). Furthermore, it is the 
source of multiple orexigenic peptides (see Section 1.3.2; α-MSH and Section 1.4.3; 
Orexins). 
The dorsomedial hypothalamus (DMN) is well connected to other medial (VMH) and 
lateral (LH and PVN) hypothalamic nuclei. It acts to mediate both neural and 
humoral signals from these pathways that are associated with feeding and 
bodyweight (Elmquist, Ahima, et al., 1998; Elmquist, Maratos-Flier, et al., 1998). 
The nucleus of tractus solitarius (NTS) is a brainstem nucleus in the upper medulla 
that provides reciprocal connections between the hypothalamus and the brainstem 
(Bray, 2000). The NTS receives viscerosensory information, i.e. it receives sensory 
innervation from internal organs, such as the GIT, that is subsequently integrated 
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with homeostatic signals from central nuclei (e.g. the pons, diencephalon and 
forebrain; Grill & Hayes, 2009). Of primary importance to the role of the NTS in 
appetite regulation is its highly perforated endothelial cells that provide a permeant 
blood-brain barrier (Gross et al., 1990), and thus the potential for integration with 
the systemic circulation, allowing a range of peptides to contribute to the regulation 
of appetite. Furthermore, the NTS has a high density of anorexigenic binding sites 
(see Section 1.4.1; NPY). 
The amygdala (AMY) is located within the medial temporal lobes. Traditionally 
considered to be an “emotional” part of the brain (Kluver & Bucy, 1939; Weiskrantz, 
1956), more recent research into orexigenic and anorectic signal receptor 
expression has implicated the AMY in appetite regulation (Parker & Bloom, 2012). 
Lesions of the AMY lead to obesity and the preference of a high carbohydrate diet 
(King et al., 2003; King et al., 1994). It is also now been shown that a number of 
neuropeptides administered directly into the AMY, can regulate feeding behaviour 
(Heilig et al., 1993; Zhang, Li, et al., 2011; see Section 1.4.1; NPY). In addition, the 
AMY is thought to play a role in the learning and experiencing of food through 
reward mechanisms (i.e. conditioned taste aversion; CTA).  
1.2 Adiposity Signals 
It is known that numerous signals convey information about food intake and body 
fat status from the periphery to brain areas that control energy homeostasis. The 
first discovered signals were found to circulate in proportion to body fat mass and 
are referred to as "adiposity signals". 
1.2.1 Insulin 
Insulin is a 51-amino-acid polypeptide hormone, initially extracted in 1921 by 
Banting and Best (1922). After the discovery by Minkowski and von Mering in 1889 
that pancreatic removal in dogs induces diabetes, the islets of Langerhans within 
the pancreas were isolated and insulin extracted (Banting & Best, 1922; Luft, 1989). 
The administration of this extract to a diabetic human drastically improved the 
patient’s condition (Macleod, 1924).  
Insulin is secreted from pancreatic β cells (islets of Langerhans) in response to 
increased blood glucose levels following a meal (Polonsky et al., 1988). It acts in 
three major ways to (1) promote the use of glucose as the primary source of 
energy, (2) initiate the conversion of blood-borne fuels to forms that can be stored 
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and, (3) promote the storage of glycogen within the liver, fat in the form of adipose 
tissue, and amino-acids as proteins. (UFSC, 2010). 
Insulin is not just involved in glucose homeostasis, linking back to Kennedy’s (1953) 
adipostatic model of appetite, insulin was thought to be the missing link between 
adipose tissue and the brain. It was discovered that elevations in circulating insulin 
are directly proportional to fat mass (Bagdade et al., 1967). As such, insulin levels 
are elevated with a positive energy balance and decreased with a negative energy 
balance (Woods & Porte, 1974).  
The insulin receptor is part of a large receptor family of tyrosine kinases, including 
insulin growth factor receptor (IGF-1R), insulin related receptor (IRR) and several 
insulin receptor substrates (IRSs). The highest concentrations of insulin receptors 
are found in the olfactory bulbs and hypothalamus (e.g. ARC, DMH, PVN, 
suprachiasmatic and periventricular nuclei; Arora & Anubhuti, 2006). Pro-
opiomelanocortin neurons (POMC; see Section 1.3.1) express IRSs, via which 
insulin directly inhibits their firing. Although produced peripherally, once in the brain 
it acts as an anorectic signal, enhancing catabolic pathways and inhibiting the 
anabolic NPY and melanocortin systems (Arora & Anubhuti, 2006; Valassi et al., 
2008). CNS and cerebrospinal fluid (CSF) administration of insulin therefore results 
in a reduction of food intake in rodents (Baskin et al., 1987; Benoit et al., 2004; 
Brown et al., 2006) and humans (Hallschmid et al., 2004). Furthermore, IRS-R1 and 
IRS-R2 knock-out (KO) mice exhibit hyperphagia and increased fat stores in 
addition to insulin resistance and reduced glucose tolerance, whereas IRS-R3 and 
IRS-R4 KO mice exhibit relatively normal phenotypes (for review see: Saltiel & 
Kahn, 2001). It is as yet unclear as to the specific roles of the insulin receptor 
subtypes in the regulation of appetite. 
Insulin is found to interact with other signals to regulate energy balance; for 
example, the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although 
there is limited evidence for a direct effect of insulin on GABA receptors, insulin-
induced hyperphagia can be blocked by GABA receptor antagonists (Kamatchi et 
al., 1984), thereby suggesting that GABA receptors play some role in the effects of 
insulin on the regulation of food intake (for review see: Pang & Han, 2012). Insulin 
also appears to act upon adipocytes to increase leptin secretion, potentially via 
increased gluconeogenesis and suppressed glycogenolysis to decrease net hepatic 
glucose production (Ramnanan et al., 2010).  
Interestingly, elevated levels of insulin, in both the basal state and in response to 
glucose, are associated with obesity (Bagdade et al., 1967), indicating a link 
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between obesity and insulin resistance. It is therefore unsurprising that, in 1996, the 
Food and Drug Administration (FDA) approved a modified version of human insulin 
(Humalog®) for the treatment of type-1 and type-2 diabetes (Nobelprize.org, 2013). 
1.2.2 Leptin  
In 1950, the Jackson Laboratory discovered the genotypes ob/ob (leptin deficiency) 
and db/db (leptin receptor deficiency), both phenotypically characterised by 
hyperphagia, decreased energy expenditure and early onset obesity in mice 
(Hummel et al., 1966; Ingalls et al., 1950). Five years later, Jeffery Friedman’s 
laboratory successfully cloned the ob gene in mice and its homolog in humans, 
terming the purified gene product “leptin” (Zhang et al., 1994). At the time, this 
discovery was thought to be the physiological feedback system that regulates 
energy balance and was soon followed by an explosion of research.  
It is now known that leptin is a 16-kDa protein hormone encoded by the ob gene. 
Secreted from adipocytes in proportion to body fat mass, it was originally thought to 
be produced only in white adipose tissue. However, it is has since been found to 
also be synthesised in brown adipose tissue, the stomach, placenta, mammary 
gland, ovarian follicles, and in fetal organs such as the heart, bone and cartilage 
(Arora & Anubhuti, 2006; Margetic et al., 2002). Despite peripheral production, 
leptin is able to cross the BBB and act upon receptors (leptin receptors; OB-R) that 
are highly expressed in hypothalamic regions such as the ARC, VMH, DMH and 
PVN (Mercer et al., 1996). Leptin receptors are of two distinct types, long (OB-RL) 
and short (OB-RS), with the difference lying primarily in the intracellular domains. It 
is the long form that is found primarily within the hypothalamus and which is 
responsible for regulating energy balance (see review: Tartaglia, 1997). 
In laboratory animals, leptin administration decreases food intake and increases 
energy expenditure (Ahima & Flier, 2000b; Friedman & Halaas, 1998), centrally-
produced anorectic effects thought to be mediated by activation of pro-
opiomelanocortin (POMC; Section 1.3.1) neurons in the ARC. Activation of these 
neurons inhibits feeding by both increasing the release of α-melanocyte-stimulating 
hormone (α-MSH; Section 1.3.2) and down-regulating neuropeptide-Y (NPY; 
Section 1.4.1), agouti-related peptide (AgRP; Section 1.4.2) and melanin 
concentrating hormone (MCH; Section 1.5.4.2; Ahima & Flier, 2000a; Ahima & Flier, 
2000b; Ahima et al., 2000; Arora & Anubhuti, 2006; Harrold et al., 2012). 
Conversely, as a dual regulator, NPY/AGRP circuits are enhanced and catabolic 
circuits blocked during periods of low circulating leptin, resulting in increased meal 
size and reduced energy expenditure (Schwartz, 2000; Valassi et al., 2008). 
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Somewhat incongruously, circulating leptin is increased considerably in obesity. 
Although rising levels of leptin should signal the storage of excess energy, and thus 
bring about a decrease in appetite and increase in energy expenditure, chronic 
hyperleptinemia leads to leptin desensitization/resistance (Kennedy et al., 1997). 
The specific mechanisms for leptin resistance are still under investigation, but may 
reflect dysregulation of synthesis, secretion or transport, or the existence of 
abnormal receptors or post-receptor signalling (Ahima et al., 2000; Munzberg et al., 
2005; Myers et al., 2008). OB-RL signal attenuation is also thought to play a crucial 
role in leptin resistance, as supported by the identification of SOCS-3 (suppressor 
of cytokine signalling-3) as a potential mediator of leptin signalling. Elevation of 
SOCS-3 in direct response to leptin treatment, as well as its affinity for OB-RL, is 
thought to be associated with its role in inhibiting leptin signalling (Bjorbaek et al., 
1998) and may therefore contribute to leptin resistance (Myers et al., 2008).  
Leptin dysregulation is also seen at the other extreme. Although leptin levels 
decrease rapidly following periods of fasting or prolonged exercise (Matejek et al., 
1999; Neary et al., 2004; Zheng et al., 1996), and while patients with anorexia 
nervosa or those with restricted food intake have significantly reduced circulating 
leptin, they experience un-expectantly high leptin transport rates (Arora & Anubhuti, 
2006; Frederich et al., 1995; Mantzoros et al., 1997; Margetic et al., 2002).  
The phenomenon of leptin resistance ultimately thwarted optimism that leptin could 
be the “anti-obesity” hormone. Despite initial studies demonstrating that ob/ob and 
db/db phenotypes could be normalised by leptin administration (Campfield et al., 
1995; cited in Harrold et al., 2012), and findings that recombinant leptin could 
normalise the eating behaviour of humans with similar leptin inhibiting mutations 
(Farooqi et al., 1999; Licinio et al., 2004; Montague et al., 1997), clinical trials on 
obese populations yielded disappointing results (Heymsfield et al., 1999; Hukshorn 
et al., 2003).  
There has also been a suggested synergy between leptin and peripheral signals 
such as cholecystokinin (CCK; Section 1.5.1.1). Low dose leptin administration has 
per se been found to enhance CCK-induced c-Fos expression in the PVN, thereby 
suggesting that centrally administered leptin acts via the PVN to enhance satiety 
signals such as CCK (Halford et al., 2003). As an alternative therapeutic route, sub-
threshold administration of leptin and CCK has been found to dose-dependently 
reduce food intake (Emond et al., 1999).  
This rapid progress in the understanding of leptin’s role in energy intake and 
metabolism was a watershed event for yet further major developments in our 
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understanding of the CNS, its signals, and their significance in the regulation of 
appetite. Table 1-1 summarises the wide range of centrally-released chemical 
signals thought to either stimulate or inhibit appetite.  
Table 1-1: Centrally Released Appetite Modulators 
The table displays both anorexigenic and orexigenic signals, that are primarily thought to be 
released centrally. 
Appetite Simulants 
Peptide Biochemistry Site of synthesis Receptors 
Receptor 
localization 
Neuropeptide Y 
36-amino-acid 
neuropeptide 
ARC Y1 and Y5 
Hypothalamus, 
Hippocampus, 
AMY 
Agouti-related protein 
132-amino-acid 
neuropeptide 
ARC 
MC3R and 
MC4R 
ARC, PVN, AMY 
Melanin concentrating 
hormone 
19-amino-acid 
neuropeptide 
LH 
MCH-1R and 
MCH-2R 
Cerebral cortex, 
AMY, 
hypothalamus, 
thalamus 
Orexins 
28- and 33-
amino-acid 
peptide 
dorsal and lateral 
hypothalamus 
OX-1R and 
OX-2R 
VMH, PVN, 
hippocampus and 
raphe nucleus 
Galanin 
29-amino-acid 
peptide 
Hypothalamus GAR-1R, 
GAL-2R, and 
GAL-3R 
PVN, LH, VMH, and 
AMY 
Galanin-like peptide 
Identical first 13-
amino-acids 
ARC 
Endogenous Opioids 
B-endorphin 
Wide distribution 
throughout the brain 
μ - and δ - All present within 
hypothalamic 
nuclei, differential 
distribution for 
each subtype 
dynorphin κ - 
enkephalins δ - 
Endocannabinoids lipids 
Wide distribution 
throughout the brain 
CB1 and CB2 
Differential 
distribution for 
individual subtypes 
Appetite Suppressants 
Peptide Biochemistry Sit of synthesis Receptors 
Receptor 
localization 
Pro-opiomelanocortin 
241-amino-acid 
peptide 
The pituitary, ARC, PVN, 
NTS, and VTA 
MC1R – 
MC5R 
ARC, VMH, PVN 
and AMY 
Cocaine and 
amphetamine-
regulated transcript 
CART(42–89) and 
CART(49–89) 
PVN, ARC, PBN 
Not yet 
identified 
Not yet identified 
α-Melanocyte 
stimulating hormone 
13-amino-acid 
polypeptide 
ARC 
MC3R and 
MC4R 
ARC, PVN, AMY, 
and spinal cord 
Neuropeptide W 
NPW30 and 
NPW23 
PVN, VMH, ARC, LH and 
NTS 
NPBWR1 and 
NPBWR2 
PVN, SON, DMH, 
VMH and ARC 
Neurotensin 
13-amino-acid 
peptide 
PVN, VMH, SON 
NTS-1, NTS-2 
and NTS-3 
DH and VTA 
Oxytocin 
Neuro-
hypophysial 
hormone 
PVN and SON OTR 
Prefrontal cortex, 
AMY, ventral 
striatum 
Serotonin 
Indoleamine 
transmitter 
Dorsal raphe nucleus 5-HT1 - 7 
Widespread 
distribution 
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1.3 The Melanocortin System 
Historically, the POMC- and NPY- neurons within the ARC were identified as the 
two neurochemical sites of leptin receptor expression in the CNS and the site of c-
Fos activation by both peripheral and central administration of leptin (Cowley et al., 
2001; Elias et al., 1999). The central melanocortin system is now widely known as 
the system of neurons that expresses NPY/AgRP or POMC and their associated 
receptor subtypes (see Figure 1-4 and reviews: Balthasar et al., 2005; Benoit et al., 
2001; Butler & Cone, 2002; Cone, 1999; Cummings & Schwarts, 2000; Ellacott & 
Cone, 2004; Gantz & Fong, 2003; Vergoni et al., 2000; Wisse & Schwartz, 2001)  
1.3.1 POMC  
Pro-opiomelanocortin is a precursor 241-amino-acid peptide. Expressed in the 
periphery, the pituitary, and the CNS (primarily the ARC, PVN, NTS, and the ventral 
tegmental area; VTA; Morton et al., 2006; Schwartz et al., 2000), POMC neurons 
co-express cocaine amphetamine-related transcript (CART) and GABA (Millington, 
2007). POMC is a potent anorectic agent, with agonists inhibiting and antagonists 
stimulating feeding behaviour / food intake (Boston et al., 1997; Fan, 1997; Hansen 
et al., 2005; Murphy et al., 1998; Sainsbury, Cooney, et al., 2002).  
 
Figure 1-4: Melanocortin System 
Schematic of the melanocortin system within the ARC of the hypothalamus (Cone, 2005). Lep-
R, leptin receptor; μ-OR, μ-opioid receptor; Y1-R, type 1 NPY receptor; Y2-R, type 2 NPY 
receptor; MC3-R, melanocortin type 3 receptor. 
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POMC is the precursor to adrenocorticotropin hormone (ACTH), β-endorphin (see 
Chapter 4) and α-, β-, γ- melanoctye-stimulating hormones (α-, β-, and γ-MSH), 
with the latter mediating their effects through five G-protein coupled receptors; 
MC1R – MC5R (Coll & Tung, 2009). Peripheral melanocortin peptides in skin and 
hair regulate the production of yellow-red/brown-black pigments through MC1R, 
whereas ACTH regulates adrenal glucocorticoid production through MC2R, and 
MC5R expressed in the periphery (Cone, 2005). The remaining receptors, MC3R 
and MC4R, are expressed primarily within the ARC and VMH and are considered 
key regulators in appetite control (see review: Butler & Cone, 2002).  
MC4R is more widely distributed than MC3R, and is considered particularly 
important in regulating food intake. Selective MC4R agonists have been shown to 
significantly reduce food intake and bodyweight (McMinn, Sindelar, et al., 2000), 
conversely, antagonists dose-dependently increase feeding and induce bodyweight 
gain (Murphy et al., 1998). Whole-body deletion of MC4R in mice produces 
hyperphagic obesity and hyperinsulinaemia. Interestingly, the hyperinsulinaemia is 
out of proportion to the degree of obesity, which may suggest an interaction with 
insulin/leptin. The hyperphagic obese profile is also mirrored by POMC neuron 
ablation (Gropp et al., 2005). As might be expected, selective MC4R knock-out 
mice are obese and hyperphagic. However the administration of MC3R agonists 
reduces food intake substantially less in these mice than in wild-type controls, 
thereby further supporting MC4R as the primary receptor in food intake regulation 
(Chen, Williams, et al., 2004).  
Comparatively, selective MC3R antagonists/agonists do not alter food intake 
(Abbott et al., 2000), and MC3R knock-out mice exhibit only a mild overweight 
phenotype; exhibiting a small increase in bodyweight and fat mass but lacking 
hyperphagia (Butler & Cone, 2002; Chen et al., 2000). However, this does not 
exclude the role of MC3R in energy regulation. For example, it is thought that 
MC3R may act as an inhibitory auto-receptor on ARC POMC neurons, creating a 
positive feedback circuit whereby agonists (such as α-MSH) act to stimulate their 
own release (Cowley et al., 2001). Additionally, human mutations of both receptor 
subtypes (MC3R and MC4R) produce an obese phenotype (Mencarelli et al., 2004). 
Indeed, the inability to synthesise melanocortin ligands from POMC is linked to 
early onset obesity syndrome (Fan, 1997).  
1.3.2 α-Melanocyte Stimulating Hormone  
α-melanocyte stimulating hormone (α-MSH) is a 13-amino-acid polypeptide. Its 
precursor ACTH, a 39-amino-acid polypeptide tropic hormone, is cleaved from 
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POMC expressed in the pituitary gland (Mountjoy & Wong, 1997). Expressed also 
in the anterior hypothalamus (DMH, PVN and ARC), it is a tonic inhibitory signal in 
appetite regulation, reducing food intake and bodyweight (Giraudo et al., 1998) via 
action at MC3R and MC4R (Marks & Cone, 2001).  
In addition to the literature on the effects on intake of MC3 and MC4 receptor 
ligands, specific central administration of α-MSH has been found to elicit an 
anorectic action (Matsuda et al., 2006; McMinn, Wilkinson, et al., 2000). Conversely 
α-MSH antagonists, such as SHU-9119, increase food intake and bodyweight 
(Raposinho et al., 2000). Further support for the significance of α-MSH in appetite 
regulation comes from studies on prolylcarboxypeptidase (PRCP), an enzyme that 
cleaves α-MSH and inactivates it. Mice lacking PRCP demonstrate higher α-MSH 
levels, have lower bodyweights and exhibit hypophagia (Wallingford et al., 2009).  
1.3.3 Cocaine and Amphetamine-Regulated Transcript 
The cocaine and amphetamine-regulated transcript (CART) gene encodes a 
peptide, of 116-amino-acid residues, expressed peripherally in the pituitary, 
pancreatic islets and stomach, and centrally, in the ARC, PVN and NTS (Koylu et 
al., 1998; Zhang, Han, et al., 2012). Within the hypothalamus, CART is thought to 
interact with a variety of other signals. For example, within the PVN, CART is co-
expressed with oxytocin; in the LH, it is thought to be co-localised with MCH; in the 
VTA, it is co-expressed with dopamine; and in the ARC, it is co-localised with 
POMC (Larsen & Hunter, 2006; Parker & Bloom, 2012; Vrang, 2006; see review: 
Zhang, Han, et al., 2012)  
Although there are no currently identified CART specific receptors, CART antiserum 
has been found to increase food intake. Similarly, endogenous CART is anorectic 
when administered centrally, suggesting that it plays some role in the regulation of 
feeding (Aja et al., 2001; Kristensen et al., 1998; Lambert et al., 1998; Larsen et al., 
2000; Vettor et al., 2002). Surprisingly, despite its co-localization with POMC in the 
ARC, its action does not appear to be mediated via the melanocortin system 
(Edwards et al., 2000). In fact, discrepancies between the effects of hypothalamic 
and ICV (intracerebroventricular) injections suggest that its anorectic effects are not 
in fact mediated by hypothalamus. It has been suggested that CART could have 
opposing effects in the hypothalamus and brainstem (Aja et al., 2001). This is 
supported by the observation that CART null mutants exhibit increased food intake 
and obesity, whereas the heterozygotes demonstrate reduced food intake (Asnicar 
et al., 2001; Kokkotou et al., 2005; Wierup et al., 2005). CART could therefore be a 
component of both anorectic and orexiogenic circuits (Parker & Bloom, 2012). 
16 
 
1.4 The ARC NPY/AgRP System 
1.4.1 NPY 
NPY, a 36-amino-acid residue with tyrosine at either end (hence the Y), was 
isolated from porcine hypothalamus in 1982 (Adrian et al., 1983; Allen et al., 1983). 
It is a member of the PP-fold family of proteins consisting of NPY, polypeptide Y 
(PYY; Section 1.5.1.7) and pancreatic polypeptide (PP; Section 1.5.1.8), named 
after a common tertiary structural motif known as the “PP fold”. It is synthesised in 
the brain stem and hypothalamus (ARC and DMN), with the latter projecting to the 
PVN (Currie & Coscina, 1996; Kalra et al., 1999; Ramos et al., 2005). Central or 
peripheral administration of NPY potently induces hyperphagia and obesity, by 
promoting meal initiation, increasing meal size and the duration of feeding (Kamiji & 
Inui, 2007; Stanley et al., 1986; Stanley & Leibowitz, 1984; Tiesjema et al., 2007). 
Conversely, NPY antagonists suppress food intake (Clark et al., 1984; Corp et al., 
2001; Levine & Morley, 1984; Myers et al., 1995; Stanley & Leibowitz, 1984) and 
deprivation-induced feeding (Ishihara et al., 1998). 
There are six currently identified receptor sub-types for NPY (Y1 – Y6). However, it 
is generally considered that only receptors Y1 and Y5 are important in mediating the 
effects of NPY on appetite (see review: Blomqvist & Herzog, 1997; Kalra et al., 
1991). Central administration of a selective Y1 receptor agonist, such as N-acetyl 
[Leu28, Leu31] NPY (24-36), stimulates food intake (Silva et al., 2002), whereas Y1 
receptor antagonists inhibit food intake and dose-dependently induce weight loss 
(Kask et al., 1998; MacNeil, 2007; Poindexter et al., 2002). Together with Y1 
receptor KO mice, which display a hypophagic phenotype in addition to an impaired 
fasting-induced re-feeding (Kanatani, 2000), these findings would support a 
significant role for Y1 receptors in the control of food intake and obesity.  
It was initially thought that Y1 receptors alone mediated the feeding-related effects 
of NPY. However, selective Y1 receptor agonists have been shown to elicit only 
50% of maximum feeding response (Oshea et al., 1997). Unfortunately, the precise 
role of these receptors in appetite regulation cannot be understood until a highly 
selective Y1 receptor antagonist reduces food intake independent of other systems; 
no such agent has yet been found (Chamorro et al., 2002). Currently-developed Y1 
antagonists (although similar results are found with Y5 antagonists) suppress food 
intake in NPY-deficient mice and Y5 KO mice, suggesting they act beyond the Y5 
receptor and are not specific (Bannon et al., 2000). 
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Y5 receptor agonists are similarly orexigenic when administered centrally, and Y5 
receptor antagonists, such as GlaxoSmithKline’s Y5 receptor antagonist 
GW438014A, are found to reduce food intake, bodyweight and fat mass in rodents 
(Daniels et al., 2002). On the other hand, some studies have found that selective Y5 
receptor agonists have no influence on food intake, but do contribute to the 
maintenance of the NPY feeding response (Flynn et al., 1999). Y5 receptor knock-
out studies have also yielded conflicting results (Marsh et al., 1998).  
NPY is thought to interact with a wide variety of other pathways. For example, it has 
been shown to be stimulated by the gut peptide ghrelin (see Section 1.5.3.1) and 
inhibited by amylin (see Section 1.5.1.6), insulin, leptin and serotonin (Harrold et al., 
2012; Valassi et al., 2008; Wang & Leibowitz, 1997). Ghrelin increases c-Fos 
activation in ARC, and increases NPY mRNA (Wang et al., 2002). Administration of 
amylin, a pancreatic hormone, can block the hyperphagic effects of NPY (Morris & 
Nguyen, 2001). Activation of serotonin receptors (5-HT1B and/or 5-HT2A) is found to 
suppress levels of NPY in the PVN and to induce hyperphagia, conversely, 
antagonising 5-HT receptors increases NPY function (Halford et al., 2003).  
As discussed earlier, NPY is thought to be the key component responsible for 
obesity in leptin-deficient mice (ob/ob). The co-expression of leptin receptor mRNA 
and NPY mRNA in ARC implies that the two peptides may act together. This was 
confirmed when ob/ob mice were also bred to be NPY-deficient, reducing obesity 
by 50% compared to ob/ob mice alone (Sainsbury, Schwarzer, et al., 2002). Further 
study found that insulin receptor agonism reduces levels of NPY mRNA, thereby 
inhibiting NPY synthesis and secretion (Arora & Anubhuti, 2006; Kalra et al., 1991; 
Schwartz et al., 1992). As NPY-induced hyperphagia can be blocked by leptin 
administration (Smith et al., 1998), NPY inhibition may be the mechanism of action 
for leptin-induced hypophagia.  
1.4.2 Agouti-Related Peptide 
The agouti gene was identified in 1992 (Bultman et al., 1992), when it was 
discovered to be the basis of Ay obesity, a monogenetic obesity model. The 
hypothalamic protein homolog, agouti-related peptide (AgRP), subsequently 
discovered in 1997 (Shutter et al., 1997), is a 132-amino-acid peptide, co-
expressed with NPY in the ARC and PVN (Broberger et al., 1998). The central 
administration of AgRP has a strong orexigenic action (Ebihara et al., 1999; 
Ollmann et al., 1998), so much so that acute AgRP administration can increase 
food intake for up to a week (Hagan et al., 2000). In contrast, overexpression 
produces hyperphagia and obesity (Arvaniti et al., 2001; Shutter et al., 1997). AgRP 
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acts to increase food intake via competitive antagonism of central MC3R and 
MC4R, thus blocking the anorectic action of the agonist α-MSH (Ollmann et al., 
1997). Interestingly, AgRP knock-out mice exhibit no unusual phenotype (Qian et 
al., 2002), suggesting that AgRP may have an indirect a role in energy expenditure. 
Studies have demonstrated that reduced AgRP levels elicit increases in energy 
expenditure and weight loss, without food intake changes (Makimura et al., 2002).  
There is conflicting evidence for the role of AgRP in obesity. Studies have shown 
that models of diet-induced-obesity (DIO; mice fed on 22week schedule of high fat 
diet) have reduced hypothalamic AgRP mRNA expression and increased MC4R 
expression (Huang et al., 2003). Similarly, suppressed AgRP mRNA expression is 
seen in obese mice (Tritos, Elmquist, et al., 1998), and yet obese humans express 
elevated levels of AgRP (Barsh et al., 2000).  
Further, evidence suggests that leptin acts to reduce food intake via the 
suppression of AgRP (Korner et al., 2001). The expression of AgRP within 
peripheral tissues (including the adrenal gland) further emphasises the potential 
role for AgRP within leptin-regulated feedback mechanisms (Stutz et al., 2005). 
This, in addition to leptin resistance seen in obese humans, may explain the 
elevated AgRP levels in obese humans (Barsh et al., 2000).  
1.4.3 Orexins 
The discovery of the orexin system was reported almost simultaneously by two 
separate research groups. de Lecea et al., (1998) identified the mRNA for a pro-
hormone pre-pro-hypocretin and its products hypocretin-1 and hypocretin-2. 
Independently, Sakurai et al. (1998) identified two peptide ligands; orexin-A and 
orexin-B and its pro-hormone, pre-pro-orexin (see review: Rodgers et al., 2002). 
The orexins are 33- and 28- amino-acid peptides (Orexin-A and Orexin-B, 
respectively) localised to the DMH, LH and PVN (Sakurai et al., 1998) and which 
act at via two G-protein coupled receptors; Orexin-1 (OX-1R) and Orexin-2 (OX-
2R). Orexin-A has an equal affinity for both receptor types whereas orexin-B has a 
much greater preference for the OX-2R (Sakurai et al., 1998). Both receptors are 
widely expressed within the hypothalamus; OX-1R chiefly in the VMH, whereas OX-
2R is found principally in the PVN (Trivedi et al., 1998). OXR is also found 
                                               
 Due to the more common use of the term “orexin” in the appetite literature, the term “orexin” will be used 
throughout this discussion. 
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elsewhere in CNS; DMH, VTA, nucleus accumbens (NAcc) Shell, and NTS 
(Rodgers et al., 2002). Peripherally, OX-1 receptors are found in brown adipose 
tissue and OX-2 receptors in the adrenal medulla. 
Both orexins are orexigenic in that, when injected centrally, they dose-dependently 
increase food intake and water consumption in rats, mice (Sakurai et al., 1998) and 
goldfish (Volkoff & Peter, 2001). Conversely, the administration of selective orexin 
receptor antagonists (Duxon et al., 2001; Porter et al., 2001; Rodgers et al., 2001; 
Smart et al., 2001) or anti-orexin antibodies produce the reverse effect (Yamada et 
al., 2000). Furthermore, orexin KO mice (prepro-orexin gene) are hypophagic with 
genetic ablation of orexin neurons associated with a 30% reduction in bodyweight 
(Hara et al., 2001), and narcolepsy (Chemelli et al., 1999; Chemelli et al., 2001).  
It is possible that orexins increase food intake indirectly via fluctuations in arousal 
levels. To assess behavioural specificity the behavioural satiety sequence 
methodology is often employed (BSS; see Chapter 3; Halford et al., 1998; Rodgers 
et al., 2010). It uses the orderly transition of eating, active grooming to resting to 
discriminate between drugs that reduce food intake via natural physiological 
mechanisms or those that do so by interference (Halford et al., 1998; Rodgers et 
al., 2010). Data using this technique has demonstrating that orexin-A increases 
food intake by delaying the onset of the BSS. This delay is then associated with 
elevated levels of locomotion, sniffing, rearing and feeding (Rodgers et al., 2000). 
In contrast, orexins may elicit their orexigenic action via direct regulation of central 
neurotransmitters. For example, orexins act on NPY, POMC and glucose-
responsive neurons in the ARC and VMH, in a manner reciprocal to leptin (Muroya 
et al., 2004; Tsujino & Sakurai, 2009). It is also possible that orexins act in the 
hindbrain to inhibit post-ingestive feedback from peripheral signals (Baird et al., 
2009). This is based on evidence that orexin administered directly into the 4th 
ventricle increases intake and meal duration (Zheng et al., 2005). 
Orexins are also linked to hedonic aspects of feeding. High levels of orexin neurons 
are found in brain regions associated with motivation and reward aspects of 
feeding, such as the VTA (Fadel & Deutch, 2002; Korotkova et al., 2003). 
Furthermore, administration of both OX-A and OX-B increases the firing frequency 
of dopaminergic neurons in the VTA (Borgland et al., 2009; Borgland et al., 2006), 
while intra-VTA administration of OX-A increases dopamine activation in the 
NAccShell (Narita et al., 2006; Vittoz et al., 2008). Additionally, increased place 
preference induced by a reward is associated with increased activation of orexin 
neurons (Harris et al., 2005). Specifically, OX1R antagonists block place preference 
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for morphine reward (Harris et al., 2007), whereas OX2R antagonism is ineffective 
(Smith, See, et al., 2009).  
Interestingly, depleted nutritional state (such as that produced by 48-hour fasting) 
causes an up-regulation of pre-pro-orexin (Cai et al., 1999; Griffond et al., 1999; 
Mondal et al., 1999; Yamamoto et al., 2000). Furthermore, orexin neurons 
expressing both orexin and leptin receptors have been identified in the GIT and are 
activated during starvation. It is therefore unsurprising that peripheral administration 
of orexins increase blood insulin levels. Additional peripheral effects include 
increases gastric acid secretion and gut motility (Bengtsson et al., 2007; Rodgers et 
al., 2002; Takahashi et al., 1999).  
1.5 Other Systems 
The central melanocortin and NPY systems are sensitive to episodic and tonic 
signals expressed within the hypothalamus as well as those that are able to cross 
the BBB from the periphery. In other words, NPY/AgRP and POMC/CART neurons 
act as downstream targets for circulating hormone signals to regulate appetite (see 
Figure 1-5). 
 
Figure 1-5: Peripheral appetite signals 
Schematic of the integration of peripheral signals including, adiposity signals, gut peptides, and 
pancreatic peptides (Badman & Flier, 2005). DVC, dorsal vagal complex; GIP, gastric inhibitory 
polypeptide; PP, polypeptide 
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Table 1-2: Peripherally Released Appetite Peptides and Adiposity Signals 
The Table displays both anorexigenic and orexigenic peptides, that are primarily thought to be 
released peripherally 
Orexigenic Peripheral Signals 
Peptide Biochemistry Discovery 
Site of 
synthesis 
Site of Action Receptors 
Ghrelin 
28-amino-acid 
peptide 
1999 
Gastric mucosa, 
DMN, VMH, 
PVN and ARC 
Hypothalamus, 
Hippocampus, 
VTA, pituitary 
GHS-R1 
Anorectic Peripheral Signals 
Peptide Biochemistry Discovery 
Site of 
synthesis 
Site of Action Receptors 
Leptin cytokine 1994 Adipose tissue 
ARC, VMH, 
DMH, and PVN 
OB-R 
Insulin 
51-amino-acid 
polypeptide 
1921 
Pancreatic β 
cells 
Hypothalamus, 
Hippocampus, 
Olfactory bulb 
IR-A, IR-B, 
IGF 
CCK 
58-, 39-, 33- and 
8-amino-acid 
peptide 
1928 
ARC, VMH, VTA 
and Duodenum 
PVN, DMN, 
SON, NAcc and 
Pancreas and 
Vagal nerve 
CCK-1, 
CCK-2 
GLP-1 
31-amino-acid 
peptide 
1980 
L cells, NTS, 
ARC and PVN 
ARC, PVN, 
VMH, SON 
GLP-1R 
Peptide YY 
36-amino-acid 
peptide 
1980 
Lower GI tract 
(distal gut) 
Hypothalamus 
and Pancreas 
NPY Y-2 
Bombesin 
14-amino-acid 
peptide 
1986 
GI Tract, spinal 
cord and 
hypothalamus 
AMY 
BBR-1, 
BBR-2 and 
BRS-3 
Corticotropin 
releasing 
hormone 
41-amino-acid 
neurohormone 
1981 PVN 
Anterior lobe 
and pituitary 
gland 
CRF-1 and 
CRF-2 
Somatosatin 
14- and 28-
amino-acid 
peptide 
1973 
Stomach, 
Hypothalamus 
and Pancreas 
Stomach, 
Duodenmum, 
pancrease 
SST1-5 
Oxyntomodulin 
37-amino-acid 
peptide 
1981 Colon, and NTS 
ARC, PVN, 
VMH, SON 
GLP-1R 
Pancreatic 
Polypeptide 
36-amino-acid 
peptide 
Early 1970s 
Pancreatic islets 
(F-cells) 
Arc, PVN, AMY, 
Thalamus 
NPY Y4 > 
Y1, Y5 
Enterostatin pentapeptide 1988 Pancreas Unknown 
beta subunit 
of F1-
ATPase 
Apolipoprotein 
A-IV 
glycoprotein 1977 small intestine NTS 
As yet 
Unknown 
Amylin 
37-amino-acid 
peptide 
1987 
Pancreatic islets 
(B-cells) 
NTS and 
hypothalamus 
AMY-1, -2 
and -3 
 
1.5.1 Anorectic –Peripheral 
Appetite and food intake are regulated peripherally by a variety of tissues and 
organs such as adipose tissue and the GIT. Signals released from the periphery 
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(see Table 1-2) are then relayed via the general circulation and vagal nerve to the 
brain, where they interact with receptors in the hypothalamus, NTS and elsewhere. 
1.5.1.1 Cholecystokinin 
Cholecystokinin (CCK) is a family of hormones, comprising a varying number of 
amino-acids (58-, 39-, 33- and 8-amino-acid peptides). Originally identified in 1928 
(Ivy & Oldberg, 1928), it is secreted from duodenal and ileal cells in response to 
nutrients (primarily fat and protein). Endogenous CCK rises rapidly post-prandially, 
remaining elevated for up to 5 hours (Koulischer et al., 1982).  
There are two currently identified types of CCK receptor; CCK1, originally named 
CCK-A ‘alimentary type” and CCK2, originally named CCK-B ‘brain type’ (Little et 
al., 2005). CCK1 receptors are primarily located in the CNS; particularly regions 
associated with appetite regulation, such as the NTS, the DMN and the area 
postrema (AP; Little et al., 2005; Moran, 2009; Moran, 2000). Peripherally, CCK 
enters the gastrointestinal lumen and binds to CCK1 receptors located on the vagal 
sensory terminals (Valassi et al., 2008).  
Centrally, CCK increases expression of CART and NPY2 receptors, while inhibiting 
the expression of MCH, its receptors and cannabinoid receptors (Harrold et al., 
2012). Lee et al. (2011) found that the absence of CCK1 receptors is linked to an 
elevation of ghrelin-induced hyperphagia, potentially mediated by CART. 
Peripherally, CCK mediates satiety and meal termination (Antin et al., 1975; Burton-
Freeman & Schneeman, 2002; Gibbs et al., 1973; Gutzwiller et al., 2000; Lieverse 
et al., 1995) through many actions within the GIT including; the slowing of gastric 
emptying (Debas et al., 1975), modulation of gastrointestinal motility (Brennan et 
al., 2005), and pancreatic secretion (Brennan et al., 2007; Owyang, 1996).  
Central administration of CCK (Ballinger et al., 1995; Figlewicz et al., 1992; Gibbs 
et al., 1973; Hirosue et al., 1993; Pisunyer et al., 1982) and agonists for CCK1 and 
CCK2 receptors dose-dependently suppresses energy intake by reducing meal size 
and duration (Bignon et al., 1999; Kissileff et al., 1981; Stacher et al., 1982). As 
might be expected, the blockade of both CCK receptor subtypes (via antagonists or 
CCK antibodies), in addition to genetic deletion of CCK receptors, results in 
hyperphagia and obesity (Beglinger et al., 2001; Corwin et al., 1991; Dourish et al., 
1989; Funakoshi et al., 1995; Gutzwiller et al., 2000). 
It should be noted, however, that the majority of peptide dose levels used to induce 
feeding effects are likely to have produced supraphysiological plasma 
concentrations (Little et al., 2005). Furthermore, research has found that only 
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specific CCK1 receptor agonists suppress appetite, while receptor deficiency or 
blockade results in hyperhagia and obesity in rodent models (Moran & Bi, 2006). In 
humans, the hypophagic effect is very modest (7% increase in intake; Beglinger et 
al., 2001). Clinical findings show that obese patients produce higher CCK secretion 
following a high energy meal than their lean counterparts (French et al., 1993). 
However, bulimic patients have impaired CCK secretion in response to food intake, 
which correlates with an impaired sense of post-meal satiety (Geracioti & Liddle, 
1988; Hannon-Engel, 2012). In this context, there appear to be differential effects in 
lean and obese rats (Meereis-Schwanke et al., 1998), in addition to gender and diet 
composition effects (Maggio et al., 1988; Strohmayer & Smith, 1987). 
1.5.1.2 Oxyntomodulin 
Oxyntomodulin (OXM) is a naturally occurring 37-amino-acid peptide discovered in 
1981 (Bataille et al., 1981; see review: Pocai, 2012). Found in the colon, it is 
produced by the epithelial cells of the oxyntic (fundic) mucosa. It is released in 
response to caloric intake, rises 5-10 minutes after a meal, and peaks at 30mins 
post-ingestion (Anini, 1999).  
Central or peripheral administration of OXM dose-dependently inhibits feeding in 
fasted and non-fasted rats (Dakin et al., 2001; Dakin et al., 2004). Chronic OXM 
administration studies confirm an inhibition of food intake, with no evidence of 
tolerance (Dakin et al., 2002). Additionally, chronic OXM-induced reductions of 
intake and bodyweight can be produced in obese subjects, an effect that 
maintained for up to 4 weeks (Wynne et al., 2006; Wynne et al., 2005). 
Furthermore, a OXM-induced reduction in hunger scores and energy intake has 
been demonstrated in healthy humans (Cohen et al., 2003). 
These anorectic actions are very similar to the actions of glucagon-like peptides 
(GLP; see Chapter 7). There are two glucagon-like peptides; GLP-1 and GLP-2, 
both impacting at different levels on the regulation of appetite and energy 
homeostasis. GLP-2 research has primarily focused on its therapeutic use to treat 
gastrointestinal disorders, whereas research on GLP-1 is more relevant in the 
present context (Janssen et al., 2013; Kieffer & Habener, 1999). Identified in 1980 
(Lund et al., 1980), GLP-1 is an anorectic incretin hormone. GLP-1 has two distinct 
forms: GLP-17-36amide and GLP-17-37, the former being the main circulating peptide 
associated with feeding (for a detailed discussion see Chapter 7). All GLP-1 
subtypes act on GLP-1 receptors (GLP-1R) which are widely expressed in the 
pancreatic islets, lung, heart, kidney, intestine and the CNS; hypothalamus and 
brainstem (Baggio & Drucker, 2007; Drucker, 2006). 
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No OXM-specific receptors have been currently identified. However, OXM has 
affinity for GLP-1R two orders of magnitude lower than that of GLP-17-36amide, yet it 
produces a bioequivalent anorectic effect (Dakin et al., 2001). Furthermore, the 
anorectic effects of OXM can be blocked by GLP-1 receptor antagonist, exendin9-
39, whereas OXM fails to alter feeding in GLP-1R KO mice (Baggio et al., 2004a). 
These findings would support an action of OXM at the GLP-1 receptor. 
Similarly, OXM has a weak affinity for the glucagon receptor. OXM may act as a 
glucagon mimetic within the liver and pancreas (Baldissera et al., 1988), whereby it 
simulates insulin secretion (Drucker, 2007). However, knock-out studies 
demonstrate that although OXM may act at these receptors, its administration to 
Gcgr-/- mice (glucagon receptor-deficient mice) can still elicit OXM-induced 
anorexia (Baggio et al., 2004a).  
Some evidence suggests that the anorectic effects of OXM may not be direct. For 
example, OXM administration has metabolic actions; whereby it increases heart 
rate (Sowden et al., 2006) and activity levels (Wynne et al., 2006). Furthermore, 
OXM acts peripherally to inhibit meal-stimulated gastric acid secretion (Jarrousse et 
al., 1986). 
1.5.1.3 Bombesin 
Bombesin is a 14-amino-acid peptide, originally isolated from the skin of an 
amphibian (Bombina bombina; Spindel, 1986). It has two known homologues in 
mammals (known as bombesin-like peptides); Neuromedin B (NMB) and gastrin-
releasing peptide (GRP). Gastrin is a peptide hormone that stimulates the release 
of hydrochloric acid in the stomach and which aids gastric motility (Arora & 
Anubhuti, 2006). NMB was originally isolated from pig spinal cord, but has now 
been shown to be present in human CNS and GIT (Minamino et al., 1983). 
Bombesin and related peptides have three, currently known, G-protein-coupled 
receptor subtypes: BBR-1 (NMB specific), BBR-2 (GRP specific), and BRS-3 (as 
yet uncharacterised; Battey & Wada, 1991; Ohki-Hamazaki et al., 2005), all of 
which are widely expressed in the CNS and GIT (Moran et al., 1988; Plamondon & 
Merali, 1994; Wada et al., 1992). 
Central administration of bombesin or GRP elicits a suppression of food intake 
(Gibbs et al., 1979; Muurahainen et al., 1993; Sayegh, 2013). Conversely, 
bombesin receptor antagonists both enhance food intake and block bombesin-
induced satiation (Flynn, 1997); the PVN and NTS are particularly sensitive to these 
effects (Flynn, 1992). Furthermore, when bombesin is systemically administered, 
central pre-treatment with antagonists can attenuate the satiation effects (Kirkham 
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et al., 1994). For these reasons, bombesin-induced feeding effects are believed to 
be centrally activated. Specifically, as GRP-R KO mice (but not NMB-R KO mice) 
exhibit increased weight gain (Maekawa et al., 2004; Wada et al., 1997), these 
actions are probably mediated via the BBR-2 receptor.  
Similarly, BRS-R3 KO mice display a mildly obese phenotype and hyperphagia. 
However they also show elevated circulating leptin levels (Maekawa et al., 2004). 
Typically, when leptin is administered ICV food intake is inhibited in wild-type mice, 
however, this effect is attenuated in BRS-3 KO mice (Maekawa et al., 2004), 
suggesting that bombesin may act via other central satiety mechanisms. Bombesin 
is also thought to at least partly mediate its feeding effects through CRF 
(corticotropin-releasing factor) release, as CRF antagonists have been found to 
attenuate the bombesin-induced satiety effect (Plamondon & Merali, 1994). 
Furthermore, BRS-3 KO mice display elevated MCH levels, and present an 
orexigenic response to MCH administration. The up-regulation of MCH could be, at 
least partially, responsible for the hyperphagia and leptin resistance in BRS-3 KO 
mice (Maekawa, 2004). This research implies a significant mediating role of MCH in 
the feeding effects of bombesin in normal animals. Interestingly, although 
pharmaceutical research is focusing on BRS-3 receptor agonists for the treatment 
of obesity (Guan et al., 2010; Guan et al., 2011; Jensen et al., 2008; Ramos-
Alvarez et al., 2013), bombesin actually has a low affinity for the BRS-3 receptor 
(Jensen et al., 2008), despite its name and sequence similarity.  
1.5.1.4 Somatostatin 
Somatostatin (SS), identified and isolated in 1973 from the sheep hypothalamus 
(Siler et al., 1973), is also known as growth-hormone inhibiting hormone (GHIH). It 
is a peptide formed by cleavage from pre-somatostatin, and has two active forms; 
primarily as the tetradecapeptide somatostatin-14 (SS-14) but also as somatostatin-
28 (SS-28; Yamada et al., 1992). SS is generally found in the GIT and pancreas, 
where it is produced by paracrine and endocrine-like D cells to inhibit 
gastrointestinal endocrine secretion (McIntosh et al., 1978). High levels of SS are 
also found in the hypothalamus and limbic regions, including the AMY and 
hippocampus (Johansson et al., 1984). SS acts on five different SS receptors, four 
of which do not differentiate SS-14 and SS-28 (Patel, 1999).  
The effect of SS on feeding is inconsistent. Whereas, SS is found to increase food 
intake in rats (Aponte et al., 1984; Feifel & Vaccarino, 1994) and chicks (Tachibana 
et al., 2009), it is reported to reduce intake in goats (Mogi et al., 2003) and baboons 
(Lotter et al., 1981). Central administration of ‘physiological doses’ in rats increases 
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feeding at 1hour post-treatment, while ‘pharmacological doses’ decrease food 
intake, and no effects at all are found with dark-phase administration (Vaccarino et 
al., 1990). This suggests that the inconsistencies may be due to variation in doses 
and/or testing protocols. It is also thought that the differential effects of SS between 
studies are due to the relative affinities of the compounds used.  
SS is also believed to exert its action via suppressed release and absorption of 
peripheral appetite signals (Eisenbraun & Ehrlein, 1996). For example, SS 
suppresses circulating ghrelin (Norrelund et al., 2002), and insulin (Kleinman et al., 
1994). It also inhibits digestive processes such as gastric motility (Scalera & 
Tarozzi, 1998) and gastric emptying, via the suppression of CCK-induced smooth 
muscle contraction (Kabemura et al., 1991). However, studies shows that a 
vagotomy abolishes SS-induced effects on food intake (Levine & Morley, 1982), 
suggesting an ultimate central mechanism of action (Stengel et al., 2010). 
Much of the current research focuses now on S2 receptor agonists such as 
octreotide (SMS 201–995; Grace et al., 2006), and ODT8-SST (Erchegyi et al., 
2008; Stengel et al., 2010; Tachibana et al., 2009), both of which act to stimulate 
gastric acid secretion and gastric emptying (Yoneda et al., 1991). 
1.5.1.5 Fat-Specific Satiation Peptides 
Fat-specific satiation peptides are gastrointestinal peptides specifically stimulated 
by the ingestion of fat, and which regulate the intake and metabolism of lipids 
(Cummings & Overduin, 2007). Two known fat-specific satiation peptides are; 
Enterostatin and Apolipoprotein A-IV (APO-AIV). 
Enterostatin is a pentapeptide, discovered in 1988 (Erlanson-Albertsson, 2011). It is 
primarily secreted from pancreatic procolipase during fat digestion 
(Erlansonalbertsson & Larsson, 1988) but has also been found centrally in the PVN, 
supraoptic nucleus (SON), ARC, DMH and AMY (Lin et al., 2006; Lin & York, 1997; 
York & Park, 2006). The receptor for enterostatin is the beta subunit of F1-ATPase 
(Berger et al., 2002; Park et al., 2004).  
Both peripheral (Erlansonalbertsson & Larsson, 1988) and central (Lin et al., 1994; 
Shargill et al., 1991) administration of enterostatin dose-dependently suppresses 
food intake in rats. In fact, administration of enterostatin produces a preferential 
reduction in dietary fat intake (Lin et al., 1997; Lin et al., 2007; Lin & York, 1998; 
York & Park, 2006). However, this particular effect has not proven to be replicable 
in humans (Kovacs et al., 2003). Conversely, administration of enterostatin 
antagonists increases dietary fat intake (Shargill et al., 1991).  
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Timecourse methodology has established that enterostatin decreases food intake 
directly by accelerating satiety (Lin et al., 2003). This effect is potentially due to the 
inhibition of gastric motility and gastric emptying (Erlanson-Albertsson, 2011), 
through the stimulation of other peptides such as CCK (Lin, 2003) and amylin 
(Arsenijevic et al., 2005). Enterostatin is also known to interact with serotonin (Lin & 
York, 2005) and the melanocortin system (Lin et al., 2007). 
APO-AIV is a glycoprotein secreted from the small intestine in response to lipid 
absorption and may be involved in the inhibition of food intake following fat 
ingestion (Fujimoto et al., 1992; Swaney et al., 1977). Fujimoto et al. (1992) found 
an inhibition of food intake by intestinal lymph collected from rats actively absorbing 
fat. After ruling out the possibility that the mere presence of lipid in the chylous 
lymph is responsible for inhibiting food intake, the authors concluded that the agent 
responsible was APO-AIV. In APO-AIV-deficient chylous lymph failed to produce 
any significant effects on feeding behaviour (Yoshimichi et al., 2012). Hypothalamic 
administration of APO-AIV produces a dose-dependent reduction in food intake that 
is 50-fold greater than that seen with peripheral administration (Fujimoto et al., 
1993); conversely, APO-AIV antibodies increase intake (Derosa & Salvadeo, 2011). 
It was later found that intracisternal administration of purified APO-AIV dose-
dependently inhibits gastric acid secretion and gastric motility (Okumura et al., 
1996). As intravenous administration failed to elicit the same gastric effects, a 
hindbrain/brainstem site of action seems likely (Stan et al., 2003). 
1.5.1.6 Amylin 
Amylin, a 37-amino-acid known as an islet amyloid polypeptide, was first identified 
in 1987 (see reviews: Arora & Anubhuti, 2006; Lutz, 2009; Reda et al., 2002). It is 
co-released with insulin from pancreatic β-cells in response to food consumption 
(Pittner et al., 1994).  
Central and peripheral administration of endogenous and exogenous amylin dose-
dependently reduces food intake (Bhavsar, Watkins, et al., 1998b; Chance et al., 
1991; Chapman et al., 2005; Kelly & Cline, 2007; Lutz et al., 1994; Mack et al., 
2003; Morley & Flood, 1991; Rushing et al., 2000). Conversely, administration of 
amylin antagonists, such as AC187, increases food intake and meal size (Mollet et 
al., 2004; Reidelberger et al., 2004; Rushing et al., 2001). As expected, amylin-
deficient mice exhibit the typical obese phenotype characterized by hyperphagia 
and increased adiposity (Devine & Young, 1998). Similarly, Pramlintide, a human 
amylin analogue, reduces food intake and lowers subjective feelings of hunger, in 
both lean and obese subjects (Chapman et al., 2007). 
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Amylin receptors are expressed primarily in the AP (Zuger et al., 2013) In fact, the 
satiating effect of peripheral amylin seems to be mediated by direct action on AP 
neurons. Amylin administration induces c-fos activation on AP neurons and AP 
lesions profoundly attenuate the amylin-induced anorectic response (Becskei et al., 
2007; Lutz et al., 1998). Amylin appears to decrease food intake and meal size via 
a combination of central and peripheral mechanisms (see review: Lutz, 2013). 
Although all of these mechanisms are not completely understood at the present 
time, amylin has been shown to: inhibit the digestive secretion of gastric acid and 
pancreatic enzymes (Young et al., 2005), inhibit nutrient-stimulated glucagon 
secretion (Fineman et al., 1998), but not hypoglycaemia-stimulated glucagon 
secretion (Silvestre et al., 2001); slow gastric emptying (Jodka et al., 1996) via 
amylin receptors in the AP (Edwards et al., 1998); reduce the expression of 
orexigenic neuropeptides in the LH (Lutz, 2005); up-regulate leptin receptor 
expression and increase leptin binding in the rat VMH (Lutz, 2010); and increase 
the release of noradrenaline via AP neuron activation (Potes et al., 2010).  
Amylin is also thought to act as an adiposity signal. Although, evidence shows that 
obese patients have higher mean basal amylin concentration than their lean 
counterparts (Reda et al., 2002), research on the sensitivity of amylin receptors in 
obese models remains inconclusive. For example, some DIO models suggest an 
attenuated sensitivity to peripheral amylin (Boyle et al., 2011), implicating some 
form of amylin resistance. Furthermore, amylin also elicits effects on bodyweight 
and food intake via a metabolic action. Amylin increases energy expenditure 
(Arsenijevic et al., 2005; Osaka et al., 2008; Roth et al., 2006) by means of 
increases in body temperature (Bouali et al., 1995), actions which may have a 
secondary effect on food intake. Amylin also decreases locomotor activity (Clementi 
et al., 1996) and increases anxiety like behaviours in rodents (Kelly & Cline, 2007). 
1.5.1.7 Peptide YY 
Peptide YY is a 36-amino-acid peptide identified in 1980 (Tatemoto & Mutt, 1980). 
Secreted from the L cells of the GIT in response to ingested calories, circulating 
PYY exists in two forms; PYY1-36 and PYY3-36 (Adrian et al., 1985). The latter is 
claimed to be peripherally active anorectic signal, and has a relatively selective 
affinity for Y2 receptors as expressed on NPY-releasing neurons in the ARC.  
Acute and chronic administration of PYY3-36 to both fasted and free-feeding rodents 
and monkeys has been reported to inhibit food intake (Adams et al., 2006; 
Batterham et al., 2002; Halatchev et al., 2004; Koda et al., 2005; Koegler et al., 
2005; Moran et al., 2004; Sileno et al., 2005; Sloth et al., 2007; Stoeckel et al., 
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2008). This effect is lost in Y2 receptor KO mice, and attenuated by selective Y2 
antagonists (Scott et al., 2005; Talsania et al., 2005). Research using BSS 
methodology has demonstrated a selective action of PYY3-36 to accelerate yet 
preserve the behavioural satiety sequence in rats (Boggiano et al., 2005; Scott et 
al., 2005; Tschop et al., 2004). As expected, PYY3-36 knockout mice exhibit a 
phenotype characteristic of increased bodyweight and body fat together with 
increased food consumption (Batterham et al., 2006). Interestingly, obese humans 
and rodents have low circulating PYY3-36, compared to lean controls (le Roux et al., 
2006), and yet retain sensitivity to exogenous administration. Clinical studies have 
shown that PYY3-36 infusions reduce calorific intake in both lean and obese subjects 
(Batterham, Cohen, et al., 2003; Batterham et al., 2002; Degen et al., 2005).  
It has been proposed that PYY3-36 elicits its anorectic effect via inhibitory Y2 auto-
receptors on NPY neurons. It dampens NPY release and stimulates reciprocal 
POMC neurons and orexigenic circuit activation (Ueno et al., 2008; Zhang, Nguyen, 
et al., 2012). Systemic administration of PYY3-36 significantly decreases NPY mRNA 
expression and increases that of POMC mRNA (Parkinson et al., 2008). 
Additionally, PYY3-36 acts peripherally to delay gastric emptying, and the release of 
pancreatic and stomach secretions, while increasing the rate of ileum absorption 
(Steinert et al., 2010). 
Despite the above reports, there are major inconsistencies within the literature, and 
many findings have not been successfully replicated (Tschop et al., 2004). 
Dramatically, Boggiano (2005) claims that 90% of the literature has failed to 
demonstrate an anorectic effect using PYY3-36. 
1.5.1.8 Pancreatic Polypeptide 
Pancreatic Polypeptide (PP) is a 36-amino-acid peptide discovered in the early 
1970’s. Secreted by pancreatic islets in response to food ingestion (Adrian et al., 
1976), it mediates its appetite effects centrally via NPY Y4 and Y5 receptors 
(Larhammar, 1996).  
Peripheral administration or the transgenic overproduction of PP decreases food 
intake and bodyweight (Asakawa et al., 2003; McLaughlin & Baile, 1981); 
conversely, peripheral administration of anti-PP antiserum increases food intake 
(Ueno et al., 1999). Systemic infusions can also decrease calorific intake in healthy 
human subjects by 22% (Batterham, LE Roux, et al., 2003).  
However, there are discrepancies within the literature. For example, Clark et al. 
(1984) found that PP injected directly into the brain can in fact increase food intake. 
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Similarly, Okumura et al. (1994) found that the central administration of PP 
increases food intake, via a dose-dependent acceleration of gastric emptying. More 
recent research demonstrates that PP acts peripherally to decrease the rate of 
gastric emptying (Katsuura et al., 2002). It is also pertinent to note that PP 
increases oxygen consumption, suggesting that its effect on bodyweight could be a 
result of increased energy expenditure rather than a direct effect on appetite. Due 
to these inconsistencies, the mechanism by which PP elicits an anorectic response 
is currently uncertain.  
Plasma PP levels are reduced in obese patients (Glaser et al., 1988; Reinehr et al., 
2006), while anorexia nervosa sufferers experience an increased response to PP 
(Batterham, LE Roux, et al., 2003; Fujimoto et al., 1997; Uhe et al., 1992). 
Additionally, Prader-Willi syndrome, characterised by dramatic hyperphagia and 
obesity, is associated with a deficiency in basal and meal-stimulated levels 
(Berntson et al., 1993).  
1.5.2 Anorectic – Central 
1.5.2.1 Neuropeptide W  
Neuropeptide W (NPW) has two forms: NPW30 (comprising 30 amino-acids) and 
NPW23 (comprising 23 amino-acids; see review: Takenoya et al., 2010). Identified 
in 2002 from porcine hypothalamus (Shimomura et al., 2002), NPW is expressed 
primarily within the substantia nigra and spinal cord of humans, and the PVN, VMH, 
ARC and LH of rats (Dun et al., 2003). NPW, is also found peripherally in the 
gastric antral G cells (Mondal et al., 2006), pancreatic islets (Hochol et al., 2007), 
and stomach mucosa (Caminos et al., 2008).  
NPW interacts with two G protein-coupled receptors, Neuropeptide B/W receptor 1 
(NPBWR1; also known as GPR7) and Neuropeptide B/W receptor 2 (NPBWR2; 
also known as GPR8). It should be noted that the latter is not present in rodents 
(Tanaka et al., 2003). NPBWR1 are found in the hippocampus, AMY and 
hypothalamus, including the PVN, SON, DMH, VMH and ARC (Fujii et al., 2002). 
Generally, central administration of neuropeptide W increases food intake in rats 
(Levine et al., 2005; Shimomura et al., 2002). However, continuous infusion of NPW 
has been found to suppress feeding and bodyweight gain, while anti-NPW 
(neutralising) antibodies stimulate feeding (Mondal et al., 2003). 
NPW is thought to elicit its effect on intake via the MC4R signalling pathways (Date, 
2010). Using RT-PCR and electro-physiological methodologies, findings show that 
NPW increases POMC mRNA expression and decreases AgRP mRNA, but doesn’t 
31 
 
appear to have an effect on that of NPY or CART (Date et al., 2010). Furthermore, 
MC4R antagonism has been found to inhibit the anorectic effects of NPW (Date et 
al., 2010).  
Neuronal interactions have also been observed between NPW and both orexin- and 
MCH- producing neurons (Takenoya et al., 2008). For example, NPW ICV 
administration increases c-fos activation in orexin-producing neurons (Levine et al., 
2005). There is also evidence that NPW interacts with leptin function, as NPW 
levels are significantly up-regulated in leptin-deficient (ob/ob) and leptin receptor-
deficient (db/db) mice (Date et al., 2010). Other views suggest that NPW acts to 
inhibit growth hormone release via SS neuron activation (Price et al., 2008). 
1.5.2.2 Neurotensin and Neuromedin 
Neurotensin (NT) is a 13-amino-acid neuropeptide, first isolated from extracts of 
bovine hypothalamus (Carraway & Leeman, 1973). Although distributed throughout 
the CNS, highest levels are found in the AMY, NAcc and many hypothalamic sites 
associated with feeding and bodyweight regulation (Manberg et al., 1982). In the 
gut, NT is produced in endocrine N cells and regulates gastrointestinal motility as 
well as pancreatic and biliary secretion (Mazella et al., 2012). NT acts through two 
G-protein-coupled receptors; NT-1 and NT-2, in addition to the single 
transmembrane receptor NT-3 (also known as sotilin-1; Vincent et al., 1999).  
Central administration of NT decreases food intake (Cooke et al., 2009; Levine, 
Kneip, et al., 1983; Luttinger et al., 1982), an action thought to be mediated by the 
NT-1 receptor. Research shows that genetic deletion of NT-2R does not cause a 
specific phenotype in mice (Maeno et al., 2004), whereas NT-1R KO mice exhibit 
increased weight gain and hyperphagia in addition to blocked NT-induced anorexia 
(Remaury et al., 2002).  
ICV administration of neurotensin has been found to block MCH-induced, but not 
NPY-induced, hyperphagia. This suggests a complex functional interaction between 
central anorectic and orexigenic systems (Tritos, Vicent, et al., 1998). NT is also 
involved in the mediation of leptin’s action on feeding. NT levels are reduced in 
ob/ob mice (Wilding et al., 1993), and NT neurons in the hypothalamus express 
leptin receptors (Mazella et al., 2012). Furthermore, leptin-induced satiety is 
reversed both by NT immunoneutralization and NT receptor antagonism (Sahu et 
al., 2001). Likewise, NT is thought to play a role in the regulation of CRF. NT has 
been found to stimulate CRF release (Rowe et al., 1995), while NT antagonism 
decreases CRF mRNA levels in the PVN (Rowe et al., 1997). In this respect, NT 
has been also been linked with prolactin and dopamine (Stolakis et al., 2010). 
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Xenin, a neurotensin-related peptide, has also been found to reduce food intake in 
rodents and chicks via stimulation of hypothalamic areas (Cline et al., 2007; Cooke 
et al., 2009; Leckstrom et al., 2009). Xenin is a 25-amino-acid peptide discovered in 
1992 (Feurle et al., 1992). Co-expressed in intestinal K-cells with GIP (Anlauf et al., 
2000), xenin is thought to play a role in the regulation of glucose homeostasis and 
may potentiate the action of GIP on glucose-mediated insulin release via NT-1R 
(Mazella et al., 2012). However, there is also evidence for a non-neurotensin 
receptor-mediated effect of xenin (Heuser et al., 2002). 
Neuromedin-U (NMU) and Neuromedin-S (NMS) are 25- and 36- amino-acid 
peptides, respectively (Peier et al., 2011). NMU is expressed both peripherally and 
centrally, with highest levels found in the hypothalamus (VMH and ARC), the 
striatum (Hosoya et al., 2000) and the GIT (Nakashima et al., 2010). In contrast, 
NMS is found primarily in the suprachiasmatic nucleus (SCN).  
Both peptides are endogenous ligands for two orphan G protein-coupled receptors, 
FM-3/GPR66 and FM-4/TGR-1; also known as NMU receptor type 1 (NMU1R) and 
type 2 (NMU2R; Ida et al., 2005). NMU1R is located widely in peripheral tissues, 
such as the intestine and pancreas, whereas NMU2R is thought to be limited to the 
brain and specifically the PVN (Ida et al., 2005).  
Acting similarly to NT, NMU and NMS suppress food intake and reduce bodyweight 
when centrally administered (Howard et al., 2000; Ida et al., 2005; Nakazato et al., 
2000; Peier et al., 2011), although it should be noted, that activation of NMU2R also 
increases locomotor activity and core body temperature (Peier et al., 2009; Zeng et 
al., 2006). As would be expected, transgenic overexpression of NMU results in 
hypophagic, lean phenotypes (Kowalski et al., 2005), whereas NMU deficient mice 
are obese and have reduced energy expenditure (Hanada et al., 2004). In further 
support for a role of NMU in appetite regulation, human NMU variants are also 
associated with obesity (Hainerova et al., 2006). Despite these interesting findings, 
however, the exact mechanism/s responsible for regulation of feeding and energy 
metabolism by NMU and NMS remains unclear (Nakahara et al., 2010). 
1.5.2.3 Oxytocin 
Oxytocin is a neurohypophysial hormone that was primarily thought to play a role in 
reproduction and attachment but, in 1989, was also found to be an anorectic agent 
(Arletti et al., 1989). Expressed primarily within the PVN and SON, oxytocin has 
only one, currently identified, receptor (OTR). Interesting, OTRs are also found 
peripherally in adipocytes (Ho & Blevins, 2013). 
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Typically, when food is consumed, plasma levels of oxytocin rise (Verbalis et al., 
1986; Zhang, Bai, et al., 2011), while oxytocin mRNA is reduced during periods of 
fasting (Kublaoui et al., 2008). Food consumption also increases c-Fos activation in 
hypothalamic oxytocin neurons (Johnstone et al., 2006). When administered either 
centrally (Arletti et al., 1989) or peripherally (Morton et al., 2012) oxytocin is 
anorectic, while, conversely, OTR antagonism stimulates food intake (Blevins et al., 
2004; Zhang, Bai, et al., 2011). Interestingly, oxytocin KO mice display an 
increased preferential intake of carbohydrate (Olszewski et al., 2010). 
It is thought that oxytocin mediates its feeding effects by decreasing meal size. In 
line with this, oxytocin antagonists dose-dependently increase meal size (Blouet et 
al., 2009). Furthermore, oxytocin neurons link extensively to the NTS, where it is 
thought they modulate responsivity to peripheral satiety signals such as CCK. For 
example, as impaired oxytocin expression blunts the anorexgienic effects of CCK 
administration, oxytocin may contribute to CCK-induced satiety (Baskin et al., 2010; 
Blevins et al., 2003; Blevins et al., 2004; Ho & Blevins, 2013; Verbalis et al., 1986). 
Recent research has found that oxytocin-induced changes in body mass are 
independent of food intake (Deblon et al., 2011). As oxytocin also elicits effects on 
energy expenditure, through an increase in heart rate, body temperature, and 
oxygen consumption (Ho & Blevins, 2013), as well as effects on gastric motility (Qin 
et al., 2009; Wu et al., 2003), it may not have a direct impact upon appetite 
regulation per se.  
1.5.2.4 Corticotropin-releasing factor 
Corticotropin-releasing factor (CRF) is a 41-amino-acid glycoprotein hormone, 
secreted by the PVN (Vale et al., 1981). Its primary function is to stimulate the 
synthesis and release of pituitary ACTH which, in turn, stimulates corticosterone 
secretion from the adrenal cortex (Owens & Nemeroff, 1991).  
CRF exerts its actions via two receptor subtypes: CRF-1 and CRF-2 (Behan et al., 
1996; Chalmers et al., 1996), although it is thought that CRF-2 is more important in 
mediating the effects of CRF and CRF-related peptides on appetite (Martinez et al., 
1998). CRF-2R antagonists (Cullen et al., 2001), but not CRF-1R antagonists or 
CRF-1R genetic deletions, block the anorectic effects of CRF administration 
(Bradbury et al., 2000; Sekino et al., 2004). In contrast, the two endogenous ligands 
for CRF-2, Stresscopin and Urocortin, both reduce food intake and delay gastric 
emptying (Arora & Anubhuti, 2006; Inoue et al., 2003; Zorrilla et al., 2004). 
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Central administration of exogenous CRF, specifically into the PVN, decreases 
feeding, while chronic administration leads to sustained anorexia and weight loss 
(Levine, Rogers, et al., 1983; Morley & Levine, 1982; Wang, Stengel, et al., 2011). 
As might be expected, CRF overexpressing mice exhibit reduced food intake in 
response to fasting (Stengel et al., 2009), whereas, mice that overexpress CRF 
binding protein, which sequesters CRF, exhibit increased food intake. CRF may act 
via tonic restriction of orexigenic signals within the hypothalamus. This is supported 
by evidence that CRP receptor blockade enhances NPY-stimulated feeding (Hulsey 
et al., 1995). It should be noted that, CRF also exerts stimulatory effects on arousal 
and locomotor activity and elicits “anxiogenic-like” effects in rats (Britton et al., 
1982; Monnikes et al., 1992; Morley & Levine, 1982; Zorrilla & Koob, 2004; Zorrilla 
et al., 2004), suggesting its effects on food intake may not be direct. 
1.5.3 Orexigenic – Peripheral 
1.5.3.1 Ghrelin 
Ghrelin, a 28-amino-acid acylated peptide, discovered in 1999, is found primarily in 
the “A-X like” cells of the oxyntic glands in the gastric mucosa of the stomach 
(Kojima et al., 1999). Also found in the ARC, ghrelin is a specific GHS-R ligand 
(growth-hormone secretagogues receptor; located primarily in the hypothalamic 
pituitary unit, especially on NPY neurons) that stimulates the release of growth 
hormone (GH; Wren et al., 2000). GHS-R receptors are found in the VMH, ARC 
and PVN, as well as the hippocampus and VTA (Guan et al., 1997). 
Known as the circulating appetite stimulant, ghrelin increases two-fold just before a 
meal and falls rapidly post-prandially. This rise and fall within an hour of eating 
suggests that ghrelin plays an important role in meal initiation (Cummings et al., 
2001). Ghrelin administration, both central (ICV) and peripheral (i.p.) results in an 
immediate and sustained increase in food intake similar to that seen with NPY ICV 
administration (Wren et al., 2001); indeed, ghrelin administration can increase the 
calorific value of one meal by 28% (Wren et al., 2001). Conversely, ghrelin 
neutralising antibodies are anorectic (Nakazato et al., 2001). Ghrelin is also thought 
to play a role in long-term appetite regulation, as supported by the hyperphagic 
response to chronic ghrelin administration (Tschop et al., 2000). 
Although ghrelin regulates GH release from the pituitary via GHS-R (Kojima et al., 
1999), it is believed that ghrelin-stimulated appetite and weight gain are 
independent of ghrelin-mediated GH release. Evidence demonstrates that ghrelin-
induced adiposity is not attenuated in GH-deficient dwarf rats compared to intact 
rats (Tschop et al., 2000). Instead, ghrelin is thought to achieve its orexigenic action 
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via stimulation of hypothalamic neurons (Nakazato et al., 2001) and inhibition of 
gastric vagal afferents (Date et al., 2002). Ghrelin stimulates ARC NPY neurons 
and orexin neurons in the LH (Kohno et al., 2003). Although it has been found that 
the presence of NPY is not obligatory for ghrelin’s role in stimulating fat accretion 
and reducing lean body mass (Tschop et al., 2000), ghrelin-induced hyperphagia 
does appear to be mediated by an enhancement of NPY/AgRP and inhibition of 
POMC (Park et al., 2005). Central ghrelin administration has been found to 
increase c-Fos expression in NPY and AgRP neurons; antibodies and antagonists 
that inhibit NPY and AgRP have been found to modulate ghrelin-induced feeding 
(Lawrence, Snape, et al., 2002; Wang et al., 2002); and administration of ghrelin 
fails to produce hyperphagia in NPY/AgRP KO mice (Chen, Trumbauer, et al., 
2004). 
Interestingly, the effect of ghrelin on feeding behaviour seems to be the exact 
opposite to that of leptin, suggesting competitive interaction in appetite regulation. 
As discussed, ghrelin causes an increase in food intake and bodyweight gain by 
stimulating the production of NPY and AgRP in the ARC, whereas leptin acts to 
decrease food intake and bodyweight gain by stimulating the production of POMC 
in the ARC. Ghrelin and leptin are complementary players in this regulatory system, 
whereby ghrelin may act centrally to directly counter-regulate leptin and insulin 
signalling in the hypothalamus (Horvath et al., 2001; Zigman & Elmquist, 2003). 
Despite the apparent role ghrelin in hyperphagia and weight gain, obese patients 
are found to have reduced circulating ghrelin levels compared to age-matched lean 
controls (Ariyasu et al., 2001; Tschop et al., 2001). This corresponds with findings 
that ghrelin levels increase with chronic over-eating (Shiiya et al., 2002). Although 
ghrelin is down-regulated in human obesity, ghrelin levels are elevated in those with 
a negative energy balance, for example during high levels of exercise or anorexia 
nervosa (Neary et al., 2004). This is similar to insulin resistance, whereby the 
negative feedback loop that stimulates ghrelin release is absent (Finlayson et al., 
2007).  
Recent findings suggest that ghrelin may play a role in the rewarding and 
motivational aspects of feeding. GHS-Receptors are co-located on neurons known 
to play a role in hedonics; for example, GABAergic and dopaminergic neurons in 
the VTA (Parker & Bloom, 2012). Administration of ghrelin to this area increases the 
firing frequency of dopaminergic VTA neurons and preferences for highly palatable 
food (King et al., 2011; Parker & Bloom, 2012). GHS-R antagonism and genetic KO 
studies have also demonstrated ghrelin’s involvement in other hedonic behaviours, 
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such as operant responding for sucrose and food-induced conditioned place 
preference (Blum et al., 2009; Egecioglu et al., 2010; Jerlhag et al., 2010; Jerlhag et 
al., 2009; Parker & Bloom, 2012; Skibicka et al., 2011). Furthermore, human fMRI 
studies show that ghrelin administration produces increases in neural activity in 
areas associated with hedonic aspects of eating, including the amygdala, 
orbitofrontal cortex, anterior insula, and striatum (Malik et al., 2008). 
1.5.4 Orexigenic - Central 
1.5.4.1 Galanin and Galanin-like peptide (GALP) 
Galanin is a 29-amino-acid neuroendocrine peptide, originally identified from 
porcine intestinal extracts (Tatemoto et al., 1983). Found in the brain and GIT 
(Bonnefond et al., 1990), it is co-produced in NPY-releasing neurons in the 
brainstem and hypothalamus. It also co-exists with GABA, NA and 5-HT (Melander 
et al., 1986). Its receptors (GalR-1, GalR-2 and GalR-3) are widely distributed, 
including the PVN, LH, VMH, AMY and NTS (Waters & Krause, 2000).  
Although central administration of galanin into the PVN and NTS has been found to 
increase feeding behaviours (Koegler & Ritter, 1998; Schick et al., 1993), genetic 
models of over-expression or KO have failed to produce a phenotype characterised 
by altered food intake or bodyweight (Hohmann et al., 2003). However, galanin may 
have a preferential effect on macronutrient intake. For example, PVN administration 
of galanin increases fat intake, while galanin antagonists injected into the PVN 
reduce fat intake (Leibowitz & Kim, 1992; Nagase et al., 2002).  
Galanin-like peptide (GALP), a 60-amino-acid peptide, is structurally similar to 
galanin and is identical for first 13 amino-acids (Ohtaki et al., 1999). GALP 
expression, unlike that of galanin, is primarily limited to the basomedial ARC and 
DMH (Jureus et al., 2000; Larm & Gundlach, 2000). GALP is able to interact with 
the same receptors as galanin, although it has a higher affinity for GalR-3 (Lang et 
al., 2005). However, as GalR-2/3 agonists fail to elicit any change in feeding 
behaviours (Man & Lawrence, 2008), these receptors are not those that mediate 
GALP’s action on food intake. At present, the identity of the latter remains unknown 
(Parker & Bloom, 2012). 
Initial studies demonstrated ICV injection of GALP stimulates food intake with a 
much greater potency than galanin itself (Matsumoto et al., 2002). However, further 
investigation revealed that, while central administration of GALP stimulated feeding 
over a 2h period, it reduced bodyweight and food intake over 24-h (Lawrence, 
Baudoin, et al., 2002). Some theories propose that GALP may initially act upon 
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galanin receptors, but that subsequent anorectic effects are a result of stimulation 
of an unidentified GALP receptor (Krasnow et al., 2003). This pattern might also 
suggest that GALP’s action is biphasic in nature, a proposal supported by germline 
knock-out mice which exhibit no specific phenotype (Dungan Lemko et al., 2008).  
1.5.4.2 Melanin-concentrating hormone 
Melanin-concentrating hormone (MCH) is a cyclic 19-amino-acid neuropeptide. 
Initially discovered in chum salmon pituitaries as a regulator of skin colour change 
(Nahon, 1994), it is cleaved from the precursor prepro-MCH (ppMCH) found 
primarily in the LH (Bittencourt et al., 1992). MCH acts at two types of G-protein 
coupled receptor; MCH-1R and MCH-2R. MCH has higher affinity for MCH-2R, 
which widely distributed in the hippocampus, AMY and cerebral cortex of humans 
although, interestingly, it is not present in rodents. MCH-1R is expressed 
predominantly in pituitary tissue and GH cell adenomas. 
MCH is orexigenic when administered centrally, and studies show that fasting 
increases MCH expression (Georgescu et al., 2005; Qu et al., 1996). Conversely, 
MCH antagonist administration has anorectic effects (Della-Zuana et al., 2012; 
Verty et al., 2013). However, it should be noted that MCH antagonism also results 
in increased locomotor activity and energy expenditure (Borowsky et al., 2002), 
suggesting that effects on feeding behaviour may be secondary.  
As would be expected, genetic studies have shown that mice over-expressing MCH 
display hyperphagia and increased bodyweight (Ludwig et al., 2001), while global 
MCH knockout mice exhibit hypophagic phenotypes and are 28% lighter than the 
wild-type controls (Shimada, 1998). Similar findings are seen with specific MCH 
neuron ablation (14% reduction in bodyweight; Alon & Friedman, 2006). 
Interestingly, rats lacking MCH display reduced operant responding for high fat 
foods (Mul et al., 2011). Conversely, MCH administration has been found to 
increase the hedonic value of sweet foods (Lopez et al., 2011), suggesting that this 
peptide may also play a role in the hedonic aspects of feeding. 
1.5.5  Summary 
An understanding of the neurobiology of appetite in normal circumstances is critical 
in characterising clinical disturbances of appetite regulation, such as obesity. 
Effective manipulation of the systems that regulate appetite are critical for the 
development of novel therapeutics. 
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Chapter 2 Obesity: Prevalence and Treatment 
Advances in our understanding of the basic neurobiology of appetite (see Chapter 
1) are important not only for their own sake but also because of their potential to 
inform therapeutic innovation for disorders such as obesity. 
2.1 The obesity problem 
Obesity is the excessive accumulation of body fat a condition currently diagnosed 
using the body mass index (BMI). BMI is a measure of body fat based on height 
and weight, that defines people as overweight if their BMI is greater than 25 kg/m2, 
and obese when it is greater than 30kg/m2 (WHO., 2013). It is pertinent to note that 
BMI alone cannot always accurately portray a patient's risk. BMI can be 
misleadingly dependent on levels of muscle tissue, or oedema. However, the more 
accurate methods to measure body fat, such as air displacement, bioelectrical 
impedance, dual-energy x-ray absorptiometry, and skin fold calipers, also have 
limitations and are not currently used in clinical practice (Burkhauser & Cawley, 
2008). 
Obesity has reached global epidemic (i.e pandemic) proportions. As of 2008, more 
than 1.4 billion adults were overweight, of whom 200 million men and nearly 300 
million women were obese (WHO., 2013). The incidence of obesity in children is 
also on the rise; in 2011, more than 40 million children under the age of five were 
overweight (WHO., 2013). Obesity is a growing concern in children and 
adolescents, due to the serious long-term health and psychological consequences 
(Adair, 2008; Franks et al., 2010; Reilly & Kelly, 2011). Children exhibiting weight 
gain and those who are exposed to unhealthy eating habits have a greater risk of 
obesity in later life. The “developmental origin hypothesis” (Volkow & O'Brien, 2007) 
suggests calorie content and nutrient exposure, as early as pregnancy, can alter 
how the brain and body develop in anticipation of future environment. Therefore, 
even foetal exposure to high fat foods can lead to obesity through the selection of 
similar nutrients in later life (Anzman et al., 2010).  
Obesity is not just a cosmetic problem. The health ramifications for overweight and 
obese people are serious and potentially life-threatening. Obese patients 
experience day-to-day problems with back pain and osteoarthritis (Lean et al., 
1998), in addition to sleep apnea and breathing problems, associated with the 
excess fat reducing lung volume (Kopelman, 2007). Obesity is a major risk factor in 
the development of: chronic metabolic disorders, such as type-2 diabetes and 
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hypertension; some cancers, such as endometrial, breast, and colon; 
musculoskeletal disorders, especially osteoarthritis; and cardiovascular diseases, 
primarily heart disease and stroke (Kopelman, 2007; WHO., 2013). It has been 
estimated that obesity can reduce life expectancy by up to 20 years (Fontaine et al., 
2003). 
Furthermore, the financial costs of obesity are huge. In England, it has been 
estimated that the annual cost of obesity and its consequences is £3.3 – 3.7 billion, 
increasing to £6.6 – 7.4 billion when including overweight patients. That is roughly 
equivalent to 2.5% of the total net NHS expenditure in 2001/2002 (Commons, 
2004). Effective interventions that can reduce bodyweight and decrease the 
prevalence of obesity-related diseases in the long-term are therefore essential. 
2.2 Treatment Options 
Current options for the treatment of obesity include lifestyle interventions (dieting, 
exercise and behavioural therapies), surgical procedures (mal-absorptive and 
restrictive), and pharmacotherapy (see reviews: Brown et al., 2009; Wyatt, 2013). 
2.2.1 Lifestyle Interventions 
Energy balance is the key to obesity treatment. A positive energy balance occurs 
when the calories consumed exceed those used through metabolism and exercise; 
this leads to weight gain and obesity. Interventions that encourage a negative 
energy balance, whereby calories are restricted or energy expenditure is increased, 
have the potential to reduce obesity and associated risk factors (see reviews: 
Douketis et al., 2005; Wadden et al., 2012). 
2.2.1.1  Diet  
The “thrifty genotype” hypothesis (Neel, 1999) states that evolution has shaped the 
way that our bodies access and store food. It proposes that our ancestors lived with 
limited resources, and that we therefore evolved to maximise our intake at every 
possible opportunity in order to avoid a nutritional deficit and death. This helps 
explain increased food consumption in the modern world, where there is a surplus 
of palatable, high fat and energy dense foods (Holt, 2005).  
Diet modification therapies aim to restore energy balance and decrease bodyweight 
via food restriction and the reduction of caloric intake (Astrup et al., 2002). Diet 
therapies typically reduce caloric intake by 600 kcal/day (LCD; low calorie diet), or 
up to 800kcal/day (VLCD; very low calorie diet; Astrup et al., 2000). A caloric deficit 
of 500-1000 kcal/day could enable a loss of 0.5-1.0 kg/week to achieve a 10% 
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reduction in bodyweight over 6 months of therapy. An average loss of 10kg is 
usually observed over 6 months (Health, 2000). Dietary interventions vary in the 
method by which they achieve calorie restriction. For example, some reduce portion 
size (Rolls et al., 2002), while others emphasise calorie counting or manipulate the 
specific macronutrient intake, such as low dietary fat (Bray & Popkin, 1998), low 
carbohydrate (Saris et al., 2000), low sugar (Ebbeling et al., 2006), low glycemic 
and high protein (Martens et al., 2013) and mediterranean (Hedner et al., 2013) 
diets. 
Despite the range of dietary interventions, the best predictor for weight loss is not 
the specific programme but adherence to the diet (Dansinger et al., 2005; Webber 
et al., 2010). As such, dietary interventions generally only exhibit short-term 
success. Patients reach maximum weight loss at 6 months and then regain the 
weight for non-significant outcomes at 24-36 months, possibly due to compensatory 
eating following restricted intake (Franz et al., 2007; Littman et al., 2005). 
2.2.1.2 Exercise 
A decline in manual labour and the increase in sedentary lifestyle has also 
contributed to the prevalence of obesity (Holt, 2005). Physical activity interventions 
increase levels of exercise to roughly 30-60mins of moderate-to-intense exercise 
(500kcal per session) 5-7 days a week (Donnelly et al., 2009). This reduces 
sedentary time and promotes energy expenditure and weight loss, in addition to 
direct and indirect benefits to other parameters including reducing the risk of 
chronic diseases and adverse health conditions, such as type 2 diabetes, 
cardiovascular diseases, osteoporosis, and some cancers (Fang et al., 2003; 
Gorely et al., 2011; Kriska et al., 2003; Sesso et al., 2000; Wannamethee & Shaper, 
2001). As increases in physical activity alone produce minimal weight reductions 
(Franz et al., 2007; Jakicic & Otto, 2005), exercise therapies are thought to be more 
beneficial in the maintenance of weight loss (Catenacci & Wyatt, 2007; Jakicic et 
al., 2008; Turk et al., 2009; Wing & Hill, 2001). Therefore, lifestyle therapies should 
be used in conjunction with exercise to achieve the maximal effects (Foster-
Schubert et al., 2012; Hill & Astrup, 2003). Although, more recent literature has 
suggested that the disappointing outcomes from weight loss interventions can be 
largely explained by the huge inter-individual variability in predictors and correlates 
of outcomes (Stubbs et al., 2011), therefore the perceived failure of these 
interventions may be improved by the use of a more individualized approach. 
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2.2.2 Behaviour Therapy 
Socio-economic status, occupation and individual experiences all influence 
psychological food-related beliefs, preferences and behaviour (Kumanyika, 2008). 
Furthermore, theories such as the “Berridge model of food reward” (Berridge, 1996) 
propose that overconsumption is a result of “hedonic hunger” as opposed to 
“metabolic hunger” (Lowe & Butryn, 2007). This is considered by some to be similar 
to ‘need’ states seen in drug users (Cota et al., 2006). Thus, driven by the incentive 
salience of food sources (wanting), and the appealing taste of food (liking), the 
motivation to eat is enhanced (Finlayson et al., 2007; Volkow & Wise, 2005).  
Behaviour therapy is based on these theories and focuses on the differentiation 
between food hunger and appetite, as well as psychological concepts of target 
attainment, self-monitoring through the use of food and exercise diaries, problem-
solving and stimulus control. Behaviour therapy can teach obese patients about 
social and environmental cues, and provide skills to modify bad habits to avoid 
undesirable eating (snacking), such as stress management, contingency 
management, and cognitive restructuring (Lang & Froelicher, 2006). With 
counselling, obese patients can achieve modest but clinically signiﬁcant (3 to 5 kg), 
sustained (1 to 2 years) weight loss (Appel et al., 2011; Keranen et al., 2009), in 
addition to improvements in stress eating (Daubenmier et al., 2011) and life 
satisfaction (Niemeier et al., 2012). 
2.2.3 Surgical Interventions 
Research has shown that lifestyle therapies (dieting, exercise and psychological 
therapies) are not always effective in the long-term maintenance of weight loss 
(Klein et al., 2004). An alternative option for those with morbid obesity (BMI≥40 or 
BMI≥35 with significant co-morbidities) is bariatric surgery. There are typically four 
surgical procedures available, which are categorised into ‘restrictive’ (1+2) and 
‘mal-absorptive’ procedures (3,4+5). These include: (1) gastric banding, (2) 
gastroplasty (3) gastric bypass, (4) gastrectomy and (5) biliopancreatic diversion 
(aka. duodenal switch). 
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Figure 2-1: Diagram of Surgical Treatment Options 
The diagram shows: (1) gastric banding, a small band is placed around the top of the stomach 
to restrict the size of the opening from the throat to the stomach; (2) gastric bypass; whereby 
food is sent directly into the small intestine affecting food absorption; (3) gastrectomy, whereby 
most of the stomach is removed; (4) bilopancreatic diversion, whereby food is re-routed away 
from the small intestine to limit how the body absorbs food (Pories, 2011). 
The percentage of excess weight loss at the outcome point for surgery is much 
higher than those seen for lifestyle interventions. On average, a 61.2% reduction in 
excess weight, a 14.2 decrease in BMI and a 39.7kg absolute weight loss can be 
seen following a surgical procedure. More specifically, 47.5% of excess weight is 
lost after a gastric banding, 61.6% after a gastric bypass; 68.2% after a gastroplasty 
and 70.1% after a biliopancreatic diversion or duodenal switch (Buchwald et al., 
2004). 
Obesity interventions have traditionally focused on weight loss outcomes (Balsiger 
et al., 2000), but recently there has been a change of emphasis to the metabolic 
improvements, such as those seen post-surgery (Pories et al., 1995). Patients see 
improvements in diabetes (76.8% maintain a normal blood glucose level), 
hyperlipidemia (a total population decrease in cholesterol levels), hypertension 
(resolved in 61.7%), obstructive sleep apnea (resolved in 85.7%), and longevity 
(80% decrease in annual mortality; Buchwald et al., 2004; Sjostrom et al., 1998). 
Furthermore, these changes in metabolic profile can be seen in moderately obese 
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patients who exhibit little weight loss, suggesting that these metabolic changes 
have no direct link to weight loss (Kashyap et al., 2013). 
However, there are a wide variety of risk factors associated with surgical 
interventions. The typical side-effects include; pain, wound infection, anxiety, 
complications and the risk of reoperation, due to the wearing away or breakdown of 
gastric bands or staple lines. In fact, 10-20% of patients who undergo weight-loss 
surgery require follow-up procedures to correct complications (Beyond, 2012). Such 
complications include gastrointestinal leaks and dumping syndrome (whereby 
stomach contents move too rapidly through the small intestine, producing 
symptoms such as nausea, weakness, faintness and diarrhoea). Nutritional 
deficiencies are also a common side-effect of mal-absorptive procedures, with up to 
75% of patients who undergo bariatric surgery developing nutritional deficiencies 
such as anaemia, osteoporosis and metabolic bone disease (Davies et al., 2007; 
Xanthakos & Inge, 2006). 
However, despite the risks, the outcomes for surgical procedures are generally 
more significant and enduring than with other interventions, not just for weight loss 
but for quality of life measures as well (Fontaine, 2001; Karlsson et al., 1998). Over 
a 10-year period, surgically-treated subjects exhibited greater weight loss, more 
physical activity, and lower energy intake than control subjects (Sjostrom et al., 
2004). It is thought that the improved outcomes for bariatric surgery over the more 
traditional lifestyle interventions are associated with a change in gut hormone 
profiles (Mingrone et al., 2012; Schauer et al., 2012). More specifically, surgery is 
associated with decreased ghrelin and insulin levels and increased levels of PYY 
and GLP-1 (Chronaiou et al., 2012; le Roux et al., 2006; Thomas & Schauer, 2010), 
resulting in reduced appetite and adiposity signalling. 
2.2.4 Pharmacological Interventions 
Although lifestyle modifications remain the cornerstone of anti-obesity intervention, 
they only produce short-term weight loss, with patients experiencing significant 
weight regain after two years (Rossner et al., 2000; Wadden, 2004). Consequently, 
current guidelines advocate the use of adjunct pharmacotherapy (NHMRC, 2003). 
2.3 An Historical Perspective  
The guidelines for the development of anti-obesity drugs are issued by the FDA and 
EMEA (European Medicines Evaluation Agency). The clinical endpoint for approval 
of anti-obesity drugs is maintained weight loss for one year post-cessation of 
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treatment. To be clinically meaningful, weight reduction must be ≥5% (placebo 
subtracted; USA) and >10% of baseline weight which is also ≥5% than that of the 
placebo (Europe). Furthermore, 35% of patients must achieve this outcome in 
addition to improvements in secondary endpoints, such as cardiovascular factors; 
blood pressure, lipids, glycemia and, in Europe, improvements in waist-hip ratio, 
sleep apnea episodes and quality of life parameters (EMEA, 2006; FDA, 2007). 
As early as the 19th century, sheep thyroid extract was used to increase metabolic 
rate and induce weight loss (Colon-Gonzalez et al., 2013). However, it was also 
associated with cardiac arrhythmias and cardiac arrest (Bhasin et al., 1981). Later, 
in the 1930s, 2,4-dinitrophenol (an Adenosine-5'-triphosphate (ATP) inhibitor; ATP 
transports chemical energy within cells for metabolism) was introduced as a weight-
loss drug, but was discontinued as it caused cataracts, dermatitis, and fatal 
hyperthermia (Valentino et al., 2010). Then, in the 1940s-1950s, amphetamine-like 
compounds were found to suppress appetite (Macphail & Gollub, 1974), and were 
approved in the USA. Amphetamines are sympathomimetics, increasing locomotor 
activity and decreasing food intake. However, the high incidence of tachycardia and 
hypertension, in addition to abuse potential led to the development of alternatives, 
continuing into the 1970s when phentermine (Achiphex®), benzphetamine 
(Didrex®), phendimetrazine (Bontril®, Plegine®; Statobex®), mazindol 
(Mazanor®, Sanorex®), methamphetamine (Desoxyn®), and diethylpropion 
(Tenuate®, Dospan®), were approved. See Table 2-1 for an overview of the drugs 
historically approved for obesity treatment, and Table 2-1 for a more detailed 
overview of the main anti-obesity drugs over the last 60 years. 
Around the same time, a sympathomimetic amine phenylpropanolamine (PPA), 
present in cough and cold remedies, was commonly used as an appetite 
suppressant. However, this was linked to intracranial bleeding and strokes (Kernan 
et al., 2000) and, in 2005, the FDA removed it from all over-the-counter products 
(FDA, 2005). Interestingly, PPA is still available in prescription decongestants 
(Rinexin®) in Europe and its use is completely unrestricted in the United Kingdom.  
The 1980-90s saw the development of serotonergic agents, such as fenfluramine 
(Pondimin®) and dexfenfluramine (D-fenfluramine; d-FEN; Redux®). These 
agents increased satiety by stimulating the release and inhibiting the reuptake of 
serotonin (5-HT; for a more detailed review of serotonergic agents see Chapter 6 
and Halford et al., 2011; Rowland & Carlton, 1986). Although structurally similar to 
amphetamines, these monoamine-releasing drugs were predicted to have “lower 
liability for psycho-stimulant abuse” (Heal et al., 2009). However, there remained 
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the problem of adverse cardiovascular side-effects (Bays, 2004) such as pulmonary 
hypertension and cardiac valvulopathy (Abenhaim et al., 1996). Thus, despite the 
perceived success of phentermine and fenfluramine (so called ‘Phen-fen’), a 
combination widely prescribed "off-label" for the long-term management of obesity 
(FDA, 1997b), the FDA announced their withdrawal from the market in 1997 
(Connolly et al., 1997; Heal et al., 2009). Regardless of adverse side-effect profiles, 
these drugs clearly emphasised the importance of the serotonergic system in 
appetite regulation.  
Table 2-1: History of drugs for the treatment of obesity 
Adapted from: (Adan, 2013; Colon-Gonzalez et al., 2013; Powell et al., 2011). Off-Label Usage: 
prescribed for an alternative usage 
Drug FDA Approval FDA Withdrawal 
Phentermine May-1959 Present (U.S only) 
Amphetamine Off-Label Usage 
Dextroamphetamine Off-Label Usage 
Methamphetamine Off-Label Usage 
Phenylpropanolamine Off-Label Usage (Europe only) 
Benzphetamine Oct-1960 
 
Deithlpropion Aug-1959 
 
Phendimetrazine Sep-1982 
 
Dexfenfluramine Jun-1973 Sep-1997  
Fenfluramine Apr-1996 Sep-1997 
Bupropion Off-Label Usage 
Desvenlafaxine Off-Label Usage 
Sibutramine Nov-1997 Oct-2010 
Rimonabant 01/06/2006 Oct-2008 
Topiramate Off-Label Usage 
Orlistat Apr-1999 Present 
Exenatide Off-Label Usage 
Liraglutide Off-Label Usage 
Alogliptin Off-Label Usage 
Saxagliptin Off-Label Usage 
Sitagliptin Off-Label Usage 
Vildagliptin Off-Label Usage 
Pramlintide Off-Label Usage 
Lorcaserin 2012 Present (U.S only) 
Qsymia  
(phentermine and topiramate) 
2012 Present (U.S only) 
 
Subsequently, sibutramine (see Chapter 6; Meridia®, Reductil®), a centrally-
acting dual serotonin and noradrenaline reuptake inhibitor, was introduced to the 
market in 1997. In preclinical studies, it demonstrated its action to reduce food 
intake both acutely (Luque & Rey, 1999) and chronically (Wirth et al., 2001). In 
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chronic clinical studies, sibutramine reduced bodyweight by at least 5% in 56% of 
patients over a one year trial (Smith et al., 2001). However, data from the 
Sibutramine Cardiovascular Outcome Trial (SCOUT; James, 2005) showed an 
increased risk of serious, non-fatal cardiovascular events, such as stroke or heart 
attack (EMEA, 2010) and, in January 2010, sibutramine was suspended from the 
market (FDA, 2011). 
More recently, a selective cannabinoid-1 (CB1) receptor inverse agonist, 
rimonabant (see Chapter 4; also known as SR141716; trade name: Acomplia®) 
was approved for the treatment of obesity in Europe. The placebo-subtracted 
weight loss for rimonabant ranged from 3.9 kg to 5.4 kg, with up to 58% of subjects 
losing ≥5% of their baseline bodyweight (Aventis, 2007). However, 
recommendations to the FDA suggesting a link with severe adverse psychiatric 
side-effects (MHRA, 2008a), such as depression and anxiety (Hill & Gorzalka, 
2005), led to the withdrawal of rimonabant from the market in October 2008 
(MHRA, 2008b). The prevalence of depression and suicide rose not only in patients 
already suffering mild symptoms, but also in patients with no history of mental 
illness (Gadde & Allison, 2006; Moreira & Crippa, 2009). These actions triggered 
Sanofi-Aventis to terminate studies on rimonabant. Nevertheless, the development 
of other CB1 receptor antagonists has continued (see reviews: Bermudez-Silva et 
al., 2010; Cluny et al., 2011; Kunos et al., 2009). 
In view of these developments and until recently, there was only one drug approved 
for the long-term treatment of obesity; Orlistat (Xenical®, Alli™; WHO, 1999). 
Orlistat is an irreversible lipase inhibitor that prevents the absorption of up to 30% of 
digested fat (Bray & Greenway, 2007). A two-year placebo controlled randomised 
study found that doses of 60mg and 120mg per day reduced weight by 6.8kg and 
7.6kg, respectively, compared to only 4.3kg in the placebo condition (Rossner et al., 
2000). Recently, however, there have also been questions over the safety of 
orlistat. In addition to the undesirable gastrointestinal effect of steatorrhea, the FDA 
released a warning in May 2010 regarding the prevalence of liver injuries in patients 
taking orlistat. Furthermore, Public-Citizen (a consumer advocacy group and drug 
safety watchdog) requested the ban of orlistat in 2011. They cited data on 
increased incidence of liver toxicity, pancreatitis and liver stones in orlistat patients 
(Citizen, 2011; Weir et al., 2011). 
In 2012, the FDA approved the marketing and distribution of two novel drug 
treatments for obesity. In late June, lorcaserin (see Chapter 6; Belviq®), a 
selective 5-HT2c receptor agonist, was approved (as an adjunct to a reduced calorie 
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diet and exercise) for the management of chronic weight in obese and overweight 
adults with at least one weight related co-morbidity. Those receiving lorcaserin lost 
up to 6kg of bodyweight from baseline compared to placebo (~3kg), with 47% of 
subjects losing ≥5% bodyweight from baseline (Smith et al., 2010). This new drug 
had previously reached phase II/III trials but the FDA had initially denied it due to its 
association with tumour formation and the relatively low weight loss outcomes in 
rodent preclinical screeing (Arena, 2010). However, more recent trials demonstrate 
that the most common side-effects of lorcaserin in non-diabetic patients are 
headaches, fatigue, nausea, dry mouth, and constipation (FDA, 2012). 
Then, in mid-July 2012, Qsymia® (a.k.a. Qnexa; Topiramate plus Phentermine) 
was approved. The exact mechanism by which it acts is not fully understood, but 
may involve GABA receptors, inhibition of carbonic anhydrase, and antagonism of 
glutamate (Vivus, 2008). The first “Equate” trial elicited an impressive 9kg weight 
loss using the full dose over 28 weeks (Vivus, 2008). The second “Equip” trial, 
achieved up to 12kg weight loss on the full dose over 56 weeks (Vivus, 2009), and 
the third “Conquer” trial produced similar weight loss, in addition to dose-dependent 
reductions in blood pressure, triglycerides and HbA1C (a measure of blood 
glucose). An average weight loss of 10% was seen in ≥60% of participants 
(Kennett, 2010). However, the highest dose was also associated with increased 
heart rate (Vivus, 2010). Although it had previously been rejected by the FDA due 
to concerns about birth defects, heart palpitations and suicidal thoughts (Vivus, 
2010), the more accepted side-effects of Qsymia now comprise dry mouth, 
constipation, altered taste and insomnia (Powell et al., 2011).  
Table 2-2: Summary of the main anti-obesity treatments developed over the past 60 
years 
Adapted from: (Adan, 2013; Dietrich & Horvath, 2012; McGavigan & Murphy, 2012) 
Drug Mechanism of Action Side-effects 
Mean 
Weight loss 
(Drug minus 
Placebo) 
Phentermine Noradrenaline releaser 
Valvular heart disease and 
pulmonary hypertension 
4.0kg 
Fenfluramine Serotonin releaser 
 
2.4 kg 
Sibutramine 
Serotonin/noradrenaline reuptake 
inhibitor 
Increased risk of stroke and 
myocardial infarction 
4.2 kg 
Rimonabant CB1 receptor antagonist Depression and Anxiety 4.7 kg 
Orlistat 
Gastric and pancreatic lipase 
inhibitor 
Fatty and oily stools 3.0 kg 
Lorcaserin Serotonin 2C agonist 
Dizziness, headache and 
insomnia 
4.8 kg 
Qsymia 
(phentermine 
and topiramate) 
Noradrenaline releaser and anti-
convulsant 
Dizziness, headache and 
insomnia 
12.2 kg 
48 
 
2.4 Recent developments of anti-obesity treatments 
(Monotherapy) 
The above overview demonstrates that, despite the scale of the problem, the 
treatment options for obesity are limited. The global epidemic of obesity has 
outpaced the pharmaceutical industry’s ability to develop new and safe drugs. 
Before the FDA/EMEA can approve any drug treatments, they must have 
completed all the phases of clinical research. Firstly, potential compounds must go 
through preclinical testing which is done primarily, although not exclusively, in 
rodent models. The aim of this phase is to assess the pharmacodynamics, 
pharmacokinetics and toxicity of the compound. Further preclinical testing is then 
used to establish a behavioural profile and a safe dose range for development into 
clinical testing, of which there are four phases. In Phase I, the experimental 
treatment is given to a small sample (20-80 subjects) of healthy volunteers to 
assess safety, dose-range and side-effect potential. In phase II, the treatment is 
administered to a larger clinical sample (100-300 subjects) and, in Phase III, an 
even larger sample (1,000-3,000 subjects) with long-term follow up. These phases 
continually assess the safety profile and confirm its efficacy in reducing a variety of 
parameters including mortality rates. Phase IV is the final, post-marketing, phase 
which is used to confirm the risks and benefits of the drug and assess its optimal 
use (ABPI, 2013). See Table 2-3 for a summary of the potential treatments, 
currently undergoing clinical testing (see recent reviews; Adan, 2013; Carter et al., 
2012; Colon-Gonzalez et al., 2013; Kennett & Clifton, 2010; Rodgers et al., 2012).  
2.4.1 Central signalling 
2.4.1.1 Melanocortin system 
As discussed in Chapter 1, the melanocortin system consists of the primary 
anorectic and orexigenic centrally-acting neuropeptides, POMC and NPY. The use 
of NPY antagonists as anti-obesity drugs is in development. In view of the 
evidence implicating Y1 and Y5 receptors as critical to the orexigenic actions of 
NPY, NPY5 antagonists, such as velnepreit (S-2367), have been found to produce 
significant weight loss in patients during phase II trials; ≥5% weight loss in 35% of 
subjects (Shionogi, 2011). These changes are accompanied by improvements in 
additional parameters such as waist circumference and lipid panels (Shionogi, 
2011). In contrast, another NPY5 receptor antagonist (MK-0557) has been 
abandoned due to the lack of clinically significant weight loss (Erondu et al., 2006). 
On the other hand, NPY receptor agonist and pancreatic polypeptide analogues; 
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obinepitide (Y2/Y4 receptor agonist) and TM30339 (Y4 agonist) are currently in 
phase II (Colon-Gonzalez et al., 2013).  
A variety of drug discovery programmes have focused on the development of a 
MC4R agonist for the treatment of obesity. First in this series was bremelanotide, 
derived from melanocortin. However, this comound was largely associated with 
flushing, nausea, vomiting and, in some cases, hypertension (Wikberg & Mutulis, 
2008). More recently, the MC4R agonist MK-0493, has been found to be effective 
in preclinical trials. However, it has failed to produce significantly relevant outcomes 
in phase II (Krishna et al., 2009). Another MC4R agonist, RM-493, is currently 
undergoing preclinical trials (Rhythm, 2011). It is pertinent to note that there are 
likely to be approval problems with compounds that affect cardiovascular and 
sexual function, such as MC4R agonists (Wikberg & Mutulis, 2008).  
Similarly, MCH-1 antagonists (BMS-830216 and ALB-127158(a)) are currently 
undergoing clinical testing (see review: AMRI, 2011; BMS, 2011; Macneil, 2013). 
Although phase II results for BMS-830216 have not yet been released, findings 
from ALB-127158(a) phase I are positive. However, another MCH antagonist, NGD-
4715, was withdrawn from clinical trials due to sleep disturbances and vivid dreams 
(Sargent & Moore, 2009).  
AgRP and α-MSH play an integral role in food intake and bodyweight. Based on the 
principle that an imbalance of both these neuropeptides is seen in obese subjects, 
the inhibition of AgRP may be of therapeutic benefit in treating obesity. As such, the 
AgRP antagonist, TTP435, is currently undergoing phase II trials (ClinicalTrials.gov, 
2013). 
2.4.1.2 Monoamine systems 
In the past, drugs targeting the serotonergic system (e.g. fenfluramine) have shown 
some success in the regulation of appetite (see Section 2.3 and Chapter 6). Of the 
fourteen currently recognised 5-HT receptor subtypes 5-HT1b, 5-HT2c and 5-HT6 are 
currently considered viable targets for obesity drugs. The problem with the 
previously mentioned serotonergic drugs is their lack of selectivity, and side-effect 
profile. In addition to targeting receptors for weight modulation, they also produce 
cardiovascular problems via 5-HT2B receptor mechanisms (Elangbam, 2010). 
Lorcaserin is an example of a more selective 5-HT2c receptor agonist that doesn’t 
exhibit side-effects such as valvulopathy. Additionally, a number of selective 5-HT6 
receptor agonists have been developed (Heal et al., 2008), although these are 
currently targeted at Alzheimer’s disease.  
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Table 2-3: Summary of the monotherapies currently under investigation 
Adapted from: (Adan, 2013; Chugh & Sharma, 2012; Colon-Gonzalez et al., 2013; Rodgers et 
al., 2012) 
Drug Company 
Clinical 
Phase 
Mechanism of Action 
Tesofensine NeuroSearch Phase III 
Serotonin/noradrenaline/dopamine reuptake 
inhibitor 
Liraglutide NovoNordisk Phase III GLP-1R agonist 
Cetilistat Alizyme Phase III Lipase inhibitor 
Metreleptin Amylin/Takeda Phase III Leptin receptor agonist 
Velneperit Shionogi Phase II Y5 receptor antagonist 
Pramlintide Amylin Phase II Amylinomimetic 
KRP-204 Kyorin Phase II Selective B3-adrenoceptor agonist 
ATHX-105 Athersys Phase II 5-HT2c receptor agonist 
BMS-830216 Bristol Myers Squibb Phase II MCH1 receptor antagonist 
MK-0493 Merck Phase II Selective MC4R agonist 
TM30339 7TM Phase II Selective Y4 receptor agonist 
TTP435 TransTech Pharma Phase II AgRP inhibitor 
MK-0557 Merck Phase II Y5 receptor antagonist 
HPP404 TransTech Pharma Phase II Histamine H3 receptor antagonist 
SCH-497079 Schering-Plough Phase II Histamine receptor antagonist 
Vanoxerine ChanRx Phase II Dopamine reuptake inhibitor 
Exenatide Amylin Phase II GLP-1R agonist 
Davalintide Amylin Phase II Amylin mimetic 
GI 181771X GlaxoSmithKline Phase II CCK-A agonist 
CYT009-GhrQb Cytos Phase II Ghrelin vaccine 
Cabergoline Pfizer Phase II Long-acting D2 receptor agonist 
PYY3-36 Merck/Pfizer/Nastech Phase I/II Y4 and Y2 receptor agonist 
PYY3-36/SNAC Emisphere Phase I/II Y4 and Y2 receptor agonist 
BVT.74316 Biovitrum Phase I 5-HT2C receptor agonist 
PRX-07034 EPIX Pharma Phase I 5-HT6 receptor antagonist 
ALB-127158(a) AMRI Phase I MCH 1 antagonist 
GSK598809 GlaxoSmithKline Phase I Dopamine (D3) antagonist 
NOX-B11 Pfizer/Nozzon Phase I Bind and inhibit ghrelin 
NN9924 Novo Nordisk Phase I GLP-1R agonist 
Oxyntomoduline Prolor Phase I GLP-1R agonist; OXM mimetic 
TKS1225 Thiakis/Wyeth/Pfizer Phase I GLP-1R agonist; OXM mimetic 
PP1420 Wellcome Trust Phase I Pancreatic polypeptide analogue 
ZGN-433 Zafgen Phase I Methionine aminopeptidase 2 inhibitor 
AZD7687 AstraZeneca Phase I Diglyceride acytransferase inhibitor 
AZD8329 AstraZeneca Phase I llp-HSD1 inhibitor 
INCB13739 Incyte Phase I llp-HSD1 inhibitor 
AZD4017 AstraZeneca Phase I llp-HSD1 inhibitor 
Maraviroc Pfizer Phase I Selective chemokine receptor CCR5 antagonist 
Betahistine OBEcure Ltd Phase I 
Histamine H1 receptor agonist with partial H3 
antagonistic activity 
A331440 Abbott Labs Preclinical Histamine H3 receptor antagonist 
AEZS-123 Aeterna Zentaris Preclinical Ghrelin receptor antagonist 
Fumagillin Zafgen Preclinical Methionine aminopeptidase 2 inhibitor 
RM-0493 Merck Preclinical MC4R agonist 
Ezlopitant Pfizer Preclinical Neurokinin receptor-1 antagonist 
STO-609 Merck Preclinical Calmodulin-dependent protein kinase 2 inhibitor 
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Dopamine stimulation is associated with increases in palatable food intake (see 
Chapter 5) and more recent research using fMRI methodology has assessed the 
effect of the selective D3 antagonist, GSK578809, on food reward in obese and 
overweight individuals (Colon-Gonzalez et al., 2013).  
As discussed above, the majority of drugs that act upon noradrenaline systems, 
such as amphetamine-related compounds, also have sympathomimetic and 
psychostimulant properties (Craddock, 1976). Therefore, the use of these drugs 
has been discontinued. More recently, compounds that utilise the noradrenergic 
system in combination with the other monoamine systems have been developed. 
Older, examples include phentermine (noradrenaline and dopamine reuptake 
inhibitor), sibutramine (noradrenaline and 5-HT reuptake inhibitor), and bupropion 
(noradrenaline and dopamine reuptake inhibitor; see Chapter 5). Tesofensine 
(NS2330) is a novel serotonin–noradrenaline–dopamine reuptake inhibitor. 
Originally developed for Alzheimer and Parkinson patients, phase II trials in 
predominantly non-obese patients found modest placebo-adjusted weight loss 
(Astrup, Meier, et al., 2008). Phase II trials have shown all doses to differ 
significantly on intake and bodyweight parameters compared to placebo after 
24weeks (Astrup, Madsbad, Breum, Kroustrup, et al., 2008). The highest dose of 
tesofensine tested resulted in ≥10kg weight loss in 74% of patients compared to 7% 
in a dietary control group (Astrup, Madsbad, Breum, Kroustrup, et al., 2008). 
Adverse side-effects include dry mouth, nausea, dizziness, constipation, and 
abdominal pain. Another concern is that, in phase II clinical trials, there was a 
notable increase in heart rate and blood pressure at the highest dose (Astrup, 
Madsbad, Breum, Jensen, et al., 2008). Despite the latter reports, this compound 
has currently reached clinical trial phase III (Neurosearch, 2011).  
Research has shown that histamine3 receptor activation blocks histamine synthesis 
and release. Preclinical trials of histamine3 receptor antagonists, such as A331440, 
have found reduced intake and bodyweight in mice on high-fat diets (Hancock et 
al., 2004; Hancock & Brune, 2005). Other histamine receptor antagonists, HPP404 
and SCH497079 have reached phase I and phase II, respectively.  
2.4.2 Peripheral peptide signals 
As discussed in Chapter 1, diverse peptide and adiposity signals interact in the gut 
and the hypothalamus to control energy homeostasis and appetite. They modulate 
peripheral physiology (the storage and metabolism of digestive products), and 
signal nutritional status to the brain. Therefore, the manipulation of these signals 
may be the key to the effective treatment of obesity. 
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Ghrelin administration increases food intake. However, ghrelin neutralising RNA 
(NOX-BII-2) has provided non-significant results in the treatment of obesity (Moran 
& Dailey, 2009). Although prototype ghrelin vaccines (CYT009-GhrQb) have also 
shown non-significant effects, some second generation vaccines have 
demonstrated therapeutic potential (Zorrilla et al., 2006). The potency of 
endogenous ghrelin on appetite still provides hope, and some ghrelin antagonists, 
such as AEZS-123, are still in preclinical phases (Zentaris, 2009). Others, e.g. BIM-
28163, have unexpectedly produced increases in bodyweight (Halem et al., 2005). 
Ghrelin O-acyltransferase (GOAT) is the active (octanoylated) form of ghrelin 
protein located in the stomach and pancreas, which acts on the GHSR receptor. 
Administration of this agent may also have potential (Yang et al., 2008).  
The synthetic amylin analogue, pramlintide, is primarily used in the treatment of 
type-1 and type-2 diabetes (Hollander et al., 2003; Thompson et al., 1998). 
However, in a diabetes study, it has been shown to reduce bodyweight by up to 
2.6kg over a 52week period (post-hoc data; Maggs et al., 2003). More recently, 
pramlintide has been assessed in non-diabetic obese individuals, with sufficient 
weight loss (3.5kg) at 4 months (Smith et al., 2008). Davalintide, a second 
generation amylin analogue, has completed phase II clinical trials. However, the 
weight loss efficacy and tolerability profile was not improved over that of pramlintide 
(Mack et al., 2010). 
Anorectic mimetics, such as CCK-A agonists (GI181771X), which have previously 
been shown to slow gastric emptying in subjects, have failed to produce 
significantly meaningful weight loss at phase III (Jordan et al., 2008). However, 
aspects of the study design have been brought into question (Roses, 2009).  
On the other hand, proteolysis-resistant GLP-1 analogues (see Chapter Seven) 
such as liraglutide (Victoza™) are currently in phase III. Liraglutide, currently 
approved for type-2 diabetes, can produce a 6kg weight loss, and ≥35% of subjects 
reduce their baseline bodyweight by ≥10% (Astrup et al., 2009). Other GLP-1 
analogues, such as exenatide (Byetta™; see Chapter 7), have been reported to 
reduce bodyweight by only 5.8lbs over a 2 year period of weekly treatment exendin 
(Verdich et al., 2001). Another agent in this series, NN9924, is in phase I 
(Emisphere, 2011). However, the FDA have flagged concern about cardiac 
problems associated with these targets. Interestingly, inhibitors of dipeptidyl 
peptidase-4 (DPP-IV), the enzyme responsible for the degradation of GLP-1, 
appear to have little to no effect on weight loss (Amori et al., 2007; Fakhoury et al., 
2010; Pratley & Gilbert, 2008; see Chapter 7).  
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PYY13-36, a Y2 analogue known as PEG, has reached phase I clinical testing and 
has been found to significantly reduce intake and bodyweight (Ortiz et al., 2007). 
However, oral forms of PYY have had a non-significant impact on clinically relevant 
parameters in phase II testing, producing only a 12kg reduction on bodyweight 
compared to the 6.7kg weight loss seen under placebo conditions (Gantz et al., 
2007; Steinert et al., 2010). Furthermore, these compounds have been associated 
with a dose-dependent induction of vomiting and nausea (Degen et al., 2005). 
Pancreatic secretions have also been assessed as therapeutic targets, with 
synthetic PP analogues, such as PP-1420, entered into phase I trials in 2010 (Tan 
et al., 2012).  
Long-lasting OXM analogues (TKS1225 and OXY-RPEG) are currently in phase I. 
These agents not only have a longer half-life but also exhibit a greater potency 
compared to endogenous OXM. Weekly OXY-RPEG administration produces 
significantly greater effects on outcome measures compared to natural OXM 
(PROLOR, 2011). 
2.4.3 Other Targets 
A second generation lipase inhibitor, cetilistat, is currently in a phase III clinical trial 
(Kopelman et al., 2007; Kopelman et al., 2010). Although it produces outcomes 
similar to that of orlistat, it apparently has a better side-effect profile. 
ZGN-433 is a methionine aminopeptidase 2 inhibitor. The mechanism through 
which this agent affects weight loss in obesity is unclear. It was found to produce 
weight loss in mice and, in dogs, was associated with weight loss and improved 
glycaemic control (Chugh & Sharma, 2012; Colon-Gonzalez et al., 2013). In human 
trials, it produced reductions of 1 kg of bodyweight per week, alongside improved 
lipid profiles beyond that expected from weight loss alone (Powell et al., 2011). 
Phase II testing is due to begin in the very near future.  
Ezlopitant is a neurokinin receptor-1 antagonist that reduces sucrose intake, and 
the consumption of sweetened foods and drinks (Steensland et al., 2010). This 
profile supports the involvement of the neurokinin-receptor system in reward-related 
behaviours, and provides a therapeutic target for obesity induced by the over-
consumption of positive reinforcers, such as high sugar/fat foods. 
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2.5 Recent development of anti-obesity treatments 
(Combination Therapies) 
Clearly food intake and bodyweight are controlled by multiple mechanisms. 
Problems arise when homeostatic responses counter the effects of manipulating 
any one of these mechanisms. History demonstrates that few “single mechanism” 
approaches to obesity have been successful in achieving the FDA and EMEA 
criteria of ≥5% weight loss. Advantages of polytherapy, which actually began some 
20 years ago with the phentermine/fenfluramine combination, include the use of 
lower drug doses, possible synergistic but at least additive weight loss, fewer and 
less serious side-effects and reduced potential for counter-regulation (Greenway, 
Whitehouse, et al., 2009; Padwal, 2009; Rodgers et al., 2012; Roth et al., 2010). 
Table 2-4 summarises the main combination therapies currently in late phase 
clinical testing for the treatment of obesity.  
2.5.1 Clinical Phase 
There are currently two combinations seeking FDA approval: Contrave™ and 
Empatic™.  
Contrave™ (see Chapter 5) is the combination of bupropion and naltrexone 
(Greenway, Dunayevich, et al., 2009; Greenway, Whitehouse, et al., 2009; Inc, 
2007). Naltrexone doesn’t significantly produce weight loss on its own (Atkinson et 
al., 1985; Malcolm et al., 1985), but is currently approved for treatment of 
alcoholism (Volpicelli et al., 1992). It acts by blocking the µ-opioid receptor, 
augmenting the release of POMC in the ARC and suppressing the release of α-
MSH, hence increasing the weight loss effect of the noradrenaline and dopamine 
reuptake inhibitor, bupropion (Bray & Greenway, 2007; Greenway, Dunayevich, et 
al., 2009). During phase III, Contrave™ showed significant weight loss and reduced 
HbA1C (a measure of blood glucose) after 56 weeks (6.1kg vs. 1.4kg placebo; 
Orexigen Theapreutics, 2010). As patients on Contrave™ experienced an 
increased heart rate of 1bpm (Orexigen Theapreutics, 2010), it was rejected by 
FDA in 2011 pending a larger cardiovascular trial (Orexigen Theapreutics, 2011). 
Despite this, there has been progress with the FDA using a faster path to 
resubmission of the Contrave™ New Drug Application (NDA). 
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Table 2-4: Summary of the combination therapies currently under investigation 
Adapted from: (Adan, 2013; Rodgers et al., 2012). NDA: New Drug Application 
Drug Company Status Mechanism of Action 
Contrave™ 
(bupropion and 
naltrexone) 
Orexigen 
Declined 2011 
(NDA submission 
expected soon) 
Noradrenaline/dopamine reuptake 
inhibitor and opioid receptor 
antagonist 
Empatic (bupropion 
and zonisamide) 
Orexigen 
Phase III 
(NDA submission 
expected soon) 
Noradrenaline/dopamine reuptake 
inhibitor and anti-convulsant 
Pramlintide and 
Metreleptin 
Amylin Phase II Amylinomimetic and leptin 
Dov 21947 
Dov 
Pharmaceutic
al 
Phase II 
Serotonin/noradrenaline/dopamine 
reuptake inhibitor 
Obinepitide 7TM Phase II Neuropeptide Y2 and Y4 agonist 
Vytorin Merck Phase III 
Inhibition of cholesterol synthesis 
and absorption 
 
Empatic™ is the combination of sustained release formulations of bupropion and 
zonisamide, an antiepileptic drug that affects serotonergic and dopaminergic 
activity, in addition to inhibiting sodium and calcium channels. It was proposed that 
the addition of one would offset the adverse side-effects of the other; i.e. the 
depressive and sedative issues associated with zonisamide and the seizures 
associated with bupropion (Gadde, 2007). In phase II, Empatic™ showed a 7.5% 
weight reduction and, after 24 weeks, patients had not yet reached a plateau 
suggesting that greater levels of weight loss could be possible (Orexigen 
Theapreutics, 2009). Although reported adverse events were primarily headaches, 
insomnia and nausea, zonisamide has been associated with cognitive impairment, 
mood disorders and potentially, teratogenicity (Kennett GA, 2010; Mula & Sander, 
2007; Rosenstock et al., 2007). Therefore, further testing is required. However, 
the FDA stated that Phase III data may be sufficient to support submission of an 
NDA without data from a cardiovascular outcomes trial. 
Recently, there has been considerable interest in Pramlintide-and-metreleptin, 
which uses a neurohormonal strategy to combine a synthetic analogue of amylin 
with an analogue of human leptin (Roth, Roland, et al., 2008; Trevaskis, Lei, et al., 
2010; Turek et al., 2010). Low dose ranges of amylin (0, 10, and 50µg/kg-d) and 
leptin (0, 5, 25, and 125µg/kg-d), synergistically reduced food intake and bodyweight 
after continuous infusion over 28 days (Trevaskis, Coffey, et al., 2008). In fact, the 
co-administration of amylin and leptin can further reduce food intake and weight 
gain compared to control by an additional 16% and 4%, respectively (Roth, Roland, 
et al., 2008). The basis of this combination is that amylin agonism can restore leptin 
responsiveness in preclinical models and obese humans (Trevaskis, Coffey, et al., 
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2008; Trevaskis, Lei, et al., 2010; Turek et al., 2010). A 24 week trial found that 
after a 4 week lead-in period with pramlintide alone, the combination treatment led 
to significantly greater weight loss (12.7%) than treatment with pramlintide or 
metreleptin alone (8.4% and 8.2%, respectively; Ravussin et al., 2009). 
Furthermore, following a continued 52 week extension, subjects maintained their 
weight loss post-treatment (Takeda, 2010). An interesting point to note is that the 
weight loss in the combination treatment did not plateau post-experiment, as is 
typical following cessation of monotherapies. Despite this profile, however, the 
combination was suspended in March 2011 due to safety concerns (Takeda, 2011).  
DOV 21,947, is a triple monoamine reuptake inhibitor ("TRIP") primarily developed 
for the treatment of depression. Phase I trials demonstrated a bodyweight loss of 
≥4.6lb after 8 weeks. Interestingly, the study did not include dietary restrictions or 
exercise programs that are often incorporated in obesity trials. Therefore, it is 
remarkable that DOV 21,947 produced such a robust reduction in bodyweight. Due 
to the significant co-morbidity of major depressive disorder with obesity, this 
particular combination treatment could not only manage depression but also impact 
weight gain (Sargent & Moore, 2009; Tizzano et al., 2008). 
2.5.2  Preclinical Phase 
Due to the current issues (such as cardiovascular risk) associated with gaining FDA 
and EMEA approval for anti-obesity drugs, a huge variety of polytherapies are in 
early stage (typically preclinical) development (see Table 2-5). Four research 
strategies can be identified in the current polytherapy literature (see review: Roth et 
al., 2010); (1) satiety peptides plus satiety peptides, (2) adiposity signals plus 
satiety peptides, (3) small molecule agents plus adiposity signals or satiety 
peptides, and (4) small molecule agents plus small molecule agents. 
2.5.2.1 Satiety Peptides + Satiety Peptides 
Successful combinations of satiety peptides include CCK with either bombesin and 
glucagon (Gibbs & Smith, 1982; Hinton et al., 1986; Stein & Woods, 1981) or 
amylin (Bhavsar, Watkins, et al., 1998a). Amylin has also been successfully 
combined with PYY (Roth et al., 2007). 
GLP-1 receptor agonists, including Exendin-4 (for a full review of GLP-1 
combinations, see Chapter 6) have been successfully combined with; glucagon 
(Day, 2009), GIP (Finan, in submission), calcitonin (Bello et al., 2010), PYY3-36 
(Paulik et al., 2011; Reidelberger et al., 2011b; Steinert et al., 2010; Talsania et al., 
2005) and amylin (Bello et al., 2010; Roth et al., 2012). Combining an amylin 
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agonist with exenatide in non-human primates, has revealed a synergistic anorectic 
effect at 1–4 hours and an additive anorectic profile at 5-6 hours (Bello et al., 2010). 
2.5.2.2 Adiposity signals + Satiety Peptides 
In addition to the leptin-amylin combination (see Section 1.5.1, above), amylin has 
been co-administered with phentermine and sibutramine (Roth, Trevaskis, et al., 
2008). Leptin has also been combined with a variety of other anorectic agents such 
as; PYY3–36 (Trevaskis, Lei, et al., 2008), GLP-1 analogues AC3174 (Roth, Roland, 
et al., 2008) and exendin-4 (Bojanowska & Nowak, 2007; Mueller et al., 2012), and 
CCK (Emond et al., 1999; Matson et al., 2000; Trevaskis, Turek, et al., 2010). 
However, none of these combinations has resulted in the synergistic weight loss 
observed with the amylin-leptin combination. 
2.5.2.3 Small Molecule Agents + Adiposity/Satiety peptides 
Simultaneous targeting of both central and peripheral mechanisms has also been 
investigated. For example, the combination of leptin with; rimonabant (Boustany-
Kari et al., 2011), FGF21 (fibroblast growth factor gene; Mueller et al., 2012), 
sibutramine (Boozer et al., 2001) and topiramate (Lalonde et al., 2004). 
Furthermore, sibutramine and phentermine, have been combined with 
pramlintide (amylin analogue; Aronne, Halseth, et al., 2010). Here, the 
combination treatments were significantly different from any treatments given alone, 
and the percentage of subjects achieving ≥5% and ≥10% weight loss was 
significantly higher in the combination treatments compared to that of the 
monotherapies and placebo (28 and 3%, respectively; Roth, Trevaskis, et al., 
2008). In addition, amylin has been co-administered with bupropion/naltrexone 
treatment (Clapper et al., 2013) revealing additive effects with the combination of 
the catecholaminergic and opioidergic systems. Opioid antagonists, such as 
naltrexone (Liang et al., 2013; for a full review of GLP-1 combinations see Chapter 
7) have also been combined with peripheral peptides such as GLP-1 receptor 
agonists. 
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Table 2-5: Summary of treatment combinations under preclinical investigation  
The efficacy of these combination are categorised as: Sub-additive, whereby the combination treatment produced intake/bodyweight data lower than the sum of the 
individual drug effects; Additive, whereby the combination treatment produced intake/bodyweight data equivalent to the sum of the individual drug effects; and Synergistic, 
whereby the combination treatment produced intake/bodyweight data greater than the sum of the individual drug effects. 
 
Combination Action Measures References 
 
  
Food 
Intake 
Weight 
loss 
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CCK 
Bomesin Additive X 
  
Stein and Woods (1981) 
Glucagon and Bomesin Synergistic X 
  
Hinton et al. (1986) 
Amylin Synergistic X 
  
Bhavsar, Watkins, et al. (1998a) 
Exendin-4 
/ GLP-1 
Glucagon Additive X X X Day, 2009 
GIP Additive X X X Finan (in submission) 
Glucagon, GIP Additive X X X Finan (unpublished) 
Amylin Additive X X 
 
Bello et al. (2010); Roth et al. (2012) 
PYY3–36 Synergistic X X  
Paulik et al. (2011); Reidelberger et al. (2011b); Steinert 
et al. (2010); Talsania et al. (2005) 
Amylin PYY3–36 Additive X X  
Roth et al. (2007) 
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+
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Amylin Leptin Synergistic X X 
 
Ravussin et al. (2009); Roth, Roland, et al. (2008); 
Trevaskis, Coffey, et al. (2008) 
Leptin 
PYY3–36 Sub-additive X X 
 
Trevaskis, Lei, et al. (2008); Trevaskis, Coffey, et al. 
(2008) 
Exendin-4 / GLP-1 Additive X X 
 
Bojanowska & Nowak (2007); Mueller et al. (2012) 
CCK Synergistic X X 
 
Emond et al. (1999); Matson et al. (1997); Trevaskis, 
Turek, et al. (2010) 
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Amylin 
Bupropion/ Naltrexone Additive X X 
 
Clapper, 2013 Clapper et al. (2013) 
Sibutramine Synergistic X X X 
Aronne, Halseth, et al. (2010); Roth, Trevaskis, et al. 
(2008) 
Phentermine Synergistic X X X 
Aronne, Halseth, et al. (2010); Roth, Trevaskis, et al. 
(2008) 
Leptin 
Rimonabant Additive X X 
 
Boustany-Kari et al. (2011) 
Topiramate Additive X X X Lalonde et al. (2004) 
FGF21 Additive 
 
X 
 
Mueller et al. (2012) 
Sibutramine Synergistic X X 
 
Boozer et al. (2001) 
PYY NPY2 antagonist Additive X X  
Moriya et al. (2009) 
Rimonabant / 
AM259 
Exendin-4 / GLP-1 Sub-additive X X 
 
Bojanowska & Radziszewska (2011) 
Oleoyl-estrone Sub-additive X 
 
X Ferrer-Lorente et al. (2007) 
Oleoylethanolamide Sub-additive X 
  
Serrano et al. (2008) 
GIP antagonist Sub-additive X X X Irwin et al. (2008) 
mGlu(5) antagonist Synergistic X 
  
Varga et al. (2012) 
Naltrexone Exendin-4 Additive X 
  
Liang et al. (2013) 
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NPY1 NPY5 
Supra-
additive 
X X 
 
Mashiko et al. (2009) 
Topiramate Metaformin Sub-additive 
 
X X Toplak et al. (2007) 
Rimonabant / 
AM256 
Sibutramine Sub-additive X X 
 
Tallett et al. (2010a) 
mCPP Synergistic X 
  
Ward et al. (2008) 
Naloxone Synergistic X X 
 
Kirkham & Williams (2001); Rowland et al. (2001); 
Tallett et al. (2008b, 2009a) 
Dexfenfluramine Additive X 
  
Rowland et al. (2001) 
Nalmefene Additive X 
  
Chen, Huang, et al. (2004) 
MCH agonists Synergistic X X X Verty et al. (2013) 
Phentermine Fenfluramine Sub-additive 
 
X 
 
Li et al. (2003) 
Naloxone Sibutramine Sub-additive X X 
 
Tallett et al. (2010b) 
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Interactions between the cannabinoid system (for a full review of CB1 antagonist 
combinations, see Chapter 4) and peripherally acting peptides is seen with 
combinations such as CB1 receptor antagonist/inverse agonists with; exendin-4 
(Bojanowska & Radziszewska, 2011), oleoyl-estone (Ferrer-Lorente et al., 2007), 
oleoylethanolamide (Serrano et al., 2008), GIP antagonists (Irwin et al., 2008) 
and mGlu(5) antagonists (Varga et al., 2012). 
Furthermore, PYY3-36 in combination with GLP-1 (Steinert et al., 2010) and 
peripherally administered NPY Y2 receptor agonists produces an additive effect on 
bodyweight, adiposity and food intake in DIO mice over 14 days (Moriya et al., 
2009).  
2.5.2.4 Small Molecule Agents + Small Molecule Agents 
Combinations of two centrally-acting agents, such as NPY1 and NPY5 antagonists, 
are currently undergoing preclinical testing. Results demonstrate a greater 
suppression of 24 hour food intake and bodyweight gain compared to that of either 
mono-therapy in DIO mice, thus demonstrating a supra-additive effect (Mashiko et 
al., 2009). However, NPY1 receptor antagonists are known to have cardiovascular 
side-effects (Gullestad et al., 2003; Malmstrom, 2002), and may also impact 
processes such as affect, mood and reproductive function (Eva et al., 2006).  
Interaction between two centrally acting systems, for example, the cannabinoid 
system (for a full review of CB1 antagonist combinations, see Chapter 4), the 
monoaminergic system (for a full review of 5-HT agonist combinations, see 
Chapter 6) and/or the opioid system (for a full review of opioid antagonist 
combinations, see Chapter 4), has also been assessed. Combinations include, 
rimonabant with serotonogeric agents: mCPP, a 5-HT2C receptor agonist (Ward et 
al., 2008), sibutramine, a 5-HT and noradrenaline reuptake inhibitor (Tallett et al., 
2010a), dexfenfluramine, a serotonin releaser (Rowland et al., 2001) MCH 
agonists (Verty et al., 2013), and opioid receptor antagonists (Chen, Huang, et al., 
2004; Rowland et al., 2001; Tallett et al., 2008b). These opioid antagonists have 
also been assessed in combination with sibutramine (Tallett et al., 2010b).  
Topiramate has also been combined with metformin, an anti-diabetic drug that 
enhances insulin sensitivity (Toplak et al., 2007). This combination produced 
significant weight loss at both doses tested (96mg/day and 192mg/day), and an 
improvement in glycaemic control in obese subjects with type 2 diabetes. This is in 
line with the recent trend towards drug development that acts to reduce the severity 
of metabolic disorders rather than having a sole focus on bodyweight reduction. 
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2.6 Summary 
Cannabinoid, serotonergic, dopaminergic, opioid and peptidergic receptors offer 
new targets for the modulation of eating behaviour and hence the induction of 
weight loss. Drugs that can affect adipogenesis, thermogenesis and energy 
expenditure also hold considerable potential as effective agents. More importantly, 
drugs not originally developed for obesity, such as simvastatin and ezetimibe 
(developed for hyperlipidaemia), maraviroc (developed for HIV treatment) and DOV 
21,947 (developed for major depressive disorder), are now being considered as 
potential options for obesity treatment. 
Encouragingly, some combination therapies are in late phase clinical trials after 
demonstrating superior efficacy and an improved safety profile compared with the 
single agents (for example Contrave™ and Empatic™). However, a huge range of 
combinations shown to be effective in preclinical research remain to be assessed in 
human trials. The most recent development is the increased focus on 
improvements in the metabolic syndrome and not just bodyweight parameters. 
2.7 Overall Thesis Aims  
Neurobiological research over the past decade has identified a large number of 
biological (peripheral & central) signalling pathways involved in appetite regulation 
and energy homeostasis. Consistent with this multiplicity of mechanism, drug 
monotherapies for obesity and related disorders, although initially achieving weight 
loss, more often than not are subject to counter-regulation. As such, current interest 
in this field is focusing on the therapeutic potential of drug polytherapy or 
combination treatment. It is argued that combination treatments, comprising 
pharmacological agents acting on different but related pathways, may ultimately be 
more effective in producing sustained weight loss and improvements in co-
morbidity. In principle, polytherapy also permits the use of lower (sub-anorectic) 
doses of individual agents, thereby opening up the possibility of (i) 
additive/synergistic effects on food intake and weight gain as well as (ii) the 
reduction/elimination of side-effects normally associated with higher (individually 
anorectic) doses of the constituent agents.  
The current thesis aims to expand our understanding of the interacting systems that 
contribute to the regulation of appetite and bodyweight. In this context, the vast 
majority of behavioural research on appetite tends to naively focus on simple 
outcome measures or endpoints e.g. a reduction in food intake and/or a reduction in 
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bodyweight. However, as such outcomes can be reached either directly by an 
action on the normal physiological regulation of appetite or indirectly via a host of 
non-specific mechanisms, this thesis will be as much concerned with process as 
with outcome (Blundell & Latham, 1978; Halford et al., 1998; Rodgers et al., 2010). 
Therefore, the current research will employ a continuous behavioural monitoring 
technique (typical of BSS methodology; see Chapter 3) to assess the extent to 
which given pharmacological manipulations suppress food intake in a 
behaviourally-selective and physiologically-relevant manner.  
Several recent reviews in the area, (Adan, 2013; Rodgers et al., 2012) have 
emphasised that, of the novel therapies in the anti-obesity drug development 
pipeline, very few (if any) have been researched beyond the level of outcome 
measures. Thus, the overarching objective of the current thesis is to provide the 
missing ‘process’ detail for at least some of these treatments and treatment 
combinations, using the dependent measures of intake, feeding and non-feeding 
behaviour and the BSS during one-hour tests with palatable food. The potential 
effects of these manipulations on weight gain for up to 7 days following acute 
treatment will also be explored. 
2.7.1 Chapter Four Aims 
The first three experiments of the present series further address the nature of the 
interaction/s between the endocannabinoid and endogenous opioid systems. 
Although previous research has demonstrated the effectiveness of cannabinoid 
CB1 receptor antagonist/inverse agonists in the suppression of food intake and/or 
bodyweight, it is unclear whether this is a selective action. Preclinical research 
suggests that the acute anorectic effect of the cannabinoid CB1 receptor 
antagonist/inverse agonists rimonabant in rats may occur as an indirect 
consequence of response competition from compulsive scratching and grooming 
(Tallett et al., 2007b). As rimonabant’s pruritic effects can be attenuated by low 
doses of the opioid receptor antagonist naloxone (Tallett et al., 2008b), this 
hypothesis is to be further investigated.  
The specific aim of Chapter 4 is therefore to directly test the response competition 
hypothesis of acute rimonabant anorexia in male rats using the co-administration of 
two sub-anorectic doses of naloxone with a moderate rimonabant dose (Experiment 
1). Due to the somewhat ambiguous outcome of Experiment 1, two further 
experiments (Experiment 2 and 3) were conducted on the identical theme.  
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2.7.2 Chapter Five Aims 
Chapter 5 focuses on interactions between the endogenous opioid and monoamine 
(noradrenaline & dopamine) systems, such as those that underpin the recent 
development of Contrave™. This novel agent is a combination of naltrexone and 
bupropion, whereby naltrexone acts to inhibit the µ-opioid receptor, augmenting the 
activity of POMC neurons, thus increasing the anorectic effect of bupropion (Bray & 
Greenway, 2007; Greenway, Dunayevich, et al., 2009; Greenway et al., 2010; 
Greenway, Whitehouse, et al., 2009). 
The three experiments that form Chapter 5 examine the individual anorectic effects 
in male rats of acute treatment with (i) the general opioid receptor antagonist 
naltrexone (Experiment 4) and (ii) the noradrenaline and dopamine reuptake 
inhibitor bupropion (Experiment 5), and (iii) their combination (Experiment 6). The 
dose-response information provided by Experiments 4 and 5 informed the design of 
the interaction experiment (Experiment 6).  
2.7.3 Chapter Six Aims 
It was initially intended that we follow the previous thread of research and focus on 
interactions between the constituents of other combination “anti-obesity” drugs that 
are in the process of gaining FDA approval, e.g. Empatic® (bupropion and 
zonisamide) and Qnexa® (aka Qsymia™; phentermine and topiramate). However, 
limitations in commercial availability and/or funding meant this would not be a 
feasible avenue of research for the current thesis. As such, our revised strategy 
maintained a focus on opioid receptor antagonists in combination with other 
anorectic agents. Chapter 6 assesses opioid-serotonergic interactions through a 
combination of naltrexone with the preferential 5-HT2C receptor agonist mCPP.  
The two studies reported in Chapter 6 examine the anorectic effects of acute 
treatment with the serotonin 5-HT1B/2C receptor agonist mCPP in male rats. 
Although quality behavioural research with this compound has previously been 
reported, it was felt essential to obtain detailed dose-response data under present 
conditions (Experiment 7). Those data informed the design of Experiment 8, which 
explored the acute anorectic effects of co-treatment with a sub-anorectic dose of 
mCPP and two low doses of naltrexone.  
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2.7.4 Chapter Seven Aims 
Chapter 7 investigated the anorectic efficacy of endogenous peptide exendin-4, 
alone and in combination with naltrexone. In view of the limited behavioural 
research available, Experiment 9 assessed the dose-response anorectic effects of 
acute treatment with the naturally-occurring GLP-1R mimetic exendin-4 in male 
rats. These data, in turn, informed the design of Experiment 10 which examined the 
acute anorectic effects of co-treatment with a low dose of exendin-4 and naltrexone 
(two doses).  
2.7.5 Summary: Thesis Aims 
To summarise, the overall aims of the current thesis were to characterise: 
 the acute anorectic effects in male rats of individual treatment with the general 
opioid receptor antagonist naltrexone, the noradrenaline and dopamine 
reuptake inhibitor bupropion, the serotonin 5-HT1B/2C receptor agonist mCPP, 
and the naturally-occurring GLP-1R mimetic exendin-4; 
 the acute anorectic effects in male rats of co-treatment with rimonabant and 
naloxone, bupropion and naltrexone, mCPP and naltrexone, and exendin-4 and 
naltrexone. 
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Chapter 3 General Methodology 
The general methodology for all experiments is summarised in this chapter. Any 
deviations are specified within the individual empirical chapters. 
3.1 Ethics 
All experimental procedures were licensed by the Home Office, and conducted in 
accordance with the UK Animals (Scientific Procedures) Act of 1986. Experiments 
were conducted under my own Personal Licence (PIL: 40/9977) and Project 
Licences held by Professor R.J. Rodgers (40/3014 January 2011 – December 
2011 inclusive, and 40/3547 January 2012 – April 2013 inclusive) 
 
3.2 Subjects, and Housing 
All studies used adult male Lister hooded rats, obtained from Charles River 
(Manston, Kent, UK), weighing between 190.3g and 233.3g on arrival. The animals 
were initially pair-housed (46 x 26.5 x 26 cm) for 7 days, following which they were 
transferred for the remainder of the study to individual cages (45 x 20 x 20 cm) 
containing environmental enrichment (polycarbonate rat tunnels; Datesand Ltd, 
Figure 3-1: Laboratory Floor Plan  
(Adapted from Ishii, 2003; Tallett, 2009) White areas signify those used during the current 
research. B.08, holding room; B.12, testing room; B.01/B0.05, injection rooms. Note: Floor 
plan is not to scale. 
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Manchester, UK). Single housing facilitated initial familiarisation with the test diet 
as well as daily bodyweight tracking. Subjects were housed within visual, auditory 
and olfactory range of conspecifics held in adjacent cages.  
Animals were normally held in B.08 with the exception of Experiments 7 and 8 in 
which, to avoid any disruption to animals currently undergoing testing, new animals 
were briefly housed in B.01 (see Figure 3-1).  
Animals were maintained on a 12-h normal light cycle (lights on: 0700h; lights off 
1900h) in an environment controlled for temperature (21  1ºC) and humidity (50  
2%). A normal light cycle was employed in view of the much clearer BSS profiles 
seen when animals are tested during the light phase of the light/dark cycle (Tallett 
et al., 2009b).  
Animals were handled on a daily basis for routine husbandry, habituation to 
handing and recording of body weights (daily between 09.00-10.00h for the 
duration of the study). Animal cages were cleaned out on a bi-weekly basis. 
Although no animals were removed due to signs of ill health, one animal was 
removed from Experiment 5 due to an inconsistent baseline.  
3.3 Diet 
Food (standard pelleted chow; BK No.1 Rodent Breeder and Grower, Special Diets 
Services, UK; digestible energy value = 13.62 KJ/g or 3.25 kcal/g) and tap water 
were generally available ad libitum in the animals’ home cages throughout the 
study. The only exception was during the injection-test interval when both chow 
and enrichment were removed.  
The test diet (mash) consisted of a hydrated mash made freshly each morning by 
adding water to the powdered form of the diet (BK No.1 Rodent Breeder and 
Grower, Special Diets Services, UK; 1g dry powder = 3.125g mash; digestible 
energy value = 4.48 KJ/g). Portions of mash were then evenly distributed to glass 
pots, covered and refrigerated until required. Mash has the advantage of being 
more palatable than the standard chow (Ishii, Blundell, Halford, Rodgers, et al., 
2003), increasing baseline intake levels and eliminating the need for prior food 
deprivation to motivate feeding. Furthermore, its consistency minimises spillage 
and the likelihood of being removed from the pot for hoarding and/or consumption 
elsewhere (Halford et al., 1998).  
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3.4 Drugs & Administration 
Drugs employed in the current thesis were rimonabant (Experiments 1 - 3), 
naloxone (Experiments 1 - 3), bupropion (Experiments 4 + 5), naltrexone 
(Experiments 5, 8 + 10), mCPP (meta-chlorophenylpiperazine; Experiments 7 + 8) 
and exendin-4/exenatide (Experiments 9 + 10).  
Details of the compounds, their sources, injection-test intervals and corresponding 
vehicle solutions are summarised in Table 3-1. All drugs were administered via the 
intraperitoneal (i.p.) route, in a volume of 1 ml/kg body weight in either the Surgery 
(B.05) or B.01 dependent upon room availability (see Figure 3-1).  
For Experiments 1-8, test solutions were freshly prepared in the morning of each 
test day in the Prep Room (B.03; see Figure 3-1). For Experiments 9 and 10, 
exenatide was prepared to required concentrations, dispersed into individual 
aliquots (0.7ml) and frozen at -20ºC until shortly before use. 
Drug doses were selected on the basis of previous research or from dose-
response studies during the current work; details may be found in individual 
experimental chapters. All doses cited are expressed as the salt. 
3.5 Apparatus 
Daily bodyweights were recorded using Mettler Toledo (VIPER SW 6) weighing 
scales. Feeding tests were conducted in glass arenas (60 x 30 x 45 cm) large 
enough to allow animals the freedom to engage in a variety of behaviours (see 
Figure 3-2; for review see: Rodgers et al. 2010). The arena floor was lightly 
covered in clean wood shavings for each subject, and a water bottle suspended 
from one of the end walls. A glass (Pyrex) pre-weighed food pot filled with 
hydrated mash was placed in the centre of the arena and fixed to the floor using 
Velcro™ attached on the base of the food pot. An annular metal mounting was 
then placed over the food pot.  
Two video cameras (JVC TK-S530 and Vista VPC520CM) recorded the test 
sessions for subsequent behavioural analysis. One camera was positioned above 
the arena and the other placed horizontal to the front wall (see Figure 3-2). This 
multi-angled view facilitates behavioural analysis and enhances scoring accuracy 
by minimising any coding ambiguity arising from a single angle (Halford et al., 
1998).  
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Table 3-1: Details of Drugs Administered 
Drug Doses Used Supplier Vehicle Solution 
Injection-Test 
Interval 
Rimonabant  
(SR141716A; [N-piperidin-5-(4-
chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-3-
pyrazole-carboxamide]) 
1.5mg/kg 
Sanofi-Aventis  
(Chilly-Mazarin, France; Exps: 1 
+ 2) 
 
Cambridge Bioscience, 
(Cambridge, UK; Exp 3) 
Rimonabant was initially dissolved in 3 drops (0.42ml) of 
dimethyl-sulfoxide (DMSO; Sigma-Aldrich, Poole, UK) and 
then made up to required concentration in 0.5% 
methylcellulose (Sigma-Alrich, Poole, UK). A 
methylcellulose/DMSO mixture was used for control 
injections. 
30 minutes 
Bupropion hydochloride 
10mg/kg 
20mg/kg 
40mg/kg 
Sigma-Aldrich  
(Poole, UK) 
Bupropion, Naloxone, Naltrexone, and m-CPP were 
dissolved in physiological saline (0.9%), which alone acted as 
the control injection 
15 minutes 
Naloxone hydrochloride 
0.01mg/kg 
0.05mg/kg 
0.1mg/kg 
Sigma-Aldrich  
(Poole, UK) 
30 minutes 
Naltrexone hydrochloride 
0.1mg/kg 
1mg/kg 
3mg/kg 
Sigma-Aldrich  
(Poole, UK) 
15 minutes 
mCPP hydrochloride 
0.1mg/kg 
1mg/kg 
3mg/kg 
Tocris Bioscience  
(Bristol, Avon, UK) 
30 minutes 
Exendin-4 
(exenatide) 
0.025µg/kg 
0.25 µg/kg 
2.5 µg/kg 
Tocris Bioscience  
(Bristol, Avon, UK) 
Exendin-4 was dissolved in distilled water, which alone acted 
as the control 
30 minutes 
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Figure 3-2: Photograph of the lab layout  
A. Top view camera, B. Side view camera, C. Television, D. Merger, E. DVD recorder, F. 
Glass tank, G. Food pot, H. Water Bottle  
The video-cameras were linked to a DVD recorder (Panasonic DMR-E55) and 
monitor (SONY black and white video monitor PVM-145E) via and image merger 
(JVC video effector; TK-C50E) 
Five arenas were simultaneously utilized for habituation. However, due to limited 
availability of recording equipment, only one test arena could be used for 
experimental sessions. Observation arenas were emptied and wiped down 
between each subject and thoroughly cleaned in a cage-wash at the end of each 
experiment.  
3.6 Design 
All studies used a within-subjects design with a Latin Square method employed to 
counterbalance the different dose conditions. A between-treatment washout period 
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of seven days was used in Experiments 1-3 and 7-10. However, a three day wash-
out period was adequate for Experiments 4, 5 and 6. To ensure the elimination of 
the test compound’s and any active metabolites, each experiment carefully 
compared individual animal data for those subjects receiving the highest dose 
followed by the vehicle condition. Any unusual behaviour seen within the vehicle 
condition could then be attributed to carry-over effects. However, no carry-over 
effects were found in any of the present experiments.  
3.7 The Behavioural Satiety Sequence (BSS) 
The vast majority of preclinical behavioural research on appetite still naively 
focuses on simple outcome measures (i.e. reductions in food intake and/or 
bodyweight gain). However, such outcomes can be reached either directly by an 
action on the normal physiological regulation of appetite or indirectly via a host of 
non-specific mechanisms. As research should be as much concerned with process 
as with outcome (Rodgers et al., 2010), a continuous behavioural monitoring 
technique (typical of Behavioural Satiety Sequence [BSS] methodology) was 
employed to assess the extent to which currently-used test compounds (alone 
and/or in combination) suppress food intake in a behaviourally-selective manner 
(Halford et al., 1998). 
BSS methodology profiles changes in behavioural structure by plotting the time 
course of three primary behavioural parameters; eat duration, groom duration and 
rest duration. The model is a reliable means of differentiating primary anorectic 
drug effects (whereby drugs act via normal physiological mechanisms of appetite 
control) from secondary anorectics (whereby any anorectic effect is mediated by 
some non-specific mechanism such as, increased or decreased locomotion or 
malaise; Rodgers et al., 2010). This methodology has advantages over techniques 
which purely concentrate on food intake and/or changes in body weight. 
Behavioural analysis can identify drugs that affect components of eating motivation 
by acting on the processes that initiate, sustain and terminate feeding behaviour.  
Initially documented 40years ago (Bindra & Blond, 1958; Bolles, 1960) and further 
developed in the 1970s (Antin et al., 1975; Blundell JE, 1979), the BSS has been 
used to characterize the effects both of pharmacological and non-pharmacological 
manipulations on the predictable behavioural pattern associated with satiation in 
rats (Halford et al., 1998; Rodgers et al., 2010). The BSS methodology is based 
upon the principle that, as rats eat to satiety, they exhibit a characteristic sequence 
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of the three primary elements, i.e. progression from feeding, through exploratory 
active behaviours such as locomotion and grooming, to resting/sleeping. The 
transition to resting is indicative of post-absorptive satiety (Antin et al., 1975). 
Anorexia not only affects food intake and feeding behaviours, it can also impact 
upon other aspects of the behavioural repertoire.  
The complete BSS profile is initiated by stomach distension and/or movement of 
food through the intestine, but is not seen in sham-feeding animals (Antin et al., 
1975). As the structural integrity of the BSS can be preserved by some anorectic 
agents but disrupted by others, the BSS reflects the satiety process rather than the 
simple cessation of feeding (Antin et al., 1975; Blundell et al., 1985). A 
normal/control BSS profile (as seen in Figure 3-3) should display a peak feeding 
response at the start of the session followed by a reduction in eating, bouts of 
grooming and a gradual increase in resting. Drugs that act specifically by inducing 
satiety should therefore produce an orderly sequence of post-consumptive 
behaviours with a premature termination of eating and premature onset of resting, 
i.e. an acceleration (or shift to the left) in the sequence (as seen in Figure 3-3). 
Specific behavioural recording allows for the distinction between several different 
natural behavioural signatures. For example, pre-feeding induced anorexia is 
coupled with increased latency to eat and a reduced eating period alongside an 
acceleration in the eat-rest transition, whereas prior fasting results in a shift to the 
right (a delay) alongside increased food intake and duration of feeding behaviour 
(Ishii, Blundell, Halford, & Rodgers, 2003). The administration of lithium chloride 
(LiCl) or diet adulteration with quinine also reduce food intake. However, in 
contrast to the behavioural signature of free feeding, LiCl anorexia is a result of 
reduced eating bouts and reduced eat rate, and quinine-induced anorexia is 
characterized by highly atypical intermittent food sampling/digging, a large number 
of short eating bouts, a slow eating rate, and a reduction in practically all active 
behaviours in the first half of the session (Blundell et al., 1985; Ishii et al., 2004; 
Rodgers et al., 2010). The behavioural signatures of LiCl and quinine are therefore 
useful for the identification of appetite suppressants that induce malaise or which 
alter taste sensitivity and/or palatability (Ishii, Blundell, Halford, & Rodgers, 2003). 
The variation in behavioural profiles demonstrates the utility of the BSS in 
identifying primary and secondary reductions in food intake such as nausea (LiCl) 
or food contamination (quinine). Other anorectics also act non-specifically, 
disrupting the structural integrity of the BSS by the induction of 
hyperactivity/stereotypy as seen with amphetamine (Blundell & McArthur, 1981; 
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Halford et al., 1998) and rimonabant (Tallett et al., 2007b). Additionally, the BSS 
has successfully defined the effects of serotonergic drugs, such as fenfluramine 
and fluoxetine (Hewitt et al., 2002; Lee et al., 2004), as well as the role of orexin, 
cannabinoid and opioid systems on the expression of feeding behaviour (Ishii, 
Blundell, Halford, Upton, Porter, Johns, Jeffrey, et al., 2005; Ishii et al., 2004; Ishii, 
Blundell, Halford, Upton, Porter, Johns, & Rodgers, 2005; Rodgers et al., 2000; 
Rodgers et al., 2001; Tallett et al., 2007b, 2008a). 
This preclinical model of feeding behaviour is a powerful diagnostic tool allowing 
for early insight into the behavioural specificity and therapeutic potential of the anti-
obesity agents. However, it has yet to be fully utilized in the study of combination 
therapies. Following BSS analysis, promising treatment combinations should 
ideally be subject to more thorough behavioural assessment such as meal 
patterning analysis, macronutrient preference and dietary-induced hyperphagia in 
addition to studies investigating hedonics and motivation. More thorough 
preclinical work should result in a greater understanding of how agents produce 
the endpoints outlined by the FDA and EMEA (Rodgers et al., 2010). 
 
Figure 3-3: A 'typical' BSS profile (Adapted from Experiment One, Current Thesis) 
The behavioural satiety sequence (BSS) in non-deprived adult male Lister hooded rats tested 
for 1 h with palatable mash (n=10). Data shown are mean duration (s) scores for the three 
component behaviours (eat, groom, rest) in each of 12×5 min timebins comprising the 1 h test. 
As shown by the horizontal arrows, the vertical line (representing the transition from eating to 
resting i.e. behavioural satiety) would shift to the left (accelerate) with an anorectic agent and 
to the right (delay) with an appetite stimulant. Behavioural selectivity of treatment would be 
indicated by preservation of the sequence despite acceleration or delay. 
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3.8 Procedures and Behavioural Testing 
All habituation and test sessions were conducted during the light phase of the 
light/dark cycle (1000-1600h) under normal laboratory illumination (265 lux). See 
Figure 3-4 for a flow chart summary of the current protocol. 
3.8.1 Acclimatization Period  
The body weight of each animal was recorded daily between 09.00 and 10.00h. 
The acclimatisation period lasted three weeks following the arrival of animals from 
the commercial supplier. During the first week, the animals were housed in pairs 
and then individually for the remainder of the study. This period allows for 
habituation to laboratory conditions, including the light cycle, personnel and 
handling. At the end of the final week of the acclimatization period, subjects were 
exposed to the mash diet in the home cage for 3h on 2 consecutive days. 
3.8.2 Habituation Phase  
Over the week following acclimatisation, animals were habituated to pseudo-
experimental conditions daily for 5 days. The exception to this protocol was 
Experiment 10 in which subjects underwent an additional habituation day due to 
timetabling issues (see Chapter 7, Methodology). Habituation sessions involved 
the removal of home cage chow and enrichment, and i.p. injection of vehicle prior 
to a one-hour exposure to the behavioural test arena (including mash). For 
combination studies, the subjects were left in their home cage in the preparation 
room for the required time before administration of the second i.p. injection 
(vehicle). This process was run concurrently with five animals due to the 
availability of five identical test arenas. The food pot was weighed before and after 
the one-hour exposure allowing for calculation of consumption, while accounting 
for any evaporation and spillage. Tweezers were used to extract any stray wooden 
shavings or fecal matter from the food pot before weighing. An extra portion of pre-
weighed mash positioned beside the test arena during testing allowed accurate 
assessment of loss of food mass through evaporation. This evaporation control 
occurred during two test sessions a day; test session two (in the morning) and test 
session four (in the afternoon). This daily habituation process familiarised animals 
with the test environment and ensured the development of a stable food intake 
pattern prior to the experimental phase. Any animals not displaying a steady 
baseline food intake of palatable mash towards the end of the habituation week 
were excluded from the experiment (see Experiment 5). 
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Figure 3-4: Summary of Experimental Procedure  
(Adapted from Rodgers, et al, 2010) 
Holding 
• 12h Normal light cycle  
(Lights on 0700h; Lights off 1900h) 
• Regulated temperature and humidity 
Acclimatisation and familiarisation 
 On arrival animals housed in pairs for week one 
 Individual housing from week two onwards 
 Daily handling and bodyweight recording between 0900h and 1000h. 
 Home cage familiarisation to mash in week three 
Habituation Phase 
• 5 x daily habituation to pseudo-experimental conditions: 
• Injection procedure with vehicle solution or drug solution, administered i.p., 
volume 1ml/kg, before exposure to test arena 
• Exposure to the behavioural test arena for one hour, with food (palatable 
mash) and water available ad libitum.  
• Food intake measured following exposure to test arena 
Experimental Phase  
(weekly for X weeks, depending upon the number of treatment conditions) 
• Test solutions prepared on the day of testing and administered i.p. (1ml/kg).  
• Over two days, animals (5 per day) given injections of either: Vehicle controls or Drug 
solution at varied dosages 
• Animals returned to their home cage (with hopper food and environmental enrichment 
stimuli removed) between injections and before a one hour DVD-recorded exposure to 
the behavioural test arena.  
• Food intake is measured after one hour, and animals returned to their home cage.  
Bodyweight Tracking 
• Recording of bodyweights daily for up to 7 days 
post-treatment 
 
 
 
 
Study End 
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3.8.3 Experimental Phase  
The experimental weeks followed on directly and consecutively from the 
habituation period. Each subject was individually transported to a preparation room 
(Surgery/B.01; see Figure 3-1) and administered the appropriate agent (vehicle or 
drug; as indicated by the study-specific Latin Square) via i.p. injection, before 
being returned to the home cage (food and environmental enrichment stimuli 
removed). For combination studies, the subjects were then left in their home cage 
in the preparation room for the required time before administration of the second 
i.p. injection (vehicle or drug). Following the appropriate total injection-test-interval, 
subjects were then transported to the test laboratory (B.12; Figure 3-1) and placed 
in the test arena (with pre-weighed mash and water) for the one hour DVD-
recorded test session (Figure 3-2). As only one animal could be tested at any one 
time, injections and testing were staggered throughout the light phase, with five 
animals tested daily. After the test session, subjects were returned to their home 
cages in which standard chow diet and environmental enrichment had been 
reinstated. Food pots were re-weighed, accounting for any spillage, and the test 
food intake calculated. During each session, two control food pots (positioned 
adjacent to the test arena) were used to assess loss of food mass simply through 
evaporation: these measurements confirmed minimal evaporation loss. Body 
weights were then tracked for either 3 or 7 days (dependent upon experimental 
design) to determine whether there were any prolonged acute treatment effects on 
weight gain.  
3.8.4 Error Protocol 
Any errors occurring throughout the 10 experiments underwent the same error 
protocol: (i) If the error was identified before the end of an experiment, the 
individual animal was re-run on its allocated day in the week following the 
predicted end of study; (ii) If the error was identified after the end of an experiment, 
the data points for the specific dose for that individual animal were statistically 
calculated using mean substitution; replacing missing data points with the mean of 
the variables within that dose condition. This procedure avoided removal of the 
entire dataset for an individual animal. This would have been unethical, and would 
have reduced the number of subjects thus increasing variance in the dataset.  
3.8.4.1 Types of Error 
For specific details refer to individual experimental chapters. 
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3.8.4.1.1 Electronic Failure 
Cases where any electronic equipment malfunctioned during data collection; e.g. a 
DVD player error or lighting fault. 
3.8.4.1.2 Animal Illness 
Cases where an animal exhibited unusual behaviour before, during, or following 
testing; e.g. high levels of resting or awkward walking.  
3.8.4.1.3 Data loss 
Cases where data points were lost due to a computer or DVD error.  
3.9 Behavioural Analysis 
DVDs were scored blind by a highly trained observer (intra-rater reliability > 0.8), 
using ethological analysis software (‘Hindsight’; Weiss, 1995) that permits real-time 
scoring of behaviour via direct keyboard entry to a PC. The continuous monitoring 
methodology used, to record the duration and frequency of behaviour throughout 
the 1h test session, is particularly time consuming. The scoring of test DVDs for 
the whole thesis required a total of 480 hours (Experiments 2, 3, 4, 5, 7 and 9: 
40hours each; Experiments 1, 6, 8 and 10: 60hours each). Although this is a 
labour-intensive method, the alternative options such as time-sampling techniques 
are associated with observer bias and typically overestimate the true duration and 
frequency of behaviour (Halford et al., 1998). Based on previous research (for 
recent review see: Rodgers et al., 2010), measures recorded from DVD were: 
latency to locate food source, and latency to eat (see Table 3-3), together with the 
frequency and duration of the following behaviours: eating; drinking; grooming; 
scratching; sniffing; locomotion; rearing; and resting (see Table 3-2 and Figure 3-
5). It should be noted that, in all studies, levels of drinking were generally very low, 
undoubtedly due to the use of hydrated test food; as such, these data are not 
reported. Two further measures of feeding behaviour were derived from the 
recorded parameters: average duration of eating bouts, and average eating rate.  
In addition to analysing treatment effects on total scores, each 60-minute test 
period was divided into 12 x 5-min timebins, thus permitting analysis of treatment 
effects on behaviour over the session. For these timecourse analyses, specific 
attention was paid to the behavioural satiety sequence (BSS), i.e. the temporal 
relationship between eating, grooming, and resting (Rodgers et al., 2010). 
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Table 3-2: Definitions of behavioural variables scored during the one-hour test 
session  
Adapted from Tallett (2009) 
Behaviour Description 
Eating 
Biting, gnawing, or swallowing wet mash from food pot or directly 
from front paws. 
Grooming 
Licking of the body, feet and genitals. Stroking whiskers with 
paws. Biting of tail. 
Scratching Use of the hind legs to scratch the coat or head. 
Locomotion 
Walking around the cage or circling; movements that involve all 
four limbs. 
Rearing 
Front paws raised from the tank floor, either supported against 
the tank wall or free standing in front of the body. 
Sniffing 
Rapid wrinkling of the nose (twitching of vibrissae) at an aspect 
of the environment. Head movements with rear limbs immobile. 
Resting 
Lying in a relaxed position with head curled to the body or resting 
n the bottom of the tank; animal inactive. 
Drinking Licking the spout of the water bottle. 
 
Table 3-3: Definitions of additional feeding variables scored during the one hour test 
session  
Adapted from Tallett (2009) 
Measure Description 
Food Intake (g) 
The calculated difference between pre-test and post-test food pot 
weight, accounting for spillage 
Eat Bout Length (s) 
Average duration of feeding bout calculated by division of total 
eating duration (s) by total eating frequency 
Eat Rate (g/minute) 
Average eating rate calculated by division of total food intake (g) 
by total eat duration (m) 
Food Identification 
Latency (s) 
Time in seconds from the start of the test session to first contact 
with the food pot 
Eat Latency (s) 
Time in seconds from the identification of the food source to the 
first bout of feeding 
Figure 3-5 (overleaf): Scored Behaviours  
From top left to bottom right; overhead and side views of eating, drinking, sniffing, rearing, 
locomotion, resting, scratching and grooming. 
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3.10 Statistical Analysis 
Following Hindsight scoring, data were transferred into Microsoft Excel where it 
could be suitably organized for export into SPSS (Statistical Package for the Social 
Sciences; v16-20) for statistical analysis. For combination studies (Experiments 1, 
2, 3, 6, 8 and 10) Bonferroni post-hoc analyses were conducted in STATISTICA 7 
(StatSoft, Tulsa, USA). In all cases, where datasets failed Mauchly’s Test of 
Sphericity, Greenhouse-Geisser significance levels are reported. For the purposes 
of brevity, all degrees of freedom reported within the text refer to the ‘sphericity 
assumed’ values. The Greenhouse-Geisser altered degrees of freedom can be 
found in the relevant appendices. Findings were accepted as significant when p ≤ 
0.05 
3.10.1 Habituation Phase Data 
To confirm the development of stable levels of intake before commencement of the 
experimental phase, food intake during the habituation phase was analysed using a 
one-way repeated measures ANOVA (analysis of variance), followed by Bonferroni 
comparisons. 
3.10.2 Experimental Phase Data 
The raw data produced by Hindsight was organised by treatment condition before 
drug effects on one-hour food intake and one-hour behavioural measures 
(frequency and duration) were analysed. One-way repeated measures ANOVAs 
were used for dose-response studies. Combination studies underwent two-way 
repeated measures ANOVA. In each case, significant ANOVAs were followed by 
the appropriate Bonferroni comparisons.  
To analyse changes over time, the 12 x 5 minute timebins for each behaviour 
(frequency and duration) were subject to repeated measures ANOVA: treatment x 
time, for dose-response studies, and treatment x treatment x time, for combination 
studies. Any significant treatment x time interactions were followed up by one-way 
ANOVAs for each timebin. Where the data failed Mauchly’s test of sphericity, 
corrected Greenhouse-Geisser values are reported.  
3.10.3 Bodyweight Data 
Treatment effects for test day bodyweight, and 7-day absolute weight gain (3-day 
absolute weight gain where necessary) were analysed by one-way repeated 
measures ANOVA for dose response studies, and two-way repeated measures 
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ANOVA for combination studies. Percentage bodyweight gain over the 7 day post-
treatment (3-day where necessary) were analysed by two-way repeated measures 
ANOVA (drug x day) for dose-response studies. For combination studies three-way 
repeated measures ANOVA was used. Significant interactions were initially 
explored using one-way ANOVA (two-way ANOVA for combination studies) for 
each day followed by, where significant, Bonferroni tests. 
3.11 Data Reporting 
Statistical details from individual experiments in the current thesis will be reported 
using a common format (see Table 3-4). At the end of each Chapter, the main 
findings from the constituent experiments will be briefly outlined in bullet point 
format. The main discussion issues from each empirical chapter are reserved for 
Chapter 8. 
Table 3-4: An outline of the template used to report experimental results. 
n/a: not applicable 
Heading Purpose Figures and Tables 
Habituation Phase 
Food Intake 
To confirm the development of stable 
intake prior to experimental testing 
n/a 
Test Day Bodyweight 
To confirm the comparability of bodyweight 
across treatment conditions 
n/a 
Test Day Food Intake 
To emphasise minimal evaporation loss, 
and outline treatment effects on food intake 
A figure will summarise the effect of 
acute treatment on mash intake 
Total (one-hour) 
Behavioural Analyses 
To outline treatment effects on feeding 
related parameters (Table 3-3) as well as 
frequencies and durations of the 
behavioural variables (Table 3-2) 
A table will summarise the acute effects 
of treatment on eating-related 
parameters and a figure will show the 
effects of treatment on the duration 
(upper panel) and frequency (lower 
panel) of ingestive and non-ingestive 
behaviours 
Timebin Behavioural 
Analyses 
To confirm expected behavioural time 
effects and outline main effects and/or 
interactions of behaviours within specific 
timebins 
A figure will illustrate the effects of 
treatment on timecourses for any 
relevant behaviours. 
Behavioural Satiety 
Sequence (BSS) 
To visually assess the eat-to-rest transition 
and the structural integrity of the BSS 
following treatment 
A figure will show effects of treatment on 
the BSS 
Bodyweight Gain 
To confirm normal growth patterns and 
reveal any post-treatment effects on 
bodyweight gain 
n/a 
Summary of Main 
Findings 
To summarise the findings and conclusions n/a 
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Chapter 4 Cannabinoid and Opioid System Interactions 
4.1 The Cannabinoid System 
The past decade has witnessed substantial advances in our understanding of the 
neurobiology of appetite and energy homeostasis (Halford, Boyland, Blundell, et al., 
2010; Kennett, 2010; Rodgers et al., 2012; Vickers et al., 2011). Of major 
significance in this regard is the endocannabinoid system, with particular emphasis 
on the anti-obesity potential of cannabinoid CB1 receptor antagonist/inverse 
agonists such as rimonabant (for reviews see: Cota et al., 2006; DiMarzo, 2008; 
Kirkham, 2009; Marco et al., 2012).  
The cannabinoid system is a lipid signalling system (Bermudez-Silva et al., 2010; 
Matias & Di Marzo, 2007), based on several endogenous cannabinoids including 
anandamide (Devane et al., 1992) and 2-arachidonoylglycerol (2-AG; Sugiura et al., 
1995). Anandamide and 2-AG act at two cannabinoid receptor subtypes CB1 
(Devane et al., 1988; Matsuda et al., 1990) and CB2 (Howlett, 2002; Munro et al., 
1993), both of which are distributed widely throughout brain (including the olfactory 
bulb, hippocampus, amygdala, thalamic nuclei, cerebellar cortex, and brainstem) 
and periphery (Piomelli, 2003). Although CB1 receptor expression in the 
hypothalamus is surprisingly low, the presence of the cannabinoids in this region 
nonetheless suggests important functions relating to appetite regulation (Marsicano 
& Lutz, 2006). Peripherally CB1 receptors are present in adipose tissue, liver cells, 
skeletal muscle and the pancreas (Cota, Marsicano, Lutz, et al., 2003; Osei-
Hyiaman et al., 2005). CB2 receptors are also peripherally located and primarily 
play a role in immunological functions (Howlett, 2002). 
4.1.1 Cannabinoids & Appetite Regulation 
It has long been established that cannabis administration increases food intake 
(Abel, 1975). The active ingredient, Δ9-tetrahydrocannabinol (THC), is responsible 
for this action and has been shown to increase feeding both in animal models 
(Brown et al., 1977; Koch, 2001; Williams et al., 1998) and humans (Foltin et al., 
1988; Hart et al., 2002; Hollister, 1971). Similarly, the administration of 
endocannabinoids has also been shown to produce hyperphagia (Hao et al., 2000; 
Jamshidi & Taylor, 2001; Kirkham et al., 2002; Williams & Kirkham, 1999).  
These cannabinoid effects on food intake are mediated via the CB1 receptor. Thus, 
THC-induced hyperphagia is reversed by CB1 (but not by CB2) receptor 
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antagonists (Williams & Kirkham, 2002). Similarly, CB1 KO mice exhibit a lean and 
hypophagic phenotype (Di Marzo et al., 2001; Ravinet Trillou et al., 2004). 
Furthermore, research has repeatedly confirmed that selective CB1 receptor 
antagonist/inverse agonists, such as rimonabant (SR141716A; Rinaldicarmona et 
al., 1994), dose-dependently reduce intake of a variety of diets (see below). 
4.1.2 Cannabinoid Receptor Antagonists & Appetite Regulation 
Rimonabant, the first selective CB1 receptor antagonist/inverse agonist 
(Rinaldicarmona et al., 1994) has been found to significantly and dose-dependently 
decrease intake of sucrose (Freedland et al., 2001) and ethanol (Higgs et al., 2003; 
see Section 4.1.2). It has therefore been suggested as a target for the treatment of 
alcohol, nicotine and marijuana abuse (Colombo et al., 2007; Le Foll & Goldberg, 
2005). However, evidence has also shown reductions in normal lab chow 
consumption (Colombo et al., 1998; De Vry & Jentzsch, 2004; Freedland et al., 
2001; Gomez et al., 2002; Hildebrandt et al., 2003; Hodge et al., 2008; McLaughlin 
et al., 2006; McLaughlin et al., 2003; McLaughlin et al., 2005; Rowland et al., 2001; 
Simiand, Keane, Keane, & Soubrié, 1998; Thornton-Jones, 2005; Verty, McGregor, 
et al., 2004a; Verty et al., 2003; Vickers, Webster, et al., 2003; Werner & Koch, 
2003; Wiley et al., 2005; Williams & Kirkham, 2002), suggesting that there may be 
no real difference in effect between different types of test diet (McLaughlin et al., 
2003; Verty, McGregor, et al., 2004a). 
Other CB1 receptor antagonists have also been found to reduce food intake, 
including: AM251 (Chambers et al., 2006; Chambers et al., 2004; Chen, Huang, et 
al., 2004; Hildebrandt et al., 2003; McLaughlin et al., 2003; McLaughlin et al., 2005; 
Rutkowska, 2004; Shearman et al., 2003; Tallett et al., 2007a); AM281 (Werner & 
Koch, 2003); AM1387 (McLaughlin et al., 2006); LH21 (Pavon et al., 2006); 
taranabant (MK-0364; Addy et al., 2008; Fong et al., 2007); AM4113 (Hodge et al., 
2008; Järbe et al., 2008; Sink et al., 2008; Sink et al., 2010; Sink KS, 2009); 
otenabant, surinabant (SR147778; Lamota et al., 2008), Ibipinabant (SLV319) and 
LY320135 (see Di Marzo, 2008). 
The short-term effects of cannabinoid receptor antagonists on appetite regulation 
are thought to be mediated centrally in the basal forebrain (Cota, Marsicano, 
Tschop, et al., 2003; Jamshidi & Taylor, 2001; Kirkham et al., 2002) and 
peripherally via capsaicin-sensitive, CCK-1 receptor vagal afferents in the stomach 
and duodenum (Coutts & Izzo, 2004; Gomez et al., 2002). Centrally, the 
cannabinoid system is thought to regulate the expression of various orexigenic and 
anorexigenic neuropeptides. In this context, CB1 receptors are co-localised with 
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CRH in the PVN, MCH in the LH and with pre-pro-orexin in the VMH (Cota, 
Marsicano, Tschop, et al., 2003). The cannabinoid system has also been found to 
interact with NPY, with cannabinoid receptor agonists stimulating and cannabinoid 
receptor antagonists inhibiting NPY expression (Gamber et al., 2005). Additionally, 
the orexigenic effects produced by NPY can be blocked by rimonabant pre-
treatment and by CB1 receptor KO (Di Marzo et al., 2001; Poncelet et al., 2003). 
However, rimonabant administration in NPY-null mice still produces an anorectic 
effect (Di Marzo et al., 2001). The lack of co-localisation of the two neuropeptides in 
the ARC (Cota, Marsicano, Tschop, et al., 2003) suggests that the cannabinoid 
system acts downstream of NPY. Evidence also demonstrates a central 
cannabinoid interaction with dopamine (Duarte et al., 2004; Verty, McGregor, et al., 
2004b) and opioid (see section 4.3; Chen, Huang, et al., 2004; Rowland et al., 
2001; Tallett et al., 2008b, 2009a; Verty et al., 2003; Williams & Kirkham, 2002) 
systems. Peripherally, evidence suggests that CB1 receptor antagonism is 
associated with reduced plasma ghrelin levels (Cani et al., 2004) and blockade of 
ghrelin-induced hyperphagia (Tucci et al., 2004).  
Interestingly, significant effects of CB1 receptor antagonist on bodyweight often 
outlast those seen on food intake, suggesting the development of tolerance to the 
acute anorectic effect of these agents (Colombo et al., 1998; Vickers, Webster, et 
al., 2003). CB1 receptor KO mice exhibit resistance to high-fat diets and do not 
become as obese as their wild-type littermates (Cota, 2003; Ravinet Trillou et al., 
2003). These findings suggest that CB1 receptor antagonists may have actions 
additional to appetite suppression, e.g. increasing energy expenditure (Liu et al., 
2005) or acting peripherally on adipocytes to inhibit lipogenesis (Bermudez-Silva et 
al., 2008; Cota, Marsicano, Tschop, et al., 2003; Osei-Hyiaman et al., 2005; 
Pagano et al., 2008). Such possibilities are supported by evidence showing that 
blockade of CB1 receptors increases the levels of adiponectin, an enzyme that 
blocks lipogenesis and which is therefore inversely associated with adiposity levels 
(Bensaid et al., 2003; Poirier et al., 2005). It is suggested that rimonabant mediates 
its effects on bodyweight directly on adipose tissue, potentially via the enhancement 
of the adiponectin gene (Bensaid, 2003; however see: Thornton-Jones & Clifton, 
2006). The peripheral effect of the cannabinoid system on bodyweight is further 
supported by evidence that CB1 receptor antagonists that cannot cross the BBB 
have produced similar effects on bodyweight suppression to those seen with brain-
penetrant CB1 receptor antagonists (Wu et al., 2011). This suggests a dissociative 
effect of CB1 receptor antagonists on intake and bodyweight, dependent upon site 
or sites of action. 
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Despite the apparent success of CB1 receptor antagonists, they may have a floor 
effect. The administration of rimonabant (Freedland et al., 2000; McLaughlin et al., 
2003), AM251 (Hildebrandt et al., 2003; McLaughlin et al., 2003) and taranabant 
(Aronne, Tonstad, et al., 2010) has failed, even at high doses, to completely abolish 
feeding. Whereas fenfluramine and dexfenfluramine can completely abolish lever-
pressing for food, the maximum suppression seen with rimonabant and 
AM251/1387 is only 60-70% (McLaughlin et al., 2006; McLaughlin et al., 2003; 
McLaughlin, 2010). 
4.1.3 Cannabinoids and the Rewarding Aspects of Appetite 
Regulation 
As discussed in Chapter 3 (Section 3.7), food intake can be reduced by drug 
actions unrelated to the normal physiological regulation of appetite (Halford et al., 
1998; Rodgers et al., 2010). In this context, it is pertinent to note that CB1 receptor 
antagonists also influence food reward and the rewarding effects of drugs of abuse 
(Carai et al., 2005; Cota et al., 2006), anxiety (Griebel et al., 2005), and learning 
and memory (Marsicano et al., 2002). 
Although, THC increases food intake in humans (Hart et al., 2002), more detailed 
findings suggest that this is specific to increases in palatable foods (Foltin et al., 
1986). Similarly, the CB1 receptor agonist, Arachidonyl-2-chloroethylamide (ACEA), 
also produces increases in specific macronutrient (carbohydrate) intake (Erick 
Escartin-Perez et al., 2009). Furthermore, monkeys and mice have been found to 
self-administer endocannabinoids and cannabinoid receptor agonists, an effect 
blocked by rimonabant (Justinova et al., 2005; Martellotta et al., 1998). Therefore, it 
is thought that the cannabinoid system acts, at least in part, to enhance the 
rewarding aspects of food, thereby increasing the motivation to eat (Kirkham & 
Williams, 2001). This aspect of cannabinoid-induced hyperphagia is thought to be 
mediated by dopamine. CB1 receptors are co-localised with dopamine D2 receptors 
in the nucleus accumbens (Pickel et al., 2004), and rimonabant attenuates 
dopamine release following the consumption of palatable food (Melis et al., 2007). 
Reciprocally, CB1 receptor antagonist/inverse agonists, such as rimonabant, have 
been found to selectively reduce the intake of palatable foods (Arnone et al., 1997; 
Simiand, Keane, Keane, & Soubrie, 1998). This effect is thought to be a result of 
reduced palatability (exemplified with sucrose licking) and reward value 
(exemplified with break points; Maccioni et al., 2008; Rasmussen & Huskinson, 
2008; Sanchis-Segura et al., 2004; Ward et al., 2008), rather than induction of 
satiation (Higgs et al., 2003).  
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4.1.4 Side-Effects of CB1 receptor Antagonists 
4.1.4.1 Scratching and Grooming (Pruritus) 
It had been established that changes in feeding produced by cannabinoid receptor 
antagonists are not due to sedation (Gardner & Mallet, 2006; Jarbe et al., 2006; 
McLaughlin et al., 2005). However, nausea and pruritus (an itching syndrome; 
Hodge et al., 2008; Tallett et al., 2007b, 2007c) were found in preclinical testing in 
rodents.  
Of particular relevance to the present thesis is the observation that CB1 receptor 
antagonists reliably induce cannabinoid withdrawal symptoms (Aceto et al., 1996; 
Cook et al., 1998; Navarro et al., 1997; Rubino et al., 1998), and/or motor effects 
(Bass et al., 2002; Compton et al., 1996; Pavon et al., 2006). More specifically, this 
can be characterised as a syndrome of compulsive grooming and scratching in 
rodents (e.g. Janoyan et al., 2002; Jarbe et al., 2002; Jarbe et al., 2003; Jarbe et 
al., 2004; Jarbe et al., 2006; Tallett et al., 2007a, 2007b, 2007c). In humans, this 
itching of the skin is known as pruritus and was reported in human clinical trials as a 
significant adverse effect both of rimonabant (MHRA, 2008b) and taranabant (Addy 
et al., 2008; Aronne, Tonstad, et al., 2010). In fact, intense scratching/grooming is 
even seen in rodents treated with the newer neutral CB1 receptor antagonist (see 
later, Section 4.1.3.3) such as AM4113 (Hodge et al., 2008; Järbe et al., 2008). The 
latter finding implies that not all of the adverse effects of rimonabant and similar 
agents can be attributed to their inverse agonist properties. Interestingly, 
rimonabant-induced scratching is not seen following intracerebroventricular 
administration (Schlosburg et al., 2011), suggesting a peripheral site of action. 
Although the grooming and scratching syndrome is now a well-established feature 
of rimonabant (Schlosburg et al., 2011; Tallett et al., 2007b; Ward et al., 2008) and 
AM251 (Hodge et al., 2008; Tallett et al., 2007a) treatment, it was infrequently 
reported in feeding studies with this class of agent. Recently, work from The 
University of Leeds showed that the CB1 receptor antagonist/inverse agonist-
induced scratching and grooming severely disrupts the BSS in rats, leading to the 
suggestion that the acute anorectic effect of such agents may simply be due to 
response competition (Tallett et al., 2007a, 2007b). However, this hypothesis has 
been challenged by Hodge and colleagues (2008) whereby the pattern of drug-
induced grooming was yoked to forced locomotion in an un-drugged group of rats 
fed in a modified running wheel. As this particular form of disruption did not affect 
food intake, it was concluded that simple response competition could not account 
for the anorectic response to CB1 receptor antagonist/inverse agonists. However, it 
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is debatable whether locomotion-induced disruption is equivalent to the behavioural 
disruption caused by continuous drug-induced itching, scratching and grooming. An 
alternative approach to testing the response competition hypothesis would be to 
identify a means of attenuating the scratching/grooming syndrome and to assess 
the effects of this manipulation on food intake and feeding behaviour. 
4.1.5 Therapeutic potential for the Treatment of Obesity 
4.1.5.1 Rimonabant 
In addition to the extensive preclinical work with rimonabant and related 
compounds, CB1 receptor antagonist/inverse agonist administration has been 
shown to reduce food intake, bodyweight gain, waist circumference, cardiovascular 
risk factors and hunger ratings in humans over periods of up to 12 weeks (Despres 
et al., 2009; Heshmati et al., 2001; Scheen et al., 2006; Van Gaal et al., 2005). 
More specifically, the preclinical data on rimonabant was confirmed in obese 
humans by four separate phase III clinical trials known as; the Rimonabant in 
Obesity (RIO) - Europe (Van Gaal et al., 2005), RIO – Lipids (Despres et al., 2005), 
RIO – Diabetes (Scheen et al., 2006) and RIO – North America (Pi-Sunyer et al., 
2006) trials. All four studies produced similar results indicating that, after 1-year of 
treatment, >60% of patients achieved weight loss of ≥5%, and >30% of patients 
achieved weight loss of ≥10%. However, five meta-analyses of these clinical trials 
brought to light major safety concerns regarding rimonabant treatment (Chavez-
Tapia et al., 2009; Christensen et al., 2007; Curioni & Andre, 2006; Johansson et 
al., 2009). 
4.1.5.2 Depression, Anxiety and Suicidal Thoughts 
On top of the already increased risk of depression in obese patients (Luppino et al., 
2010), the most common complaint from patients undergoing rimonabant treatment 
was depression (Johansson et al., 2009; Nissen et al., 2008; see Serra & Fratta, 
2007). In fact, CRESCENDO, a rimonabant cardiovascular trial, was halted due to 
five suicides (Topol et al., 2010). Furthermore, pooled data from a number of trials 
revealed that while on rimonabant, the risk of depression is double that of the 
placebo group (Rumsfeld & Nallamothu, 2008). Considering the ‘reward’ 
components of rimonabant anorexia and the role of the cannabinoid system in 
motivated behaviours, such as sex and social interaction (Melis et al., 2007), it is 
unsurprising that rimonabant is found to block reward and lead to mood disorders 
such as depression (Bermudez-Silva et al., 2010).  
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Additionally, 1% of patients discontinued rimonabant treatment due to feelings of 
anxiety (Pi-Sunyer et al., 2006), an effect also seen with taranabant treatment 
(Proietto et al., 2010). Interestingly, administration of CB1 receptor agonists in 
animals has been found to exert both anxiogenic (anxiety inducing; Arevalo et al., 
2001; Navarro et al., 1997; Onaivi et al., 1990) and anxiolytic (anxiety inhibiting; 
Haller et al., 2004; Kinsey et al., 2011; Patel & Hillard, 2006; Sciolino et al., 2011) 
actions. Similarly, CB1 receptor antagonist/inverse agonists have also been found 
to exert both anxiogenic (Rodgers et al., 2005) and anxiolytic actions (Degroot & 
Nomikos, 2004; Rodgers et al., 2003). These conflicting findings may relate to 
variations in dose level and hence the affected neural circuits.  
4.1.5.3 Second Generation CB1 Antagonists 
Enthusiasm for CB1 receptor antagonist/inverse agonists as a potential obesity 
treatment waned as a result of the 2008 suspension (psychiatric risk) of marketing 
authorisations for Acomplia® (rimonabant; see Chapter 2), and the subsequent 
termination of several commercial CB1-receptor drug development programmes, 
including Merck abandoning the development of alternative CB1 receptor 
antagonists such as taranabant (Aronne, Tonstad, et al., 2010). Nevertheless, a 
number of findings would support retention of the CB1 receptor as a molecular 
target relevant to the regulation of appetite and energy homeostasis (Bermudez-
Silva et al., 2010; Kunos et al., 2009; McLaughlin, 2012; Rodgers et al., 2012; 
Vemuri et al., 2008). These include growing evidence that: (i) neutral or ‘silent’ CB1 
receptor antagonist (such as AM4113) retain the anorectic and weight loss 
advantages of rimonabant but with an improved side-effect profile, and (ii) 
peripherally-restricted CB1 receptor antagonists (such as AM6545, LH-21, MJ15, 
URB 447) significantly reduce both intake and weight gain, thereby possibly 
avoiding the psychiatric complications associated with CNS-penetrant compounds. 
Additional hope rests in related research avenues including the development of 
CB1 receptor partial agonists, allosteric modulators of CB1 receptors, and agents 
that alter endocannabinoid levels (Bermudez-Silva et al., 2010).  
Furthermore, recent work has emphasised the positive effect of rimonabant in 
producing metabolic improvements such as decreased coronary artery 
atherosclerosis (Nissen et al., 2008), improved glycemic control (Rosenstock et al., 
2008), and reduced accumulation of intra-abdominal fat and liver fat (Despres et al., 
2009). Such findings suggest that rimonabant may still be a beneficial obesity 
treatment with improved patient selection. 
4.1.5.3.1 Neutral CB1 Receptor Antagonists 
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Drugs such as rimonabant are inverse agonists/antagonists at the CB1 receptor; 
this means that in addition to blocking the receptor site, the inverse agonists 
simultaneously induce a pharmacological response opposite to that of an agonist 
(see Figure 4-1). The poor side-effect profile of rimonabant is thought to be related 
to blocking the constitutive CB1 activity. On the other hand, the use of neutral CB1 
receptor antagonist that lack intrinsic activity at the receptor (Pertwee, 2005), 
provide the potential for weight loss without the adverse side-effects (Greasley & 
Clapham, 2006).  
 
Figure 4-1: Diagram demonstrating the pharmacological effects of different ligands. 
Full agonist: a ligand that binds to and activates a receptor and elicits a physiological response; 
Partial agonist: ligand that elicits only a partial response when compared to a full agonist; 
Neutral Antagonist: any ligand that blocks binding of endogenous agonists to the receptor; 
Inverse agonist: a ligand that binds to a receptor and inhibits the basal or constitutive activity of 
a receptor. Source: Tate (2012) 
These include: O-2050 (Gardner & Mallet, 2006; Higuchi et al., 2010); LH-21 
(Alonso et al., 2012; Chen et al., 2008; Pavon et al., 2006); AM4113 (Cluny et al., 
2011); PSNCBAM-1 (Horswill et al., 2007; Wang, Horswill, et al., 2011); and NESS 
0327, a rimonabant analogue (Ruiu et al., 2003).  
Generally, it is considered that these ‘neutral’ antagonists exhibit a safer side-effect 
profile. For example, neutral CB1 receptor antagonist, AM4113, does not induce 
nausea (Järbe et al., 2008; Salamone et al., 2007). However, as previously 
mentioned, some of the newer CB1 receptor antagonist (AM4113 and AM251) still 
induce pruritus (Hodge et al., 2008; Järbe et al., 2008). Furthermore, they may not 
be as effective as appetite suppressants. For example, O-2050 fails to block the 
hyperphagic effects of THC (Wiley et al., 2011). Since LH-21 is able suppress 
intake in CB1 knockout mice (Chen et al., 2008), some of these newer compounds 
may not be selective CB1 receptor antagonists but, instead, elicit their effects on 
food intake via a different system. 
4.1.5.3.2 Peripherally-restricted CB1 Receptor Antagonists 
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In view of the psychiatric nature of the risks associated with drugs like rimonabant, 
an alternative route would be to target CB1 receptor antagonists that cannot cross 
the BBB. Peripherally-restricted CB1 receptor antagonists thus far developed 
include: MJ15 (Chen et al., 2010); URB-447 (DiPatrizio et al., 2011; Ward & Raffa, 
2011); AM6546 (Cluny et al., 2010; Randall et al., 2010) and LH-21, described as a 
poor CNS penetrant (Alonso et al., 2012; Pavon et al., 2006). These compounds 
elicit a similar effect on bodyweight to that seen with rimonabant, supporting the 
hypothesis that the bodyweight effects of these drugs are peripherally mediated. 
However, it is interesting to note that these compounds have failed to produce 
comparable effects on metabolic parameters (Pavon et al., 2006). 
4.1.5.3.3 Other CB1 Receptor Strategies 
Alternative CB1-related strategies include the use of CB1 receptor partial agonists 
and manipulation of endocannabinoid levels. Partial agonists can also act as partial 
antagonists when levels of endogenous agonists are elevated, as seen with 
endocannabinoids and obesity (Matias & Di Marzo, 2007). Therefore, by blocking 
the elevated levels of obesity-induced endocannabinoids, such compounds could 
potentially prevent the psychiatric side effects. Similarly, drugs that target the 
enzymes responsible for synthesis and degradation of endocannabinoids may 
counteract the dysregulation. Target enzymes include: NAPE-PLD, for the 
production of anandamide; DAGL, for the production of 2-AG; FAAH for the 
breakdown of both endocannabinoids; and MAGL, for the breakdown of 2-AG (Di 
Marzo, 2008; DiMarzo, 2008; DiMarzo, 2009). Recent developments include O-
5596, which inhibits the biosynthesis of 2-AG and has been found to decrease food 
intake in mice (Bisogno et al., 2009). 
The final option available is an adjunctive strategy (Pertwee, 2009). As discussed in 
Chapter 2, the combination of two drugs at sub-anorectic dose levels can 
significantly improve the side-effect profile compared to the individual compounds. 
4.1.5.4 Potential Combinations (preclinical) 
Although there are no current cannabinoid combinations in clinical testing, known 
cannabinoid interactions with other systems, including the serotonergic and opioid 
systems (see later, Section 4.3), have encouraged preclinical interest in 
cannabinoid combinations. 
The co-localisation of CB1 receptors and 5-HT transporters in the brain (Ashton et 
al., 2006; Hermann et al., 2002) suggests the existence of potentially important 
cannabinoid-serotonergic interactions. In this context, CB1 receptor agonists 
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reduce 5-HT expression (Molina-Holgado, 1993; Nakazi et al., 2000; Sagredo, 
2006) through binding to 5-HT receptors (Kimura, 1998), while CB1 receptor 
antagonism increases serotonin release (Tzavara et al., 2003). In feeding research, 
CB1 receptor-induced alcohol intake is prevented by 5-HT1A receptor blockade 
(Kelai, 2006). These findings would suggest that the administration of CB1 receptor 
antagonist with compounds that enhance serotonergic activity should produce an 
enhanced suppression of intake. Co-treatment studies have assessed the effect of 
rimonabant with serotonergic agents, such as d-fenfluramine (a serotonin releaser; 
Rowland et al., 2001), mCPP (serotonin 2c receptor agonist; Ward et al., 2008), 
and sibutramine (serotonin and noradrenaline reuptake inhibitor; Tallett et al., 
2010a). However, each study found differing results (Ward, Synergistic; Rowland, 
Additive; Tallett, Sub-additive). 
In the same vein, evidence has shown that CB1 receptors inhibit the anorectic 
effects of downstream melanocortin-4 receptors (Verty, McFarlane, et al., 2004). 
Further investigation confirmed that the combination of sub-anorectic doses of 
rimonabant and α-MSH synergistically attenuated feeding in rats (Verty, McFarlane, 
et al., 2004). It is also known that leptin administration decreases cannabinoid 
levels (Di Marzo et al., 2001), whilst leptin deficiency up-regulates CB1 levels (Di 
Marzo et al., 2001; Thanos et al., 2008). Furthermore, CB1 receptor KO mice 
display an increased sensitivity to leptin (Ravinet Trillou et al., 2004). These data 
suggest that the co-administration of leptin and CB1 receptor antagonists has 
potential for synergy in the treatment of obesity and related co-morbidities such as 
diabetes (Tam et al., 2012). 
4.1.6 Summary; The Cannabinoid System 
Cannabinoid CB1 receptor antagonist/inverse agonists, such as rimonabant, 
suppress food intake and weight gain in both rodents and humans. However, a 
variety of side-effects, such as mood disorders and pruritus, have thus far 
undermined full clinical exploitation of the therapeutic potential of such agents. 
Nevertheless, a range of novel CB1 research strategies is currently being explored, 
including drug polytherapy. 
4.2 The Opioid System 
There are four families endogenous opioid peptides; β-endorphin, enkephalin, 
dynorphin and endomorphin (Mansour et al., 1988; Snyder, 1977; Waldhoer et al., 
2004), derived respectively from the prohormones; POMC, proenkephalin, 
prodynorphin. The precursor to endomorphin has yet to be identified.  
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There are now known to be multiple opiate receptor sites (mu: μ; delta: δ; kappa: κ) 
throughout CNS and peripheral tissues (Goldstein & Naidu, 1989; Magnan et al., 
1982; Raynor et al., 1994). All receptor sub-types are expressed in the VTA, and 
VMH. Additionally, κ-receptors are expressed in the PVN, and μ-receptors in the LH 
(Adan, 2013). Interestingly, κ-receptors are expressed on AgRP releasing neurons, 
while μ-receptors are expressed on POMC neurons, where they act as inhibitory 
auto-receptors blocking the release of β-endorphin. Therefore, μ-receptor 
antagonists would increase POMC release (Greenway, Whitehouse, et al., 2009). 
4.2.1 Opioid Receptor Antagonists & Appetite Regulation 
The role of opioids in appetite (see reviews; Bodnar, 2004; Cooper, 1993; Yeomans 
& Gray, 2002) was initially highlighted in patients with eating disorders. 
Underweight anorexic (Kaye et al., 1987) and bulimic patients (Brewerton et al., 
1992) exhibit suppressed levels of various endogenous opioid peptides, which 
normalise upon weight gain.  
The administration of plant-derived opioids (Martin et al., 1963) and other opioid 
receptor agonists (Bodnar, 2004; Grandison & Guidotti, 1977; Leibowitz & Hor, 
1982; McCarthy et al., 1981; McKay et al., 1981; Morley & Levine, 1981; Sanger et 
al., 1981) induce hyperphagia, an effect blocked by opioid receptor antagonists 
(Sanger et al., 1981). When given alone, broad spectrum antagonists, such as 
naloxone and naltrexone, significantly inhibits food intake in food-deprived animals 
(Barbano & Cador, 2006; Brands et al., 1979; Brown & Holtzman, 1979; Carey et 
al., 1981; Cooper, 1980; Glass et al., 2001; Hadjimarkou et al., 2004; Holtzman, 
1974; Kirkham & Blundell, 1984, 1987; Koch & Bodnar, 1994; Lowy & Yim, 1981; 
Markskaufman & Balmagiya, 1985; Markskaufman & Kanarek, 1981; McCarthy et 
al., 1981; Sanger & McCarthy, 1981b, 1982). Opioid receptor antagonists also 
suppress hyperphagic responses to: glucoprivation (Koch & Bodnar, 1994; 
Ostrowski et al., 1981), stress (Morley et al., 1980; Teskey et al., 1984), stimulation 
of the LH (Carr & Simon, 1983), and lesions of the VMH (King et al., 1979). The 
anorectic effects of opioid antagonists are also more pronounced in obese vs. lean 
animals (Margules et al., 1978; McLaughlin & Baile, 1984) and in satiated vs. 
deprived animals (Barbano & Cador, 2006; Brown & Holtzman, 1979). Moreover, 
opioid receptor antagonism is more effective in reducing the intake of palatable 
foods compared to regular chow (see Section 4.2.2).  
Interestingly, selective opioid receptor antagonists, such as: the κ-opioid receptor 
antagonist, nor-binaltorphamine (Arjune & Bodnar, 1990; Carr et al., 1989); the μ-
receptor antagonists, β-funaltrexamine (Arjune & Bodnar, 1990; Ukai & Holtzman, 
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1988) and GSK1521498 (Giuliano, 2012); and the δ-receptor antagonist, naltrindole 
(Arjune et al., 1991; Jackson & Sewell, 1985a), elicit differential effects on feeding. 
Evidence suggests that there may be a more dominant role for μ-receptors. For 
example, μ-receptor KO mice display a diminished anorectic response to 
naloxone/naltrexone (Zhang et al., 2006), and μ-receptor antagonism elicits a 
similar potency to general opioid antagonism (Simone et al., 1985), whereas κ-
opioid receptor and δ-receptor antagonists often fail to alter feeding (Koch & 
Bodnar, 1994).  
When assessing macronutrient intake (Koch & Bodnar, 1994; Markskaufman & 
Kanarek, 1981) and meal patterns (Glass et al., 2001; Kirkham & Blundell, 1987), 
evidence shows that opioid antagonists only suppress intake following the 
consumption of food. Therefore, opioid antagonism does not delay the latency to 
approach or initiate feeding (Beczkowska, Bowen, et al., 1992; Beczkowska, Koch, 
et al., 1992; Glass et al., 2001; Kirkham & Blundell, 1986; Tallett et al., 2008a) but, 
instead, elicits its anorectic effects through the acceleration of meal termination 
(Kirkham & Blundell, 1987) via reductions in eat duration and increased resting 
behaviour (Kirkham & Blundell, 1984; Tallett et al., 2008a). In other words, opioid 
receptor blockade elicits the early onset of satiety, and is involved in the 
maintenance rather than initiation of feeding (Levine & Billington, 2004).  
It is generally considered that the opioid antagonist-induced anorexia is centrally 
mediated (Carr & Simon, 1983; Markskaufman & Kanarek, 1981; Sanger & 
McCarthy, 1981a). POMC neurons are not only involved in the synthesis of 
endogenous opioids (Pennock & Hentges, 2011) but also express opioid receptors, 
activation of which hyperpolarise the neurons and inhibit firing (Ibrahim et al., 2003; 
Kelly et al., 1990); thus acting as auto-inhibitory receptors. Unsurprisingly then, 
morphine reduces POMC and α-MSH in the hypothalamus (Wardlaw et al., 1996), 
while μ- and κ- receptor blockade prevents AgRP-induced hyperphagia (Brugman 
et al., 2002). Conversely, there is an increase in NPY mRNA following naltrexone 
treatment (Kotz et al., 1996), and NPY-induced feeding is attenuated by naloxone 
and naltrexone (Kotz et al., 1995; Rudski et al., 1996; Schick et al., 1991) but not by 
δ- receptor antagonism (Kotz et al., 1993). Opioids may also produce anorectic 
effects by blunting melanocortin and oxytocin signalling (Olszewski & Levine, 2007). 
Naltrexone administration blocks the orexigenic effect of Orexin A (Sweet, 2004), 
while butorphanol (a μ- and κ- agonist) reduces c-Fos-positive oxytocin cells in the 
PVN (Olszewski & Levine, 2007). Conversely, orexin administration increases 
enkephalin levels in the VTA, PVN and amygdala (Karatayev et al., 2009). 
Interestingly, galanin hyperphagia is also attenuated by naloxone (Dube et al., 
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1994) while μ-receptor, but not κ-receptor, antagonism abolishes galanin-induced 
hyperphagia (Barton et al., 1996). 
Despite this strong support for central mechanisms of action, there is still some 
evidence for peripheral mediation of opioid-induced anorexia via insulin. For 
example, insulin administration attenuates the increase in sucrose intake (Sipols et 
al., 2002) and conditioned place preference (Figlewicz et al., 2004). 
4.2.2 Opioids & the Rewarding Aspects of Appetite Regulation 
Opioids are thought to be involved in the hedonics of feeding (Berridge, 2000; 
Cooper, 2004; Hayward & Low, 2007; Yeomans & Gray, 2002). As previously 
mentioned, opioid receptor antagonism is more effective at reducing the intake of 
palatable foods compared to regular chow (Apfelbaum & Mandenoff, 1981; Barbano 
& Cador, 2006; Cleary et al., 1996; Cooper et al., 1985; Cooper & Turkish, 1989; 
Giraudo et al., 1993; Glass et al., 1999; Glass et al., 2001; Hayward et al., 2006; 
Islam & Bodnar, 1990; Levine & Billington, 2004; Markskaufman et al., 1984; 
Sanger & McCarthy, 1981a, 1982), effects thought to be mediated via μ- and κ- 
receptors. Evidence shows that agonism of these receptors preferentially increases 
the consumption of energy dense food but not normal chow (Cooper et al., 1985; 
Zhang et al., 1998). Conversely, the novel selective μ-receptor opioid antagonist, 
GSK1521498, has been shown to elicit a dual effect on motivation for and hedonic 
impact of food, supressing intake via reductions in food seeking and binge-eating 
(reward seeking) behaviours (Giuliano et al., 2012). In overweight patients, this 
novel agent has been shown to reduce intake and pleasurable responses to high 
fat/sugar foods (Nathan et al., 2012). 
There is an on-going debate (see: Taha, 2010) as to whether opioid receptor 
agonism increases intake (and opioid antagonism decreases intake) of preferred 
foods independent of macronutrient intake (Giraudo et al., 1993; Gosnell et al., 
1990; Leventhal et al., 1995; Zhang et al., 1998) or if this effect is preferential to fat 
consumption (Markskaufman & Balmagiya, 1985; Markskaufman et al., 1984; 
Markskaufman & Kanarek, 1981). On the other hand, some have argued that the 
opioid system affects feeding driven by sweet taste (Apfelbaum & Mandenoff, 1981; 
Cooper et al., 1985; Giraudo et al., 1993), as demonstrated with sucrose and 
saccharin solutions (Beczkowska et al., 1993; Gosnell & Majchrzak, 1989; Kirkham, 
1990). However, due to the natural baseline of fat preference, it is important to 
dissociate fat/sugar content from preferred foods, which can be done by 
establishing baseline preferences for fat/carbohydrate. Data can be further 
confounded by total caloric intake; for example, while naltrexone administration 
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decreases cookie consumption, it actually increases total chow consumption 
(Cooper & Turkish, 1989). 
Interestingly, Glass (2000) found that intake of preferred/non-preferred foods was 
dependent upon the site of administration. For example, naltrexone administered 
into the PVN reduced the intake of both foods, potentially targeting energy 
regulation, whereas, naltrexone administered into the amygdala reduced intake of 
preferred foods only, targeting hedonic or affective processes. As expected from a 
compound targeting hedonic feeding, opioid receptor antagonism is also found to 
decrease animal and human food preferences (Bertino et al., 1991; Fantino et al., 
1986; Yeomans & Gray, 2002; Yeomans & Wright, 1991) and reduce sham feeding 
(Cooper, 2004; Cooper & Kirkham, 1993; Kirkham & Blundell, 1987; Kirkham & 
Cooper, 1988). This is thought to be mediated via opioid receptor activation 
stimulating an increase in NAcc dopamine release (Devine et al., 1993; Hirose et 
al., 2005), thereby increasing food intake and hedonic taste reactivity (Zhang et al., 
1998; Zhang & Kelley, 2000), both of which can be blocked by opioid receptor 
antagonism (Sahr et al., 2008). These findings suggest that opioid-induced food 
intake is mediated via the mesolimbic dopamine pathway, a perspective strongly 
supported by the discovery of ‘hot-spots’ for µ-opioid enhancement of taste 
hedonics in the ventral forebrain (Berridge, 2009; Berridge et al., 2010; Nathan & 
Bullmore, 2009).  
4.2.3 Opioids and Non-Appetite Regulatory Behaviours 
In addition to appetite regulation, opioids are involved in a range of psychological 
and physiological processes including; analgesia, stress, learning and memory, 
alcohol and drug abuse, sexual activity, mood and mental illness (see recent 
review: Bodnar, 2012). Of primary interest within the context of this thesis are its 
effects on mood and pruritus. 
4.2.3.1 Pruritus 
One of the most common adverse effects of morphine administration in humans is 
pruritus (Ballantyne et al., 1988; Cousins & Mather, 1984). Conversely, opioid 
receptor antagonists, such as naloxone and naltrexone, are among the most 
effective treatments for various human skin disorders, characterised by pruritus 
(Bernstein et al., 1982; Cies & Giamalis, 2007; Phan et al., 2010; Terra & Tsunoda, 
1998). It is interesting the note the efficacy of methyl naltrexone (Friedman & Dello 
Buono, 2001) and topical naltrexone (Bigliardi et al., 2007) in the treatment of 
human pruritus, which suggests a peripheral site of action (Schlosburg et al., 2011).  
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4.2.3.2 Depression and Anxiety 
Opioid δ-receptor agonists dose-dependently induce anxiolytic effects, while 
antagonism or genetic deletion of these receptors produces an anxiogenic profile 
(Filliol et al., 2000; Perrine et al., 2006). Interestingly, δ-receptor deletion or KO also 
produces a depressive behavioural profile (Filliol et al., 2000) whereas agonism 
reduces depression-like behaviour (Broom et al., 2002). This is of particular 
relevance when considering the therapeutic potential of opioid receptor antagonists 
for the treatment of obesity, a condition known to already be associated with high 
levels of depression and anxiety. 
4.2.4 Therapeutic Potential for the Treatment of Obesity 
4.2.4.1 Given Alone 
Naloxone and naltrexone have been shown to acutely suppress intake and cravings 
in lean, bulimic and obese humans (Atkinson et al., 1985; Cohen et al., 1985; 
Drewnowski et al., 1995; Fantino et al., 1986; Marrazzi et al., 1995; Trenchard & 
Silverstone, 1983; Wolkowitz et al., 1988). However, naltrexone is less effective 
than naloxone in humans (Maggio et al., 1985; Malcolm et al., 1985; Mitchell et al., 
1987). This short-term suppressant effect of the opioid antagonists on food intake 
(~11-29%; Yeomans & Gray, 2002) does not result in a subsequent reduction in 
bodyweight (Atkinson et al., 1985; Malcolm et al., 1985; Mitchell et al., 1987). This 
lack of impact on bodyweight parameters means that there is little potential for the 
therapeutic exploitation of opioid receptor antagonism when administered alone.  
4.2.4.2 Given in Combination 
Despite the minimal weight loss seen with naloxone alone, the combination of 
broad spectrum opioid antagonists with other appetite suppressants has produced 
additive and supra-additive effects on food intake and bodyweight reduction. For 
example, Contrave™; the combination of bupropion and naltrexone (Greenway 
Whitehouse, et al., 2009; see Chapter 5), has reached phase III clinical trials. As 
discussed in Chapter 2, the naltrexone element acts by inhibiting the µ-opioid 
receptor, augmenting the release of POMC in the ARC and supressing the release 
of α-MSH, hence increasing the weight loss effect of bupropion (Bray & Greenway, 
2007; Greenway, Whitehouse, et al., 2009).  
Preclinical animal studies demonstrated a fully additive interaction in lean mice, and 
a synergistic action in DIO mice (Greenway, Whitehouse, et al., 2009). It is 
pertinent to note the degrees of drug action varied dependent upon the animal 
model used (Lalonde et al., 2004; Serrano et al., 2008). However, clinical studies 
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have suggested a sub-additive effect with the majority of the anorectic action 
produced by bupropion (Greenway et al., 2010). In 2010, the Contrave® Obesity 
Research I (COR-I) study was conducted (Greenway et al., 2010). Evidence 
demonstrates clinically meaningful reductions in bodyweight; 48% of the naltrexone 
(32mg) plus bupropion group lost 5% of their body weight while 25% lost 10% of their 
baseline bodyweight (Greenway et al., 2010; Makowski et al., 2011). 
Additive and synergistic interactions on food and alcohol intake have also been 
reported for co-treatment with opioid receptor antagonists and drugs that enhance 
5-HT activity (Beczkowska, 1991; Fernandez-Tome, 1988; Gardell, 1997; Hagan et 
al., 1997; Johnson, 2000; Le & Sellers, 1994; Rezvani et al., 2000). Disappointingly 
however, a more detailed assessment of feeding behaviours with the sub-anorectic 
combination of naloxone and sibutramine produced effects that were substantially 
lower than those predicted on the basis of the sum of the individual drug effects 
(Tallett et al., 2010b). 
There have also been numerous reports of additive and/or supra-additive 
interaction between sub-anorectic doses of opioid receptor antagonists (naloxone, 
nalmefene) and CB1 receptor antagonist/inverse agonist (rimonabant, AM251; 
Chen, Huang, et al., 2004; Pietras & Rowland, 2002; Rowland et al., 2001; Tallett et 
al., 2008b, 2009a; Williams, 2001; see Section 4.3). 
The manipulation of both the satiety and reward systems simultaneously (as 
discussed in Chapter 2) has the potential to produce additive actions on food 
intake. Therefore, the opioid antagonist, naltrexone has also been assessed in 
combination with the GLP-1 agonist, Exendin-4 (Liang et al., 2013; see also chapter 
7), with the combination producing a greater suppression of short-term food intake 
than that seen with either drug individually. 
4.2.5 Summary; The Opioid system  
Broad spectrum opioid receptor antagonists, such as naloxone and naltrexone, 
suppress food intake and weight gain in both rodents and humans. It is now 
generally considered that the opioid system plays a prominent role in the hedonics 
of feeding. Research also points to the therapeutic potential of opioid receptor 
antagonists in combination with manipulations of the cannabinoid and 5-HT 
systems. 
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4.3 Cannabinoid-Opioid System Interactions 
There is substantial evidence for biologically-relevant molecular cross-talk between 
the endocannabinoid and endogenous opioid systems (Rios et al., 2006; 
Schoffelmeer et al., 2006). In behavioural research, such interactions have been 
reported for nociception (Manzanares et al., 1999), drug reward (Tanda & 
Goldberg, 2003) and appetite (Gallate et al., 1999; Lockie et al., 2011; Skelly et al., 
2010; Trojniar & Wise, 1991; Williams & Kirkham, 2002).  
4.3.1 System Interactions in Appetite Regulation 
Early studies demonstrated that naloxone administration blocked the orexigenic 
(Trojniar & Wise, 1991; Williams & Kirkham, 2002) and antinociceptive (Pietras & 
Rowland, 2002) effects of THC. Conversely, rimonabant was found to block 
morphine-induced hyperphagia (Verty et al., 2003). Evidence that opioid antagonist 
administration blocks cannabinoid-induced feeding has also been shown in regards 
to the hedonic aspects of feeding. Naloxone blocks the CB1 receptor agonist-
induced increase in breakpoints in operant responding for palatable food (Gallate et 
al., 1999). Conversely, opioid-induced food-reinforced responding can be blocked 
by CB1 receptor antagonism (Gallate et al., 1999; Solinas & Goldberg, 2005; 
Trojniar & Wise, 1991; Verty et al., 2003; Williams & Kirkham, 2002). Similarly, 
naloxone blocks the ability of CB1 receptor agonists to stimulate alcohol intake 
(Colombo et al., 2005).  
Of primary relevance to this thesis, is the finding that the co-administration of sub-
anorectic doses of naloxone and rimonabant (or AM251) suppresses food intake 
(Kirkham & Williams, 2001; Rowland et al., 2001; Tallett et al., 2008b, 2009a). 
Additional evidence shows that sub-anorectic co-treatment with nalmefene (another 
opioid receptor antagonist) and AM251 (Chen, et al., 2004) also produces a 
synergistic effect on food intake. These reports suggest that there may be potential 
for the combination of these systems in the treatment of obesity.  
4.3.2 System Interactions in Non-Appetite Regulatory Behaviours 
4.3.2.1 Reward 
Genetic deletion and pharmacological receptor blockade demonstrate that CB1 
receptors modulate both opiate reward and motor functions (Braida et al., 2001; 
Ledent et al., 1999; Navarro et al., 2001) and, conversely, that opioid receptors are 
implicated in the motivational effects of cannabinoids (Ghozland et al., 2002). 
Within the NAcc, stimulation of both opioid and cannabinoid CB1 receptors 
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enhances food reward, whereas their antagonism reduces palatability (Mahler, 
2007). This is unsurprising as both systems stimulate dopamine-containing neurons 
in the VTA (Johnson & North, 1992; Pickel et al., 2004; Rodriguez et al., 2001; 
Tanda et al., 1997), which may act as the downstream mediator for their hedonic 
effect on food intake.  
4.3.2.2 Scratching and Grooming 
Of particular relevance in regards to scratching and grooming are the previously 
mentioned studies by Tallett et al. (Tallett et al., 2008b, 2009a). The studies 
explored opioid-cannabinoid system interaction in appetite regulation using 
combination treatment with sub-anorectic doses of a CB1 receptor 
antagonist/inverse agonist (rimonabant or AM-251) and the opioid receptor 
antagonist, naloxone. The combination treatments produced additive effects on 
food intake and ingestive behaviour. Furthermore, both CB1 receptor antagonists 
induced significant amounts of scratching (Tallett et al., 2007a, 2007b). However, 
most interestingly, the authors demonstrated that naloxone markedly attenuate the 
compulsive scratching response seen in response to low doses of CB1 receptor 
antagonists.  
4.4 Rationale: Chapter Four 
The ‘response competition’ hypothesis holds that the acute anorectic response to 
conventional CB1 receptor antagonist/inverse agonist (e.g. rimonabant, AM-251) is 
due primarily (if not exclusively) to the induction of an intense scratching and 
grooming syndrome that interferes with feeding behaviour during tests of finite 
duration (Tallett et al., 2007a, 2007b).  
As scratching and grooming are also features of the newer ‘silent’ or neutral CB1 
receptor antagonist (Hodge et al., 2008; Järbe et al., 2008), the aim of studies 
reported in Chapter 4 was to test a clear prediction of the response competition 
hypothesis; namely, that low dose naloxone treatment should attenuate both the 
pruritic and anorectic responses to a moderate dose of rimonabant. 
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4.5 Experiment One; Rimonabant (1.5mg) and Naloxone (0.1 
and 0.01mg/kg) Interaction 
4.5.1 Method  
All procedures were conducted under Home Office licence in accordance with the 
UK Animals (Scientific Procedures) Act 1986. For the main methodological details, 
please refer to Chapter 3 (General Methods). 
4.5.1.1 Subjects and Design 
10 adult male Lister hooded rats (216.09 + 2.75g on arrival from Charles River, U.K 
and 483.00 + 10.10g by the end of the study) were used. A within-subjects design 
was adopted whereby each subject received all six treatments according to a Latin 
Square (with a 7 day wash out period): Vehicle + Vehicle (VV); Vehicle + Naloxone 
0.01mg/kg (VNL); Vehicle + Naloxone 0.01mg/kg (VNH); Rimonabant 1.5mg/kg + 
Vehicle (RV); Rimonabant 1.5mg/kg + Naloxone 0.01mg/kg (RNL); or Rimonabant 
1.5mg/kg + Naloxone 0.1mg/kg (RNH).  
4.5.1.2 Drugs 
Naloxone hydrochloride (Sigma-Aldrich, Poole, UK) was dissolved in physiological 
saline (0.9%) which, alone, served as a vehicle control. Rimonabant ([N-piperidin-5-
(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide]), kindly 
donated by Sanofi-Aventis (Chilly-Mazarin, France), was suspended in a small 
volume of dimethyl sulfoxide (DMSO; Sigma-Aldrich) and subsequently made up to 
required concentrations in 0.5% methylcellulose (Sigma-Aldrich). Doses of 
naloxone (0.01 mg/kg and 0.1 mg/kg) and rimonabant (1.5 mg/kg) were selected on 
the basis of recent dose-response studies in our laboratory (Tallett et al., 2008b and 
references therein). All solutions were freshly prepared on test days and 
administered i.p. in a volume of 1ml/kg 30 minutes (rimonabant/vehicle) or 15 
minutes (naloxone/vehicle) prior to testing. 
4.5.1.3 Procedure 
Testing occurred over six weeks, with two test days per week and 5 animals tested 
per day. Treatment order was counterbalanced both within and between test days 
according to the Latin Square 
4.5.2 Results 
Full statistical details can be found in Appendix 1. 
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4.5.2.1 Habituation Phase Food Intake 
As is typical of the current protocol, mash consumption differed significantly over 
the course of habituation (trial 1: 10.7 ± 1.5g; trial 2: 14.8 ± 1.4g; trial 3: 16.9 ± 1.5g; 
trial 4: 17.8 ± 2.1g; trial 5: 19.2 ± 1.8g (F(4,36) = 11.04, p < 0.001). Trial 1 intake 
was significantly lower than on trials 3 and 5 (p ≤ 0.05), and trial 2 intake lower than 
on trial 5 (p < 0.01). The lower intake scores on the first two habituation trials was 
probably due to environmental novelty. However, the development of stable 
consumption was confirmed by the lack of significant differences across trials 3-5 (p 
> 0.05), as well as the close similarity in intake scores between those habituation 
trials and the vehicle condition in the main experiment (16.56 ± 1.22g). 
4.5.2.2 Test Day Bodyweight 
Test-day bodyweights were comparable across treatment conditions (VV: 412.6 ± 
11.3g; VNL: 412.5 ± 17.0g; VNH: 420.4 ± 17.1g; RV: 421.5 ± 14.3g; RNL: 427.3 ± 
14.5g; RNH: 424.6 ± 11.2g (rimonabant: F(1,9) = 0.65, p > 0.05; naloxone: F(2,18) 
= 0.16, p > 0.05; rimonabant x naloxone: F(2,18) = 0.07, p > 0.05).  
4.5.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.30% throughout the experiment (range = 0.13-0.52%). Treatment effects on 
food intake are summarised in Figure 4-2. There was a significant main effect of 
rimonabant (F(1,9) = 58.49, p < 0.001), but no significant main effect for naloxone 
(F(2,18) = 2.28, p > 0.05) or a drug interaction (F(2,18) = 1.46, p > 0.05).  
 
Figure 4-2: Experiment One: Effects of acute rimonabant and naloxone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle, R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 mg/kg; NH = naloxone 0.1 
mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
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Bonferroni comparisons confirmed that, whereas neither dose of naloxone alone 
altered intake compared with VV control, significant suppression was evident in all 
conditions receiving rimonabant (RV: p = 0.001; RNL: p = 0.032; RNH: p = 0.001). 
Despite the apparently reduced anorectic effect of rimonabant when co-
administered with the lower dose of naloxone (see Figure 4-2), the fact that RNL 
remained significantly different from VV, but did not differ from rimonabant given 
alone (RV), suggests only a weak low dose naloxone attenuation of rimonabant 
anorexia.  
4.5.2.4 Total (one-hour) Behavioural Analyses 
Data for eating-related parameters are summarised in Table 4-1, while treatment 
effects on total 1-h frequency and duration scores for ingestive and non-ingestive 
behaviours are illustrated in Figure 4-3.  
Table 4-1: Experiment One. Acute effects of rimonabant and naloxone, alone and in 
combination, on eating-related parameters 
Data are mean values (± S.E.M). V = vehicle; R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 
mg/kg; NH = naloxone 0.1 mg/kg (Mean + SE) 
Measure VV RV VNL VNH RNL RNH 
Latency to locate food (s) 10.45 ± 
2.73 
12.43 ± 
3.64 
7.47 ± 
2.49 
9.18 ± 
3.19 
12.98 ± 
4.18 
6.38 ± 
2.24 
Latency to eat (s) 22.13 ± 
8.64 
36.05 ± 
15.62 
21.64 ± 
7.91 
24.50 ± 
7.81 
13.48 ± 
2.77 
57.48 ± 
13.92 
Eat bout duration (s) 20.99 ± 
3.46 
12.88 ± 
1.08 
20.84 ± 
2.91 
18.98 ± 
1.75 
13.94 ± 
1.57 
14.49 ± 
1.87 
Eating Rate (g/min) 1.31 ± 
0.12 
1.37 ± 
0.22 
1.44 ± 
0.23 
1.41 ± 
0.20 
1.86 ± 
0.78 
1.78 ± 
0.48 
 
There were no rimonabant x naloxone interactions for any of the test variables 
(F(2,18) ≤ 3.42, p > 0.05), although the F-value for groom duration closely 
approached significance (p = 0.055). Significant main effects of rimonabant were 
revealed for eat bout duration (Table 4-1) as well as the duration (Figure 4-3) of 
eating and locomotion, and both the frequency and duration of grooming, scratching 
and sniffing (F(1,9) ≥ 7.27, p ≤ 0.05). Significant main effects of naloxone were 
found only for the frequency and duration of grooming (F(2,18) ≥ 5.45, p ≤ 0.02), 
although the main effect for eat latency closely approached significance (F(2,18) = 
3.51, p < 0.052).  
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Figure 4-3: Experiment One. Effects of rimonabant and naloxone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash 
Data are mean values (± S.E.M). V = vehicle, R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 
mg/kg; NH = naloxone 0.1 mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 
0.001 versus VV 
Post-hoc analyses showed that, relative to VV control, neither dose of naloxone 
alone significantly influenced feeding duration (Figure 4-3). In contrast, rimonabant 
alone (RV, p = 0.003) and in conjunction with the higher dose of naloxone (RNH, p 
= 0.001) significantly reduced time spent feeding. Co-administration of rimonabant 
and the lower dose of naloxone (RNL) just failed to reach an acceptable level of 
statistical significance (p = 0.076 vs VV) and, since this combination did not differ 
significantly from either drug given alone, this profile (like that for mash intake) 
would be consistent with a weak low dose attenuation of rimonabant’s inhibitory 
effect on time spent feeding. As post-hoc analysis of the data for eat bout and 
locomotion duration failed to reveal any significant differences between drug 
treatment groups and VV control, the significant main effect for rimonabant most 
likely reflects relatively minor influences of the compound that emerge only as a 
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result of large sample sizes. The absence of significant pairwise contrasts for eat 
latency suggests that the main effect of naloxone on this measure can similarly be 
attributed to the enhanced power of main effects analysis.  
Neither the duration nor frequency of grooming or scratching was significantly 
altered by either dose of naloxone given alone. However, while the duration of 
grooming was markedly enhanced by rimonabant given alone (RV vs VV; p = 
0.001), this measure was not significantly increased when the CB1 receptor 
antagonist/inverse agonist was given in combination with either dose of naloxone 
(RNL, RNH). While a lack of difference between RNL and RV would be consistent 
with partial low dose attenuation of rimonabant-induced grooming, the significant 
difference between RV and RNH (p < 0.01) is indicative of full high dose reversal 
this aspect of the compulsive syndrome. Although groom frequency was also 
significantly increased only by rimonabant given alone (RV vs VV; p < 0.02, 
incomplete naloxone attenuation was suggested by the lack of difference between 
rimonabant alone and when given together with either dose of naloxone (RNL, 
RNH). The duration of scratching was significantly increased by rimonabant given 
alone (p = 0.001) and in combination with the lower (p = 0.03), but not higher, dose 
of naloxone. Again, however, the absence of a significant difference between RV 
and either RNL or RNH would support a pattern of partial attenuation. Naloxone 
had a lesser effect on the frequency of rimonabant-induced scratching which, 
despite a clear dose-dependent trend towards naloxone attenuation (Figure 4-3), 
remained elevated relative to VV control in all conditions receiving rimonabant (RV: 
p < 0.001; RNL: p < 0.03; RNH: p < 0.05).  
4.5.2.5 Timebin Behavioural Analyses 
ANOVA revealed a strong main effect of time for all behavioural measures (F(11, 
99) ≥ 1.98, p ≤ 0.04), confirming the characteristic temporal decline in active 
behaviours and increase in inactive behaviours associated with this paradigm 
(Rodgers et al., 2010). There were no significant three-way interactions (rimonabant 
x naloxone x time; F(22,198) ≤ 1.48, p > 0.05) or any significant naloxone x time 
interactions (F(22,198) ≤ 1.21, p > 0.05). However, significant rimonabant x time 
interactions were found for the duration of eating and locomotion, as well as the 
frequency and duration of grooming, scratching and rearing (F(11,99) ≤ 1.98, p ≤ 
0.05). Although the rimonabant x time interactions for other measures failed to 
reach significance (F(11,99) ≤ 1.19, p > 0.05), the F-value for locomotion frequency 
closely approached significance (F(11,99) = 1.87, p = 0.053).  
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Figure 4-4: Experiment One. Effects of rimonabant and naloxone, alone and in 
combination, on the timecourses of eating, scratching and grooming.  
Data are expressed as the mean duration of each behaviour in 12 x 5-min timebin. V = vehicle, 
R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 mg/kg; NH = naloxone 0.1 mg/kg. See text for 
further details. 
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A series of 2-way ANOVAs within each timebin subsequently revealed that 
rimonabant significantly reduced eat duration in timebins 1-3 and 10 (p < 0.02), 
locomotion duration in timebins 4-6, 8 and 11 (p ≤ 0.05) and both rear frequency 
and duration in timebins 1, 3, 4, and 8 (p ≤ 0.052). The frequency of grooming was 
significantly increased in timebins 1, 2, and 5-10 (p ≤ 0.04) while its duration was 
enhanced in timebins 1, 2, 4, 6 and 8 (p ≤ 0.05). Most dramatically of all, both the 
frequency (timebins 1-12 inclusive, p ≤ 0.05) and duration (timebins 1-11 inclusive, 
p ≤ 0.04) of scratching was effectively increased throughout the entire test session.  
Treatment effects on the temporal profiles of eating, scratching and grooming 
(Figure 4-4) clearly illustrate that rimonabant (i) suppressed the peak feeding 
response, an effect unaltered by naloxone co-administration, (ii) induced 
compulsive scratching throughout the session, an effect dose-dependently 
attenuated by naloxone co-administration, and (iii) induced compulsive grooming 
behaviour, particularly over the second half of the session, an effect again dose-
dependently attenuated by the opioid receptor antagonist.  
4.5.2.6 Behavioural Satiety Sequence (BSS)  
Treatment effects on the behavioural satiety sequence (BSS) are summarised in 
Figure 4-5. The control condition (VV, top left panel) shows that the peak feeding 
response (first 20 mins) gradually waned as the test session progressed. A 
transition between eating and resting occurred at approximately 30min, with resting 
then becoming the predominant behaviour for the remainder of the session. This 
pattern was essentially unaltered by the lower dose of naloxone given alone (VNL; 
centre left panel), but with some evidence of a modest acceleration of the sequence 
(eat – rest transition around 25 min) in the higher naloxone condition (VNH; bottom 
left panel). This profile is consistent with the trend (albeit non-significant) towards a 
weak anorectic effect of 0.1 mg/kg naloxone (Figure 4-5). 
Rimonabant by itself (RV; top right panel) not only markedly suppressed the peak 
feeding response, but also disrupted the normal BSS with grooming dominating the 
profile particularly over the second half of the test session. Co-administration of 
naloxone (RNL; centre right panel, and RNH; bottom right panel) dose-dependently 
reduced this intense grooming response thereby tending to ‘normalise’ the 
behavioural profile between 30 and 60min. Although the data for the first half of the 
test session showed eating to once again be the prepotent behaviour in RNL and 
RNH conditions, the peak feeding response in these treatment conditions remained 
much lower relative to VV, VNL and VNH (Figure 4-5). Nevertheless, compared 
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with RV profile, eat-rest transitions were more clearly evident in both RNL (30-
35min) and RNH (20-25min) conditions. 
4.5.2.7 Bodyweight Gain 
Data not shown. ANOVA on 7-day absolute bodyweight gain failed to reveal a 
significant rimonabant x naloxone interaction (F(2,18) = 1.15, p > 0.05) or significant 
main effects for either rimonabant (F(1,9) = 2.56, p > 0.05) or naloxone (F(2,18) = 
1.41, p > 0.05). Nevertheless, all animals in treatment conditions involving 
rimonabant generally gained a few grams less (mean: 17.2g) than those in the 
other conditions (mean: 20.8g: see Tallett et al, 2000a). This lack of a significant 
effect on post-treatment weight gain was confirmed by analysis of percent weight 
gain, which also failed to reveal a three-way interaction (F(12,108) = 0.97, p > 
0.05), any two-way interactions (rimonabant x naloxone: F(2,18) = 0.88, p > 0.05; 
day x rimonabant: F(6,54) = 0.56, p > 0.05; day x naloxone: F(12,108) = 0.89, p > 
0.05), or any drug main effects (rimonabant: F(1,9) = 1.77, p > 0.05; naloxone: 
F(2,18) = 1.53, p > 0.05). The significant main effect for day (F(6,54) = 108.74, p < 
0.001) confirms treatment-independent growth patterns. 
4.5.3 Summary of Main Findings 
In Experiment 1, the effects of combined treatment with rimonabant and naloxone 
differed slightly depending upon the dose of the opioid receptor antagonist. Thus, 
while dose-dependently attenuating both the frequency and duration of scratching 
and grooming, the anorectic response to rimonabant appeared totally unaffected by 
the higher dose (0.1 mg/kg) of the opioid antagonist. In fact, treatment with the 
lower naloxone dose (0.01 mg/kg) appeared to attenuate the effects of rimonabant 
on intake and time spent feeding, although these effects were statistically weak. 
Thus, while apparently reducing the degree of anorexia, combined treatment with 
rimonabant and the low dose of naloxone nevertheless still reduced intake to a 
significant level versus vehicle control. Furthermore, there was no difference in 
intake scores between rimonabant given alone and when co-administered with 0.01 
mg/kg naloxone. For time spent feeding, although statistical significance was lost 
(vs vehicle) in the rimonabant/low naloxone treatment condition, once again the 
combination did not differ significantly from rimonabant when given alone. In view of 
these factors, and the results obtained with the higher naloxone dose, it would be 
difficult to argue for any truly meaningful impact of naloxone on rimonabant-induced 
anorexia.  
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Figure 4-5: Experiment One. Effects of rimonabant and naloxone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting; this line is dashed for the RV treatment condition in view of the lack of a clear transition; 
V = vehicle, R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 mg/kg; NH = naloxone 0.1 mg/kg. 
See text for further details. 
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4.6 Experiment Two; Rimonabant (1.5mg/kg) and Naloxone 
(0.5mg/kg) Interaction 
Due to the somewhat unclear nature of Experiment 1, it seemed prudent to verify its 
conclusions in a follow-up experiment which assessed the effects of an 
intermediate dose (0.05 mg/kg) of naloxone on rimonabant-induced behavioural 
changes. 
4.6.1 Method 
4.6.1.1 Subjects and Design 
10 adult male Lister hooded rats (216.60 + 2.79 g on arrival and 480.98 ± 11.42g by 
the end of the study) were used. A within-subjects design was adopted whereby 
each subject received all four treatments according to a Latin Square (with a 7 day 
wash out period): Vehicle + Vehicle (VV); Vehicle + Naloxone 0.05mg/kg (VN); 
Rimonabant 1.5mg/kg + Vehicle (RV); or Rimonabant 1.5mg/kg + Naloxone 
0.05mg/kg (RN). 
4.6.1.2 Drugs 
Naloxone hydrochloride (Sigma-Aldrich, Poole, UK) was dissolved in physiological 
saline (0.9%) which, alone, served as a vehicle control. Rimonabant ([N-piperidin-5-
(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide]), kindly 
donated by Sanofi-Aventis (Chilly-Mazarin, France), was suspended in a small 
volume of dimethyl sulfoxide (DMSO; Sigma-Aldrich) and subsequently made up to 
required concentrations in 0.5% methylcellulose (Sigma-Aldrich). The doses of 
naloxone (0.05 mg/kg) and rimonabant (1.5 mg/kg) were selected on the basis of 
Experiment 1 (see Section 4.5). All solutions were freshly prepared on test days 
and administered i.p. in a volume of 1ml/kg 30 minutes (rimonabant/vehicle) or 15 
minutes (naloxone/vehicle) prior to testing. 
4.6.1.3 Procedure 
Testing occurred over four weeks, with two test days per week, and 5 animals 
tested per day. Treatment order was counterbalanced both within and between test 
days according to the Latin Square 
4.6.2 Results 
Full statistical details can be found in Appendix 2. 
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4.6.2.1 Habituation Phase Food Intake 
As expected, mash consumption differed significantly over the course of habituation 
(trial 1: 9.7 ± 0.78g; trial 2: 13.04 ± 1.71g; trial 3: 13.98 ± 1.45g; trial 4: 19.08 ± 
1.43g; trial 5: 17.71 ± 2.25g (F(4,36) = 11.493, p < 0.001). Although food intake on 
trial 1 was significantly lower than most other trials (3-5; p ≤ 0.05), the development 
of stable intake was confirmed by the lack of difference across trials 4-5 (p > 0.05), 
as well as the close similarity in intake scores between those habituation trials and 
the vehicle condition in the main experiment (18.39 ± 1.57g). 
4.6.2.2 Test Day Bodyweight 
Consistent with the Latin Square design, test-day bodyweights were comparable 
across the various treatment conditions (VV: 418.76 ± 13.45g; VN: 419.91 ± 
15.48g; RV: 430.58 ± 14.66g; RN: 425.56 ± 12.47g (rimonabant: F(1,9) = 0.45, p > 
0.05; naloxone: F(1,9) = 0.05, p > 0.05; rimonabant x naloxone: F(1,9) = 0.07, p > 
0.05).  
4.6.2.3 Test Day Food Intake 
Control food pot measurements showed an average weight loss via evaporation of 
only 0.28% throughout the experiment (range 0.12 - 0.38%). Treatment effects on 
food intake are summarised in Figure 4-6. There was a significant main effect of 
rimonabant (F(1,9) = 43.335, p ≤ 0.001), but no significant main effect for naloxone 
(F(1,9) = 1.447, p > 0.05) or a significant drug interaction (F(1,9) = 0.03, p > 0.05). 
Bonferroni comparisons confirmed that, although naloxone given alone did not alter 
intake compared with VV control, significant suppression was evident in both 
conditions receiving the CB1 receptor antagonist/inverse agonist (RV: p = 0.003; 
RN: p = 0.001; RNH). The apparently weaker anorectic response to rimonabant 
alone compared to co-administration with naloxone (see Figure 4-6) was not 
objectively confirmed by a significant difference between the RV and RN conditions 
(p > 0.05).  
4.6.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on the total frequency and duration of ingestive and non-ingestive 
behaviours are illustrated in Figure 4-7, while data for feeding-related parameters 
are summarised in Table 4-2. It should be noted that levels of drinking were 
extremely low in this study and are not reported.  
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Figure 4-6: Experiment Two. Effects of rimonabant and naloxone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle, R = Rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg; See text for further 
details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
 
There were no significant rimonabant x naloxone interactions for any of the test 
variables (F(1,9) ≥ 2.32, p > 0.05). Significant main effects of rimonabant were 
found for eat bout (Table 4-3) as well as the frequency and duration (Figure 4-7) of 
feeding, locomotion, grooming, sniffing, scratching, and rear frequency (F(1,9) ≤ 
3.66, p ≤ 0.05). In contrast, there were no significant main effects of rimonabant on 
eat rate, the latency to identify the food source or to commence eating, or the 
duration of rearing (F (1,9) ≥ 3.08, p > 0.05). Significant main effects of naloxone 
were not seen for any of the behavioural measures (F(2,18) ≥ 2.95, p > 0.05). 
Table 4-2: Experiment Two. Acute effects of rimonabant and naloxone, alone and in 
combination, on eating-related parameters 
(Mean ± SE); V = vehicle, R = Rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg; * p < 0.05, ** p 
< 0.01, *** p < 0.001 versus VV. See text for further details. 
Measure VV VN RV RN 
Latency to locate food (s) 45.88 ± 20.36 21.71 ± 8.33 18.26 ± 6.24 15.61 ± 4.96 
Latency to Eat (s) 57.81 ± 19.60 32.17 ± 7.22 39.68 ± 12.40 50.11 ± 13.61 
Eat bout Duration(s) 14.58 ± 2.36 15.41 ± 1.81 13.10 ± 2.25 10.12 ± 1.08 
Eating rate (g/min) 1.53 ± 0.19 1.55 ± 0.15 1.57 ± 0.28 1.41 ± 0.15 
 
Post-hoc analyses showed that, relative to VV control, naloxone when given alone, 
failed to significantly influence feeding duration. In contrast, rimonabant alone (RV, 
-7.15% 
 
-45.57% 
 
** 
-50.46% 
 
*** 
0
5
10
15
20
VV VN RV RN
M
as
h
 In
ta
ke
 (
g)
 
111 
 
p = 0.003) and in conjunction with naloxone (RN, p < 0.005) significantly reduced 
time spent feeding. In addition, rimonabant alone did not produce a significant 
reduction in food intake compared to naloxone alone (p = 0.117) whereas the 
combination was significantly different (p < 0.05), demonstrating that the 
combination reduced time spent feeding more so than rimonabant alone. 
  
 
 
 Figure 4-7: Experiment Two. Effects of rimonabant and naloxone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash 
(Mean ± SE); V = vehicle, R = Rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg; * p < 0.05, ** p 
< 0.01, *** p < 0.001 versus VV. See text for further details. 
Post-hoc analyses of the data for eat frequency, eat bout, rear frequency and 
frequency and duration of sniff and locomotion failed to reveal any significant 
differences between drug treatment groups and VV control. Therefore, the 
significant main effect for rimonabant must reflect relatively weak inhibitory effects 
of the CB1 receptor antagonist/inverse agonist that emerge only as a result of large 
sample sizes. Neither the duration nor frequency of grooming or scratching was 
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significantly altered by naloxone given alone or in combination. All measures of 
grooming and scratching were significantly increased with the administration 
rimonabant alone and in combination. There is a trend for naloxone in combination 
to enhance scratching duration (RV, p = 0.01; RN, p > 0.005) compared to vehicle 
(VV). Whereas the opposite can be said for grooming behaviours (Frequency; RV, 
p > 0.005; RN, p > 0.05; Duration; RV, p > 0.001; RN, p > 0.05). This suggests that 
naloxone, somewhat unexpectedly, is having minimal effects upon the rimonabant-
induced grooming and scratching behaviours. 
4.6.2.5 Timebin Behavioural Analyses 
Confirming the expected temporal decline in active behaviours and increase in 
inactive behaviours across the test session, ANOVA revealed a strong main effect 
of time for most behavioural measures (F(11, 99) ≥ 2.16, p ≤ 0.05). The exceptions 
being groom duration (F(11,99) = 1.64, p > 0.05) and groom frequency (F(11,99) = 
1.83, p ≤ 0.06), although the latter closely approached significance.  
ANOVA revealed only one significant three-way interaction for eat duration 
(rimonabant x naloxone x time; F(11,99) = 2.43, p < 0.01). Two significant 
rimonabant x time interactions were found for eat duration (F(11,99) = 4.00, p < 
0.001) and scratch frequency (F(11,99) = 7.74, p < 0.001). One naloxone x time 
interaction was found for rest duration (F(22,198) = 2.88, p < 0.01). Although the 
drug x time interactions for other measures failed to reach significance, the F-value 
for sniff duration (F(11,99) = 1.85, p = 0.056) closely approached significance. A 
series of 2-way follow up ANOVAs within each timebin subsequently revealed that 
rimonabant significantly reduced eat frequency in timebin 2 (F(1,9) = 10.73, p < 
0.01), potentially indicating a rimonabant-induced suppression of the peak feeding 
response. Furthermore naloxone reduced eat frequency in timebin 10 (F(1,9) = 
6.02, p < 0.05). Similar follow up 2 way (rimonabant x naloxone) ANOVAs for eat 
duration revealed a rimonabant x naloxone interaction in timebins 4 and 12. 
The rimonabant treatment effects on the temporal profiles of eating, scratching and 
grooming (Figure 4-8) illustrate similar patterns seen in Experiment 1. This is that 
rimonabant (i) suppressed the peak feeding response, (ii) induced compulsive 
scratching throughout the session, and (iii) induced compulsive grooming 
behaviour, particularly over the second half of the session. Unexpectedly, unlike 
that seen in Experiment 1, naloxone co-treatment displayed relatively weak effects  
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Figure 4-8: Experiment Two. Effects of rimonabant and naloxone, alone and in 
combination, on the timecourses of eating, scratching and grooming 
Data are expressed as the mean duration of each behaviour in the mean duration of each 
behaviour in 12 x 5-min timebin V = vehicle, R = rimonabant 1.5 mg/kg; N = naloxone 0.05 
mg/kg. See text for further details 
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on the rimonabant scratching and grooming. The temporal profiles (Figure 4-8) and 
statistical analysis show little evidence of a naloxone-induced attenuation of 
rimonabant’s scratching and grooming syndrome.  
4.6.2.6 Behavioural Satiety Sequence (BSS) 
Treatment effects on the behavioural satiety sequence (BSS) are summarised in 
Figure 4-9. Most unusually, the control condition (VV; top left panel) fails to show a 
convincing peak feeding response. Normally seen within the first 15mins, the peak 
should gradually wanes as the test session progresses. Although, the naloxone 
alone condition (VN; top right panel) does demonstrate this more clearly, the 
vehicle condition instead demonstrates a gradually waning in duration of what 
appears to be continuous sampling. Eat-to-rest transitions can be seen within the 
7th timebin (30-35 minutes into the session) for both VV and VNL conditions, with 
resting then becoming the predominant behaviour for the remainder of the test 
session (more so in VN). Similar to Experiment 1, rimonabant alone (RV; bottom left 
panel) not only markedly suppressed the peak feeding response, but also disrupted 
the normal BSS with grooming dominating the profile throughout most the test 
session. (Eat/Rest cross over at 35mins). Co-administration of naloxone (RN; 
bottom right panel) fails to restore the peak feeding behaviour. However, it does 
appear to reduce grooming behaviour towards the end of the session, allowing 
resting to become the dominant behaviour. An eat-rest transition is still unclear in 
the RN condition although it does show a groom-rest transition at 40mins. 
4.6.2.7 Bodyweight Gain 
Data not shown. ANOVA on 7-day absolute bodyweight gain failed to reveal a 
significant rimonabant x naloxone interaction (F(2,18) = 0.67, p > 0.05) or indeed 
significant main effects for either rimonabant (F(1,9) = 0.32, p > 0.05) or naloxone 
(F(2,18) = 0.107, p > 0.05). The lack of treatment effect on weight gain was further 
confirmed by analyses of percent weight gain. ANOVA failed to reveal a three-way 
interaction (F(7,63) = 1.147, p > 0.05), or any two-way interactions ( F(1,9) = 0.122, 
p > 0.05; rimonabant: F(1,9) = 0.764, p > 0.05; naloxone: F(7,63) = 1.36, p > 0.05). 
Furthermore, there were no main effects of either rimonabant (F(1,9) = 3.17, p > 
0.05) or naloxone (F(1,9) = 0.085, p > 0.05). The highly significant main effect for 
day (F(7,63) = 119.32, p < 0.001) simply reflects the natural growth patterns in all 
condition. 
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Figure 4-9. Experiment Two. Effects of rimonabant and naloxone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting, this line is dashed for the R treatment conditions in view of the lack of a clear transition; 
V = vehicle, R = rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg. See text for further details 
4.6.3 Summary of Main Findings 
The vehicle/control data from this study demonstrated a very unusual BSS profile, 
somewhat reminiscent of that seen with quinine; i.e. a suppressed peak feeding 
response, in addition to intermittent food sampling (characterised by an increased 
number of feed bouts and reduced eating rate), and the virtual absence of resting 
behaviour (Blundell et al., 1985; Ishii, Blundell, Halford, Rodgers, et al., 2003). This 
quinine-like behavioural profile indicates appetite suppression as a result of 
reduced palatability (Ishii, Blundell, Halford, Rodgers, et al., 2003). Furthermore, in 
this study, naloxone did not have a significant effect on either rimonabant induced 
anorexia or the scratching/grooming syndrome. 
After further investigation, an infestation of Tribolium confusum (aka a flour beetle) 
was discovered within the powered food supply. The suppliers were contacted the 
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problem quickly resolved (see Appendix 3). However, due to the contamination of 
the diet, and the unusual behavioural profile of the control animals, the data from 
this study must be considered suspect. As such, it seemed prudent to repeat the 
study in the hope of gaining a more reliable control profile with which to compare 
experimental interventions.  
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4.7 Experiment Three; Rimonabant (1.5mg/kg) and Naloxone 
(0.5mg/kg) Interaction 
4.7.1 Method 
4.7.1.1 Subjects and Design 
10 adult male Lister hooded rats (215.94 ± 1.86g on arrival from Charles River, U.K 
and 479.00 ± 11.03g by the end of the study) were used. A within-subjects design 
was adopted whereby each subject received all four treatments according to a Latin 
Square (with a 7 day wash out period): Vehicle + Vehicle (VV); Vehicle + Naloxone 
0.05mg/kg (VN); Rimonabant 1.5mg/kg + Vehicle (RV); or Rimonabant 1.5mg/kg + 
Naloxone 0.05mg/kg (RN). 
4.7.1.2 Drugs 
Naloxone hydrochloride (Sigma-Aldrich, Poole, UK) was dissolved in physiological 
saline (0.9%) which, alone, served as a vehicle control. Rimonabant ([N-piperidin-5-
(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide]), 
purchased from Cambridge Bioscience (Cambridge, UK), was suspended in a small 
volume of dimethyl sulfoxide (DMSO; Sigma-Aldrich) and subsequently made up to 
required concentrations in 0.5% methylcellulose (Sigma-Aldrich). All solutions were 
freshly prepared on test days and administered i.p. in a volume of 1ml/kg 30 
minutes (rimonabant/vehicle) or 15 minutes (naloxone/vehicle) prior to testing. 
4.7.1.3 Procedure 
Testing occurred over four weeks, with two test days per week and 5 animals tested 
per day. Treatment order was counterbalanced both within and between test days 
according to the Latin Square 
4.7.1.4 Error 
One animal became ill during the first week of the test phase and was removed 
from the study, with a consequent reduction in sample size to 9 
4.7.2 Results 
Full statistical details can be found in Appendix 4. 
4.7.2.1 Habituation Phase Food Intake 
Mash intake again differed over the course of the 5-day habituation period (trial 1: 
10.3 ± 1.3g; trial 2: 15.0 ± 1.7g; trial 3: 14.7 ± 0.9g; trial 4: 17.0 ± 1.4g; trial 5: 15.7 ± 
1.3g (F(4,36) = 9.85, p < 0.001). Although food intake on trial 1 was significantly 
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lower than on trials 3-5 (p ≤ 0.05), the development of stable intake was confirmed 
by the lack of a significant difference across trials 2-5 (p > 0.05), as well as the 
close similarity in intake scores between those habituation trials and the vehicle 
condition in the main experiment (17.70 ± 0.78g). 
4.7.2.2 Test Day Bodyweight 
Test-day bodyweights were comparable across treatment conditions (VV: 411.9 ± 
15.2g; VN: 418.8 ± 12.3g; RV: 413.5 ± 10.9g; RN: 412.7 ± 14.7g: rimonabant: 
F(1,8) = 0.03, p > 0.05; naloxone: F(1,8) = 0.12, p > 0.05; rimonabant x naloxone: 
F(1,8) = 0.08, p > 0.05).  
4.7.2.3 Test Day Food Intake 
Control food pot measurements showed an average weight loss via evaporation of 
only 0.19% throughout the experiment period (range = 0.07-0.29%). Treatment 
effects on food intake are summarised in Figure 4-10. There was a significant main 
effect of rimonabant on food intake (F(1,8) = 115.63, p < 0.001), but no main effect 
for naloxone (F(1,8) = 4.46, p > 0.05) or a drug interaction (F(1,8) = 0.88, p > 0.05).  
 
Figure 4-10: Experiment Three. Effects of rimonabant and naloxone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle, R = Rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg; See text for further 
details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
Bonferroni comparisons confirmed that, relative to vehicle control (VV), rimonabant 
both by itself (RV) and in the presence of naloxone (RN) strongly suppressed mash 
consumption (p < 0.005). The inability of the opioid receptor antagonist to alter 
rimonabant anorexia was confirmed by the lack of significant difference between 
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the RV and RN treatment conditions. It is important to note that naloxone per se 
(VN) did not significantly influence intake relative to VV control. 
4.7.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on behavioural frequencies and durations are illustrated in Figure 
4-11, while data for feeding-related parameters are summarised in Table 4-3. Again 
it should be noted that levels of drinking were extremely low in this study and are 
not reported. 
Significant rimonabant x naloxone interactions were found for the duration both of 
grooming (F(1,8) = 15.53, p < 0.005) and scratching (F(1,8) = 13,26, p < 0.01), 
while the interaction for groom frequency approached significance (F(1,8) = 4.40, p 
< 0.07). There were no other significant interactions (F(1,8) ≤ 3.27, p > 0.05). 
Significant main effects of rimonabant were found for the frequency and duration of 
eating, locomotion and rearing (F(1,8) ≥ 7.50, p ≤ 0.03) as well as the frequency of 
scratching (F(1,8) = 155.21, p < 0.001), duration of sniffing (F(1,8) = 10.35, p < 
0.02), and eat rate (F(1,8) = 8.36, p = 0.02). Main effects of naloxone were found 
only for the frequency of eating (F(1,8) = 12.94, p < 0.01) and duration of resting 
(F(1,8) = 6.38, p < 0.04).  
Table 4-3: Experiment Three. Acute effects of rimonabant and naloxone, alone and in 
combination, on eating-related parameters 
Data are mean values (± S.E.M). V = vehicle, R = Rimonabant 1.5 mg/kg; N = naloxone 0.05 
mg/kg; See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
Measure VV RV VN RN 
Latency to locate food (s) 9.31 + 2.33 11.97 + 4.93 6.63 + 2.96 10.98 + 3.48 
Latency to eat (s) 9.22 + 2.67 16.22 + 4.86 12.03 + 3.18 13.08 + 7.07 
Eat bout duration (s) 10.94 + 1.39 11.19 + 1.79 13.06 + 1.95 10.20 + 1.22 
Eating rate (g/min) 1.74 + 0.10 1.40 + 0.13 1.78 + 0.23 1.45 + 0.10 
 
Post-hoc analyses showed that, relative to VV control, neither drug when given 
alone (RV, VN), or in combination (RN), significantly altered eat rate, the frequency 
of eating, rearing and locomotion, or the duration of rearing and sniffing. This profile 
suggests that the significant main effects described above reflect the increased 
power of main effects analysis. In contrast, whereas naloxone per se (VN) was 
ineffective in altering time spent eating, rimonabant alone (RV, p < 0.03) and in 
combination with naloxone (RN, p < 0.01) significantly reduced this measure. The 
apparent failure of naloxone to block the rimonabant-induced reduction in eat 
duration was further confirmed by the absence of a significant difference between 
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RV and RN conditions. A very similar pattern was evident for the duration of 
locomotion where, in the absence of an intrinsic effect of naloxone (VN), 
rimonabant both alone (RV; p < 0.03) and in combination with naloxone (RN; p < 
0.04) significantly reduced this behaviour relative to VV control. The lack of 
significant difference between RV and RN conditions confirmed the inability of 
naloxone to influence the locomotor suppressant effect of rimonabant.  
 
 
Figure 4-11. Experiment Three. Effects of rimonabant and naloxone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash 
Data are mean values (± S.E.M). V = vehicle, R = rimonabant 1.5 mg/kg; N = naloxone 0.01 
mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
 
Bonferroni comparisons also showed that, relative to VV, rimonabant alone (RV) 
produced substantial increases in both the frequency and duration of grooming and 
scratching (p ≤ 0.01); Figure 4-11. Although naloxone per se (VN) was devoid of 
intrinsic effects on all of these measures, the opioid receptor antagonist strongly 
attenuated the stimulatory effects of the CB1 receptor antagonist/inverse agonist. 
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Thus, for all four measures, combined drug treatment (RN) did not differ 
significantly from VV control. Furthermore, for the frequency and duration of 
grooming, as well as the duration of scratching, there were significant differences (p 
≤ 0.05) between rimonabant when given alone (RV) and when given in combination 
with naloxone (RN).  
4.7.2.5 Periodic (Timebin) Behavioural Analyses 
As confirmed by significant main effects of time for all variables recorded (F(11,88) 
≥ 2.04, p ≤ 0.04), active behaviours waned and inactive behaviours increased as 
the session progressed. Although there were no significant three-way (rimonabant x 
naloxone x time) interactions (F(11,88) ≤ 1.76, p > 0.05) and only two significant 
naloxone x time interactions (rest duration, sniff duration: F(11,88) ≥ 2.55, p ≤ 0.01), 
ANOVA revealed seven significant rimonabant x time interactions (eat frequency & 
duration, groom frequency, scratch frequency and duration, rear duration, and sniff 
duration: F(11,88) ≥ 2.19, p ≤ 0.03).  
A series of 2-way ANOVAs within each timebin revealed that rimonabant 
significantly reduced eat duration in timebins 1-3 (p ≤ 0.02),eat frequency in 
timebins 1, 3, 5, 6, 11 and 12 (p ≤ 0.054), rear duration in timebins 4-6 and 8 (p ≤ 
0.05), and sniff duration in timebins 1, 4, 7 and 10 (p ≤ 0.05). Rimonabant also 
significantly increased the frequency of grooming in timebins 1-4, 6, 7, 9 and 10 (p 
≤ 0.05) as well as the frequency of scratching in timebins 1-10 and 12 (p ≤ 0.01) 
and scratching duration in timebins 1, 2, 5, 10 and 11 (p ≤ 0.02). Figure 4-12 shows 
that treatment effects on the timecourses of eating, scratching and grooming were 
remarkably similar to (but even clearer than) those seen in Experiment 1; namely, 
that while naloxone failed to impact the anorectic effect of rimonabant, it did 
markedly attenuate/reverse the effects of the CB1 receptor antagonist/inverse 
agonist on compulsive scratching and grooming.  
4.7.2.6 Behavioural Satiety Sequence (BSS) 
Treatment effects on BSS profiles are summarised in Figure 4-13. The control 
profile (VV; top left panel) confirms that feeding was the predominant response 
during the first 20-25min. Feeding gradually gave way to resting as the session 
progressed, with an eat-to-rest transition around 30min. A very similar behavioural 
pattern was evident under naloxone (VN; top right panel), with some evidence of a 
slight temporal acceleration (shift to left) in the BSS (see also the effects of 
naloxone in Experiment 1, Section 4.5). 
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Figure 4-12. Experiment Three. Effects of rimonabant and naloxone, alone and in 
combination, on the timecourses of eating, scratching and grooming 
Data are expressed as the mean duration of each behaviour in 12 x 5-min timebin V = vehicle, 
R = rimonabant 1.5 mg/kg; NL = naloxone 0.01 mg/kg; NH = naloxone 0.1 mg/kg. See text for 
further details 
When given alone, rimonabant disrupted the BSS (bottom left panel), not only 
suppressing feeding but also enhancing grooming. Although it is possible to discern 
an eat-to-rest transition, the behavioural profile under rimonabant is clearly far from 
normal (compare with VV). Interestingly, combined rimonabant/naloxone treatment 
(RN; bottom right panel), while doing little to alter the suppressant effect of 
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rimonabant on peak feeding, once again appeared to ‘normalise’ the BSS by 
countering the rimonabant-induced grooming response. Thus, co-treatment 
produced an acceleration of the BSS relative to RV and VN, and reinstated resting 
as the predominant behaviour during the second half of the test session.  
  
  
Figure 4-13. Experiment Three. Effects of rimonabant and naloxone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting, this line is dashed for the R treatment conditions in view of the lack of a clear transition; 
V = vehicle, R = rimonabant 1.5 mg/kg; N = naloxone 0.05 mg/kg. See text for further details 
4.7.2.7 Bodyweight Gain 
Data not shown. ANOVA on 7-day absolute bodyweight gain failed to reveal a 
significant rimonabant x naloxone interaction (F(1,8) = 0.18, p > 0.05) or main 
effects for either rimonabant (F(1,8) = 0.02, p > 0.05) or naloxone (F(1,8) = 0, p > 
0.05). 
The lack of effect of either drug alone or in combination was further confirmed by 
analyses of percent weight gain: there was no three-way interaction (F(6,48) = 0.64, 
p > 0.05), any two-way interactions (rimonabant x naloxone: F(1,8) = 0.05, p > 0.05; 
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rimonabant x day: F(6,48) = 1.33, p > 0.05; naloxone x day: F(6,48) = 0.06, p > 
0.05), or any main effects for either rimonabant (F(1,8) = 0.05, p > 0.05) or 
naloxone (F(1,8) = 0.003, p > 0.05). The significant main effect for day (F(6,48) = 
259.29, p < 0.001) confirms normal growth patterns over the week following 
behavioural testing. 
4.7.3 Summary of Main Findings 
The results of Experiment 3 clearly show that, while markedly attenuating 
compulsive scratching and grooming, 0.5 mg/kg naloxone failed to have any 
significant impact on the anorectic response to the CB1 receptor antagonist/inverse 
agonist. These findings are consistent with those obtained with the higher dose of 
naloxone in Experiment 1, and suggest that the weak attenuation of rimonabant 
anorexia by the lower naloxone dose may have been more apparent than real. 
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4.8 Chapter Four Main Findings 
The ‘response competition’ hypothesis holds that the acute anorectic response to 
conventional CB1 receptor antagonist/inverse agonists (e.g. rimonabant, AM-251) 
is due primarily (if not exclusively) to the induction of an intense scratching and 
grooming syndrome that interferes with feeding behaviour during tests of finite 
duration (Tallett et al., 2007a, 2007b).  
 Experiment 1 showed that sub-anorectic doses of naloxone (0.1 and 1.0mg/kg) 
dose-dependently attenuate the scratching and grooming syndrome induced by 
an anorectic dose of rimonabant (1.5mg/kg). Although the higher dose of 
naloxone (1.0mg/kg) had no effect on the anorectic response to rimonabant, a 
lower naloxone dose of the opioid receptor antagonist (0.1mg/kg) appeared to 
slightly attenuate rimonabant anorexia. 
 Experiment 2 showed that an intermediate dose of naloxone (0.5mg/kg) did not 
significantly affect rimonabant-induced anorexia or the scratching and grooming 
syndrome. However, due to diet contamination, and an unusual behavioural 
profile in the control condition, the data from this study was considered 
questionable. 
 Experiment 3 confirmed that an intermediate dose of naloxone (0.5mg/kg) 
attenuates the scratching and grooming, but not anorectic, response to 
rimonabant (1.5mg/kg). 
Together with evidence from Hodge and colleagues (Hodge et al., 2008), the 
present studies imply that the anorectic and pruritic responses to CB1 agents such 
as rimonabant are largely independent phenomena. As such, the results reported in 
Chapter 4 failed to support the response competition hypothesis of rimonabant-
induced anorexia in rats (Tallett et al., 2007b). 
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Chapter 5 Monoamine and Opioid System Interactions 
5.1 Bupropion 
Bupropion (2-tert-butylamino-3-chloropropiophenone-HCl) is a selective 
catecholamine (dopamine and noradrenaline) presynaptic reuptake inhibitor 
(Ascher et al., 1995; Ferris & Beaman, 1983). It acts on dopamine and 
noradrenaline reuptake transporters to decrease reuptake into rat and mouse 
synaptosomes (pre-synaptic neuronal membranes). The increased synaptic levels 
of dopamine and noradrenaline subsequently act to inhibit firing via auto-receptor 
mediated negative feedback mechanisms (Cooper et al., 1994; Stahl., 2004).  
In vitro studies have demonstrated that bupropion acts primarily on dopaminergic 
systems (Ferris et al., 1983; Ferris et al., 1982; Ferris et al., 1981). In vivo studies 
have supported this, with evidence showing increased dopamine concentrations 
following bupropion administration (Nomikos et al., 1992). However, doses required 
to inhibit dopamine transport are far higher than those required to elicit its known 
therapeutic effects (Golden et al., 1988).  
Interestingly, bupropion has minimal effect on indoleamines (serotonin; Golden et 
al., 1988) and lacks any appreciable affinity for postsynaptic receptors, including 
histamine, α- and β- adrenergic, acetycholine, serotonin or dopamine (Stahl et al., 
2004). Furthermore, despite its known role as an antidepressant, it does not inhibit 
monoamine oxidase or release catecholamines (Ferris et al., 1978; Soroko et al., 
1977). 
Bupropion has three metabolites: threo-hydrobupropion (TB), erythro-
hydrobupropion (EB) and hydroxybupropion (HB; Ascher et al., 1995). Although the 
plasma half-life of bupropion is ~10hours, the metabolites take much longer to 
decay (TB, ~20h; EB, ~27h; HB, ~22h; Laizure et al., 1985). Bupropion’s primary 
metabolite is HB and, in humans and mice, the concentration of HB following 
bupropion administration is approximately 6-fold higher than bupropion itself. It is 
thought that this metabolite plays a functional role in bupropion’s therapeutic action 
as an anti-depressant (Ascher et al., 1995; Bondarev et al., 2003; Martin et al., 
1990). GlaxoSmithKline even developed this metabolite as a separate drug called 
radafaxine, but discontinued development in 2006 due to a poor side-effect profile 
(Halford, 2006). It is pertinent to note that not all of bupropion’s metabolites, 
specifically HB, are produced in significant quantities in rats (Bondarev et al., 2003; 
Suckow et al., 1986; Welch et al., 1987a). 
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In the late 1970s, bupropion was identified as a potential target for the treatment of 
depression (Fabre & McLendon, 1978; Fann et al., 1978; Lineberry et al., 1990; 
Zung et al., 1983) and, subsequently (1989), an immediate release formulation was 
approved for the treatment of major depressive disorder (Wellbutrin™). In 1996, a 
sustained release formulation (Wellbutrin-SR™) was also approved as an atypical 
antidepressant. In 1997, following reports that bupropion elicited “anti-smoking” 
effects in the clinical depression trials, bupropion slow release was approved as a 
smoking cessation aid (Zyban™; Ferry & Johnston, 2003; Fossati et al., 2007; Hurt 
et al., 1997; Jorenby et al., 1999; Lerman et al., 2004; Tashkin et al., 2001; Tonstad 
et al., 2003). An extended-release formulation (Wellbutrin-XL™) became available 
in 2003. 
It is now known that bupropion is also an antagonist at nicotinic acetyl choline 
receptors (Arias, 2009; Miller et al., 2002; Slemmer et al., 2000). Bupropion is found 
to block nicotine-induced antinociception, hypothermia, hypomotility and seizure 
activity (Damaj et al., 1999; Slemmer et al., 2000). It is thought to aid smoking 
cessation via the attenuation of acute nicotine effects, thereby reducing the level of 
reinforcing effects and craving (Brody et al., 2004; see review: Warner & Shoaib, 
2005).  
Bupropion has also been used in the treatment of: mania (Shopsin, 1983; Wright et 
al., 1985); bipolar disorder (Haykal & Akiskal, 1990; Sachs et al., 1994); seasonal 
affective disorder (Dilsaver et al., 1992; Modell et al., 2005); attention 
deficit/hyperactivity disorder (Barrickman et al., 1995; Conners et al., 1996; Wender 
& Reimherr, 1990; Wilens et al., 2005); bulimia (Horne et al., 1988); and obesity 
(Anderson et al., 2002; Gadde et al., 2001; Greenway, Whitehouse, et al., 2009; 
Jain et al., 2002). 
5.1.1 Bupropion and Appetite Regulation 
Early depression trials demonstrated that bupropion did not elicit the weight gain 
typically seen with other antidepressants (Gardner & Johnston, 1985; for review 
see: Fava et al., 2005). Furthermore, smoking cessation studies identified that 
bupropion treatment attenuated post-cessation weight gain (Hurt et al., 1997; 
Jorenby et al., 1999; Tashkin et al., 2001; Wilcox et al., 2010), an effect lasting up 
to 2 years (Hays et al., 2001) and persisting beyond the cessation of treatment 
(Padwal, 2009; Rigotti et al., 2000). 
Subsequent preclinical studies showed that bupropion administration reduces food 
intake in rodents (Billes & Cowley, 2007; Greenway, Whitehouse, et al., 2009; 
Stairs & Dworkin, 2008; Zarrindast & Hosseininia, 1988), in addition to increasing 
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energy expenditure (Hasegawa et al., 2005), reducing body temperature (Zarrindast 
& Abolfathiaraghi, 1992), and increasing thermogenesis (Billes & Cowley, 2007; Liu 
et al., 2004). Furthermore, human experimental studies showed that bupropion 
treatment reduced appetite (Chouinard, 1983; Crone & Gabriel, 2004; Musso et al., 
1993), and cravings (Jain et al., 2002). Interestingly, however, some studies have 
failed to demonstrate that bupropion reduces food intake (Hartotruax et al., 1983; 
Liu et al., 2002; Liu et al., 2004; Miller & Griffith, 1983).  
Bupropion-induced appetite suppression is thought to be mediated by effects on 
dopamine. Evidence demonstrates that drugs that increase dopamine 
concentrations suppress hunger (Towell et al., 1988), while blockade of dopamine 
D1 and D2 receptors increases food intake and meal size (Clifton et al., 1991). This 
is consistent with evidence that dopamine levels are suppressed in obese patients 
(Wang et al., 2001). Furthermore, selective activation of the D2 receptor reduces 
NPY mRNA expression in the ARC and increases that of POMC mRNA (see 
Section 1.2.2), whereas antagonism of the D2 receptor causes the opposite effect 
(Pelletier & Simard, 1991; Tong & Pelletier, 1992). Unsurprisingly, therefore, 
bupropion-induced hypophagia can be blocked by D2 antagonist, sulpiride 
(Zarrindast & Abolfathiaraghi, 1992). This supports the role of bupropion as a 
dopamine reuptake inhibitor, a regulator of appetite, and therefore a potential 
treatment for obesity. 
5.1.2 Bupropion and Non-Appetite Regulatory Behaviours 
5.1.2.1 Reward 
Catecholamine reuptake inhibitors not only decrease standard chow intake but 
have also been found to decrease intake of more palatable and rewarding high-fat 
diets (Billes & Cowley, 2007). In addition, bupropion dose-dependently reduces 
sucrose- (Rauhut et al., 2003) and food- (Bruijnzeel & Markou, 2003; Stairs & 
Dworkin, 2008) maintained responding, is self-administered (Bergman et al., 1989; 
Lamb & Griffiths, 1990; Tella et al., 1997), induces conditioned place preference 
(CPP; Ortmann, 1985), and substitutes for drugs such as cocaine, amphetamine, 
methamphetamine, methylphenidate and diethylpropion (see review: Dwoskin et al., 
2006). Therefore, bupropion could act to increase the reinforcing effects of food 
consumption, similar to the perceived mechanism of action for smoking cession. 
5.1.2.2 Psychomotor Stimulation 
Importantly, bupropion has been found to produce significant psychomotor 
stimulation in preclinical models. This is characterised by increased levels of 
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locomotion (Billes & Cowley, 2007; Bourin et al., 1998; Carrasco et al., 2004; 
Cooper, 1980; Gomez et al., 2008; Howard et al., 1978; Martin et al., 1990; Nielsen 
et al., 1986; Paterson et al., 2010; Redolat, Gomez, et al., 2005; Redolat, Vidal, et 
al., 2005; Santamaria & Arias, 2010; Sidhpura et al., 2007; Soroko et al., 1977) and 
sniffing behaviour (Billes & Cowley, 2007; Muley et al., 1984; Zarrindast et al., 
1996; Zarrindast & Hosseininia, 1988). Additionally, bupropion has been shown to 
reverse tetrabenazine-induced sedation (Cooper et al., 1994). Tetrabenazine is 
commonly used for the treatment of hyperkinetic disorders, and is thought to act via 
the degradation of monoamines such as dopamine. Thus, bupropion-induced 
locomotion is thought to be mediated by increases in dopamine function 
(Santamaria & Arias, 2010; Sidhpura et al., 2007; Zarrindast & Minaian, 1991).  
It has been argued that the anorectic and psychomotor responses to bupropion are 
independent phenomena (Billes & Cowley, 2007; Cooper, 1980; Zarrindast & 
Minaian, 1991). For example, Billes & Cowley (2007) found that incremental 
increases in bupropion dose produce independent changes in locomotion activity 
and intake (Billes & Cowley, 2007). Despite this evidence, however, both effects are 
normally seen at similar dose levels.  
5.1.3 Bupropion and Therapeutic Potential for Treatment of 
Obesity 
Bupropion’s effects on appetite and weight gain have since been supported by 
randomised, double-blind, placebo-controlled studies (Anderson et al., 2002; Gadde 
et al., 2001; Jain et al., 2002). A meta-analysis revealed a mean weight loss of 2.66 
kg (Li et al., 2005), an effect maintained for up to one year (Croft et al., 2002). 
In the initial trials, overweight and obese patients taking bupropion (~350mg/day) 
lost 4.9% baseline bodyweight, producing significantly higher weight loss than that 
seen in the placebo group (-1.3 %) after 8 weeks and, after 24 weeks, completers 
had lost 12.9% of baseline bodyweight (Gadde et al., 2001). A similar, 24 week trial 
(Anderson et al., 2002), found that patients who completed the bupropion treatment 
(400mg/day) lost 10.1% of baseline bodyweight, significantly higher than placebo (-
5.0%). At 56 weeks (Croft et al., 2002), patients who completed the bupropion 
treatment (300mg/day) had lost 1.5kg, an effect significantly higher than placebo (-
0.02kg). 
In line with earlier evidence from depressed patients (Croft et al., 2000; Settle et al., 
1999), a trial with obese patients exhibiting depressive symptoms (as indicated by 
BDI-II scores between 10 and 30; Jain et al., 2002) found that completers in the 
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bupropion treatment group (sustained release; 400mg/day) produced weight loss of 
-5.8kg (~6.0% baseline) over a 6 month period (Placebo, -2.8kg). Furthermore, 
those treated with bupropion reported significantly greater reductions in craving and 
hunger than did those treated with placebo. Evidence from a more recent study 
(White & Grilo, 2013) with binge eating disorder patients also found bupropion 
treatment (300mg/day) to significantly increase net weight loss (-1.68kg) compared 
to placebo during an 8 week trial. 
Despite evidence that bupropion can produce mild weight loss (average 2.8 kg over 
24-52 weeks), equivalent to that seen with sibutramine and orlistat (Anderson et al., 
2002; Gadde et al., 2001; Jain et al., 2002), it falls short of the current regulatory 
criterion (a minimum 5 kg weight loss) for marketing approval (Heal et al., 2009; 
Kennett & Clifton, 2010). 
5.2 The combination of Bupropion and Naltrexone 
5.2.1 Naltrexone vs. Naloxone 
As discussed in Chapter 4, naltrexone is an opioid receptor antagonist primarily 
used for the treatment of opioid addiction (Herz, 1997; Minozzi et al., 2011) and 
alcohol dependence (Garbutt, 2010; Garbutt et al., 1999), but which is also 
associated with appetite regulation (Lee & Fujioka, 2009). 
There are known pharmacokinetic and pharmacodynamic differences between 
naloxone and naltrexone (Goldstein & Naidu, 1989; Magnan et al., 1982; Raynor et 
al., 1994; Tepperman et al., 1983). Although receptor selectivity is the same 
between the two opioid antagonists (μ ≥ κ ≥ δ; Goldstein & Naidu, 1989; Magnan et 
al., 1982; Raynor et al., 1994), the primary difference is the half-life. Naloxone has a 
half-life of ~1.5hours, whereas naltrexone has a half-life of up to 4 hours (Berkowitz 
et al., 1976). This makes it a more viable option for clinical treatment. 
In contrast to the developments with naloxone (see Chapter 4), comparatively little 
is known about the behavioural selectivity of the anorectic response to naltrexone. It 
is known that, similar to naloxone, the longer-action opioid antagonist naltrexone 
reduces motivation to eat post-ingestion (Kirkham & Blundell, 1986), an effect not 
explained by locomotor impairment (Cooper & Turkish, 1989). Despite this, and 
evidence that it acutely suppresses appetite in humans, naltrexone has not by itself 
proven clinically useful in the management of obesity (Yeomans & Gray, 2002). 
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5.2.2 The Combination; Contrave™ 
Previous evidence had implicated naltrexone in the reduction of post-cessation 
weight gain in smokers (King et al., 2006; King et al., 2013; Krishnan-Sarin et al., 
2003; O'Malley et al., 2002; Omalley et al., 1992). Therefore, it seemed logical to 
assess the combination of bupropion and naltrexone for the treatment of weight 
concerned smokers. Disappointingly however, these studies found no significant 
differences in weight gain (Toll et al., 2008; Wilcox et al., 2010). 
The combination was then considered within the domain of obesity research when 
Greenway (2009) proposed that bupropion’s influence on food intake and weight 
gain may be self-limiting due to an opioid-mediated (β-endorphin) negative 
feedback effect on POMC neurons in the ARC (Cowley et al., 2001; Greenway, 
Whitehouse, et al., 2009). The co-administration of an opioid antagonist, such as 
naltrexone, should inhibit this negative feedback, augmenting the stimulation of 
POMC neurons, with the aim of overcoming the plateau demonstrated in previous 
studies using bupropion alone (Anderson et al., 2002). Electrophysiological 
recordings of POMC neurons successfully demonstrated a positive effect of 
naltrexone on bupropion-induced POMC firing rates (Greenway, Whitehouse, et al., 
2009).  
The above hypothesis received support from initial animal and human studies 
(Greenway, Dunayevich, et al., 2009; Greenway, Whitehouse, et al., 2009) and the 
combination, now labelled Contrave™, underwent development with Orexigen 
Therapeutics Inc as a potential treatment for obesity. The combination 
demonstrated an additive inhibition of intake in obese (but not lean) mice. One 
interpretation of this finding is that basal activity of POMC neurons is lower in obese 
mice, possibly due to obesity-induced leptin resistance in POMC neurons (Cowley 
et al., 2001). The clinical proof-of-concept study (16 weeks) demonstrated greater 
weight loss with the combination of 50mg/day naltrexone plus 300mg/day 
bupropion (-3.7%) than with placebo (-0.6%) or either drug treatment alone (-1.7% 
naltrexone; -3.2% bupropion). A longer 24 week trial (Greenway, Dunayevich, et al., 
2009) demonstrated stronger results, with the combination of naltrexone (16mg/day 
or 32mg/day) plus bupropion (400mg/day) producing significant reductions in 
baseline weight (-5.4%) compared to the placebo group (-0.8%) or either drug 
treatments alone (-1.2% naltrexone 48mg/kg; -2.7% bupropion). 
The Orexigen Therapeutics Contrave™ Obesity Research (COR) Programme 
consists of four phase III, 56-week trials (COR-I, COR-II, COR-BMOD and COR-
Diabetes; see review: (Katsiki et al., 2011). The first (COR-I; Greenway et al. 2010) 
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employed 1482 women and 260 men. Weight loss started at week 4 and continued 
to be significantly higher than placebo up to week 56. The 870 completers lost 
significantly more baseline bodyweight (8.1%, 32mg naltrexone plus bupropion; -
6.7%, 16mg naltrexone plus bupropion) compared to placebo (-1.8%). The study 
found significant improvements in a range of parameters including; waist 
circumference, insulin resistance, cholesterol, triglycerides, physical function, self-
esteem, sexual life, public distress and measures of food craving and eating 
control. The naltrexone plus bupropion treatment also reduced blood pressure 
although, interestingly, failed to reduce heart rate, despite a drop seen in the 
placebo group. 
The COR-II study (Apovian et al., 2013; Rubino et al., 2010) used 1496 patients, 
and produced similar findings to the first phase III trial. The patients taking the 
combination treatment lost significantly more baseline bodyweight (6.4%) compared 
to placebo (-1.2%). 56.3% of patients receiving the combination treatment lost a 
clinical meaningful amount of weight (≥5% of baseline bodyweight; placebo, 
17.1%).  
The COR-BMOD study (Wadden et al., 2011) assessed naltrexone (32mg/day) plus 
bupropion (360mg/day) as an adjunct to intensive behaviour modification. 
Completer data showed that those in the combination plus behaviour modification 
group produced a greater percentage baseline weight loss (-11.5%) than those in 
the placebo plus behaviour modification group (-7.3%). Again there were significant 
improvements, compared to placebo, in measures of waist circumference, plasma 
triglycerides, insulin resistance, physical function, and self-esteem. 
The COR-Diabetes study (Hollander et al., 2010) assessed the combination in 
overweight/obese subjects with type 2 diabetes. Week 56 saw the combination 
produce reductions in baseline bodyweight (-5.0%) significantly higher than seen 
with placebo (-1.8%), alongside significant improvements (vs. placebo) in waist 
circumference, plasma triglycerides and insulin resistance. 
Overall, the results of the COR programme results demonstrate that Contrave™ is 
an effective combination for weight loss (see review: Padwal, 2009; Plodkowski et 
al., 2009). It also shows improvements in some cardiovascular and mood 
measures. Despite this, there are still some concerns regarding elevated systolic 
and diastolic blood pressure and pulse rate (Katsiki et al., 2011). As it was denied 
approval by the FDA in 2011, Contrave™ is now being evaluated in the Light Study, 
a multicentre, randomized, double-blind, placebo-controlled long-term research trial 
designed to further assess the cardiovascular health outcomes of Contrave™. 
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5.3 Rationale: Chapter Four 
Although co-treatment with bupropion and naltrexone has been reported (in rodents 
& obese humans) to produce significantly greater reductions in intake and 
bodyweight than either drug given alone (Contrave™; Greenway, Dunayevich, et 
al., 2009; Greenway et al., 2010; Greenway, Whitehouse, et al., 2009; Wadden et 
al., 2011; Wadden et al., 2009), comparatively little is known about the effects of 
these agents, either alone or together, on behaviour within the feeding context. 
In view of this gap in the literature, the aims of the studies reported in Chapter 5 are 
to employ BSS methodology (review: Rodgers et al., 2010) to systematically and 
comprehensively profile the effects of bupropion and naltrexone, alone and in 
combination, on ingestive and non-ingestive behaviours in non-deprived male rats 
exposed to palatable mash. 
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5.4 Experiment Four; Bupropion Dose-Response 
5.4.1 Method  
For the main methodological details, refer to General Methods (Chapter 3).  
5.4.1.1 Subjects and Design 
10 adult male Lister hooded rats (209.37 ± 1.91g on arrival from Charles River, U.K 
and 397.02 ± 9.46g by the end of the study) were employed for this study. A within-
subjects design was adopted whereby each subject received all four experimental 
conditions according to a Latin Square (with a 3-day wash out period): Vehicle (V); 
Bupropion 10mg/kg (B10); Bupropion 20mg/kg (B20); and Bupropion 40mg/kg 
(B40).  
As bupropion is eliminated rapidly in the rat (Suckow et al., 1986), with an 
elimination half-life between 11-14hours (Bryant et al., 1983; Welch et al., 1987b), a 
3-day wash out period was considered acceptable. 
5.4.1.2 Drugs 
Bupropion hydrochloride (Sigma-Aldrich, Poole, UK) was dissolved in physiological 
saline (0.9%) which, alone, served as a vehicle control. Doses of bupropion (10, 20 
and 40 mg/kg) were selected based on previous research on food intake to span 
the full range from ineffective to sub-maximal (Billes & Cowley, 2007; Greenway, 
Whitehouse, et al., 2009; Stairs & Dworkin, 2008; Zarrindast & Hosseininia, 1988). 
All solutions were freshly prepared on test days and administered i.p. in a volume of 
1ml/kg 30 minutes prior to testing 
5.4.1.3 Procedure 
Testing occurred over two weeks, with four test days per week, 5 animals tested 
per day, and a 3 day wash-out period. Treatment order was counterbalanced both 
within and between test days according to the Latin Square. 
5.4.2 Results 
Full statistical details can be found in Appendix 5. It should be noted that, as 
animals did not show appreciable amounts of scratching during Experiment 4, data 
for these variables are not reported. 
5.4.2.1 Habituation Phase Food Intake 
Mash consumption differed significantly over the course of habituation (F(4,36) = 
18.86, p < 0.001), with intake on the first two trials predictably lower (p ≤ 0.01) than 
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on the remaining trials (trial 1: 9.86 ± 0.80g; trial 2: 12.42 ± 0.59g; trial 3: 17.15 ± 
0.77g; trial 4: 16.90 ± 1.97g; trial 5: 19.86 ± 1.17g). Although intake on the first trial 
differed significantly from trials 3, 4 and 5 (p ≤ 0.01), and intake on trial 2 from trials 
3 and 5 (p ≤ 0.01), the development of a stable intake pattern was confirmed by the 
lack of difference across trials 3-5. Further emphasised by the close similarity in 
intake scores between those habituation trials and the vehicle condition in the main 
experiment (17.89 ± 1.08g). 
5.4.2.2 Test Day Bodyweight 
Test-day bodyweights were comparable across the various treatment conditions (V: 
366.3 ± 10.9g; B10: 369.2 ± 7.4g; B20: 370.4 ± 8.4g; B40: 370.4 ± 9.0g (F(3,27) = 
0.17, p > 0.05).  
5.4.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.17% throughout the experiment (range = 0.15 - 0.21%). Treatment effects on 
food intake are summarised in Figure 5-1. There was a significant main effect of 
bupropion on food intake (F(3,27) = 7.03, p = 0.001). Bonferroni comparisons 
showed a significant suppression (21% reduction relative to vehicle control, p < 
0.03) only at the highest dose tested (40 mg/kg). 
 
Figure 5-1: Experiment Four. Effects of acute bupropion on mash intake by Non-
deprived male rats during a 1-h test with palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = Vehicle, B10 = Bupropion 10 mg/kg; B20 = Bupropion 20 mg/kg; B40 = Bupropion 
40 mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus V 
+6.47% +5.38% -20.58% 
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5.4.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on total 1-h frequency and duration scores for ingestive and non-
ingestive behaviours are illustrated in Figure 5-2, while data for eating-related 
parameters are summarised in Table 5-1.  
ANOVA revealed significant treatment effects on the average duration of eating 
bouts (F(3,27) = 7.19, p < 0.001), the frequency and duration of eating (F(3,27) ≥ 
11.59, p ≤ 0.001), resting (F(3,27) ≥ 4.58, p ≤ 0.01), locomotion (F(3,27) ≥ 13.71, p 
≤ 0.002) and sniffing (F(3,27) ≥ 11.72, p ≤ 0.001), and both the duration of 
grooming (F(3,27) = 10.46, p < 0.001) and the frequency of rearing (F(3,27) = 
18.15, p < 0.001). Treatment did not significantly influence the frequency of 
grooming or the duration of rearing (F(3,27) ≤ 2.41, p ≥ 0.05), nor did it affect the 
latency of locate the food source, the latency to commence eating, or the average 
rate of eating (F(3,27) ≤ 1.40, p ≥ 0.05).  
Table 5-1: Experiment Four. Acute effects of Bupropion on eating-related parameters 
(Mean ± SE). See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus VV 
Measure Vehicle Bupropion 
10mg/kg 
Bupropion 
20mg/kg 
Bupropion 
40mg/kg 
Latency to locate food (s) 7.60 + 1.20 12.39 + 3.15 9.02 + 2.02 8.62 + 2.97 
Latency to eat (s) 34.13 + 4.68 25.27 + 6.29 18.83 + 4.32 25.36 + 7.18 
Eat bout (s) 15.43 + 2.45 17.81 + 5.04 15.79 + 4.24 6.57 + 1.59** 
Eat rate (g/min) 1.31 + 0.05 1.41 + 0.06 1.30 + 0.06 1.49 + 0.11 
 
As shown in Table 5-1 and Figure 5-2, Bonferroni comparisons confirmed that 
behaviour was primarily affected at the highest dose of bupropion (40 mg/kg), which 
significantly reduced time spent eating (p < 0.05), the average duration of eating 
bouts (p < 0.01) and grooming duration (p = 0.052), while significantly increasing 
the frequency of eating and rearing (p ≤ 0.01), and both the frequency and duration 
of locomotion and sniffing (p ≤ 0.03). An increase in locomotion frequency was also 
observed at 20 mg/kg (p = 0.021)  
Despite significant treatment effects on rest frequency and duration, and the 
apparent elimination of resting from the behavioural profile at the highest dose of 
bupropion (Figure 5-2), post-hoc tests revealed only a significant difference 
between drug doses (10 vs 40 mg/kg) and not between drug and vehicle control. 
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Figure 5-2: Experiment Four. Effects of acute bupropion on the duration (upper panel) 
and frequency (lower panel) of behaviours displayed by non-deprived male rats 
during a 1-h test with palatable mash 
Data are mean values (± S.E.M). V = Vehicle, B10 = Bupropion 10 mg/kg; B20 = Bupropion 20 
mg/kg; B40 = Bupropion 40 mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 
0.001 versus V 
However, as resting is normally absent during the first half of the test session 
(Figure 5-3), data were re-analysed focusing purely on the frequency and duration 
of resting during the second half of the session (timebins 7-12 inclusive). While 
significant treatment effects were confirmed (frequency: F(3,27) = 5.18, p ≤ 0.01; 
duration: F(3,27) = 4.58, p ≤ 0.01), the higher variability in these datasets once 
again precluded detection of a significant drug effect versus vehicle control. 
5.4.2.5 Periodic (Timebin) Behavioural Analyses 
Timebin analyses confirmed the normal temporal pattern of behaviour during the 1h 
test; a gradual reduction in most active behaviours and increase in resting as the 
session progressed (e.g. Ishii et al. 2003; Tallett et al. 2008a&b, 2009a&b). Thus, 
with the exception of groom frequency (F(11,99) = 1.27, p > 0.05), significant main 
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effects of time were found for the frequency (F(11,99) ≥ 7.18, p ≤ 0.001) and 
duration (F(11,99) ≥ 2.70, p ≤ 0.005) of all behavioural measures.  
Significant treatment x time interactions were found for the duration of eating 
(F(33,297) = 3.26, p < 0.001), the frequency and duration of resting (F(33,297) ≥ 
1.62, p ≤ 0.02); and the frequency of locomotion (F(33,297) = 1.49, p = 0.05).  
 
Figure 5-3: Experiment Four. Effects of acute bupropion on the timecourses of eating, 
sniffing and locomotion in male rats during a 1-h test with palatable mash 
Data are expressed as the mean duration of each behaviour in 12 x 5-min timebin. V = Vehicle, 
B10 = Bupropion 10 mg/kg; B20 = Bupropion 20 mg/kg; B40 = Bupropion 40 mg/kg. See text 
for further details 
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A series of one-way ANOVAs within each timebin indicated that B40 significantly 
reduced time spent eating at several timepoints during the first half of the test 
session (F(3,27) ≥ 4.05, p ≤ 0.02), and increased both the frequency and duration 
of locomotion throughout the entire test (timebins 1-12; F(3,27) ≥ 4.03, p ≤ 0.02; 
see Figure 5-3).  
Similar follow-up analyses of the treatment x time interactions for resting failed to 
reveal a significant effect of bupropion on rest frequency or duration at any 
individual timepoint. This outcome is consistent with that of the analyses for total 
resting scores (Figure 5-2). 
5.4.2.6 Behavioural Satiety Sequence (BSS)  
Treatment effects on the BSS are shown in Figure 5-4. Consistent with previous 
research (Ishii et al; 2003; Tallett et al. 2008a&b, 2009a&b), and work within the 
current thesis, the profile for the vehicle control (V; top left panel) shows a typical 
peak feeding response during the first half of the test. As resting gradually replaces 
eating as the predominant behaviour, a clear eat-to-rest transition can be seen 
around timebin 8. A similar pattern of behaviour is seen in the B10 or B20 
conditions. However, at 40 mg/kg, behaviour is completely disrupted with the typical 
BSS replaced by high levels of locomotor activity, low levels of grooming, and a 
virtual absence of resting behaviour.  
5.4.2.7 Bodyweight Gain 
Data not shown. ANOVA failed to reveal a significant effect of treatment on 3-day 
absolute weight gain (F(3,27) = 0.2, p > 0.05) or daily percent bodyweight change 
(F(3,27) = 0.44, p > 0.05). As is typical, a main effect of day (F(2,18) = 84.16, p < 
0.001) confirms treatment-independent general increase in bodyweight.  
5.4.3 Summary of Main Findings 
Experiment 4 confirmed that acute bupropion (40 mg/kg) suppresses food intake in 
rodents, a finding consistent with previous research (Billes & Cowley, 2007; 
Greenway, Whitehouse, et al., 2009; Stairs & Dworkin, 2008; Zarrindast & 
Hosseininia, 1988). However, at the same dose level (but not 10-20 mg/kg), the 
compound significantly suppressed grooming while markedly stimulating rearing, 
sniffing and locomotion. Interestingly, this behavioural activation even extended to 
the frequency of eating even though actual time spent eating was significantly 
reduced.  
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Figure 5-4: Experiment Four. Effects of acute bupropion on the behavioural satiety 
sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = Vehicle, B10 = Bupropion 10 mg/kg; B20 = Bupropion 20 mg/kg; B40 = Bupropion 
40 mg/kg. See text for further details 
Although locomotor stimulation does not always lead to a suppression of food 
intake (e.g. Cooper & Vanderhoek, 1993; Vanrossum & Simons, 1969), it would 
seem parsimonious to argue that the acute anorectic effect of bupropion (40 mg/kg) 
in Experiment 4 may have been secondary to the marked increase in non-ingestive 
behaviours (however, see: Billes & Cowley, 2007).  
  
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5 6 7 8 9 10 11 12
D
u
ra
ti
o
n
 (
s)
 
TimeBin 
V 
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5 6 7 8 9 10 11 12
D
u
ra
ti
o
n
 (
s)
 
TimeBin 
B10 Eat
Groom
Rest
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5 6 7 8 9 10 11 12
D
u
ra
ti
o
n
 (
s)
 
TimeBin 
B20 
0
20
40
60
80
100
120
140
160
180
200
1 2 3 4 5 6 7 8 9 10 11 12
D
u
ra
ti
o
n
 (
s)
 
TimeBin 
B40 
141 
 
5.5 Experiment Five; Naltrexone Dose-Response 
5.5.1 Method  
5.5.1.1 Subjects and Design 
10 adult male Lister hooded rats (204.83 + 1.79g on arrival from Charles River, U.K 
and 418.07 + 8.23g by the end of the study) were employed for this study. A within-
subjects design was adopted whereby each subject received all four experimental 
conditions according to a Latin Square (with a 7 day wash out period): Vehicle (V); 
Naltrexone 0.1mg/kg (Ntx0.1); Naltrexone 1.0mg/kg (Ntx1.0); and Naltrexone 
3.0mg/kg (Ntx3.0). 
5.5.1.2 Drugs 
Naltrexone hydrochloride (Sigma-Aldrich, Poole, UK) was dissolved in physiological 
saline (0.9%) which, alone, served as a vehicle control. Doses of naltrexone (0.1, 
1.0 and 3.0 mg/kg) were selected based on previous research on food intake to 
span the full range from ineffective to sub-maximal (Apfelbaum & Mandenoff, 1981; 
Cooper & Turkish, 1989; Hadjimarkou et al., 2004; Jackson & Sewell, 1985a, 
1985b; Kirkham & Blundell, 1986, 1987; Markskaufman & Balmagiya, 1985; Sanger 
& McCarthy, 1982). All solutions were freshly prepared on test days and 
administered i.p. in a volume of 1ml/kg 15 minutes prior to testing 
5.5.1.3 Procedure 
Testing occurred over four weeks, with two test days per week and 5 animals tested 
per day. Treatment order was counterbalanced both within and between test days 
according to the Latin Square. 
5.5.1.4 Error 
Although apparently quite healthy, one rat failed to consume any significant quantity 
of mash during habituation week and was therefore excluded from the study.  
5.5.2 Results 
Full statistical details can be found in Appendix 6. It should be noted that, as 
animals did not show appreciable amounts of scratching during Experiment 5, data 
for these variables are not reported. 
5.5.2.1 Habituation Phase Food Intake 
Mash consumption differed significantly over the course of habituation (F(4,32) = 
19.23, p < 0.001), with intake on trial 1 (10.28 + 0.77g) significantly lower (p ≤ 
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0.005) than on trials 2-5 (trial 2: 15.35 ± 1.23g; trial 3: 17.56 ± 0.90g; trial 4: 17.82 ± 
0.86g; trial 5: 16.52 ± 0.93g). The development of a stable intake pattern was 
confirmed by the lack of significant difference across trials 2-5, as well as the close 
similarity in intake scores between those habituation trials and the vehicle condition 
in the main experiment (14.91 + 0.90g). 
5.5.2.2 Test Day Bodyweight 
Test-day bodyweights did not vary significantly across treatment conditions 
(vehicle: 370.7 ± 8.6g; Ntx0.1: 377.0 ± 8.5g; Ntx1.0: 382.6 ± 8.6g; Ntx3.0: 378.4 ± 
7.5g: F(3,24) = 0.77, p > 0.05). 
5.5.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.19% throughout the experiment (range = 0.15 – 0.33%). Treatment effects 
on food intake are summarised in Figure 5-5. Naltrexone dose-dependently 
suppressed 1h mash intake (F(3,24) = 18.13, p < 0.001). Bonferroni post-hoc 
analysis confirmed that this effect was statistically significant only at the highest 
dose tested (3.0 mg/kg; 56 % reduction relative to vehicle control, p = 0.001).  
 
Figure 5-5: Experiment Five. Effects of acute naltrexone on mash intake by non-
deprived male rats during a 1-h test with palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle, Ntx0.1 = naltrexone 0.1 mg/kg; Ntx1.0 = naltrexone 1.0 mg/kg; Ntx3.0 = 
naltrexone 3.0 mg/kg. See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus V 
5.5.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on total 1-h frequency and duration scores for ingestive and non-
ingestive behaviours are illustrated in Figure 5-6, while data for eating-related 
parameters are summarised in Table 5-2.  
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Naltrexone did not significantly alter latencies to locate the food source or to 
commence eating (F(3,24) ≤ 1.60, p ≥ 0.05), nor did it significantly affect the 
duration of eating bouts or the rate of eating (F(3,24) ≤ 2.49, p ≥ 0.05). 
Nevertheless, it is interesting to note the trend towards a dose-dependent reduction 
in the rate of eating with naltrexone (Table 5-2).  
Table 5-2: Experiment Five. Acute effects of naltrexone on eating-related parameters 
(Mean ± SE). See text for further details. * p < 0.05, ** p < 0.01, *** p < 0.001 versus V 
Measure Vehicle Bupropion 
10mg/kg 
Bupropion 
20mg/kg 
Bupropion 
40mg/kg 
Latency to locate food (s) 5.70 + 2.25 5.29 + 1.84 4.93 + 1.95 6.65 + 2.84 
Latency to eat (s) 27.67 + 6.57 57.84 + 12.48 37.50 + 11.43 41.28 + 12.08 
Eat bout (s) 10.24 + 1.15 11.12 + 1.08 12.29 + 1.13 13.25 + 1.57 
Eat rate (g/min) 1.42 + 0.10 1.40 + 0.08 1.25 + 0.08 1.10 + 0.12 
 
However, ANOVA did reveal significant treatment effects of frequency and duration 
of eating (F(3,24) ≥ 9.99, p ≤ 0.001). ANOVA also, revealed significant treatment 
effects for the frequency and duration of: locomotion (F(3,24) ≥3.16, p ≤ 0.05), and 
rearing (F(3,24) ≥ 5.04, p ≤ 0.008), as well as the duration of resting (F(3,24) = 
6.63, p = 0.012) and the frequency of sniffing (F(3,24) = 6.53, p = 0.002). Treatment 
did not significantly influence any other behavioural measure (F(3,24) ≤ 2.46, p ≥ 
0.05).  
Bonferroni post-hoc analysis demonstrated that naltrexone was behaviourally most 
effective at the highest dose tested (3.0 mg/kg) with significant reductions in both 
the frequency and duration of eating (p ≤ 0.01) and the frequency of locomotion and 
sniffing (p ≤ 0.05), as well as significant increases in the frequency and duration of 
resting (p ≤ 0.02) (see Figure 5-6). The lower doses of the opioid receptor 
antagonist suppressed (p ≤ 0.03) eat frequency at 1.0 mg/kg and sniff frequency at 
0.1 mg/kg. Despite significant ANOVA main effects for the duration of locomotion, 
as well as the frequency and duration of rearing, post-hoc tests failed to identify any 
significant drug-vehicle differences for these measures.  
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Figure 5-6: Experiment Five. Effects of acute naltrexone on the duration (upper panel) 
and frequency (lower panel) of behaviours displayed by non-deprived male rats 
during a 1-h test with palatable mash 
Data are mean values (± S.E.M). V = vehicle, Ntx0.1 = naltrexone 0.1 mg/kg; Ntx1.0 = 
naltrexone 1.0 mg/kg; Ntx3.0 = naltrexone 3.0 mg/kg. * p < 0.05 versus V. See text for further 
details. 
5.5.2.5 Periodic (Timebin) Behavioural Analyses 
Timebin analyses confirmed the gradual reduction in most active behaviours and an 
increase in resting over the 1h test session (e.g. Ishii et al., 2003; Tallett et al., 
2008a&b; 2009a&b). As expected, significant main effects of time were found for 
the frequency (F(11,88) ≥ 10.98, p ≤ 0.001) and duration (F(11,88) ≥ 7.41, p ≤ 
0.001) of all behavioural measures, with the exception of the frequency and 
duration of grooming and scratching (F(11,88) ≤ 1.81, p > 0.05).  
Significant treatment x time interactions were found for the frequency and duration 
of eating (F(33,264) ≥ 1.60, p ≤ 0.03), rearing (F(33,264) ≥ 1.91, p ≤ 0.01) and 
sniffing (F(33,264) ≥ 1.54, p ≤ 0.05), as well as for the duration of resting (F(33,264) 
= 1.60, p = 0.024) and the frequency of locomotion (F(33,264) = 1.58, p < 0.03). 
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5.5.2.5.1 Treatment x Time Interaction Analysis 
These significant drug x time interactions were further explored by a series of one-
way ANOVAs within each timebin. 
5.5.2.5.1.1 Eating  
Significant treatment effects were found for eat frequency in timebins 1-3 (F(3,24) ≥ 
3.85, p ≤ 0.03) and for eat duration in timebins 1-4 (F(3,24) ≥ 4.50, p ≤ 0.02). 
Somewhat unexpectedly, the lowest dose of naltrexone (0.1 mg/kg) significantly 
increased time spent eating in timebin 1 (p ≤ 0.05) but reduced the frequency of 
eating in timebin 4 (p < 0.01), whereas the highest dose of naltrexone (3.0 mg/kg) 
reduced eat frequency in both timebins 1 and 4 (p ≤ 0.05).  
5.5.2.5.1.2 Resting  
Naltrexone significantly affected rest duration in timebin 8 and timebin 9 (F(3,24) ≥ 
5.00, p ≤ 0.01), with Bonferroni comparisons confirming significant enhancement of 
this measure by the highest dose of the compound (p ≤ 0.02).  
5.5.2.5.1.3 Locomotion  
Significant effects of drug treatment were found for locomotion frequency in timebin 
1 and timebin 8-9 inclusive (F(3,24) ≥ 3.40, p ≤ 0.04), with significant suppression 
evident at the lowest dose in timebin1 (p < 0.03), and at the highest dose in 
timebins 8 and 9 (p ≤ 0.03).  
5.5.2.5.1.4 Rearing  
Significant effects of naltrexone were found for rear frequency in T3-9 inclusive 
(F(3,24) ≥ 3.48, p ≤ 0.04) and for rear duration in timebin 1 and timebin 5-9 
inclusive (F(3,24) ≥ 3.24, p ≤ 0.04). Post-hoc tests showed that rear frequency was 
suppressed by naltrexone 1.0 mg/kg in T6 (p < 0.02) and by the highest dose in 
timebin 5, 8 and 9 (p ≤ 0.05), while rear duration was suppressed by the lowest 
dose in timebin 1 (p < 0.01) and by the highest dose in timebin 5 (p < 0.005).  
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Figure 5-7: Experiment Five. Effects of acute naltrexone on the timecourses of eating, 
resting, locomotion and sniffing in male rats during a 1-h test with palatable 
mash 
Data are expressed as the mean duration of each behaviour in 12 x 5-min timebin. V = vehicle, 
Ntx0.1 = naltrexone 0.1 mg/kg; Ntx1.0 = naltrexone 1.0 mg/kg; Ntx3.0 = naltrexone 3.0 mg/kg. 
See text for further details. 
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5.5.2.5.1.5 Sniffing  
Significant treatment effects were found for sniff frequency in timebin 1 and 
timebins 3-9 inclusive (F ≥ 3.37, p ≤ 0.04) and for sniff duration in timebin 1, 9 and 
12 (F(3,24) ≥ 3.62, p ≤ 0.03). Sniff frequency was significantly reduced by 
naltrexone 0.1 mg/kg in T1 (p < 0.001), by naltrexone 1.0 mg/kg in timebin 6 (p < 
0.01), and by naltrexone 3.0 mg/kg in timebins 8 and 9 (p ≤ 0.02). In addition, sniff 
duration was suppressed by naltrexone 3.0 mg.kg but only in timebin 9 (p < 0.04).  
 
Overall, these temporal analyses indicate that, while naltrexone suppressed eating 
in the early part of the session, resting was increased and other behaviours 
inhibited somewhat later in proceedings – a profile consistent with an increase in 
and earlier onset of postprandial resting. Figure 5-7 illustrates the timecourse 
patterns for time spent eating and resting, as well as the frequency of sniffing, 
locomotion and rearing.  
5.5.2.6 Behavioural Satiety Sequence (BSS)  
The effects of naltrexone (0.1-3.0 mg/kg) on the BSS are summarised in Figure 5-8. 
As seen in previous studies, the vehicle profile (left top panel) shows a peak 
feeding response during the first 20 min of the test. Over time, resting gradually 
begins to replace eating as the predominant behaviour with the first clear eat-rest 
transition occurring circa timebin 6. Although the structural integrity of the BSS is 
fully maintained under all doses of naltrexone, Figure 5-8 shows a dose-dependent 
acceleration (shift to left) in the entire behavioural pattern, an effect most evident at 
the highest dose tested (3.0 mg/kg; timebin 4). It is particularly important to note 
that increased resting seen in response to naltrexone occurred after (and not 
before) the ingestion of food. 
5.5.2.7 Bodyweight Gain 
Data not shown. ANOVA failed to reveal a significant effect of naltrexone on 3-day 
absolute weight gain (vehicle: 8.63 + 1.77g; Ntx0.1: 8.26 + 1.14g; Ntx1.0: 8.93 + 
0.94g; Ntx3.0: 7.46 + 0.69g; F(3,24) = 0.32, p > 0.05). Similarly, while the analysis 
of percent bodyweight change over days post-treatment confirmed a general 
increase in bodyweight over time (main effect DAY: F(2,16) = 127.49, p < 0.001), it 
too failed to support a significant main effect of treatment (F(3,24) = 1.49 p > 0.05) 
or a treatment x day interaction (F(6,48) = 0.94, p > 0.05). 
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Figure 5-8: Experiment Five. Effects of acute naltrexone on the behavioural satiety 
sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = Vehicle, Ntx0.1 = naltrexone 0.1 mg/kg; Ntx1.0 = naltrexone 1.0 mg/kg; Ntx3.0 = 
naltrexone 3.0 mg/kg. See text for further details 
5.5.3 Summary of Main Findings 
The results of Experiment 5 confirm that naltrexone dose-dependently reduced 
mash consumption (Apfelbaum & Mandenoff, 1981; Cooper & Turkish, 1989; 
Hadjimarkou et al., 2004; Jackson & Sewell, 1985a, 1985b; Kirkham & Blundell, 
1986, 1987; Markskaufman & Balmagiya, 1985; Sanger & McCarthy, 1982), in 
addition to the frequency and duration of feeding behaviour (3.0mg/kg; Cooper & 
Turkish, 1989; Kirkham & Blundell, 1987; Tallett et al., 2008a). Consistent with 
previously reported effects for broad spectrum opioid antagonists (naloxone; Tallett 
et al., 2008a), naltrexone did not significantly alter the time taken to locate the food 
or to commence eating, nor did it affect the average duration of eating bouts or 
eating rate.  
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Naltrexone treatment also led to a modest acceleration (gradual shift to the left in 
the eat-to-rest transition) in the satiety sequence, without compromising behavioural 
structure. This profile for naltrexone is quite similar to that previously obtained with 
naloxone (Tallett et al. 2008). Somewhat unexpectedly, naltrexone was less potent 
than naloxone in terms of the minimum effective anorectic dose (3.0 mg/kg vs 1.0 
mg/kg) but had a wider range of behavioural activity.  
5.5.4 Design of Experiment Six 
Based on the data from the bupropion dose response study (Experiment 4), a sub-
anorectic dose of bupropion was selected. Experiment 4 confirmed that acute 
bupropion 20mg/kg did not significantly suppress food intake. Nor did it produce 
behavioural stimulation, as characterised by a significant increase in rearing, 
sniffing or locomotion. Therefore, a bupropion dose of 20mg/kg was selected for the 
interaction study. 
Based on the data from the naltrexone dose response study (Experiment 5), a sub-
anorectic dose and a threshold dose of naltrexone were selected. Experiment 5 
confirmed that naltrexone 0.1 and 1.0mg/kg did not significantly supress food 
intake. While, these doses did lead to a small acceleration in the BSS, there was no 
evidence of behavioural disruption. Therefore, 0.1 and 1.0 mg/kg of naltrexone 
were selected for the interaction study. 
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5.6 Experiment Six; Bupropion (20mg/kg) and Naltrexone 
(1.0 and 0.1mg/kg) Interaction 
5.6.1 Method 
5.6.1.1 Subjects and Design 
10 adult male Lister hooded rats (205.13 + 2.25g on arrival from Charles River, U.K 
and 444.32 + 9.51g by the end of the study) were employed for this study. A within-
subjects design was adopted whereby each subject received all six experimental 
conditions according to a Latin Square (with a 7-day wash out period: Vehicle + 
Vehicle (Saline; VV); Vehicle + Naltrexone (0.1mg/kg; VNL); Vehicle + Naltrexone 
(1.0mg/kg; VNH); Bupropion (20mg/kg) + Vehicle (BV); Bupropion (20mg/kg) + 
Naltrexone (0.1mg/kg; BNL); and Bupropion (20mg/kg) + Naltrexone (1.0mg/kg; 
BNH).  
5.6.1.2 Drugs 
Bupropion hydrochloride and naltrexone hydrochloride (both sourced from Sigma-
Aldrich, Poole, UK) were both dissolved in physiological saline (0.9%) which, alone, 
served as a vehicle control. Doses of bupropion (20 mg/kg) and naltrexone (0.1, 
and 1.0 mg/kg) were selected based on data obtained in Experiments 4 and 5. All 
solutions were freshly prepared on test days and administered i.p. in a volume of 
1ml//kg either 30 minutes (bupropion or vehicle) or 15 minutes (naltrexone or 
vehicle) prior to testing. 
5.6.1.3 Procedure 
Testing occurred over four weeks, with two test days per week, and 5 animals 
tested per day. Treatment order was counterbalanced both within and between test 
days according to the Latin Square. 
5.6.2 Results 
Full statistical details can be found in Appendix 5. It should be noted that, as 
animals did not show appreciable amounts of scratching during Experiment 6, data 
for these variables are not reported. 
5.6.2.1 Habituation Phase Food Intake 
As expected, intake differed significantly over the course of habituation (F(4,36) = 
8.82, p < 0.001), with intake on trial 1 (13.83 + 0.85g) significantly lower (p ≤ 0.05) 
than on trials 2, 3 and 5 (trial 2: 17.58 ± 0.94g; trial 3: 19.00 ± 1.27g; trial 4: 19.29 ± 
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1.98g; trial 5: 20.36 ± 1.29g). The lack of significant difference across trials 2-5 
confirmed the development of a stable intake pattern, as well as the close similarity 
in intake scores between those habituation trials and the vehicle condition in the 
main experiment (19.30 ± 1.24g). 
5.6.2.2 Test Day Bodyweight 
Test-day bodyweights did not differ significantly across treatment conditions: VV: 
399.2 ± 14.3g; VNL: 399.0 ± 12.4g; VNH: 401.1 ± 11.3g; BV: 403.9 ± 7.2g: BNL: 
408.0 + 10.8g; BNH: 403.4 + 12.3g (main effect bupropion, F(1,9) = 0.30, p ≥ 0.05; 
main effect naltrexone, F(2,18) = 0.08, p ≥ 0.05; interaction: F(2,18) = 0.05, p ≥ 
0.05).  
5.6.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.18% throughout the experiment (range = 0.09 - 0.35%). Treatment effects on 
food intake are summarised in Figure 5-9. ANOVA confirmed significant main 
effects for bupropion (F(1,9) = 33.74, p < 0.001) and naltrexone (F(2,18) = 10.71, p 
= 0.005), but no significant interaction (F(2,18) = 0.64, p > 0.05).  
Post-hoc comparisons revealed that mash intake was significantly suppressed both 
by bupropion and the higher dose naltrexone (1.0mg/kg) when given alone (p ≤ 
0.01 vs VV), and by bupropion in combination with each dose of naltrexone (p ≤ 
0.001 vs VV). The apparently greater suppressant effect of co-administration is 
supported by significant differences between (i) the lower dose of naltrexone 
(0.1mg/kg) in the presence versus absence of bupropion (BNL vs VNL; p < 0.01), 
and (ii) bupropion in the presence versus absence of the higher dose of naltrexone 
(1.0mg/kg; BNH vs BV; p < 0.05). An additive anorectic effect of co-treatment is 
further supported by comparisons between the actual percentage reductions in 
intake (relative to VV control) for the treatment combinations and those predicted by 
simply adding the effects of the individual treatments: VNL (14.3%); VNH (26%); BV 
(23.1%); BNL (37.7% actual, vs 37.4% calculated); BNH (40.8% actual, vs 49.1% 
calculated).  
5.6.2.4 Total (one-hour) Behavioural Analyses 
Data for feeding-related measures are summarised in Table 5-3, while treatment 
effects on the total frequency and duration of ingestive and non-ingestive elements 
are shown in Figure 5-10. 
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Figure 5-9: Experiment Six. Effects of bupropion and naltrexone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle, B = bupropion 20 mg/kg NL = naltrexone 0.1 mg/kg; NH = naltrexone 1.0 
mg/kg; * p < 0.05, ** p < 0.01, *** p < 0.001 vs VV; + p < 0.01 vs VNL; # p < 0.05 v BV. See text 
for full details. 
Significant bupropion x naltrexone interactions were found for the frequency of 
rearing and sniffing and for time spent grooming (F(2,18) ≥ 10.42, p ≤ 0.01), while 
significant main effects of bupropion were found for the frequency of eating (F(1,9) 
= 12.44, p ≤ 0.01), eat bout duration (F(1,9) = 14.01, p = 0.005), eating rate (F(1,9) 
= 13.64, p = 0.005), the duration of sniffing (F(1,9) = 50.57, p < 0.001), and both the 
frequency and duration of locomotion (F(1,9) ≥ 29.61, p ≤ 0.001 ). In addition, 
significant main effects of naltrexone were found for eating rate (F(2,18) = 8.37, p = 
0.003), rear duration (F(2,18) = 8.04, p < 0.005), and both the frequency and 
duration of resting (F(2,18) ≥ 4.49, p ≤ 0.05). No other interactions or main effects 
were significant.  
As summarised in Figure 5-10, bupropion increased the frequency of rearing and 
sniffing (p ≤ 0.01, BV vs VV), effects that were blocked by the intrinsically-inactive 
higher dose of naltrexone (p ≤ 0.01; BNH vs BV). Relative to VV control, BV also 
increased the frequency (p < 0.01) and duration (p < 0.05) of locomotion, effects 
that were non-significantly attenuated by co-administration of the higher dose of 
naltrexone. No significant pairwise contrasts were found in post-hoc followups to 
the reported main effects of bupropion on eat frequency, eat bout duration or sniff 
duration, or of naltrexone on rest frequency and rear duration. Although both 
bupropion and naltrexone tended to individually reduce the rate of eating relative to 
VV control, the largest effects were seen in animals receiving combined treatment 
(Table 5-3), with post-hoc comparisons confirming a significant reduction in eat rate 
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only for the combination of bupropion and the higher dose of naltrexone (BNL vs 
VV, p < 0.05). It is also worth noting that, the difference in eating rate between the 
latter condition and bupropion given alone (BV) approached statistical significance 
(p = 0.072). Finally, relative to VV control, the higher dose of naltrexone reduced 
the duration of grooming and increased the duration of resting (p < 0.05). Despite 
the observation that the latter effect of the opioid receptor antagonist was 
significantly attenuated by co-administration of bupropion (BNL vs VNL; p < 0.05), it 
should be noted that bupropion by itself (albeit non-significantly) reduced time spent 
resting and that a simple cancellation effect most probably occurred (Figure 5-10). 
Table 5-3: Experiment Six. Effects of bupropion and naltrexone, alone and in 
combination, on mash intake and feeding-related parameters in male rats 
exposed for 1h to palatable mash 
Data are presented as mean values (+ SEM). s = seconds, g = grams. V = vehicle, B = 
bupropion 20 mg/kg NL = naltrexone 0.1 mg/kg; NH = naltrexone 1.0 mg/kg; * p < 0.05 vs VV. 
See text for full details. 
Measure VV VNL VNH BV BNL BNH 
Latency to locate 
food (s) 
7.14 + 
1.74 
7.90 + 
1.79 
7.03 + 
2.19 
11.95 + 
3.11 
5.93 + 
1.93 
7.87 + 
3.69 
Latency to eat (s) 20.65 + 
3.87 
28.33 + 
4.66 
30.18 + 
7.35 
32.10 + 
9.41 
22.57 + 
4.06 
18.90 + 
5.00 
Eat bout (s) 11.12 + 
1.63 
10.42 + 
1.36 
9.97 + 
1.55 
6.97 + 
1.12 
9.26 + 
1.97 
9.19 + 
1.80 
Eat rate (g/min) 1.70 + 
0.07 
1.66 + 
0.14 
1.63 + 
0.13 
1.66 + 
0.13 
1.36 + 
0.15 
1.15 + 
0.11* 
 
5.6.2.5 Periodic (Timebin) Behavioural Analyses  
As found in Experiment 5, significant main effects of time were found for the 
frequency (F(11,99) ≥ 8.03, p ≤ 0.001) and duration (F(11,99) ≥ 4.08, p ≤ 0.001) of 
all behavioural measures, with the exception of groom frequency (F(11,99) < 1.13, 
p > 0.05). Few parameters showed significant drug interactions involving time, the 
exceptions being 3-way (bupropion x naltrexone x time) interactions for the 
frequency of rearing and sniffing (F(22,198) ≥ 1.58, p ≤ 0.05), and a 2-way 
(bupropion x time) interaction for rest duration (F(11,99)= 2.40, p = 0.01). The 
naltrexone x time interaction for rest frequency also closely approached statistical 
significance (F(22, 198) = 1.57, p < 0.06).  
154 
 
 
 
Figure 5-10: Experiment Six. Effects of bupropion and naltrexone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash 
Data are mean values (± S.E.M). V = vehicle, B = bupropion 20 mg/kg NL = naltrexone 0.1 
mg/kg; NH = naltrexone 1.0 mg/kg; * p < 0.05, ** p < 0.01, *** p < 0.001 vs VV; + p < 0.01 vs 
VNL; # p < 0.05 v BV. See text for full details. 
Significant interactions were further explored by a series of two-way ANOVAs (& 
post-hoc tests) within each timebin. These analyses showed that bupropion alone 
significantly increased rear frequency in timebins 2, 3 and 9 (BV vs VV; p ≤ 0.03), 
effects that were significantly blocked by the co-administration of the higher dose of 
naltrexone (BNH vs BV; p ≤ 0.05). Similarly, sniff frequency was significantly 
increased by bupropion alone (BV vs VV) in timebins 1 and 2 (p ≤ 0.04), with 
additional increases in timebins 3 and 8 closely approaching significance (p ≤ 0.07). 
Given the pattern of results for rearing, it is interesting to note that the bupropion-
induced increases in sniff frequency in timebins 1 and 3 were almost significantly 
attenuated by co-administration of the higher dose of naltrexone (BNH vs BV, p ≤ 
0.08). Despite the significant main effects and/or interactions for resting parameters 
(indicating overall increases under naltrexone & decreases under bupropion), high 
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within-timebin variance largely precluded detection of meaningful significant 
pairwise contrasts. 
5.6.2.6 Behavioural Satiety Sequence (BSS)  
Figure 5-11 illustrates the BSS profiles for each of the 6 treatment conditions. 
Although the absolute level of resting in the second half of the session was not as 
great as seen in earlier experiments, the control BSS profile (VV; top left panel) 
nevertheless shows the typical peak feeding response in the first 15-20 min of the 
test. Feeding gradually gives way to grooming and resting as time progressed, with 
an eat-to-rest transition occurring around 35min into the test. Although neither dose 
of naltrexone when given alone interfered with normal behavioural structure (centre 
& bottom left panels), VNH modestly accelerated the sequence (shift to the left) by 
suppressing the peak feeding response and producing an earlier transition to, as 
well as higher levels of, resting. Given alone, BV also suppressed the peak feeding 
response but virtually eliminated resting behaviour, a pattern consistent with 
behavioural disruption (top right panel). Interestingly, while still displaying a 
reduction in the peak feeding response, co-administration of either dose of 
naltrexone with bupropion (centre & bottom right panels) appeared to reinstate a 
more normal behavioural structure with eat-to-rest transitions once again 
discernible around 35-40min. 
5.6.2.7 Bodyweight Gain 
Data not shown. As with the previous dose-response experiments, ANOVA failed to 
reveal any significant main effects or interactions for 3-day absolute weight gain 
(main effect bupropion: F(1,9) = 0.96, p > 0.05; main effect naltrexone: F(2,18) = 
0.07, p > 0.05; interaction: F(2,18) = 0.24, p > 0.05). Again the analysis of percent 
bodyweight c6hange over days post-treatment confirmed normal growth patterns 
(main effect day: F(2,18) = 71.36, p < 0.001), and it too failed to reveal any 
significant drug main effects or interactions (main effect bupropion: F(1,9) = 2.28, p 
> 0.05; main effect naltrexone: F(2,18) = 0.31, p > 0.05; interaction: F(2,18) = 0.24, 
p > 0.05). 
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Figure 5-11: Experiment Six. Effects of bupropion and naltrexone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = vehicle, B = bupropion 20 mg/kg NL = naltrexone 0.1 mg/kg; NH = naltrexone 1.0 
mg/kg; See text for full details. 
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5.6.3 Summary of Main Findings 
In Experiment 6, bupropion (20mg/kg) somewhat unexpectedly exerted significant 
anorectic activity by itself and produced evidence consistent with psychomotor 
stimulation (e.g. increased locomotion, rearing & sniffing). Furthermore, the higher 
naltrexone dose (1.0 mg/kg) produced a statistically significant reduction of intake. 
However, it is pertinent to note that the actual % suppression was very similar to 
Experiment 5 (22%, Experiment 5 vs. 26%, Experiment 6). Despite these profiles, 
the original aim of the study remained intact; to study the behavioural effects of 
these two drugs when co-administered at sub-maximal dose levels.  
The results showed that the combinations produced significantly greater reductions 
in mash intake (37-41%) than those produced by either agent alone (14-26%). 
However, unlike the theoretically-predicted synergistic interaction for the bupropion 
and naltrexone combination (Greenway, Whitehouse, et al., 2009), our findings are 
indicative of only an additive interaction. The reductions seen in response to 
combined treatment closely matched those simply calculated by the addition of 
reductions in response to the constituent agents.  
Interestingly, and unexpectedly, the higher dose of naltrexone (1.0 mg/kg) also 
counteracted the stimulant effects of bupropion (20 mg/kg) on locomotion, rearing 
and sniffing, an effect statistically significant for the latter two measures.  
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5.7 Chapter Five Main Findings 
As comparatively little is known about the combination Contrave™, Chapter 5 
aimed to comprehensively profile the effects of bupropion and naltrexone, alone 
and in combination, on ingestive and non-ingestive behaviours using BSS 
methodology. 
 Experiment 4 showed that the highest dose of bupropion (40mg/kg) 
suppressed intake and feeding behaviour. However, the same dose level (but 
not 10 or 20mg/kg) produced locomotor stimulation, characterised by marked 
stimulation of rearing, sniffing and locomotion behaviour. 
 Experiment 5 showed that naltrexone dose-dependently reduces food intake, 
and significantly suppressed the frequency and duration of feeding behaviour at 
the highest dose tested (3.0mg/kg). Naltrexone also produced a dose-
dependent acceleration in the BSS, without evidence of behavioural disruption. 
 Experiment 6 showed that bupropion (20mg/kg) and the higher dose of 
naltrexone (1.0mg/kg), alone produced anorectic effects. The combination of 
bupropion and naltrexone produces a reduction in intake indicative of an 
additive interaction. Similar to the findings of Chapter 4, it was found the 
addition of the opioid receptor antagonist counteracted any undesirable side-
effects; in this case the stimulant effects of bupropion. Interestingly, the latter 
finding indicates that the anorectic response to acute bupropion is not explained 
by its psychomotor stimulant property.  
The work reported in Chapter 5 confirms the additive effect of naltrexone and 
bupropion combination Contrave™ (Greenway, Whitehouse, et al., 2009). It also 
shows that the addition of the opioid receptor antagonists counters the psychomotor 
stimulant effects of bupropion. 
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Chapter 6 Serotonergic and Opioid System Interactions 
6.1 The Serotonergic System 
The discovery of serotonin (5-hydroxytryptamine; 5-HT) was reported almost 
simultaneously by two separate research groups. In the 1930s, Page et al., 
identified the molecule “serotonin”, named after its origin in blood ‘serum’ and its 
effect on vascular muscle ‘tone’ (Rapport et al., 1948). Meanwhile, Erspamer 
discovered “enteramine”, a molecule secreted by the enterochromaffin cells of the 
GIT and found to contract vascular muscle (Erspamer, 1940; cited in Feldman et 
al., 1997). It wasn’t until the 1950s that it was confirmed that these molecules were 
one and the same (Erspamer & Asero, 1952). 
Although widely distributed (Twarog et al., 1953), the location of 9 primary 
serotonergic cell bodies and pathways were identified using histofluorescence 
techniques by Dahlstrom and Fuxe in the 1960s (Dahlstrom & Fuxe, 1964), named 
B1 – B9, as can be seen in Figure 6-2. The serotonergic cells were located 
primarily within the dorsal raphe nucleus (Tork, 1990) and the reticular formation of 
the lower brain stem. The neurons are clustered into two groups: the caudal group 
(B1-4), projecting to the brainstem and spinal cord; and the rostral group (B5-9), 
projecting to the forebrain (Hornung, 2003). 
Serotonin is an indoleamine neurotransmitter synthesised from tryptophan into 5-
hyroxytryptophan (5-HTP) that is then decarboxylated at the terminal to produce 
serotonin. Serotonin is stored primarily in presynaptic vesicles and, on release, 
stimulates both pre- and post-synaptic receptors until it is reabsorbed or broken 
down to 5-hydroxyindole acetic acid (5-HIAA) by monoamine oxidase (MAO; 
Halford et al., 2007). There are seven serotonin receptor families 5-HT1–7 and, to 
the authors knowledge, currently 14 identified receptor subtypes (see reviews: 
Barnes & Sharp, 1999; Boess & Martin, 1994; Hoyer et al., 2002; Nichols & Nichols, 
2008; see Table 6-1). 
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Figure 6-1: Schematic drawing depicting the location of the serotonergic cell body 
groups in a sagittal section of the rat central nervous system and their major 
projections.  
OT, olfactory tuberculum; Sept, septum; C. Put, nucleus caudate-putamen; G. Pal, globus 
pallidus; T,thalamus; H, habenula; S. Nigra, substantia nigra. Source: Siegel et al., (1999) 
6.1.1 Serotonin and Appetite Regulation 
Serotonin was linked to the control of food intake and feeding behaviour 30 years 
ago, and now there are more data on the effects of serotonin on human appetite 
and rodent eating behaviour than for any other peripheral or central target (Halford 
et al., 2007).  
As serotonin is a key factor in appetite regulation, its levels and function should 
reflect the organism’s nutritional status, fed or fasted. For example, a nutritional 
deficit reduces endogenous serotonin and increases 5-HT receptor sensitivity. 
Evidence shows that malnourished animals have low serotonin levels (Barragan-
Mejia et al., 2002) and the sensitivity of 5-HT2C receptors appears to be increased 
following dieting (Cowen et al., 1996). Similarly, in humans, tryptophan levels are 
reduced after a 4-week hypocaloric diet (Wolfe et al., 1997) and 5-HIAA levels are 
reduced in anorexic patients (Kaye et al., 1988). Additionally, obese models 
demonstrate abnormal serotonin levels. For example, obese animals (Hassanain & 
Levin, 2002; Meguid et al., 2000; Svec et al., 2002) and humans (Breum et al., 
2003) display lower levels of serotonin and its metabolites than their lean 
counterparts.  
In 1977, Blundell proposed that the serotonergic system not only has an inhibitory 
role in feeding but a more significant role as a satiety factor (Blundell, 1977). 
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Numerous studies employing a BSS methodology have since supported the role of 
increased serotonin levels in the selective acceleration of the BSS (see (Rodgers et 
al., 2010). 
6.1.2 Serotonin Mechanism of Action on Appetite 
Serotonin-induced anorexia is thought to be mediated in the PVN, via its impact on 
orexigenic and anorexgenic neuropeptides such as NPY, POMC and their 
associated derivatives (Halford et al., 2003). 
The administration of serotonin releasers, such as fenfluramine and dex-
fenfluramine (d-FEN; see Section 6.1.3.1), decreases levels of NPY (Choi et al., 
2006; Dryden, Frankish, et al., 1996), whereas 5-HT antagonists have been shown 
to increase NPY in the hypothalamus (Dryden et al., 1995). Furthermore, reduced 
serotonin availability is reported to decrease the density of NPY neurons in the 
hypothalamus (Compan et al., 1996). Similarly, administration of 5-HT receptor 
agonists has been found to attenuate NPY-induced hyperphagia (Grignaschi et al., 
1995; Rogers et al., 1991; however see: Brown & Coscina, 1995). 
More specifically, the PVN has been implicated in the NPY-serotonin relationship, 
although, currently, only 5-HT2C receptor agonists/antagonists administered into the 
PVN have been shown to impact NPY-mediated feeding responses (Currie, 2003). 
Moreover, NPY neurons within the PVN are hyperpolarised by 5-HT1B receptor 
agonist administration (Heisler et al., 2006; see Section 6.1.4). 
Additionally, the anorectic action of serotonin can be attenuated by pharmacological 
and genetic inactivation of melanocortin receptors (Heisler et al., 2003; Heisler et 
al., 2002; Heisler et al., 2006; Lam et al., 2008). Evidence shows that administration 
of d-FEN or mCPP (meta-Chlorophenylpiperazine; see Section 6.1.4.1) activates 
POMC neurons in the ARC (Heisler et al., 2002; Lam et al., 2008), causing the 
release of α-MSH which then acts at MC3 and MC4 receptors. Furthermore, 
pharmacological or genetic blockade of these receptors attenuates the anorectic 
effect of serotonin (Heisler et al., 2003). In fact, specific 5-HT2C and 5-HT1B receptor 
activation (see Section 6.1.4) promotes the release of α-MSH, whilst simultaneously 
inhibiting the release of AgRP (Heisler et al., 2006). The inhibition of AgRP 
decreases the inhibitory effect on POMC neurons, further promoting the release of 
α-MSH. Evidence demonstrates that d-FEN-induced anorexia is attenuated in mice 
with ectopic expression AgRP (Heisler et al., 2006). 
Serotonin has also been thought to elicit its appetite effects via interaction with: 
orexin (Muraki et al., 2004; see Section 1.4.3), oxytocin (Jorgensen et al., 2003; see 
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Section 1.5.2.3) and noradrenaline (James et al., 2000; see Chapter 5); and CRH 
(see review: Lam et al., 2010; see Section 1.5.2.4). 
Interestingly, the systemic administration of 5-HT (with poor BBB penetration) has 
also been found to reduce food intake (Edwards, 1991; Fletcher & Burton, 1984; 
Pollock & Rowland, 1981). Furthermore, serotonin is the main transmitter in the 
gastrointestinal nervous system that regulates peripheral hormones (Feldberg & 
Toh, 1953). Together with evidence of a prolonged effect of bodyweight loss 
beyond that of intake suppression (Connoley et al., 1995; Day & Bailey, 1998; 
Vickers et al., 2000), these findings suggest an additional peripheral action of 
serotonin. 
6.1.3 Therapeutic Potential of Serotonergic Drugs 
Administration of the 5-HT precursor, 5-HTP, reduces self-reported food intake and 
induces weight loss in obese patients for up to 12 weeks (Cangiano et al., 1992). In 
contrast, neurotoxic lesioning of serotonin neurons via 5,7-dihydroxytryptamine 
(5,7-DHT), blocks serotonin-induced hypophagia and increases food intake 
(Mackenzie et al., 1979). Similarly, administration of para-chlorophenlyanine 
(pCPA), an inhibitor of tryptophan hydroxylase, and therefore of serotonin 
synthesis, also blocks serotonin induced hypophagia and increases intake (Breisch 
et al., 1976; Mackenzie et al., 1979). 
The above evidence clearly demonstrates that increased serotonin levels enhance 
satiation and meal termination (Blundell & Halford, 1998; Edwards, 1991; 
Simansky, 1996), with both central and peripheral administration found to decrease 
food intake (Hutson et al., 1988; Pollock & Rowland, 1981). The serotonergic 
system is therefore an obvious target in the development of appetite suppressants 
for the treatment of obesity. 
6.1.3.1 Fenfluramine and d-FEN 
Compounds that stimulate the release of serotonin, through the promotion of 
serotonin efflux into the synapse, such as fenfluramine and d-FEN, have been 
widely reported to reduce intake and bodyweight, (Blundell & Latham, 1980; Fisler 
et al., 1993; Gibson et al., 1993; GuyGrand, 1995; Halford & Blundell, 1993; 
McCann et al., 1997; Pringle et al., 2008; Vickers et al., 2000; Vickers, Easton, et 
al., 2003), whilst preserving the BSS in rodents (Blundell & Halford, 1998; Blundell 
& McArthur, 1981; Hewitt et al., 2002; Lee et al., 2004; Vickers et al., 1996; Vickers 
et al., 1999; Webster, 2001; however see: McGuirk, 1992; Montgomery, 1988). 
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Fenfluramine was approved for the treatment of obesity in 1996, after evidence 
showed that it reduced food intake in healthy (Blundell et al., 1979; Goodall & 
Silverstone, 1988; Willner, 1990) and obese (Halford et al., 2010) humans. For 
example, fenfluramine 60mg/day reduces food intake in one meal by ~26% 
(Blundell et al., 1979; Foltin et al., 1996) and fenfluramine 40mg/day reduces total 
daily caloric intake (Foltin et al., 1996). Furthermore, it was found to selectively 
reduce meal size rather than number of meals (Foltin et al., 1996), emphasising the 
enhanced satiation effect. Clinical research found that fenfluramine treatment 
results in a weight loss between 1.2 and 11.9kg (Pinder et al., 1975). Despite this, it 
was withdrawn from the market in 1997 due to high rates of pulmonary 
hypertension (Mark et al., 1997).  
Similarly, d-FEN reduces self-reported food intake (Drent et al., 1995; Goodall & 
Silverstone, 1988; GuyGrand, 1995; Marbury et al., 1996) and produces significant 
reductions in hunger ratings prior to a meal in both lean and obese humans 
(Blundell & Hill, 1990). It has also been successful in the inhibition of intake and 
weight regain following a VLCD (Finer et al., 1992) and has been shown to protect 
against DIO (Fisler et al., 1993). Furthermore, d-FEN has demonstrated little to no 
tolerance in chronic studies (Vickers et al., 2000). The European INDEX 
(INternational DEXfenfluramine) clinical trial (Guygrand et al., 1989), found that 
52% of obese volunteers taking d-FEN treatment for 1 year lost ≥10% baseline 
bodyweight compared to placebo with an average weight loss of 9.82kg (placebo = 
7.15kg). However, following treatment cessation, rapid weight gain was reported 
(Guygrand, 1992) and, as with fenfluramine, d-FEN was withdrawn from the market 
in 1997 (FDA, 1997a), due to cardiovascular problems. 
6.1.3.2 Selective Serotonin Reuptake Inhibitors 
Selective serotonin reuptake inhibitors (SSRIs) increase extracellular serotonin via 
the blockade of reuptake transporters and reduce food intake (see review: Heal, 
Cheetham, et al., 1998). Similarly, MAO inhibitors, that prevent the breakdown of 
serotonin, increase extracellular serotonin levels and reduce food intake (Feldman, 
1988). SSRIs, such as fluoxetine (Clifton et al., 1989; Halford & Blundell, 1996b; 
Heisler et al., 1997; Lawton et al., 1995; McGuirk et al., 1992; Pijl et al., 1991; Ward 
et al., 1999; Willner, 1990; Yen et al., 1987); femoxetine (Halford & Blundell, 1993), 
fluvoxamine (Wieczorek et al., 2001), paroxetine (Halford & Blundell, 1993; Konkle 
et al., 2003), and sertraline (Nielsen et al., 1992; Simansky & Vaidya, 1990) have all 
been found to reduce intake and bodyweight, and to accelerate the BSS in rodents.  
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In clinical trials, fluoxetine produced greater weight loss than control after 2 weeks 
(Lawton et al., 1995; McGuirk & Silverstone, 1990; Pijl et al., 1991) and, in a 16 
week study, reduced the mean number of eating sessions and total food intake 
(Ward et al., 1999). In fact, it has been reported that fluoxetine can produce weight 
loss of 0.5kg per week (Wise, 1992). Although this is not sustainable, evidence 
shows that after 60 weeks, although still producing significantly greater weight loss 
than placebo, maximal weight loss is not seen suggesting that weight is regained 
half-way through trials (Darga et al., 1991; Goldstein et al., 1995). 
6.1.3.3 Sibutramine 
Sibutramine is a dual serotonin and noradrenaline reuptake inhibitor (Gundlah et 
al., 1997; Heal, Aspley, et al., 1998; Weintraub et al., 1991) that produces 
hypophagia and weight loss in rodents (Connoley et al., 1995; Halford et al., 1995; 
Luque & Rey, 1999; Wirth et al., 2001) and humans (Barkeling et al., 2003; 
Chapelot et al., 2000; Halford, Boyland, Cooper, et al., 2010; Hansen et al., 1998, 
1999; Rolls et al., 1998) in a behaviourally-selective manner (Halford et al., 1995; 
Higgs et al., 2011; Tallett et al., 2009c). Chronic studies demonstrate that the 
effects on weight loss continue beyond the inhibition of food intake (Connoley et al., 
1995; Day & Bailey, 1998), suggesting that there may be some additional effects on 
energy expenditure (Hansen et al., 1998). 
Approved for the treatment of obesity in 1997, the STORM (Sibutramine Trial of 
Obesity Reduction and Maintenance) clinical trial demonstrated that obese patients 
lost 11.3kg over a 6-month period following sibutramine treatment (10mg/day) with 
a LCD (James et al., 2000). Evidence also reports improvements in triglycerides, 
lipoprotein, cholesterol, uric acid, waist circumference and quality of life measures 
(McMahon et al., 2000). Furthermore, meta-analyses of sibutramine treatment 
produced an average weight loss of ~4.4kg (Arterburn et al., 2004; Padwal et al., 
2003). Despite the apparent success of sibutramine (Meridia®, Reductil®) for 
weight loss treatment, it was withdrawn in October 2010 following evidence of 
serious, non-fatal cardiovascular events in the Sibutramine Cardiovascular 
Outcome Trial (SCOUT; James et al., 2010). 
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6.1.4 Selective Serotonin Receptor Subtypes 
6.1.4.1 5-HT Receptor Involvement in Fenfluramine and d-FEN 
Anorexia 
Despite the apparent utility of serotonergic drugs for the treatment of obesity, there 
have been problems with weight regain following treatment cessation (Darga et al., 
1991) and side-effects (Guygrand et al., 1989), including cardiac valve 
abnormalities (Connolly et al., 1997) and pulmonary hypertension (Mark et al., 
1997; Michelakis & Weir, 2001; for review see: Loke et al., 2002). 
Therefore, more recent research has focused on the specific receptors that mediate 
the anorectic action of serotonergic drugs. For example, the simultaneous 
administration of selective receptor antagonists and d-FEN demonstrated that its 
anorectic effects are mediated by 5-HT1B receptors (Dalton et al., 2006; Lee et al., 
2004; Simansky & Nicklous, 2002) but not 5-HT2A/2C receptors (Clifton et al., 2000; 
Neill & Cooper, 1989; Samanin et al., 1989). In contrast, Vickers (Vickers et al., 
2001) found that pretreatment with SB-242084 (a selective 5-HT2C receptor 
antagonist), but not GR-127935 and SB-224289 (selective 5-HT1B receptor 
antagonists) blocked d-FEN-induced hypophagia. It is now known that d-FEN and 
fenfluramine-induced anorexia is mediated via both 5-HT1B and 5-HT2C receptors 
(Garfield, 2009; Halford et al., 2007; Lucas et al., 1998; Simansky & Nicklous, 2002; 
Vickers et al., 1999). Evidence shows that d-FEN-induced reductions in meal size 
are attenuated by 5-HT1B receptor antagonists, while d-FEN-induced reductions in 
feeding rate are attenuated by 5-HT2C receptor antagonist (Grignaschi & Samanin, 
1992; Vickers et al., 2001). Furthermore, d-FEN’s major metabolite, 
norfenfluramine, is a full 5-HT2C agonist (Curzon et al., 1997). Additionally, 
metergoline (a non-selective 5-HT1/2 receptor antagonist) blocks fluoxetine-induced 
hypophagia (Halford & Blundell, 1996b; Lee & Clifton, 1992) and the anorectic 
effects of other SSRIs, (such as sertraline) can be blocked by selective 5-HT1B and 
5-HT2C receptor antagonists (Lucki et al., 1988) . This evidence suggests that the 
anorectic action induced by serotonergic drugs is mediated by 5-HT1B and 5-HT2C 
receptors (Hewitt et al., 2002; Kitchener & Dourish, 1994; Lopez-Alonso et al., 
2007; Schreiber et al., 2000; Vickers & Dourish, 2004) 
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6-1: Summary of the serotonin receptor subtypes and their impact on appetite 
Adapted from Lam et al. (2010) 
Subtype Agonist action Antagonist action 
Knock-out / Deletion 
models 
5-HT1A 
Increases food intake 
(Dourish, 1985) 
Decreases food intake 
(Moreau et al., 1992) 
No food intake  
or bodyweight 
phenotype  
(Heisler et al., 1998; 
Parks et al., 1998; 
Ramboz et al., 1998) 
5-HT1B (1Dβ) 
Decreases food 
intake  
(Halford & Blundell, 
1996b; Lee & 
Simansky, 1997) 
 
Increased bodysize 
(Bouwknecht et al., 
2001) 
5-HT1D (1Dα) 
Decreases food 
intake  
(Boeles et al., 1997) 
  
5-HT2A 
(Formerly 5-
HT2) 
Decreases food 
intake 
(Fox et al., 2010) 
 
No food intake 
phenotype  
 (Weisstaub et al., 
2006) 
5-HT2B   
Reduces food intake 
(Yadav, 2009) 
5-HT2C 
(Formerly 5-
HT1C) 
Decrease food intake 
(Kennett & Curzon, 
1988) 
(Kitchener & Dourish, 
1994; Martin et al., 
1998; Schreiber & De 
Vry, 2002) 
Increase food intake  
(Bonhaus et al., 1997) 
Hyperphagia and 
increased bodyweight 
(Tecott et al., 1995) 
5-HT3A-E  
Increase food intake  
(Hayes & Covasa, 2006) 
No food intake 
phenotype  
(Bhatnagar et al., 2004) 
5-HT4 
Decrease food intake 
(Jean et al., 2007) 
Increase food intake  
 (Jean et al., 2007) 
No food intake 
phenotype  
 (Compan et al., 2004) 
5-HT5A + 5B   
No bodyweight 
phenotype  
(Grailhe et al., 1999) 
5-HT6  
Decreases food intake  
(Heal et al., 2008) 
Decreases food intake  
and obesity resistant 
(Frassetto et al., 2008) 
5-HT7   
No bodyweight 
phenotype  
(Hedlund et al., 2003) 
 
6.1.4.2 Intrinsic Effects of 5-HT Receptor Ligands on Appetite 
The various 5-HT receptor sub-types induce differing effects on food intake and 
appetite regulation (see Table 1-1). 5-HT1 receptors act as autoreceptors and are 
therefore found on cell soma dendrites/terminals as well as postsynaptically 
(Lanfumey & Hamon, 2004). The administration of 5-HT1A receptor agonists, such 
as 8-OH-DPAT, reduces serotonin release (Dourish et al., 1985; Hopwood & 
Stamford, 2001), increases intake, and disrupts the BSS (Simansky & Vaidya, 
1990; however see: Lopez-Alonso et al., 2007). In contrast, the administration of 5-
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HT1B receptor agonists (such as CP 93129 and RU 24969) accelerates the BSS 
(Halford & Blundell, 1996a; Hewitt et al., 2002; Kitchener & Dourish, 1994; 
Simansky & Vaidya, 1990) and decreases food intake (Koe et al., 1992; Lee & 
Simansky, 1997; Macor et al., 1990; Torgersen et al., 1990). Conversely, 
pharmacological antagonism or genetic deletion via 5-HT1B KO increases intake 
and bodyweight in rodents (Bouwknecht et al., 2001), and attenuates the anorectic 
response to d-FEN and other serotonin agonists (Lee et al., 2004; Lucas et al., 
1998). Interestingly, 5-HT1B receptors are also expressed on non-serotonergic 
neurons and may elicit their anorectic action via inhibition of other neurotransmitters 
(Barnes & Sharp, 1999). 
Administration of 5-HT2C receptor agonists to rodents produces an enhanced BSS 
profile similar to d-FEN, exhibiting a delay of initiation, reduced meal size and meal 
rate (Clifton, 2000; Kennett & Curzon, 1988; Martin et al., 1998; Schreiber & De 
Vry, 2002), whilst selectively advancing satiety (Kitchener & Dourish, 1994; 
Simansky & Vaidya, 1990) and producing weight loss beyond that of anorexia 
(Vickers et al., 2000). On the other hand, 5-HT2C receptor blockade increases food 
intake (Bonhaus et al., 1997) while 5-HT2C receptor KO models are overweight and 
hyperphagic (Nonogaki et al., 1998; Tecott et al., 1995), with a delayed BSS profile 
(Hewitt et al., 2002; Vickers et al., 1999), marked hyperactivity (Nonogaki et al., 
2003; Xu, 2008) and attenuated responses to d-FEN and mCPP (Tecott et al., 
1995; Vickers et al., 1999). See Table 1-2 for an outline of the 5HT1B and 5HT2C 
receptor agonists currently in development. 
Table 6-2: Current 5HT1B and 5HT2C Receptor Agonists 
Receptor Subtype Name Reference 
a preferential 5-HT1A/1B 
receptor agonist 
RU 24969 
Hutson, 1988 
Kennett & Curzon, 1988 
a preferential 5-HT1A/2C 
receptor agonist 
TFMPP 
Kennett & Curzon, 1988 
Kitchener & Dourish, 1994 
Simansky & Vaidya, 1990 
a selective 5-HT1B receptor 
agonist 
CP-93129 
Lee, Aloyo, Fluharty, & 
Simansky & Vaidya, 1998 
a selective 5-HT1B agonist CP-94253 Halford & Blundell, 1996a 
a preferential 5-HT1B/2C 
receptor 
mCPP see Section 6.1.4.3 
a selective 5-HT2C receptor 
agonist 
 
YM348 Hayashi et al., 2004 
Org 12962 Halford et al., 2005 
VER 3323 Miller, 2005 
Ro 4590334 Clifton et al., 2005 
Ro 60-0175 Vickers et al., 2000 
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More recently, attention has also been drawn to 5-HT6 receptors (see review: Heal 
et al., 2008). Evidence shows that the administration of selective 5-HT6 receptor 
agonists reduces food intake and increases weight loss in lean (Bentley et al., 
1999; Woolley et al., 2001; Woolley et al., 2004) and obese (Caldirola & 
Svartengren, 2005; Shacham et al., 2005) rodents, an action thought to be related 
to satiety enhancement (Fisas et al., 2006). 
6.1.4.3 mCPP 
mCPP is a preferential 5-HT1B/2C receptor agonist, that is found to dose-dependently 
suppress food intake and weight gain, both in rodents (Clifton et al., 1993; Dalton et 
al., 2006; Hikiji, 2004; Kennett & Curzon, 1988, 1991; Kennett et al., 1987; Samanin 
et al., 1979; Vickers et al., 2000; Vickers, Easton, et al., 2003; Ward et al., 2008) 
and humans (Cowen et al., 1995; Sargent et al., 1997; Walsh et al., 1994). 
Evidence suggests that these effects are produced in a behaviourally-selective 
manner (Clifton et al., 1993; Hewitt et al., 2002; Kitchener & Dourish, 1994; Lee et 
al., 2004). 
Preclinical studies have demonstrated that mCPP chronically reduces food intake 
(Ashkzari et al., 2003), and water consumption (Buczek et al., 1994; Castro et al., 
2002). It also reduces taste preference (Badaue-Passos et al., 2003; Carli & 
Samanin, 1992; Cooper & Barber, 1994; De Gobbi et al., 2007) and attenuates the 
reinforcing efficacy of palatable food in rats (Ward et al., 2008; Wolff & Leander, 
2000) via central action at the 5-HT2C receptors (Dryden, Wang, et al., 1996; Hikiji, 
2004; Kaplan et al., 1998). mCPP has also been shown to act synergistically, with 
the cannabinoid antagonist rimonabant, to reduce breakpoints in a progressive ratio 
schedule of reinforcement in male rats (Ward et al., 2008). 
Although, mCPP may also agonise 5-HT2A and 5-HT2B receptors, the anorectic 
action is thought to be primarily a result of 5-HT2C receptor activation. Evidence 
shows that pharmacological (Hewitt et al., 2002; Kennett & Curzon, 1988; Kennett 
et al., 1997) or genetic deletion (Dalton et al., 2006; Tecott et al., 1995) of 5-HT2C 
receptors attenuates mCPP-induced hypophagia. Furthermore, pair-fed controls 
that exhibit a similar level of weight loss to mCPP-treated rodents demonstrate that 
the bodyweight effects of mCPP are secondary to its hypophagic effects (Vickers, 
Easton, et al., 2003).  
In humans, mCPP has been found to reduce food intake by ~30% in lean 
volunteers (Cowen et al., 1995; Walsh et al., 1994) and to produce a significant 
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increase in weight loss in obese patients compared to placebo (Sargent et al., 
1997). Disappointingly, however, there have been reports of increased in blood 
pressure and heart rate following mCPP treatment (Ferreira et al., 2005; 
Ghaziuddin et al., 2003). 
6.1.4.4 Lorcaserin 
Preclinical work with the preferential 5-HT2C receptor agonists, mCPP and TFMPP, 
emphasised the importance of 5HT2C receptors in the enhancement of satiety 
(Clifton et al., 2005; Hewitt et al., 2002; however see: Lopez Alonzo, 2007), and has 
led to the development of more selective 5HT2C receptor agonists (such as 
lorcaserin) for the treatment of obesity (Bickerdike, 2003). 
Lorcaserin ([1R]-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine) is a 
selective 5-HT2C receptor agonist that is thought to have an improved 
cardiovascular profile compared with previous serotonergic obesity treatments 
(Smith, Prosser, et al., 2009). Lorcaserin administration has been found to reduce 
food intake and inhibit DIO (Hayashi, Sonoda, et al., 2004; Vickers et al., 2000) in 
rodents, while producing a selective enhancement of the BSS (Higgins et al., 2012).  
Approved for marketing and distribution by the FDA in 2012 (Belviq®), the 
lorcaserin clinical trials have demonstrated huge potential for the treatment of 
obesity (Bays, 2004; Hurren & Berlie, 2011; Martin et al., 2011). Early phase II trials 
found a significant decrease in bodyweight within the intention-to-treat (ITT) 
population after 12 weeks (Smith, Prosser, et al., 2009) and subsequent phase III 
trials found ≥35% of patients lost ≥5% of their baseline bodyweight.  
The Behavioural Modification and Lorcaserin for Overweight and Obesity 
Management (BLOOM) trial found that one year of lorcaserin treatment (20mg/day) 
resulted in 47.5% of patients losing ≥5% of their baseline bodyweight (placebo = 
20.3%) and 22.6% of patients losing ≥10% of their baseline bodyweight (placebo = 
7.7%). Furthermore 67.9% of those who continued treatment for 2 years maintained 
their weight loss. There were also improvements in waist circumference, BMI, blood 
pressure, triglycerides and cholesterol (Fidler et al., 2011; Smith et al., 2010). The 
Behavioural Modification and Lorcaserin Second Study for Overweight and Obesity 
Management (BLOSSOM) trial found a weight loss of ≥10% in 22.6% of patients 
receiving lorcaserin treatment (20mg/day; placebo = 9.7%). Additionally, the 
BLOOM Diabetes Mellitus (BLOOM-DM) trial found a mean weight loss of 4.5% 
with lorcaserin treatment (20mg/day; placebo = 1.5%), however there were no 
significant improvements in secondary endpoints.  
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6.1.5 Serotonin and Non-Appetite Regulatory Behaviours 
In addition to appetite regulation, serotonergic drugs have been associated with: 
anxiety disorders such as, generalised anxiety disorder (Rickels & Rynn, 2002), 
panic disorder (Neumeister et al., 2004) and obsessive compulsive disorder 
(Goddard et al., 2008); depression (Papakostas et al., 2008; Usala et al., 2008); 
aggression, for example a lack of serotonin increases aggression (Bouwknecht et 
al., 2001; Saudou et al., 1994); sleep and arousal, for example increased serotonin 
levels increase wakefulness (Trulson & Jacobs, 1979); temperature regulation 
(Guscott et al., 2003); sexual dysfunction; epilepsy; Alzhiemers disease; urinary 
incontinence; and hot flushes (see review: Bishop & Nilsson, 2003). 
Despite this spectrum of activity, the majority of the serotonergic drugs reviewed 
above have demonstrated a behaviourally-selective induction of satiety. As 
previously mentioned, the serotonin releasers, fenfluramine and d-FEN, have 
demonstrated that they impact feeding behaviour in a manner consistent with an 
acceleration of the BSS (Blundell & Halford, 1998; Blundell & Latham, 1980; 
Blundell & McArthur, 1981; Hewitt et al., 2002; Lee et al., 2004; Vickers et al., 1996; 
Vickers et al., 1999; Webster, 2001). The same is true for SSRIs such as fluoxetine, 
sertraline, paroxetine, and femoxetine (Clifton et al., 1989; Halford & Blundell, 1993, 
1996b; Kitchener & Dourish, 1994; McGuirk et al., 1992; Simansky & Vaidya, 1990; 
Willner, 1990), and for the dual reuptake blocker sibutramine (Tallett et al., 2009c). 
Additionally, preferential 5-HT1B and 5-HT2C receptor agonists, such as CP-94253 
(Halford & Blundell, 1996a; Lee et al., 2002), mCPP (Hewitt et al., 2002; Kitchener 
& Dourish, 1994; Lee et al., 2004; Simansky & Vaidya, 1990) and TFMPP 
(Kitchener & Dourish, 1994; Simansky & Vaidya, 1990) have also demonstrated a 
behaviourally-selective enhancement of satiety. In contrast, 5-HT2 receptor 
agonists, such as DOI and MK212, and 5-HT1B receptor agonist RU-24969 have 
been found to disrupt the BSS (Blundell & Halford, 1998; Hewitt et al., 2002; 
Kitchener & Dourish, 1994; Simansky & Vaidya, 1990). 
6.1.5.1 Hypoactivity  
Despite the above reports, questions have been raised about the behavioural 
specificity of the serotonergic anorectic response. For example, it has been 
reported that 5-HT2C receptor agonists concomitantly induce excessive grooming, 
nausea and hypoactivity. This behavioural profile has been reported for a wide 
range of 5-HT2C receptor agonists, such as mCPP, DOI, MK212 CP-809101, 
lorcaserin, Ro 60-0175 and VER 23779 (Clifton et al., 2000; Halford et al., 1997; 
Hewitt et al., 2002; Higgins et al., 2012; Kennett & Curzon, 1988; Kennett et al., 
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1997; Kitchener & Dourish, 1994; Simansky & Vaidya, 1990; Somerville et al., 
2007; Stiedl et al., 2007; Vickers et al., 2000). Conversely, 5-HT2C receptor 
antagonists have been shown to produce hyperactivity (Fletcher et al., 2013). 
Evidence has also shown that the hypo-locomotion is attenuated in 5-HT1B KO mice 
(Clifton et al., 2003; Lee et al., 2004). This evidence suggests that 5-HT2C receptor 
agonists may not produce a behaviourally-specific anorexia.  
6.2 Serotonin-Opioid Interactions 
Growing evidence demonstrates that a functional relationship exists between the 
serotonergic and opioid systems. Opioid receptors have been found on serotonin 
nerve terminals (Parenti et al., 1983). Furthermore, compounds that agonise µ-
opioid receptors suppress the excitatory effects induced by 5-HT2A receptor 
activation (Marek & Aghajanian, 1998), while increased serotonin levels are found 
to negatively regulate µ- and δ- receptors (Passarelli & Costa, 1989; Yoshioka et 
al., 1993) and alter β-endorphin levels (Bagdy et al., 1990; Majeed et al., 1985).  
There is a known system interaction in pain regulation. For example, it has been 
shown that the effects of morphine treatment are enhanced by fenfluramine (Coda 
et al., 1993) and fluoxetine (Gatch et al., 1998; Hynes et al., 1985). Furthermore, 
morphine tolerance is delayed by the simultaneous administration of 5-HT1A 
receptor agonists (Nayebi & Charkhpour, 2006) while, conversely, serotonin-
induced pain tolerance is blocked by opioid antagonists (Gray et al., 1998). 
In relation to appetite regulation, the co-administration of naltrexone and fluoxetine 
has been shown to suppress ethanol consumption in a synergistic manner (Gardell, 
1997; Rezvani et al., 2000). Similarly, naloxone and fluoxetine co-administration 
has been shown to suppress food intake in an additive manner (Hagan et al., 
1997). Interestingly, fluoxetine appears to reduce carbohydrate intake, while 
naloxone reduces fat intake, resulting in an additive reduction in overall 
consumption. Furthermore, administration of 5-HTP has been found to potentiate 
naloxone-induced hypophagia in food-deprived rats (Fernandez-Tome, 1988). 
Interestingly, the 5-HT antagonist methysergide and the 5-HT3 antagonist ICS-
205,930 also potentiates naloxone-induced hypophagia (Beczkowska, 1991) and 
ethanol intake (Johnson, 2000; Le, 1994), suggesting a potential role for 5-HT3 
receptors in opioid anorexia. However, it is relevant to note that, research 
conducted the at University of Leeds, using similar BSS methodology to that used 
in the present thesis, failed to find a significant interaction on food intake using a 
combination of sibutramine and naloxone (Tallett et al., 2010b). Interestingly, mCPP 
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has been shown to act synergistically with the cannabinoid antagonist rimonabant, 
to reduce breakpoints in a progressive ratio schedule of reinforcement in male rats 
(Ward et al., 2008). The synergistic modulation of motivation for palatable foods 
using mCPP could be further assessed with a variety of anorectic compounds, 
including the opioid antagonist naltrexone.  
6.3 Rationale; Chapter Six 
In view of the recent approval of the selective 5-HT2C receptor agonist lorcaserin 
(Belviq®) for the treatment of obesity, in addition to the reported hypoactivity 
associated with preferential 5-HT2C receptor agonist mCPP, the aim of the current 
chapter is to assess the anorectic efficacy and behavioural specificity of mCPP, 
alone and in combination with low-dose naltrexone treatment. As relevant dose-
response data on naltrexone were already available (see Chapter 5, Experiment 5), 
Experiment 7 characterises the dose-response profile of mCPP while Experiment 8 
explores the effects of combined low-dose treatment with these agents.   
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6.4 Experiment Seven; mCPP Dose-Response 
6.4.1 Method  
For the main methodological details, refer to General Methods (Chapter 3).  
6.4.1.1 Subjects and Design 
10 adult male Lister hooded rats (200.51 ± 2.34g on arrival from Charles River, U.K 
and 470.60 + 9.00g by the end of the study) were employed for this study. A within-
subjects design was adopted whereby each subject received all four experimental 
conditions according to a Latin Square (with a 7 day wash out period): Vehicle (V); 
mCPP 0.1mg/kg (mCPP0.1); mCPP 1.0mg/kg (mCPP1.0); and mCPP 3.0mg/kg 
(mCPP3.0).  
6.4.1.2 Drugs 
1-(3-chlorophenyl) piperazine hydrochloride (mCPP; Tocris Bioscience, UK) was 
dissolved to required concentrations in physiological saline (0.9%) which, alone, 
served for control injections. Doses of mCPP (0.1, 1.0 and 3.0 mg/kg) were 
selected based on previous published research (e.g. Hewitt et al., 2002; Kennett & 
Curzon, 1988; Kitchener & Dourish, 1994; Lee et al., 2004; Simansky & Vaidya, 
1990; Ward et al., 2008). All solutions were freshly prepared on test days and 
administered i.p. in a volume of 1ml/kg 30 minutes prior to testing. 
6.4.1.3 Procedure 
Testing occurred over four weeks, with two test days per week and 5 animals tested 
per day. Treatment order was counterbalanced both within and between test days 
according to the Latin Square. 
6.4.2 Results 
Full statistical details can be found in Appendix 8. 
6.4.2.1 Habituation Phase Food Intake 
Mash consumption differed significantly during habituation (F(4,36) = 12.70, p < 
0.001). Intake on the first trial was lower (p ≤ 0.01) than on trials 3-5 (trial 1: 13.14 ± 
1.42g; trial 2: 15.86 ± 1.80g; trial 3: 17.62 ± 1.64g; trial 4: 18.75 ± 1.58g; trial 5: 
19.00 ± 1.86g.). The development of stable intake was confirmed both by the lack 
of significant variation across trials 2-5, and the close similarity in scores between 
the final habituation trial and vehicle control in the subsequent experiment (19.26 ± 
1.20g).  
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6.4.2.2 Test Day Bodyweight 
Test-day bodyweights were equivalent across the four treatment conditions (V: 
402.4 ± 12.2g; mCPP0.1: 407.4 ± 11.6g; mCPP1.0: 413.2 ± 15.1g; mCPP3.0: 403.2 
± 9.3g (F(3,27) = 0.18, p > 0.05). 
6.4.2.3 Test Day Food Intake  
Control food pot measures showed an average weight loss via evaporation of only 
0.17% throughout the experimental period (0.04 – 0.49%). The effects of mCPP on 
mash consumption are shown in Figure 6-2. Treatment with the 5-HT2C receptor 
agonist significantly influenced food intake (F(3,27) = 33.77, p < 0.001), with 
Bonferroni comparisons confirming significant suppression relative to vehicle 
control at 1.0 mg/kg (38.6% decrease; p < 0.01) and 3.0 mg/kg (57.4% decrease; p 
< 0.001). The intermediate (p = 0.051) and highest (p < 0.001) dose levels both 
differed significantly from 0.1 mg/kg but not from each other.  
 
Figure 6-2: Experiment Seven. Effects of acute mCPP on mash intake by non-
deprived male rats during a 1-h test with palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = Vehicle; mCPP0.1 = mCPP 0.1mg/kg; mCPP1.0 = mCPP 1.0mg/kg; and mCPP3.0 
= mCPP 3.0mg/kg. * p ≤ 0.05, ** p < 0.01, *** p < 0.001 versus V. See text for further details. 
6.4.2.4 Total (one-hour) Behavioural Analyses 
Effects of mCPP on feeding-related parameters (latencies, average duration of 
eating bouts, & average rate of eating) are summarised in Table 6-2, while effects 
on the total frequency and duration of ingestive and non-ingestive behaviours are 
shown in Figure 6-3. 
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Figure 6-3: Experiment Seven. Effects of acute mCPP on the duration (upper panel) 
and frequency (lower panel) of behaviours displayed by non-deprived male rats 
during a 1-h test with palatable mash 
Data are mean values (± S.E.M). V = Vehicle; mCPP0.1 = mCPP 0.1mg/kg; mCPP1.0 = mCPP 
1.0mg/kg; and mCPP3.0 = mCPP 3.0mg/kg. * p ≤ 0.05 versus V. See text for further details. 
ANOVA revealed significant effects of mCPP on: latency to locate the food (F(3,27) 
= 18.95, p = 0.001), the average duration of eating bouts (F(3,27) = 6.43, p < 0.01) 
and eating rate (F(3,27) = 40.15, p < 0.001), as well as the frequency of eating 
(F(3,27) =11.60, p < 0.001), sniffing (F(3,27) = 5.83, p < 0.01) and resting (F(3,27) 
= 3.13, p < 0.05), the frequency and duration of locomotion (F(3,27) ≥ 7.22, p ≤ 
0.001), and the duration of grooming (F(3,27) = 9.82, p < 0.001). No other variables 
showed a significant effect of drug (F(3,27) ≤ 2.89, p > 0.05).  
As summarised in Table 6-2 and Figure 6-3, the lowest dose of mCPP (0.1 mg/kg) 
had no significant effects on behaviour. The intermediate dose of 1.0 mg/kg 
significantly reduced the rate of eating (p < 0.001) while the reduction in eat 
frequency and the increase in eat bout duration at this dose level closely 
approached significance (p ≤ 0.06). Most treatment effects were observed at the 
highest dose tested (3.0 mg/kg), which, relative to vehicle control, increased the 
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time taken to locate the food source at the beginning of the test (p < 0.01) and time 
spent grooming (p < 0.001), while reducing the rate of eating (p < 0.001), as well as 
the frequency of eating, locomotion and sniffing (p ≤ 0.02). It is worth noting that 
this dose also produced effects on eat bout duration (increase) and the locomotion 
frequency (decrease) that only just failed to reach significance (p ≤ 0.06). 
Table 6-3: Experiment Seven. Acute effects of mCPP on eating-related parameters 
Data are presented as mean values (+ SEM). † p < 0.06 , * p < 0.05, ** p < 0.01, *** p < 0.001 
versus V. See text for further details. 
Measure Vehicle mCPP 
0.1mg/kg 
mCPP  
1.0mg/kg 
mCPP  
3.0mg/kg 
Latency to locate food 
(s) 
5.75 + 1.82 11.13 + 3.78 9.29 + 2.25 52.04 + 8.90** 
Latency to eat (s) 16.64 + 2.61 15.94 + 6.71 34.34 + 14.70 48.50 + 22.36† 
Eat bout (s) 8.23 + 0.73 10.18 + 1.33 13.31 + 1.73† 20.35 + 4.23 
Eat rate (g/min) 1.75 + 0.08 1.52 + 0.13 1.04 + 0.07*** 0.67 + 0.08*** 
 
6.4.2.5 Periodic (Timebin) Behavioural Analyses 
With the exception of grooming and scratching (F ≤ 1.78, p > 0.05), 2-way ANOVA 
revealed significant main effects of time for the frequency (F(11,99) ≥ 11.29, p ≤ 
0.001) and duration (F(11,99) ≥ 3.13, p ≤ 0.001) of all behavioural measures. This 
result confirms the typical pattern of behaviour during these 1h feeding tests which, 
as the session progresses, comprises a gradual reduction in active behaviours and 
an increase in resting (e.g. Ishii et al. 2003a&b; Rodgers et al. 2001; Tallett et al. 
2009a&b; Wright & Rodgers 2013). Significant drug x time interactions were found 
for the frequency and duration of eating (F(33,297) ≥ 1.80, p ≤ 0.01), rearing 
(F(33,297) ≥ 1.77, p ≤ 0.01) and locomotion (F(33,297) ≥ 1.82, p ≤ 0.01), as well as 
the frequency of sniffing and scratching (F(33,297) ≥ 1.74, p ≤ 0.01), and the 
duration of grooming (F(33,297) = 1.90, p < 0.01). 
A series of one-way ANOVAs (and Bonferroni post-hocs) within each timebin 
indicated that 1.0 and 3.0 mg/kg mCPP reduced the frequency of feeding during 
timebins 1-3 (p ≤ 0.01). Furthermore, over the same early timeframe, the 3.0 mg/kg 
dose additionally increased time spent grooming (p ≤ 0.05) and reduced the 
frequency of rearing and sniffing, as well as the frequency and duration of 
locomotion (all p ≤ 0.05). Figure 6-4 illustrates the temporal effects of mCPP for the 
frequency of eating, locomotion, rearing and sniffing. 
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Figure 6-4: Experiment Seven. Effects of acute mCPP on the frequency of eating, 
sniffing, locomotion and rearing in male rats during a 1-h test with palatable 
mash 
Data are expressed as the mean frequency of each behaviour in 12 x 5-min timebins. Dose-
dependent suppression of all behaviours is apparent during the early part of the test session. 
See text for further details. 
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6.4.2.6 Behavioural Satiety Sequence (BSS)  
Treatment effects on the BSS are summarised in Figure 6-5. The vehicle control 
profile shows a clear peak feeding response during the first 15-20 min of the test. 
Over time, feeding is seen to decline while time spent resting increases, with an 
eat-to-rest transition occurring just over half-way through the session (timebin 7). 
Although very similar normal behaviour patterns were evident with both the low and 
intermediate doses of mCPP, the highest dose of the compound tended to disrupt 
the BSS. Although an eat-to-rest transition is discernible (timebin 8), 3.0 mg/kg 
mCPP not only suppressed the peak feeding response but also induced an unusual 
behaviour pattern characterised by periodic feeding and higher-than–normal levels 
of grooming throughout the test session (see Figure 6-5; bottom right).  
  
  
Figure 6-5: Experiment Seven. Effects of acute mCPP on the behavioural satiety 
sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = Vehicle; mCPP0.1 = mCPP 0.1mg/kg; mCPP1.0 = mCPP 1.0mg/kg; and mCPP3.0 
= mCPP 3.0mg/kg. See text for further details. 
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6.4.2.7 Bodyweight Gain 
Data not shown. ANOVA failed to reveal any significant effect of acute mCPP 
treatment on 7-day absolute weight gain (F(3,27) = 0.11, p > 0.05). Although 
analysis of percent daily weight gain confirmed normal growth over time (F(6,54) = 
228.27, p < 0.001), this analysis also failed to reveal a main effect for drug 
treatment (F(3,27) = 0.20, p > 0.05) or a drug x time interaction (F(18,162) = 0.78, p 
> 0.05). 
6.4.3 Summary of Main Findings 
The results of Experiment 7 show that acute treatment with mCPP dose-
dependently reduces food intake and the frequency (but not duration) of feeding 
behaviour. mCPP also dose-dependently increased the time taken to find food and 
to commence feeding, and reduced the rate of eating.  
Notably, these effects were accompanied by hypoactivity characterised by a dose-
dependent reduction in the frequency (but not duration) of sniffing and locomotion. 
The frequency of all of the non-ingestive behaviours was suppressed from the very 
start of the test session and not, as would be expected with enhanced satiety, after 
the consumption of at least some food. Furthermore there is no indication 
whatsoever of an acceleration (shift to the left) in the BSS as is typical of a wide 
range of behaviourally-selective anorectic agents.  
6.4.4 Design of Experiment Eight 
Experiment 7 confirmed that acute mCPP 0.1mg/kg did not significantly suppress 
food intake, nor did it produce a suppression of active behaviours, such as sniffing, 
rearing or locomotion (see Figure 6-3). Therefore, a mCPP dose of 0.1mg/kg was 
selected for the interaction study. 
Based on the data from the naltrexone dose-response study (Experiment 5) and the 
previous combination study using naltrexone (Experiment 6), two sub-maximal 
doses of naltrexone were selected. Experiments 5 and 6 confirmed that naltrexone 
0.1mg/kg, did not significantly suppress food intake. Although Experiment 6 found a 
significant reduction in food intake for naltrexone 1.0mg/kg, it is pertinent to note 
that the actual % suppression was very similar to the non-significant reduction seen 
in Experiment 5. Therefore, 0.1 and 1.0 mg/kg of naltrexone were deemed 
appropriate for the interaction study.  
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6.5 Experiment Eight; mCPP and Naltrexone Interaction 
6.5.1 Method  
6.5.1.1 Subjects and Design 
10 adult male Lister hooded rats (216.30 + 1.38g on arrival from Charles River, U.K 
and 532.75 + 9.58g by the end of the study) were employed in this study. A within-
subjects design was adopted whereby each subject received all six experimental 
conditions according to a Latin Square (with a 7-day wash out period): Vehicle and 
Vehicle (VV); Vehicle and Naltrexone 0.1mg/kg (VNL); Vehicle and Naltrexone 
1.0mg/kg (VNH); mCPP 0.1mg/kg and Vehicle (mV); mCPP 0.1mg/kg and 
Naltrexone 0.1mg/kg (mNL); and mCPP 0.1mg/kg and Naltrexone 1.0mg/kg (mNH). 
6.5.1.2 Drugs 
1-(3-chlorophenyl) piperazine hydrochloride (mCPP; Tocris Bioscience, UK) and 
naltrexone hydrochloride (Sigma-Aldrich, Poole, UK) were dissolved in 
physiological saline (0.9%) which, alone, served as a vehicle control. A low dose of 
mCPP (0.1 mg/kg) was used in combination with one of two doses of naltrexone 
(0.1mg/kg = NL, 1.0mg/kg = NH). All solutions were freshly prepared on test days 
and administered i.p. in a volume of 1ml/kg. The first injection (mCPP or vehicle) 
was given 30 minutes prior to testing with the second (naltrexone or vehicle) given 
15 minutes prior to testing. 
6.5.1.3 Procedure 
Testing occurred over six weeks, with two test days per week, and 5 animals tested 
per day. Treatment order was counterbalanced both within and between test days 
according to the Latin Square. 
6.5.2 Results 
Full statistical details can be found in Appendix 9. 
6.5.2.1 Habituation Phase Food Intake 
Intake differed significantly during habituation week (F(4,36) = 32.75, p < 0.001), 
with intake on trial 1 significantly lower (p ≤ 0.05) than on trials 2, 3 and 5, and 
intake on trial 2 significantly different from that on trials 3-5 (p ≤ 0.05; trial 1 = 9.61 + 
1.82g; trial 2 = 16.17 ± 1.79g; trial 3 = 20.22 ± 1.51g; trial 4 = 21.94 ± 1.24g; trial 5 
= 22.18 ± 1.73g). The lack of significant difference across trials 3-5 indicates 
stabilisation of intake toward the end of the habituation period, a conclusion 
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confirmed by the similarity in scores between the final habituation trial and the 
vehicle (VV) condition (22.63 + 1.28g). 
6.5.2.2 Test Day Bodyweight 
Test-day bodyweights did not differ significantly across treatment conditions: VV: 
451.0 ± 12.2g; VNL: 481.1 ± 14.6g; VNH: 457.2 ± 16.3g; mV: 465.1 ± 16.4g: mNL: 
474.5 + 17.4g; mNH: 465.5 + 16.5g (main effect mCPP: F(1,9) = 0.14, p > 0.05; 
main effect naltrexone: F(2,18) = 2.24, p > 0.05; interaction: F(2,18) = 0.21, p > 
0.05). 
6.5.2.3 Test Day Food Intake  
Control food pot measures showed an average weight loss via evaporation of only 
0.22% throughout the experimental period (0.14 - 0.36%). Treatment effects on 
food intake are summarised in Figure 6-6. ANOVA confirmed significant main 
effects for mCPP (F(1,9) = 24.21, p < 0.001) and naltrexone (F(2,18) = 29.30, p < 
0.001), but no significant interaction (F(2,18) = 1.56, p > 0.05).  
 
Figure 6-6: Experiment Eight. Effects of mCPP and naltrexone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are presented as mean values (+ SEM). The percentages refer to intake reduction 
compared to vehicle. V = Vehicle, m = mCPP 0.1mg/kg, NL = 0.1 mg/kg naltrexone, NH = 1.0 
mg/kg naltrexone. * p < 0.05, ** p < 0.01, *** p < 0.001 v VV; + p < 0.01 v mV. See text for full 
details 
Post-hoc comparisons revealed that, relative to vehicle control (VV), mash intake 
was significantly suppressed by NL (p < 0.05) and NH (p < 0.001) when given 
alone, and when each was given in combination with mCPP (p ≤ 0.001). By 
contrast, mCPP per se had no significant effect on mash consumption. Importantly, 
appetite suppression under neither drug combination differed significantly from that 
seen with the opioid antagonist given alone (i.e. mNL vs VNL or mNH vs VNH). 
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This observation, combined with the significant differences between mCPP given 
alone and when administered with either dose of naltrexone (p ≤ 0.01), would be 
consistent with a lack of meaningful anorectic interaction between the two 
compounds.  
6.5.2.4 Total (one-hour) Behavioural Analyses 
Figure 6-7 shows treatment effects on the total frequency and duration of ingestive 
and non-ingestive elements, while Table 6-4 summarises effects on feeding-related 
measures 
Significant mCPP x naltrexone interactions were found only for the frequency and 
duration of locomotion (F(2,18) ≥ 3.93, p ≤ 0.05), while a significant main effect of 
mCPP was found only for the rate of eating (F(1,9) = 6.70, p < 0.05). By contrast, 
many variables demonstrated significant main effects for naltrexone: eating rate 
(F(2,18) = 5.59, p < 0.05); the frequency and duration of eating (F(2,18) ≥ 5.81, p ≤ 
0.05), grooming (F(2,18) ≥ 4.73, p ≤ 0.05), scratching (F(2,18) ≥ 6.87, p ≤ 0.01) and 
sniffing (F(2,18) ≥ 7.18, p ≤ 0.01) ; the frequency of rearing (F(2,18) = 5.36, p < 
0.05); and the duration of resting (F(2,18) = 6.46, p < 0.01). No other interactions or 
main effects were significant. 
Table 6-4: Experiment Eight. Acute effects of mCPP and naltrexone, alone and in 
combination, on eating-related parameters 
Data are presented as mean values (+ SEM). V = Vehicle, m = mCPP 0.1mg/kg, NL = 0.1 
mg/kg naltrexone, NH = 1.0 mg/kg naltrexone. See text for full details. 
Measure VV VNL VNH mV mNL mNH 
Latency to locate 
food (s) 
3.38 + 
0.45 
4.01 + 
1.04 
3.12 + 
0.54 
2.99 + 
0.34 
4.28 + 
0.99 
3.81 + 
1.04 
Latency to eat (s) 9.23 + 
1.92 
7.83 + 
1.24 
14.19 + 
4.28 
18.54 + 
8.27 
9.82 + 
2.66 
9.27 + 
3.87 
Eat bout (s) 11.09 + 
1.18 
9.67 + 
1.37 
8.69 + 
0.70 
9.59 + 
0.80 
11.51 + 
1.48 
11.16 + 
1.48 
Eat rate (g/min) 1.78 + 
0.06 
1.72 + 
0.11 
1.60 + 
0.13 
1.70 + 
0.08 
1.43 + 
0.11 
1.48 + 
0.07 
183 
 
 
Figure 6-7: Experiment Eight. Effects of mCPP and naltrexone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash 
Data are mean values (± S.E.M). V = Vehicle, m = mCPP 0.1mg/kg, NL = 0.1 mg/kg naltrexone, 
NH = 1.0 mg/kg naltrexone; * p ≤ 0.05, vs VV; † p ≤ 0.05 v mV. See text for full details 
As summarised in Figure 6-7, post-hoc analyses actually revealed relatively few 
treatment effects compared to VV control. This outcome suggests that the ANOVA 
pattern of drug main effects (see above) reflects relatively weak responses that 
reach significance only as a result of the increased statistical power of larger 
sample sizes. Nevertheless, eat duration was significantly reduced by NH given 
alone and by both doses of naltrexone in combination with mCPP (p ≤ 0.05), while 
the combination of mCPP and the lower (but not higher) dose of naltrexone 
significantly increased the duration of sniffing and decreased the duration of 
locomotion (p ≤ 0.05). However, in only one of these instances (locomotion 
duration) was there any significant difference between the drug combination and 
either drug given alone (mNL vs VNL, p < 0.02). All other significant pairwise 
comparisons concerned differences between mCPP given alone and when given in 
combination with naltrexone. Thus, relative to the 5-HT2C receptor agonist given 
alone (mV), the low dose combination (mNL) reduced the frequency of eating, 
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rearing, sniffing and locomotion (p ≤ 0.05) while the high dose combination (mNH) 
significantly reduced the duration of grooming and increased the duration of resting 
(p ≤ 0.05). However, as shown in Figure 6-6, none of these mCPP/naltrexone dose 
combinations differed significantly from the corresponding naltrexone only treatment 
conditions. This overall pattern confirms the large number of main effects for 
naltrexone and the minimal impact of its combination with mCPP 
6.5.2.5 Periodic (Timebin) Behavioural Analyses 
With the exceptions of the frequency and duration of grooming and scratching 
(F(11,99) ≤ 1.85, p > 0.05), significant main effects of time were found for the 
frequency (F(11,99) ≥ 7.30, p ≤ 0.001) and duration (F(11,99) ≥ 2.31, p ≤ 0.05) of all 
behavioural measures. This profile reflects the typical pattern of behavioural change 
over the course of the test session. Figure 6-7 illustrates these temporal patterns for 
the frequency of eating, locomotion, rearing and sniffing, while the BSS charts 
(Figure 6-8; see below) clearly show the general increase in resting behaviour as 
the session progressed. Significant 3-way interactions (mCPP x naltrexone x time) 
were found for four measures: eat frequency, rest duration, and both the frequency 
and duration of sniffing (F(22, 198) ≥ 1.83, p ≤ 0.05). Additional 2-way interactions 
were found for eat duration and rest frequency (naltrexone x time: F(22,198) ≥ 2.34, 
p ≤ 0.001), as well as the frequency and duration of locomotion (mCPP x time: 
F(22,198) ≥ 2.08, p ≤ 0.05).  
Significant interactions involving time were further explored by a series of two-way 
ANOVAs within each timebin. These analyses revealed significant drug main 
effects or interactions for eat frequency and/or duration in timebins 1-3, 5-6, 8 and 
10 (F(1,9) ≥ 5.15, p ≤ 0.05; F(2,18) ≥ 3.94, p ≤ 0.05), locomotion frequency and/or 
duration in timebins 3, 6, 10 and 12 (F(1,9) ≥ 5.20, p ≤ 0.05; F(2,18) ≥ 3.60, p ≤ 
0.05), rest frequency and/or duration in timebins 3, 5, 6, 7 and 12 (F(1,9) = 5.09, p ≤ 
0.05; F(2,18) ≥ 4.93, p ≤ 0.05), and sniff frequency and/or duration in timebins 2, 3, 
5, 6, 7, and 12 (F(1,9) = 5.09, p = 0.05; F(2,18) ≥ 3.65, p ≤ 0.05). Although followed 
up by a series of within-timebin Bonferroni comparisons, such fine-grain analyses 
were associated with higher variance around each data-point and, as such, 
produced few significant contrasts. However, it is worth noting that (relative to VV 
control) eat frequency was significantly reduced by mNL in timebins 1 and 2 (p ≤ 
0.05); eat duration was decreased in timebin 2 by mV and mNL (p ≤ 0.05) and, in 
timebin 3, by VNH, mV and mNH (p ≤ 0.02).  
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Figure 6-8: Experiment Eight. Effects of mCPP and naltrexone, alone and in 
combination, on the frequency of eating, sniffing, locomotion and rearing in 
male rats during a 1-h test with palatable mash 
Data are expressed as the mean frequency of each behaviour in 12 x 5-min timebins. Dose-
dependent suppression of behaviour is apparent during the early part of the test session. See 
text for further details 
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6.5.2.6 Behavioural Satiety Sequence (BSS)  
Figure 6-9 illustrates the BSS profiles for each of the treatment conditions. The 
control BSS profile (VV; top left panel) indicates the typical peak feeding response 
in the first 15-20 min of the test. Feeding gradually gives way to grooming and 
resting as time progressed, with an eat-to-rest transition occurring circa half-way 
through the test session. Although neither dose of naltrexone given alone interfered 
with normal behavioural structure (centre & bottom left panels), there is a clear 
dose-dependent acceleration (shift to the left) of the entire sequence. mCPP given 
alone (top right panel) maintained the BSS but actually produced a modest shift to 
the right (delay in the eat-rest transition), whereas its combination with either dose 
of naltrexone (centre & bottom right) produced effects indistinguishable from those 
of the opioid receptor antagonist alone (centre & bottom left).  
6.5.2.7 Bodyweight Gain 
Data not shown. No significant main effects or interactions were found for 7-day 
absolute weight gain; animals typically gained 21-25g irrespective of treatment 
condition (main effect mCPP: F(1,9) = 0.49, p > 0.05; main effect naltrexone: 
F(2,18) = 0.79, p > 0.05; interaction: F(2,18) = 0.39, p > 0.05). Analysis of percent 
bodyweight change over days following treatment confirmed normal growth patterns 
(main effect DAY: F(2,18) = 122.54, p < 0.001), but it too failed to reveal any 
significant drug main effects, drug interactions, or drug x time interactions (main 
effect mCPP: F(1,9) = 0.04, p > 0.05; main effect naltrexone: F(2,18) = 1.61, p > 
0.05; interaction: F(2,18) = 0.24, p > 0.05). 
6.5.3 Summary of Main Findings 
The results of Experiment 8 show that naltrexone had a somewhat more potent 
behavioural effect in the current study than has previously been seen in 
Experiments 5 and 6. Thus, even the lower dose (0.1 mg/kg) induced a modest 
though significant reduction in intake (~26%; p < 0.05) relative to vehicle control.  
Consistent with results obtained in Experiment 7, mCPP (0.1 mg/kg) did not when 
given alone induce any significant behavioural effects when compared with vehicle 
(VV) control. Again, it is interesting to note that it tended to marginally delay (rather 
than accelerate) the BSS. Furthermore, there was little evidence that the 
combination of mCPP with either dose of naltrexone resulted in a stronger effect on 
intake or behaviour than seen in response to naltrexone alone. Therefore, under 
present test conditions and at the dose levels currently used, our results do not 
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support a positive anorectic interaction between the 5-HT2C receptor agonist mCPP 
and the opioid receptor antagonist naltrexone. 
  
  
  
Figure 6-9: Experiment Eight. Effects of mCPP and naltrexone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores (s = seconds) in each of 12 x 5min timebins 
comprising the 1h test period. The vertical line bisecting the x-axis is merely an aid to 
visualisation of the transition between eating and resting. 12 x 5-min timebins. V = vehicle, m = 
mCPP 0.1mg/kg, NL = 0.1 mg/kg naltrexone, NH = 1.0 mg/kg naltrexone. See text for details. 
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6.6 Chapter Six Main Findings 
The aim of the current Chapter was to employ BSS methodology to assess the 
anorectic efficacy and behavioural specificity of combined low-dose treatment with 
naltrexone and mCPP. 
 Experiment 7 showed that acute administration of mCPP dose-dependently 
reduces food intake and the frequency of feeding behaviour in male rats. The 
mCPP-induced anorexia did not appear behaviourally-selective as it was 
accompanied by other behavioural changes indicative of hypoactivity, including 
(at the highest dose; 3.0mg/kg) disruption of the BSS. 
 Experiment 8 showed that the combination of a sub-anorectic dose of mCPP 
with one of two naltrexone doses (threshold and sub-maximal) did not produce 
a positive interaction on food intake or feeding behaviour. 
The findings of Chapter 6 suggest that a 5-HT – opioid interaction may not prove to 
be a fruitful avenue of appetite / weight loss polytherapy. However, future research 
should perhaps assess the generality of current findings to more recently developed 
5-HT2C receptor agonists, such as lorcaserin, Ro 60-0175, CP-809101 and/or 
VER23779. 
 
(Brown & Coscina, 1995; Loke et al., 2002; Lopez-Alonso et al., 2007; McGuirk et 
al., 1992; Montgomery & Willner, 1988) 
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Chapter 7 Peptide and Opioid System Interactions 
7.1 Incretins 
Incretins, discovered in the 1900s (Bayliss & Starling, 1902), are glucose-lowering 
intestinal-derived molecules. The subsequent postprandial enhancement of insulin 
secretion, by their release in the gut, is known as the incretin effect (Creutzfeldt, 
1979; Elrick et al., 1964; Nauck et al., 1986). 
The first identified incretin, isolated from porcine intestine, was found to inhibit 
gastric secretion in dogs (Pederson et al., 1975) and was called gastric inhibitory 
polypeptide (GIPa). However, it was later found that only pharmacological doses of 
GIPa produced inhibition of gastric secretions, whereas a stimulating effect was 
seen at physiological doses (Lauritsen et al., 1980). It was therefore renamed 
glucose-dependent insulinotropic polypeptide (retaining the acronym; GIP). It is now 
known that GIP is released from K cells in proximal regions of the GIT, such as the 
duodenum and jejunum (Kim & Egan, 2008). 
Later, it was discovered that, in addition to glucagon, the proglucagon gene (GCG), 
widely expressed peripherally and centrally (in the caudal brain stem and 
hypothalamus: Merchenthaler et al., 1999), encodes two other peptides. The two 
peptides, with 50% homology to GCG, were named glucagon-like peptide-1 (GLP-
1) and glucagon-like peptide-2 (GLP-2; Kreymann et al., 1987). 
7.1.1 Glucagon-like Peptide 1 
GLP-1 is a 30 amino-acid molecule secreted by the intestinal L cells, located 
predominantly in the distal ileum and colon, in response to nutrient ingestion 
(Brubaker, 2006) and in proportion to nutrient consumption (see reviews: Baggio & 
Drucker, 2007; Drucker, 2006; Holst, 2007; Parker et al., 2010). There are multiple 
forms of GLP-1: GLP-1(1-37) and GLP-1(1-36)NH2 (aka. GLP-1(1-36)amide), both of 
which thought to be inactive; and GLP-1(7-37) and GLP-1(7-36)NH2 (aka. GLP-1(7-
36)amide), the active forms. It is interesting to note that the majority of GLP-1 in 
humans comprises GLP-1(7-36)NH2 (Orskov et al., 1994). All GLP-1 subtypes act on 
GLP-1 receptors (GLP-1R) which are widely expressed in the pancreatic islets, 
lung, heart, kidney, intestine and the CNS; hypothalamus and brainstem (Baggio & 
Drucker, 2007; Drucker, 2006). 
The half-life of bioactive GLP-1 is less than 2 minutes due its inactivation by the 
enzyme dipeptidyl peptidase IV (DPP-IV; aka CD26; Deacon et al., 1995; Kieffer et 
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al., 1995; Mentlein et al., 1993). DPP-IV metabolises the active molecules (GLP-1(7-
37) and GLP-1(7-36)NH2) to GLP-1(9-37) and GLP-1(9-36)NH2 (respectively). However, 
evidence shows that GLP-1 remains intact in DPP-IV null mice (Kieffer et al., 1995) 
suggesting that the inhibition of DPP-IV may be a potential avenue for maintaining a 
prolonged action of GLP-1 (see Section 7.1.5). 
7.1.1.1 GLP-1 and Appetite Regulation 
Initial studies in 1996 demonstrated that central administration of GLP-1 reduces 
food intake for a short period (TangChristensen et al., 1996; Turton et al., 1996), 
whereas peripheral administration had no effect (Navarro et al., 1996; 
TangChristensen et al., 1996; Turton et al., 1996). However, later studies found that 
both central (Meeran et al., 1999; Perez-Tilve et al., 2007) and peripheral 
administration of GLP-1 produced anorexia both in rodents (Chelikani et al., 2005; 
Larsen et al., 2001; Rodriquez de Fonseca et al., 2000; for review see: Barrera et 
al., 2011) and humans (Flint et al., 1998; Gutzwiller, Drewe, et al., 1999; Gutzwiller, 
Goke, et al., 1999; Naslund et al., 1999; Naslund et al., 1998; Zander et al., 2002; 
however see: Long et al., 1999; for a meta-analysis see: Verdich et al., 2001).  
The anorectic effect of ICV GLP-1 can be blocked by pre-treatment with exendin(9-
37), a GLP-1R antagonist (Meeran et al., 1999; TangChristensen et al., 1996; Turton 
et al., 1996) which, alone, significantly increases food intake and bodyweight 
(Meeran et al., 1999; Turton et al., 1996; however see: Larsen et al., 2001) despite 
a preload (Williams et al., 2009). Exendin(9-37) is also shown to block NPY-induced 
anorexia (Turton et al., 1996). More recent studies have shown that GLP-1R null 
mice display a hyperphagic phenotype without weight gain (Hansotia et al., 2007; 
however, see: Scrocchi et al., 1996), an effect recently replicated with ICV 
exendin(9-37) administration (Knauf et al., 2008). 
Interestingly, there have been reports of differential effects of GLP-1 in obese and 
lean subjects. Evidence shows that obese humans and patients with T2DM exhibit 
reduced postprandial levels of GLP-1 (Ranganath et al., 1996; Vilsboll et al., 2001) 
due to impaired GLP-1 release (Carr et al., 2010; Muscelli et al., 2008; Vilsboll, 
Agerso, et al., 2003; Vilsboll, Krarup, et al., 2003). Futhermore, obese patients 
demonstrate an enhanced hypophagic response to GLP-1 treatment whereas, 
GLP-1 infusion has little effect in lean human studies (Long et al., 1999). 
7.1.2 GLP-1 Mechanism of Action  
GLP-1 has a complex physiological action on GLP-1R in different organs and 
tissues, as summarised in Figure 7-1. 
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Figure 7-1: Physiology of Secretion and Action of GLP-1 
Source (Drucker, 2006) 
7.1.2.1 Peripheral: Insulinotropic effect 
Of the two GLPs, only GLP-1 is found to stimulate the insulin receptor (Kieffer & 
Habener, 1999), as would be expected of an incretin (Kreymann et al., 1987). 
Evidence has since demonstrated that GLP-1 is also released in response to 
glucose administration (Unger et al., 1968), whereby it acts as an incretin to 
stimulate insulin secretion from pancreatic β-cells. It also acts in adipose, liver and 
muscle tissue to increase glucose uptake and glycogen production (Drucker, 2006; 
Nogueiras et al., 2009). These actions led to the development of GLP-1R agonists 
for the treatment of type 2 diabetes mellitus (T2DM; for review: Nielsen et al., 2004; 
Peters, 2010). Additional reports suggest that increased GLP-1 signalling is the 
mechanism by which drastic improvement in T2DM occurs following gastric bypass 
surgery (Bose et al., 2009). 
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7.1.2.2 Peripheral: Gastric slowing effects 
GLP-1 is also associated with a slowing of gastric emptying and acid secretion in 
rodents (Talsania et al., 2005) and humans (Chelikani et al., 2005; Flint et al., 2001; 
Long et al., 1999; Naslund et al., 1998) via the stimulation of the sympathetic 
nervous system (SNS; Andrews et al., 2007; Yamamoto et al., 2002). It is proposed 
that this deceleration of gastric emptying attenuates increases in meal-associated 
blood glucose (Meier et al., 2003; Willms et al., 1996). Interestingly, however, it has 
been reported that this effect is not due to a direct action, but is vagally mediated 
(Bucinskaite et al., 2009; Rocca & Brubaker, 1999). Evidence shows that 
administration of exendin(9-39) or vagal afferent denervation blocks GLP-1-induced 
gastric emptying (Baggio & Drucker, 2007) and anorexia (Abbott et al., 2005; 
Talsania et al., 2005). Furthermore, GLP-1 release appears to be biphasic. Early 
release takes place ~10-15minutes postprandially, with the later release occurring 
after ~30-60 minutes (Herrmann et al., 1995). However, given the hypothesis of 
nutrient-stimulated GLP-1R activation in the distal ileum, the early release 
component is not fully understood. Therefore, neural mediation by GRP (gastrin 
releasing peptide), acetyl-choline and GIP has been proposed. This suggests that 
there may be a proximal-to-distal neural signalling pathway for GLP-1 secretion. 
7.1.2.3 Central; Appetite regulation via the brainstem and 
hypothalamus 
GLP-1 has been reported as a ‘neurohumoral’ agent because of its ability to act 
both as a hormone and transmitter in the periphery as well as the CNS (Drucker, 
2006). GLP-1 is produced in the NTS, DMV, and AP, with projections to many GLP-
1R-expressing brain areas involved in energy balance, such as the PVN and NAcc 
(Dossat et al., 2011; Drucker & Asa, 1988; Merchenthaler et al., 1999; Rinaman, 
2010). Evidence shows that GLP-1 produces neuronal activation in the 
hypothalamus and brainstem (Abbott et al., 2005; Larsen et al., 1997; Rowland et 
al., 1997), while GLP-1R expression in these same brain regions is significantly 
altered by fasting and re-feeding (Zhou et al., 2003). GLP-1R agonists are therefore 
thought to reduce food intake via action at sites in PVN and hindbrain (Hayes et al., 
2008; McMahon & Wellman, 1998; Schick et al., 2003) and even the HPA (Larsen 
et al., 1997), amygdala (Kinzig, D'Alessio, et al., 2002; Kinzig, Figueriedo, et al., 
2002) and NAcc (Dossat et al., 2011). Moreover, evidence demonstrates that 
lesions of brainstem–hypothalamic pathways prevent peripheral GLP-induced 
anorexia and block hypothalamic activation (Abbott et al., 2005). Similarly, systemic 
pre-treatment with capsaicin, which ablates neurons and prevents vagal signalling, 
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has also been found to block peripheral GLP-1R agonist-induced anorexia 
(Talsania et al., 2005). 
In contrast, although both GLP-1 and its receptor agonists (such as exendin-4; see 
Section 1.1.3) are small molecules able to pass the BBB (Kastin et al., 2002), the 
GLP-1-albumin recombinant fusion protein, that cannot cross the BBB, is still able 
to activate CNS and inhibit intake in mice, potentially via vagal signalling (Baggio & 
Drucker, 2007). Additionally, there are reports of anorexia following i.p. 
administration of GLP-1R agonists even with lesions to AP and subfornical organ 
(Baraboi et al., 2010). This evidence emphasises that GLP-1 has a complicated 
physiology incorporating both central and peripheral mechanisms of action (Hayes, 
Leichner, et al., 2011).  
7.1.3 Exendin-4 
Exendin-4, a 39 amino-acid peptide, is a naturally occurring form of exenatide1 
(synthetic; AC2993) isolated from the salivary secretions of the lizard, Heloderma 
suspectum (Eng et al., 1992). Its 53% amino identity with GLP-1 means that 
exendin-4 is not a GLP-1 analogue, but does share many actions at the GLP-1R. 
Additionally, it is not a substrate for DPP-IV and therefore has a much longer 
circulating half-life of 60-90minutes (Kolterman et al., 2005; Parkes, Jodka, et al., 
2001). 
Similar to GLP-1, it is known to produce a glucose-dependent enhancement of 
insulin release (Egan et al., 2002; Egan et al., 2003; Parkes, Pittner, et al., 2001; 
Young et al., 1999) and a slowing of gastric emptying (Jodka et al., 1998). 
Importantly, in this context, central and peripheral exendin-4 treatment is found to 
induce satiety and reduce intake in both rodents (Aziz & Anderson, 2002, 2003; 
Bojanowska & Nowak, 2007; Bojanowska & Radziszewska, 2011; Chan et al., 
2013; Hayes, Kanoski, et al., 2011; Kanoski et al., 2011; Kanoski et al., 2012; 
Mack, Moore, et al., 2006; Perez-Tilve et al., 2007; Szayna et al., 2000; Talsania et 
al., 2005; for review see: Nielsen et al., 2004) and humans (Buse et al., 2004; 
DeFronzo et al., 2005; Edwards et al., 2001; Heine et al., 2005; Kendall et al., 2005; 
Ratner et al., 2006; Riddle et al., 2006). 
Detailed meal pattern analysis shows that exendin-4 specifically reduces meal size 
(Williams et al., 2009) in human and non-human primates (Flint et al., 1998; Scott & 
Moran, 2007). Exendin-4 has also been shown, through reduced CPP and 
                                               
1 Although the terms “exendin-4” and “exenatide” can be used interchangeably, the term “exendin-4” will be used 
throughout the present thesis. 
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progressive ratio operant-conditioning, to decrease the rewarding value of food 
(Dickson et al., 2012). Furthermore, some studies suggest that exendin-4-induced 
anorexia is dependent on specific nutrient intake (Aziz & Anderson, 2002, 2003; 
Pritchett & Hajnal, 2012). 
Interestingly, i.p. injection of exendin-4 is more potent than GLP-1 at reducing 
plasma glucose (Bhavsar, Lachappell, et al., 1998; Young et al., 1998) and food 
intake (Rodriquez de Fonseca et al., 2000). A possible explanation is that exendin-4 
has been found to have enhanced transport at the BBB compared to that of GLP-1 
(Kastin & Akerstrom, 2003). In contrast, GLP-1R agonists that lack penetration of 
the BBB have also been shown to produce anorexia (Baggio et al., 2008; Baggio et 
al., 2004b). Therefore, the greater potency of exendin-4 compared to GLP-1 may 
be a result of greater plasma concentrations or differential activation of GLP-1 
receptors (Barrera et al., 2009). 
Human trials of glycaemic control in T2DM patients over 30 weeks of exenatide 
treatment (10μg) found no evidence of a weight loss plateau and, by the end of the 
trial, subjects had lost up to 2.8kg of bodyweight from baseline (Buse et al., 2004; 
DeFronzo et al., 2005; Heine et al., 2005; Kendall et al., 2005). Similarly, longer 
studies, over an 82 week period, have found equivalent weight loss of ~2.5kg 
(Ratner et al., 2006; Riddle et al., 2006). 
Further developments of GLP-1R agonists include: the exenatide LAR (long acting 
release) formulation, which has been shown to produce 24-hour glycaemic control 
and weight loss with only one subcutaneous administration per week (Kim et al., 
2007); CJC-1134, is a modified exendin-4 analogue conjugated to recombinant 
human albumin, also shown to have an extended longer half-life (Christensen & 
Knop, 2010); albugon (naliglutide) is a recombinant GLP-1–albumin protein found to 
lower blood glucose and enhance insulin, in addition to activating c-fos expression 
in multiple regions of the central nervous system, inhibiting gastric emptying and 
reducing food intake in mice following both central and peripheral administration 
(Baggio et al., 2004b); and Liraglutide (NN2211). 
7.1.4 Liraglutide 
Liraglutide is an acylated GLP-1 molecule, and therefore a full agonist of the GLP-1 
receptor, which shares 97% of its amino acid sequence identity with human GLP-1. 
Its resistance to DPP-IV breakdown means that liraglutide has a much longer half-
life (see review: Russell-Jones, 2009). Although designed for the treatment of 
T2DM, it is also found to reduce food intake and bodyweight in rodents (Hayes, 
Kanoski, et al., 2011; Knudsen, 2010; Raun, von Voss, Gotfredsen, et al., 2007; 
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Raun, von Voss, & Knudsen, 2007) and humans (Hansen et al., 2001; Nauck et al., 
2006).  
In trials of glycemia control, patients with T2DM taking 1.9mg liraglutide daily lost 
2.99kg, a significant weight loss compared to placebo (Vilsboll et al., 2007). A trial 
of liraglutide treatment (3.0mg) in conjunction with a LCD found that participants 
lost significantly more weight (-6.3kg) over a 20week period compared to placebo (-
2.8kg) or orlistat treatment (2.1kg; Astrup et al., 2009). The trial also found 
reductions in additional obesity-related parameters, such as blood pressure and the 
prevalence of pre-diabetes (Astrup et al., 2009). Interestingly, a comparison of 
liraglutide and exentatide over a 26 week trial found similar levels of weight loss 
(liraglutide –3.24kg and exenatide –2.87kg; Buse et al., 2009). 
7.1.5 DPP-IV inhibitors 
Research comparing the effects of GLP-1R agonists and DPP-IV inhibitors on the 
potentiation of endogenous GLP-1 and GIP have highlighted some significant 
differences (Lamont & Drucker, 2008). Notably, DPP-IV inhibitors do not appear to 
produce a significant reduction in food intake and bodyweight in rats (see reviews: 
Ahren et al., 2004; Raun, von Voss, Gotfredsen, et al., 2007). Furthermore, phase I 
trials of sitagliptin, vildagliptin, alogliptin and linagliptin (DPP-IV inhibitors) found 
that, although treatment significantly reduced HbA1c (a measure of inadequate 
glycaemic control), it had no effect on bodyweight compared to placebo over a 18 
week period (DeFronzo, Fleck, et al., 2008; DeFronzo, Okerson, et al., 2008; 
Pratley et al., 2006; Raz et al., 2006; Taskinen et al., 2011). Therefore, DPP-IV is 
not currently considered a target for the development of anti-obesity agents, instead 
research should focus on the implications of these findings. For example, there may 
be an unidentified peptide or metabolite of more significance in the potentiation of 
endogenous GLP-1 and GIP than DPP-IV. 
7.2 Behavioural Specificity 
Early in the development of GLP-1R agonists, Rinaman et al., linked GLP-1R 
activation with illness and stress (Lachey et al., 2005; Rinaman, 1999b). For 
example, evidence shows that exendin-4 administration to house musk shrews 
induces emesis in 40% of animals (Chan et al., 2013). Unsurprisingly, then, 
exenatide treatment has been reported to induce nausea during clinical trials (Buse 
et al., 2004; Pinelli & Hurren, 2011; Ratner et al., 2006; Riddle et al., 2006). 
Additionally, exendin-4 has been reported to produce behavioural inhibition (Erreger 
et al., 2012; Mack, Laugero, et al., 2006; Mack, Moore, et al., 2006) while, 
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conversely, GLP-1 KO mice display increased locomotion (Hansotia et al., 2007). 
These effects are mirrored by reports of GLP-1-induced CTA and/or pica in animals 
(Chan et al., 2013; Kanoski et al., 2012). All these actions are known to suppress 
appetite indirectly (Halford, Boyland, Blundell, et al., 2010; Halford et al., 1998; 
Vickers & Clifton, 2012), and cast doubt on the behavioural specificity of GLP-1-
induced anorexia.  
Furthermore, lithium chloride (LiCl) has been shown to activate GLP-1 expressing 
neurons in the CNS (Rinaman, 1999a), triggering visceral illness or anxiogenic-like 
behaviour. Additionally, LiCl and GLP-1 produce similar neuronal activation patterns 
and behavioural profiles (Thiele & Seeley, 1998), an effect blocked by GLP-1R 
antagonists (Parkinson, 2009). Moreover, LiCl-induced CTA is blocked by exendin(9-
39) (Rinaman, 1999a; Seeley et al., 2000), demonstrating a strong case for GLP-1R 
mediated malaise. 
When considering GLP-1R agonists for the treatment of obesity, it is also pertinent 
to note that GLP-1Rs are located in the heart and stimulate the autonomic nervous 
system (ANS; Gardiner et al., 2008). It is therefore unsurprising that central and 
peripheral administration of GLP-1R agonists increases heart rate as well as 
systolic, diastolic and mean arterial blood pressure (Drucker et al., 2011). This 
problem may limit the potential of GLP-1R agonists as anti-obesity agents, 
particularly in view of the heightened awareness/concern of the FDA regarding 
matters of cardiovascular function.  
7.3 GLP-1R Agonists in Combination Therapies 
In view of the current interest in drug polytherapy for obesity, there have been 
several treatment combinations involving GLP-1R agonists that have shown 
considerable promise. For example, additive/synergistic anorectic and/or weight 
loss interactions have been reported for GLP-1 and glucagon (Day, 2009) as well 
as both GLP-1 (Paulik et al., 2011) and exenatide (Reidelberger et al., 2011b; 
Talsania et al., 2005) when given in combination with the gut peptide, PYY3-36. 
Similarly, positive effects on food intake have been reported for exendin-4 in 
combination with the adiposity signal leptin (Bojanowska & Nowak, 2007; 
Reidelberger et al., 2011a), the amylin analogue calcitonin (Bello et al., 2010), and 
the cannabinoid CB1 receptor antagonist/inverse agonist AM-251 (Bojanowska & 
Radziszewska, 2011). 
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7.4 Rationale; Chapter 7 
In view of evidence concerning the unwanted effects of exenatide given alone 
(nausea, emesis, hypoactivity), Chapter 7 aims to: (i) comprehensively profile the 
acute behavioural effects of the peptide in rats during tests of palatable food 
consumption and (ii) investigate the potential advantages of concurrently targeting 
satiety signalling and hedonics, by exploring the potential advantages of low-dose 
(sub-anorectic, sub-maximally anorectic) combinations of exendin-4 and the opioid 
receptor antagonist, naltrexone.  
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7.5 Experiment Nine; Exendin-4 Dose-Response 
7.5.1 Method  
For the main methodological details, refer to General Methods (Chapter 3).  
7.5.1.1 Subjects and Design 
10 adult male Lister hooded rats (202.53 ± 2.34g on arrival from Charles River, U.K 
and 467.81 ± 11.32g by the end of the study) were employed for this study. A 
within-subjects design was adopted whereby each subject received all four 
experimental conditions according to a Latin Square (with a 7-day wash out period): 
Vehicle (V); Exendin-4 0.025µg/kg (Exn0.025); Exendin-4 0.25µg/kg (Exn0.25); 
Exendin-4 2.5µg/kg (Exn2.5). 
7.5.1.2 Drugs 
Exendin-4 (exenatide; Tocris Bioscience, UK) was initially dissolved to a 
concentration of 1mg/10ml in distilled water, following which it was serially diluted to 
final concentrations, disbursed in 0.7ml volumes to individual aliquots, and stored at 
-20ºC until required. Distilled water, which alone served as vehicle control, was 
stored in an identical manner. On test days, the required aliquots were slowly 
thawed in hand to room temperature just prior to use, and the requisite volumes 
administered i.p. in a volume of 1ml/kg 30 minutes prior to testing. 
Doses of exendin-4 (0.025, 0.25 and 2.5µg/kg) were selected on the basis of 
previous research on food intake to span the full range from ineffective to sub-
maximal (Aziz & Anderson, 2002, 2003; Bojanowska & Nowak, 2007; Bojanowska 
& Radziszewska, 2011; Chan et al., 2013; Hayes, Kanoski, et al., 2011; Kanoski et 
al., 2011; Kanoski et al., 2012; Mack, Moore, et al., 2006; Perez-Tilve et al., 2007; 
Szayna et al., 2000; Talsania et al., 2005).  
7.5.1.3 Procedure 
Testing occurred over two weeks, with four test days per week, 5 animals tested 
per day, and a 7 day wash-out period. Treatment order was counterbalanced both 
within and between test days according to the Latin Square. It should be noted that, 
as animals did not show appreciable amounts of scratching during Experiment 9, 
data for this variables are not reported. 
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7.5.1.4 Error 
There was an error in bodyweight collection during Experiment 9 that resulted in a 
loss of two data points per animal during one test week, consequently only a 3 day 
post-treatment % bodyweight analysis could be conducted. 
7.5.2 Results 
Full statistical details can be found in Appendix 10. 
7.5.2.1 Habituation Phase Food Intake 
Mash consumption differed significantly over the course of habituation (F(4,36) = 
13.63, p < 0.001), with intake on the first trial lower than on trials 2, 3 and 5 (p ≤ 
0.01) and intake on trial 2 lower than on trial 5 (p = 0.001; trial 1: 14.58 ± 0.97g; trial 
2: 17.00 ± 1.05g; trial 3: 19.98 ± 1.20g; trial 4: 19.35 ± 1.69g; trial 5: 22.81 ± 0.78g). 
The development of a stable intake pattern was confirmed by the lack of difference 
across habituation trials 3-5, as well as the close similarity in intake scores between 
those habituation trials and the vehicle condition in the main experiment (21.07 + 
1.48g).  
7.5.2.2 Test Day Bodyweight 
Test-day bodyweights were comparable across the various treatment conditions (V: 
403.6 ± 12.2g; Exn0.025: 410.6 ± 11.3g; Exn0.25: 426.3 ± 14.8g; Exn2.5: 410.3 ± 
9.9g (F(3,27) = 1.04, p > 0.05). 
7.5.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.29% throughout the experiment (range = 0.05 - 0.67%). Treatment effects on 
food intake are summarised in Figure 7-2. There was a significant main effect of 
exendin-4 on 1h mash consumption (F(3,27) = 48.89, p = 0.001). Bonferroni 
comparisons confirmed a significant anorexia (p < 0.001) relative to vehicle control 
at both 0.25µg/kg and 2.5µg/kg (35.6% and 75.6% decreases, respectively). 
Comparisons between dose levels further confirmed the dose-dependency of these 
effects with 0.25µg/kg (p < 0.02) and 2.5µg/kg (p < 0.001) differing significantly from 
0.025µg/kg, and 2.5µg/kg differing significantly from 0.25µg/kg (p < 0.01). 
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Figure 7-2: Experiment Nine. Effects of acute exendin-4 on mash intake by non-
deprived male rats during a 1-h test with palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = Vehicle, Exn0.025 = Exendin-4 0.025µg/kg, Exn0.25 = Exendin-4 0.25µg/kg, 
Exn2.5 = Exendin-4 2.5µg/kg. See text for details. *** p < 0.001 vs V. 
7.5.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on total 1-h frequency and duration scores for ingestive and non-
ingestive behaviours are illustrated in Figure 7-3, while data for eating-related 
parameters are summarised in Table 7-1.  
Table 7-1: Experiment Nine. Acute effects of Exendin-4 on eating-related parameters 
(Mean ± SE). V = Vehicle, Exn0.025 = Exendin-4 0.025µg/kg, Exn0.25 = Exendin-4 0.25µg/kg, 
Exn2.5 = Exendin-4 2.5µg/kg. † p < 0.062, * p < 0.01, ** p < 0.01, *** p < 0.001 vs V.  
Measure V Exn0.025 Exn0.25 Exn2.5 
Latency to find food (s) 2.40 + 0.50 5.60 + 1.77 4.10 + 1.25 7.00 + 1.22 
Latency to eat (s) 18.00 + 5.26 9.40 + 3.17 4.70 + 1.17 3.10 + 0.80† 
Eat bout (s) 8.76 + 1.04 9.13 + 1.47 11.86 + 0.70* 16.68 + 1.25*** 
Eat rate (g/min) 1.94 + 0.09 2.68 + 0.42 1.44 + 0.08* 0.59 + 0.27*** 
 
ANOVA revealed significant effects of exendin-4 on virtually all measures taken: 
latency to eat (F(3,27) = 4.68, p < 0.05), the average duration of eating bouts 
(F(3,27) = 15.34, p < 0.001) and eating rate (F(3,27) = 15.18, p < 0.01), as well as 
the frequency and duration of eating (F(3,27) ≥ 3.33, p ≤ 0.05), grooming (F(3,27) ≥ 
18.51, p ≤ 0.001), resting (F(3,27) ≥ 4.43, p ≤ 0.02), locomotion (F(3,27) ≥ 30.88, p 
≤ 0.001), rearing (F(3,27) ≥ 32.85, p ≤ 0.001), and sniffing (F(3,27) ≥ 9.42, p ≤ 
0.001). The only variable not to be affected by drug treatment was the latency to 
locate the food source at the beginning of the test (F(3,27) = 2.27, p > 0.05).  
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As shown in Table 7-1 and Figure 7-3, Bonferroni comparisons indicated that 
behaviour was unaffected by the lowest dose exendin-4 (0.025 µg/kg). However, 
relative to vehicle control, the intermediate dose (0.25 µg/kg) increased the average 
duration of eating bouts (p < 0.05) and rest duration (p < 0.01), while reducing 
eating rate (p < 0.05), the frequency of eating (p < 0.01), grooming (p < 0.05), 
locomotion (p < 0.02) and sniffing (p = 0.001), and both the frequency and duration 
of rearing (p ≤ 0.01). At the highest dose tested (2.5 µg/kg), exendin-4 increased 
the average duration of eating bouts (p < 0.001), reduced eating rate (p < 0.001) 
and almost significantly reduced eat latency (p = 0.062). This dose also significantly 
enhanced the frequency and duration of resting (p ≤ 0.02), while strongly 
suppressing the frequency of eating (p < 0.001) as well as the frequency and 
duration of grooming (p ≤ 0.01), rearing (p ≤ 0.001), locomotion (p ≤ 0.001) and 
sniffing (p ≤ 0.01). 
 
Figure 7-3: Experiment Nine. Effects of acute Exendin-4 on the duration (upper panel) 
and frequency (lower panel) of behaviours displayed by non-deprived male rats 
during a 1-h test with palatable mash 
Data are mean values (± S.E.M). V = Vehicle, Exn0.025 = Exendin-4 0.025µg/kg, Exn0.25 = 
Exendin-4 0.25µg/kg, Exn2.5 = Exendin-4 2.5µg/kg. See text for further details. * p ≤ 0.05 vs V 
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7.5.2.5 Periodic (Timebin) Behavioural Analyses 
Timecourse analyses confirmed the typical pattern of behaviour over these 1h 
feeding tests, with a gradual reduction in active behaviours and increase in resting 
as the session progressed. Thus, with the exception of sniff duration (F(11,99) = 
1.57, p > 0.05) and groom frequency (F(11,99) = 0.85, p > 0.05), significant main 
effects of time were found for the frequency (F(11,99) ≥ 6.31, p ≤ 0.001) and 
duration (F(11,99) ≥ 2.36, p ≤ 0.02) of all behavioural measures. Somewhat 
exceptionally, significant treatment x time interactions were found for the frequency 
(F(33,297) ≥ 1.56 , p ≤ 0.05) and duration (F(33,297) ≥ 1.69, p ≤ 0.02) of all 
behavioural measures except groom frequency (F(33,297) = 1.33, p > 0.05).  
One-way ANOVAs and Bonferroni post-hocs within each timebin indicated that 
exendin-4 (0.25-2.5 µg/kg) dose-dependently reduced the frequency of feeding at 
several timepoints during the first half of the test (F(3,27) ≥ 8.93, p ≤ 0.001), with 
similar though weaker effects seen on feeding duration (F(3,27) ≥ 4.91, p ≤ 0.01). 
Exendin-4 also dose-dependently enhanced the frequency, and particularly the 
duration, of resting over the same timeframe (F(3,27) ≥ 4.09, p ≤ 0.02). In addition 
to these effects, exendin-4 dose-dependently suppressed the frequency and 
duration of locomotion (F(3.27) ≥ 3.93, p ≤ 0.02), rearing (F(3,27) ≥ 6,17, p ≤ 0.005) 
and sniffing (F(3,27) ≥ 3.42, p ≤ 0.05) throughout most of the test session. Figure 7-
4 illustrates the timecourse effects of exendin-4 on the frequency of eating, 
locomotion, rearing and sniffing.  
7.5.2.6 Behavioural Satiety Sequence (BSS)  
Treatment effects on the BSS are shown in Figure 7-5. Consistent with previous 
work in our laboratory (Ishii et al. 2003; Tallett et al. 2009a&b; see Experiments 1-
8), the vehicle control profile shows a typical peak feeding response during the first 
20 min of the test. Over time, resting gradually increases, with an eat-to-rest 
transition occurring during timebin 7. A very similar pattern of behaviour is evident 
with the lowest dose of exendin-4 (0.025 µg/kg) although the eat-rest transition has 
shifted to the left by approximately one timebin (i.e. 5 min). This acceleration of 
behavioural satiety is more evident at the intermediate dose (0.25µg/kg), where the 
eat-rest transition has moved substantially to the left (i.e. to timebin 3). Although 
this trend towards BSS acceleration continues with the highest dose of exendin-4 
(2.5 µg/kg), where the eat-rest transition occurs in timebin 2, the structure of 
behaviour now appears abnormal with grooming virtually eliminated from the 
repertoire and resting dominating for most of the session.  
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Figure 7-4: Experiment Nine. Effects of acute exendin-4 on the timecourses of eating, 
locomotion, rearing and sniffing frequency in male rats during a 1-h test with 
palatable mash 
Data are expressed as the mean duration of each behaviour in 12 x 5-min timebin. V = Vehicle, 
Exn0.025 = Exendin-4 0.025µg/kg, Exn0.25 = Exendin-4 0.25µg/kg, Exn2.5 = Exendin-4 
2.5µg/kg. See text for further details. 
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Figure 7-5: Experiment Nine. Effects of acute exendin-4 on the behavioural satiety 
sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = Vehicle, Exn0.025 = Exendin-4 0.025µg/kg, Exn0.25 = Exendin-4 0.25µg/kg, 
Exn2.5 = Exendin-4 2.5µg/kg. See text for further details. 
7.5.2.7 Bodyweight Gain 
Data not shown. Although ANOVA indicated a significant treatment effect on 7-day 
absolute weight gain (F(3,27) = 3.99, p < 0.02), Bonferroni tests failed to detect any 
significant drug-vehicle differences (V = 24.95 ± 1.98g; Exn0.025 = 22.40 ± 1.00g; 
Exn0.25 = 19.94 ± 0.94g; Exn2.5 = 19.39 ± 1.88g). To account for minor differences 
in absolute test day bodyweight, datasets were converted to percent bodyweight 
changes from test day (test day = 100%). This finer grain analysis, possible for only 
3 days post-dosing (see Section 1.3.1.4), confirmed the lack of effect of treatment 
(F(3,27) = 1.57, p > 0.05), day (F(2,18) = 0.85, p > 0.05), or interaction (F(6,54) = 
1.16, p > 0.05). 
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7.5.3 Summary of Main Findings 
The results of Experiment 9 showed that exendin-4 potently and dose-dependently 
suppressed mash consumption, with highly significant reductions (vs. control) of 
26% and 75.6% at 0.25 and 2.5µg/kg, respectively. The intermediate (0.25µg/kg) 
and the highest doses (2.5µg/kg) were also found to significantly increase the 
duration of eating bouts, slow the rate of eating, and reduce the frequency (but not 
duration) of eating episodes. Importantly, the effects of exendin-4 (0.25 - 2.5µg/kg) 
were not limited to ingestive behaviour, with dose-dependent reductions in the 
frequency and duration of rearing, sniffing, grooming and locomotion, as well as 
dose-dependent increases in the frequency and duration of resting. The lowest 
dose of exendin-4 (0.025µg/kg) not only failed to influence mash consumption, but 
was also without significant behavioural effect under present test conditions.  
The BSS profiles show that exendin-4 dose-dependently accelerated BSS, i.e. 
suppressed the peak feeding response and shifted the eat-to-rest transition to the 
left. However, it is important to note that, although the BSS profile of the highest 
dose (2.5µg/kg) could be interpreted as consistent with a strong satiety signal, there 
are reasons to treat this interpretation with some caution due to the gross 
reductions in active behaviours (see Discussion; Section 8.2.4). The results of 
Experiment 9 therefore raise questions about the behavioural selectivity of the 
acute anorectic response to exendin-4. 
7.5.4 Design of Experiment Ten 
Based on the data from the exendin-4 dose-response study (Experiment 9), a sub-
anorectic and a sub-maximal dose of exendin-4 were selected. Experiment 9 
confirmed that acute exendin-4 0.025μg/kg did not significantly suppress food 
intake or produce any significant behavioural effects. However, exendin-4 
0.25μg/kg did significantly decrease food intake, while displaying a general 
reduction in active behaviours. In order to further assess the hypolocomotive and 
potentially sedative effect of this higher dose, alone and in combination with 
naltrexone, this sub-maximal dose was also selected for Experiment 10.  
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7.6 Experiment Ten; Exendin-4 (0.025 and 0.25μg/kg) and 
Naltrexone (0.1mg/kg) Interaction 
7.6.1 Method 
7.6.1.1 Subjects and Design 
10 adult male Lister hooded rats (215.37 ± 1.63g on arrival from Charles River, U.K 
and 518.25 ± 13.80g by the end of the study) were employed in this study. A within-
subjects design was adopted whereby each subject received all six experimental 
conditions according to a Latin Square (with a 7-day wash out period): Vehicle 
(Distilled water) + Vehicle (Saline; VV); Vehicle (Distilled water) + Naltrexone 
(0.1mg/kg; VN); Exendin-4 (0.025µg/kg) + Vehicle (Saline; ELV); Exendin-4 
(0.025µg/kg) + Naltrexone (0.1mg/kg; ELN); Exendin-4 (0.25µg/kg) + Vehicle 
(Saline; EHV); and Exendin-4 (0.25µg/kg) + Naltrexone (0.1mg/kg; EHN). 
7.6.1.2 Drugs 
As with Experiment 9, Exendin-4 (exenatide; Tocris Bioscience, UK) was initially 
dissolved to a concentration of 1mg/10ml in distilled water, following which it was 
serially diluted to final concentrations, disbursed in 0.7ml volumes to individual 
aliquots, and stored at -20ºC until required. Distilled water, which alone served as 
vehicle control, was stored in an identical manner. On test days, the required 
aliquots were slowly thawed in hand to room temperature just prior to use, and 
requisite volumes administered 30 minutes prior to testing. Naltrexone 
hydrochloride (Sigma-Aldrich, UK) was dissolved in physiological saline (0.9%) 
which, alone, served as a vehicle control, and administered 15 minutes prior to 
testing. Both drugs were administered i.p. in a volume of 1ml/kg. Doses of exendin-
4 (0.025 and 0.25μg/kg) and naltrexone (0.1mg/kg) were selected from data 
obtained in Experiments 9 and 5 (respectively). 
7.6.1.3 Procedure 
Testing occurred over four weeks, with two test days per week, and 5 animals 
tested per day. Treatment order was counterbalanced both within and between test 
days according to the Latin Square. It should be noted that, as animals did not 
show appreciable amounts of scratching during Experiment 10, data for this 
variables are not reported. Please also note, for this Experiment only, an additional 
(6th) day was employed during the habituation period. Due to timetabling reasons, 
and to ensure animals had no more than 4 days between the habituation and 
experimental phases, an additional habituation trial was necessary. 
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7.6.2 Results 
Full statistical details can be found in Appendix 11. 
7.6.2.1 Habituation Phase Food Intake 
ANOVA revealed significant differences in mash consumption over the 6-day 
habituation period (F(5,45) = 18.63, p ≤ 0.001), with intake on the first trial lower 
than on all other trials (p ≤ 0.01) and intake on trial 2 lower than on trials 4, 5 and 6 
(p ≤ 0.01; trial 1: 9.55 ± 1.29g; trial 2: 14.71 ± 1.44g; trial 3: 18.05 ± 1.71g; trial 4: 
19.83 ± 1.46g; trial 5: 22.04 ± 1.59; trial 6: 20.30 + 1.90). However, the 
development of a stable intake pattern was confirmed by the lack of difference 
across habituation trial 3-6, as well as the close similarity in intake scores between 
the final few habituation trials and the vehicle condition in the main experiment 
(20.19 + 1.11g). 
7.6.2.2 Test Day Bodyweight 
Test-day bodyweights did not differ across treatment conditions: VV = 447.10 + 
13.8g; VN = 456.8 + 19.5g; ELV = 449.4 + 18.1g; ELN = 460.5 + 14.5g; EHV = 
449.2 + 17.8g; EHN = 453.5 + 15.3g (main effect of naltrexone: F(1,9) = 0.36, p > 
0.05; main effect exendin-4: F(2,18) = 0.08, p > 0.05; interaction: naltrexone x 
exendin-4: F(2,18) = 0.03, p > 0.05).  
7.6.2.3 Test Day Food Intake  
Control food pot measurements showed an average weight loss via evaporation of 
only 0.16% throughout the experiment (range = 0.07 - 0.25%). Treatment effects on 
mash intake are summarised in Figure 7-6. ANOVA revealed a significant exendin-
4 x naltrexone interaction (F(2,28) = 21.38, p < 0.001), with post-hoc comparisons 
confirming significant reductions in intake versus VV control in all treatment groups 
(p ≤ 0.001) except the low dose of exendin-4 given alone (ELV). Importantly, there 
were no significant differences between naltrexone when given alone (VN) and 
when given in combination with the higher dose of exendin-4 (0.25μg/kg; EHN). 
Although a significant difference (p ≤ 0.001) was seen between the lower dose of 
exendin-4 given alone (0.025μg/kg; ELV) and when co-administered with 
naltrexone (ELN), this effect was due solely to the intrinsic influence of the opioid 
receptor antagonist (Figure 7-6). Relative to VV control, ELV reduced intake by < 
10%, EHV by 41%, and NV by 35%. The observed reductions of 38.7% and 34.5% 
(vs. calculated composite reductions of 45% and 76%) for ELN and EHN, 
respectively, fully confirm the lack of an additive interaction between the two 
agents.  
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Figure 7-6: Experiment Ten. Effects of acute exendin-4 and naltrexone, alone and in 
combination, on mash intake by non-deprived male rats during a 1-h test with 
palatable mash 
Data are mean values (± S.E.M). The percentages refer to intake reduction compared to 
vehicle. V = vehicle (distilled water or saline), N = naltrexone 0.1mg/kg; EL = exendin-4 
0.025µg/kg; EH = exendin-4 0.25µg/kg; * p ≤ 0.05 vs V. See text for full details. 
 
7.6.2.4 Total (one-hour) Behavioural Analyses 
Treatment effects on the total frequency and duration of ingestive and non-ingestive 
behaviours are shown in Figure 7-7, while data for feeding-related parameters 
(latencies, average duration of eating bouts, & average rate of eating) are 
summarised in Table 7-2.  
Table 7-2: Experiment Ten. Effects of exendin-4 and naltrexone, alone and in 
combination, on mash intake and feeding-related parameters in male rats 
exposed for 1h to palatable mash 
Data are mean values (± S.E.M). V = vehicle (distilled water or saline), N = naltrexone 
0.1mg/kg; EL = exendin-4 0.025µg/kg; EH = exendin-4 0.25µg/kg; See text for full details  
Measure VV VN ELV ELN EHV EHN 
Latency to locate 
food (s) 
4.87 + 
0.61 
8.26 + 
2.32 
5.29 + 
1.29 
4.85 + 
1.56 
8.94 + 
1.94 
10.37 + 
5.25 
Latency to eat (s) 14.94 + 
4.16 
16.91 + 
6.61 
14.25 + 
3.24 
10.57 + 
2.43 
10.33 + 
4.12 
8.34 + 
1.46 
Eat bout (s) 8.56 + 
1.15 
8.19 + 
1.20 
7.70 + 
1.13 
6.74 + 
0.71 
8.61 + 
1.13 
8.24 + 
1.20 
Eat rate (g/min) 2.15 + 
0.14 
2.02 + 
0.13 
1.99 + 
0.16 
2.08 + 
0.15 
1.83 + 
0.14 
1.84 + 
0.18 
ANOVA revealed significant exendin-4 x naltrexone interactions for the frequency 
and duration of eating (F(2,28) ≥ 20.97, p ≤ 0.001) but for no other variables 
(F(2,18) ≤ 2.37, p ≥ 0.05). Significant main effects of exendin-4 were found for the 
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frequency of sniffing (F(2,18) = 9.80, p = 0.001) and for both the frequency and 
duration of resting (F(2,18) ≥ 5.76, p ≤ 0.02) and rearing (F(2,18) ≥ 6.35, p ≤ 0.01).  
 
 
Figure 7-7: Experiment Ten. Effects of exendin-4 and naltrexone, alone and in 
combination, on the duration (upper panel) and frequency (lower panel) of 
behaviours displayed by non-deprived male rats during a 1-h test with palatable 
mash. 
Data are mean values (± S.E.M). V = vehicle (distilled water or saline), N = naltrexone 
0.1mg/kg; EL = exendin-4 0.025µg/kg; EH = exendin-4 0.25µg/kg; * p ≤ 0.05 vs V. See text for 
full details.  
Significant main effects of naltrexone were found only for the frequency and 
duration of grooming (F(1,9) ≥ 6.42, p ≤ 0.03), although the effect of the opioid 
antagonist on the duration of locomotion just missed significance (F(1,9) = 4.97, p = 
0.053). While no treatment or interaction effects were found for feeding-related 
parameters (latency to identify food; latency to commence eating, eating rate, or eat 
bout duration: Table 7-2), it should perhaps be noted that the main effect of 
exendin-4 on the average duration of eating bouts closely approached significance 
(F(2,18) = 3.38, p < 0.06). Confirming the results of the dose-response study, 
Bonferroni comparisons indicated that, relative to VV control, behaviour was 
completely unaffected by the lower dose of exendin-4 (0.025μg/kg; ELV). In 
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contrast, the higher dose of the peptide (0.25μg/kg; EHV) significantly reduced both 
the frequency and duration of eating (p ≤ 0.001), and the frequency of sniffing (p ≤ 
0.01). Naltrexone by itself (VN) also significantly reduced both the frequency and 
duration of eating compared with vehicle control (p ≤ 0.002). For the frequency and 
duration of eating, and as seen for mash consumption, there were no significant 
differences between naltrexone given alone (VN) and when given in conjunction 
with the higher dose of exendin-4 (EHN). Furthermore, as the lower dose of 
exendin-4 had no effects on these measures by itself, the significant difference 
between ELV and ELN (p < 0.001) can simply be attributed to the anorectic effect of 
the opioid receptor antagonist (Figure 7-7). Interestingly, the inhibitory effect of the 
higher dose of exendin-4 on sniff frequency was also seen when the peptide was 
given with naltrexone (EHN; p < 0.03) and, since there was no difference between 
the peptide in the presence or absence of naltrexone, this further confirms the lack 
of behavioural interaction between the two agents. Since no other pairwise 
contrasts versus VV control were significant, the additional main effects of exendin-
4 and naltrexone reported above can be interpreted as weak effects arising from 
the larger sample sizes/reduced variances associated with main effects analyses.  
7.6.2.5 Periodic (Timebin) Behavioural Analyses  
As seen in Experiment 9, significant main effects of time were found for the 
frequency (F(11,99) ≥ 11.99, p ≤ 0.001) and duration (F(11,99) ≥ 3.45, p ≤ 0.001) of 
all behavioural measures except grooming (F(11,99) < 1.80, p > 0.05). The only 3-
way interaction (exendin-4 x naltrexone x time) obtained was for rear duration 
(F(22,198) = 1.80, p < 0.05), with additional 2-way interactions for eat duration 
(exendin-4 x time: F(22,198) = 3.25, p < 0.001; naltrexone x time: F(11,99) = 2.59, 
p < 0.01), eat frequency (exendin-4 x time: F(22,198) = 3.25, p < 0.001), and rest 
frequency (naltrexone x time: F(11,99) = 2.31, p < 0.02).  
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Figure 7-8: Experiment Ten. Effects of acute exendin-4 and naltrexone, alone and in 
combination, on the frequency and duration of eating, the frequency of resting 
and the duration of rearing and in male rats during a 1-h test with palatable 
mash 
Data are expressed as the mean frequency of each behaviour in 12 x 5-min timebins. V = 
vehicle (distilled water or saline), N = naltrexone 0.1mg/kg; EL = exendin-4 0.025µg/kg; EH = 
exendin-4 0.25µg/kg. See text for further details. 
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 10 11 12
Ea
t 
Fr
e
q
u
e
n
cy
 
VV
VN
ELV
ELN
EHV
EHN
0
20
40
60
80
100
120
140
160
1 2 3 4 5 6 7 8 9 10 11 12
Ea
t 
D
u
ra
ti
o
n
 (
s)
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
1 2 3 4 5 6 7 8 9 10 11 12
R
e
st
 F
re
q
u
e
n
cy
 
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12
R
e
ar
 D
u
ra
ti
o
n
 (
s)
 
Timebin 
212 
 
All significant 2- or 3-way interactions involving the time factor were further 
interrogated by a series of 2-way ANOVAs within each timebin. Significant drug 
main effects or interactions were found for: (i) eat duration in timebins 2, 3, and 6-9 
inclusive (F(1,9) ≥ 7.57, p ≤ 0.03; F(2,18) ≥ 3.64, p ≤ 0.05), reflecting a main 
(suppressant) effect of naltrexone; (ii) eat frequency in timebins 1-3, 6 and 8 (F(1,9) 
= 7.65, p < 0.03; F(2,18) > 4.32, p < 0.03) and rear duration in timebins 2-7 
inclusive (F(2,18) ≥ 4.31, p ≤ 0.03), both reflecting a dose-dependent suppressant 
effect exendin-4; and (iii) rest frequency in timebins 3, 4, 6 and 9 (F(2,18) ≥ 5.01, p 
≤ 0.02), reflecting a dose-dependent enhancement by exendin-4. These temporal 
effects of treatment are illustrated in Figure 7-8. Consistent with other current 
observations, there were no instances where a significant difference was found 
between test compounds given alone and when given in combination. 
7.6.2.6 Behavioural Satiety Sequence (BSS)  
Figure 7-9 illustrates the BSS profiles for each of the 6 treatment conditions. 
Consistent with numerous reports from our laboratory over the past 15 years 
(Halford et al. 1998; Rodgers et al 2010), the behavioural profile in the vehicle 
control condition (VV; top left) shows a peak feeding response during the first 20 
min of the test with an eat-rest transition in timebin 6 (i.e. circa half-way through the 
test). A very similar (i.e. unaltered) pattern of behaviour is evident with the lower 
dose of exendin-4 (0.025μg/kg; ELV; centre left). However, while retaining the 
normal structure of feeding behaviour, the higher dose of the peptide (0.25μg/kg; 
EHV; bottom left) was associated with a suppression of the peak feeding response 
and an acceleration (shift to the left) in the eat-rest transition to timebin 4. The latter 
behavioural signature was essentially replicated by naltrexone given alone (VN; top 
right) and in combination with either dose of exendin-4 (ELN & EHN; centre & 
bottom right). 
7.6.2.7 Bodyweight Gain 
Data not shown. No significant main effects or interactions were found for 7-day 
absolute weight gain. The animals typically gained 18-21g irrespective of treatment 
condition (main effect exendin-4: F(2,18) = 0.08, p > 0.05; main effect naltrexone: 
F(2,18) = 0.36, p > 0.05; interaction, naltrexone x exendin-4: F(2,18) = 0.02, p > 
0.05). Analysis of percent bodyweight change over days following treatment  
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Figure 7-9: Experiment Ten. Effects of acute exendin-4 and naltrexone, alone and in 
combination, on the behavioural satiety sequence (BSS) 
Data are expressed as mean duration scores in each of 12 x 5min timebins. The solid vertical 
line bisecting the x-axis is merely an aid to visualisation of the transition between eating and 
resting. V = vehicle (distilled water or saline), N = naltrexone 0.1mg/kg; EL = exendin-4 
0.025µg/kg; EH = exendin-4 0.25µg/kg. See text for further details. 
confirmed normal growth patterns (main effect day: F(2,18) = 31.01, p < 0.001), but 
it too failed to reveal any significant drug main effects, drug interactions, or drug x 
time interactions (main effect exendin-4: F(2,16) = 0.40, p > 0.05; main effect 
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naltrexone: F(1,8) = 0.48, p > 0.05; drug interactions, naltrexone x exendin-4: 
F(2,18) = 0.77, p > 0.05; drug x time interactions: F(12,96) > 0.80, p > 0.05) 
7.6.3 Summary of Main Findings 
Consistent with Experiment 9, Experiment 10 showed that, when given alone, the 
lower dose of exendin-4 (0.025µg/kg) had no significant effects on mash intake or 
behaviour, whereas the higher dose (0.25µg/kg) alone reduced consumption (41% 
vs vehicle), the frequency and duration of eating, and the frequency of sniffing. 
Alone, naltrexone (0.1mg/kg) also significantly reduced mash consumption (36% 
vs. control), and the frequency and duration of feeding behaviour. Both the higher 
dose of exendin-4 and naltrexone, when administered alone, suppressed the peak 
feeding response relative to vehicle control and modestly accelerated the BSS 
without disrupting normal behavioural structure.  
However, the combination of exendin-4 and naltrexone failed to produce any sign of 
a positive interaction. The results showed a near identical anorectic effect of 
combined treatment versus treatment with either agent alone. The higher dose of 
exendin-4 (0.25µg/kg) suppressed intake by 41%, naltrexone suppressed intake by 
36%, but their combination suppressed intake only by 35% (vs a predicted 77% 
based on simple addition of the anorectic responses to the constituent elements). 
These treatment effects on intake were mirrored by changes in the frequency and 
duration of feeding behaviour. Furthermore, although the higher dose exendin-4 
and naltrexone each produced a modest acceleration in the BSS, their combination 
did not produce any further acceleration in this measure of behavioural satiety.  
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7.7 Chapter Seven Main Findings 
The current chapter aimed to comprehensively profile the behavioural effects of the 
GLP-1R agonist, exendin-4, in rats during tests of palatable food consumption and 
to explore possible advantages of low-dose (sub-anorectic, sub-maximally 
anorectic) combinations of exendin-4 and the opioid receptor antagonist, naltrexone 
 Experiment 9 showed that exendin-4 dose-dependently reduces food intake 
and feeding behaviour in male rats. However, the exendin-4-induced anorexia 
did not appear to be behaviourally-selective as it was accompanied by other 
behavioural changes comparable to LiCl-induced hypoactivity and/or malaise. 
 Experiment 10 showed that, although exendin-4 and naltrexone each have 
intrinsic anorectic effects, co-treatment does not lead to an additive interaction 
on food intake or feeding behaviour. 
The work reported in Chapter 7 does not offer any support for the anti-obesity 
potential of an exendin-4/naltrexone combination. However, it does highlight the 
potential behavioural selectivity issues associated with exendin-4 anorexia. 
(Barrera et al., 2011; Larsen et al., 2001; Long et al., 1999; Nielsen et al., 2004; 
Scrocchi, Auerbach, et al., 1996; Scrocchi, Brown, et al., 1996; Verdich et al., 2001) 
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Chapter 8 Discussion 
8.1 Overview of Thesis Aims 
Neurobiological research has identified a large number of peripheral & central 
signalling pathways involved in appetite regulation and energy homeostasis (see 
Chapter 1). These advances have informed the development of treatments for 
obesity and, recently, interest has focused on the therapeutic potential of drug 
polytherapy or combination treatments, whereby two neurobiological pathways are 
concurrently targeted (see Chapter 2). Polytherapy may permit the use of lower 
doses and opens up the possibility of (i) additive/synergistic effects on food intake 
and weight gain and (ii) the reduction/elimination of side-effects normally 
associated with higher doses of the constituent agents. The vast majority of 
behavioural research on appetite tends to focus on simple outcome measures or 
endpoints. However, outcomes can be reached either directly by an action on the 
normal physiological regulation of appetite or indirectly via a host of non-specific 
mechanisms. Therefore, the current research employed a BSS methodology (see 
Chapter 3) to assess the extent to which individual effects of cannabinoid, opioid, 
monoaminergic and peptidergic compounds suppress food intake in a 
behaviourally-selective and physiologically-relevant manner. More specifically, the 
acute anorectic effects in male rats of individual treatment with the general opioid 
receptor antagonist naltrexone (Experiment 5), the noradrenaline and dopamine 
reuptake inhibitor bupropion (Experiment 4), the serotonin 5-HT1B/2C receptor 
agonist mCPP (Experiment 7), and the naturally-occurring GLP-1R mimetic 
exendin-4 (Experiment 9). A detailed analysis of both feeding and non-feeding 
parameters determined whether drug-induced reductions in 1hour palatable mash 
intake were a result of behaviourally-selective suppression of appetite or possibly 
an indirect drug effect that interferes or competes with feeding behaviour. 
Furthermore, the present thesis explored the acute anorectic response to co-
treatment with these compounds and an opioid antagonist (naloxone; Experiments 
1-3 / naltrexone Experiments 6, 8 and 10). More specifically, the acute anorectic 
effects in male rats of co-treatment with rimonabant and naloxone (Experiments 1-
3), bupropion and naltrexone (Experiment 6), mCPP and naltrexone (Experiment 
8), and exendin-4 and naltrexone (Experiment 10).  
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8.2 Individual Chapter Discussions 
As only the main findings were outlined within each of the four empirical chapters 
(Chapters 4 - 7), Chapter 8 will focus on present results within the context of the 
current literature and comment upon the broader implications of this research. 
8.2.1 Chapter Four; Cannabinoid and Opioid System Interactions 
In view of the potential significance of pruritus to the future development of CB1 
receptor antagonists, Experiments 1-3 aimed to test a clear prediction of the 
response competition hypothesis (Hodge et al., 2008; Tallett et al., 2007b); 
namely, that low dose naloxone treatment should attenuate both the pruritic and 
anorectic responses to a moderate dose of rimonabant.  
The results reported in Chapter 4 confirmed earlier findings that rimonabant alone 
reduces time spent feeding and supresses mash intake by 45-50% (Colombo et 
al., 1998; De Vry & Jentzsch, 2004; Freedland et al., 2001; Gomez et al., 2002; 
Hildebrandt et al., 2003; Hodge et al., 2008; McLaughlin et al., 2006; McLaughlin 
et al., 2003; McLaughlin et al., 2005; Rowland et al., 2001; Thornton-Jones, 2005; 
Verty, McGregor, et al., 2004a; Verty et al., 2003; Vickers, Webster, et al., 2003; 
Werner & Koch, 2003; Wiley et al., 2005; Williams & Kirkham, 2002), whilst 
dramatically increasing both the frequency and duration of scratching and 
grooming behaviours (Janoyan et al., 2002; Jarbe et al., 2002; Jarbe et al., 2003; 
Jarbe et al., 2004; Jarbe et al., 2006; Tallett et al., 2007a, 2007b, 2007c). At the 
doses used (0.1 and 0.01mg/kg), naloxone by itself did not produce any significant 
effects on feeding behaviour, thereby indirectly confirming a threshold anorectic 
dose of circa 1.0 mg/kg for this opioid receptor antagonist (as seen under similar 
test conditions; Tallett et al., 2008a, 2008b, 2009a; 2010b; and references therein). 
Of primary interest, co-administration with naloxone was found to attenuate 
rimonabant-induced scratching and grooming, but not the anorectic response to 
rimonabant.  
8.2.1.1 Food intake and Feeding Behaviour 
Interestingly, in Experiment 1, the results of the combined treatment appeared to 
differ dependent upon the dose of naloxone used. Although the higher dose of 
naloxone (0.1mg/kg) failed to impact food intake or feeding behaviour, the 
combination of rimonabant with the low dose of naloxone (0.01mg/kg) seemed to 
produce an attenuation of rimonabant-induced effects on food intake and feeding 
duration. However, indicative of a weak statistical effect, the reduction of food 
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intake with the low dose combination remained significantly different from control, 
and did not significantly differ from rimonabant given alone. In contrast, time spent 
feeding did not significantly differ from control, nor did it differ from rimonabant 
given alone (see Figure 4-2 and 4-3). Follow-up experiments (Experiments 2 and 
3) were therefore required to allow a meaningful conclusion regarding the impact 
of naloxone on rimonabant anorexia. Due to the unusual vehicle profile seen in 
Experiment 2 (see Chapter 4; Section 4.6), and the post-hoc discovery of food 
contamination (see Appendix 3), the results of Experiment 2 were considered 
suspect. Instead, the results of Experiment 3 will be used to elaborate upon the 
findings of Experiment 1. The intermediate naloxone dose (0.05mg/kg) used in 
Experiment 3 confirmed the results of the high dose naloxone seen in Experiment 
1, in that this dose failed to produce any significant effects on rimonabant anorexia 
(see Figure 4-10). 
In contrast to previous research (Chen, Huang, et al., 2004; Kirkham & Williams, 
2001; Rowland et al., 2001; Tallett et al., 2008b, 2009a), the present work provides 
no evidence of an additive or synergistic effect of the cannabinoid-opioid 
interaction on food intake or feeding behaviour. In theory, the cannabinoid 
antagonist should reduce the incentive value of food to delay the onset of feeding 
(Maccioni et al., 2008; Rasmussen & Huskinson, 2008; Sanchis-Segura et al., 
2004; Ward et al., 2008), whilst the general opioid antagonist should suppress the 
palatability of food following the initiation of feeding, to reduce meal duration and 
the maintenance of feeding (Apfelbaum & Mandenoff, 1981; Barbano & Cador, 
2006; Cleary et al., 1996; Cooper et al., 1985; Cooper & Turkish, 1989; Giraudo et 
al., 1993; Glass et al., 1999; Glass et al., 2001; Hayward et al., 2006; Islam & 
Bodnar, 1990; Levine & Billington, 2004; Markskaufman et al., 1984; Sanger & 
McCarthy, 1981a, 1982). The proposed combination of centrally-mediated 
reductions in the incentive value or palatability of food (and peripherally-mediated 
alterations in lipogenesis and glucose metabolism) should result in supra-
additive/synergistic effects on food intake and weight gain. The lack of such 
interaction in the present studies may relate to significant differences in 
methodology, with previous research employing sub-anorectic combinations of the 
constituent compounds.  
8.2.1.2 Non-feeding Behaviour  
In terms of non-ingestive behaviour, Experiments 1-3, fully confirmed the dramatic 
and statistically significant elevation of scratching and grooming behaviour 
following treatment with a moderate dose of rimonabant (1.5mg/kg). Furthermore, 
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the timecourses of scratching and grooming behaviour were similar to previous 
work (Tallett et al., 2007a, 2007b, 2007c), in that scratching was particularly 
prominent over the first half of the session and grooming in the second (see 
Figures 4-4 and 4-12). The present data show that these effects were attenuated 
by co-treatment with naloxone, a finding consistent with the use of opioid receptor 
antagonists to successfully treat various human pruritic disorders (Bernstein et al., 
1982; Bigliardi et al., 2007; Cies & Giamalis, 2007; Friedman & Dello Buono, 2001; 
Phan et al., 2010; Terra & Tsunoda, 1998; see also Chapter 4; Section 4.2.3.1).  
Interestingly, previous reports have suggested that rimonabant-induced scratching 
is more sensitive to naloxone (Tallett et al., 2008b), suggesting that the grooming 
and scratching behaviours induced by CB1 receptor antagonist/inverse agonists 
may be regulated via different mechanisms. In contrast, the current work showed a 
stronger naloxone-attenuation of grooming behaviour. This discrepancy may be a 
result of the lower levels of grooming produced by the sub-anorectic rimonabant 
doses used in the Tallett et al. (2008b) study. In view of these findings, it is 
possible that CB1 receptor antagonist/inverse agonists increase the release of 
endogenous opioids to induce scratching. However, the precise mechanism 
underlying these processes is poorly understood, as contradictory evidence 
demonstrates that cannabinoid receptor agonists increase the synthesis and 
release of endogenous opioids, at least in the CNS (Manzanares et al., 1999). An 
alternative hypothesis is that naloxone can prevent CB1 receptor 
antagonist/inverse agonists from binding to neuronal CB1 receptors (Schoffelmeer 
et al., 2006), potentially due to the existence of a μ-opioid/CB1 cannabinoid 
receptor heterodimeric pairing between opioid and cannabinoid receptors, which 
can create pharmacological properties distinct from either receptor alone (Christie, 
2006; Rios et al., 2006). Furthermore, opioid antagonists and CB1 receptor 
antagonist/inverse agonists have been shown to allosterically prevent each others’ 
binding to their own receptors (Schoffelmeer et al., 2006). Therefore, if rimonabant 
and naloxone act at the same heterodimeric receptor pairings, they may actually 
compete at this site. This also possibly explains why the combined drug effects on 
food intake are not as great as would have been predicted.  
The scratching and grooming syndrome aside, Experiments 1-3 reported very few 
non-ingestive behavioural effects of treatment, the exception being a significant 
decrease in locomotor duration by rimonabant, alone and in combination with 
naloxone (0.5mg/kg; Experiment 3). As only two conditions across three 
experiments identified such an effect, this may well be an anomaly or statistical 
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artefact. However, previous behavioural studies of rimonabant (Tallett et al., 
2007b, 2007c) have also shown evidence of decreased locomotive behaviour at 
higher doses (1.5-3.0mg/kg). This would be consistent with an acceleration of the 
BSS, resulting in an earlier transition from feeding to resting which, logically, leads 
to a reduction in general activity levels.  
8.2.1.3 The Behavioural Satiety Sequence 
The ‘classical’ BSS profile (see Chapter 3) was found to be largely disrupted 
following rimonabant administration, even at the moderate dose used (1.5mg/kg; 
Tallett et al., 2007b, 2007c). It is clear that grooming is the predominant behaviour 
for most of the test session, resulting in a barely discernible (see Figures 4-5 and 
4-13; dashed lines) eat-to-rest transition. The results do, however, show a clear 
naloxone-induced dose-dependent (0.01, 0.05, 0.1mg/kg) ‘normalisation’ of the 
temporal structure of the BSS. The attenuation of grooming by naloxone permits 
the re-emergence of resting in the second half of the session, allowing for a much 
clearer eat-to-rest transition. Interestingly, despite the gradual rescue of the 
‘classical’ BSS profile, naloxone co-administration does not impact the rimonabant-
induced suppression of the peak feeding response. This is true even for the lowest 
dose of naloxone (0.01mg/kg), which further supports its effect on food intake and 
feeding behaviour as a statistical artefact. Additionally, despite the lack of effect of 
the co-treatment on mash consumption and feeding measures, the BSS profiles 
demonstrate a modest naloxone-induced acceleration of the eat-to-rest transition. 
Therefore, the combination treatment may have an added benefit of enhancing 
behavioural satiety. 
8.2.1.4 Conclusions, Implications and Future Research 
In conclusion, the experiments reported in Chapter 4, fail to support the 
competition hypothesis (Tallett et al., 2007b, 2007c), but instead support Hodge 
and colleges (2008) who, albeit using an alternative methodology, also found that 
the grooming and scratching syndrome does not fully account for rimonabant-
anorexia. Therefore, Experiments 1-3 indicate that the anorectic and pruritic 
response to rimonabant treatment are independent phenomena. 
Although it is currently unclear whether this grooming/scratching syndrome is 
centrally or peripherally initiated, previous research has suggested that it may be 
centrally mediated (Pavon et al., 2006). Thus, LH-21, a cannabinoid receptor 
antagonist that is less brain-penetrant than rimonabant, inhibits food intake without 
inducing scratching/grooming. This would suggest peripheral mediation of the 
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anorectic response (Gomez et al., 2002) but central mediation of the 
scratching/grooming syndrome. CB1 receptor antagonists, including rimonabant, 
are known to increase basal ganglia function (Gueudet et al., 1995; Rubino et al., 
1998) in addition to c-Fos expression throughout the nigrostriatal system 
(Rodriguez De Fonseca et al., 1997). It is therefore possible that the scratching 
and grooming syndrome is mediated via activation or disinhibition of neural circuits 
that control these motor sequences (Tallett et al., 2007c). In contrast, rimonabant 
may induce scratching and grooming by blocking the functioning of peripherally-
located CB1 receptors, creating local irritation (Maekawa et al., 2006; Rukwied et 
al., 2003). This hypothesis is supported by research that has identified ear-swelling 
(Karsak et al., 2007) and hyperalgesia (Richardson et al., 1997) as behaviours 
caused by CB1 receptor deletion or antagonism. Furthermore, the efficacy of 
peripherally acting opioid antagonists, such as methyl naltrexone (Friedman & 
Dello Buono, 2001) and topical naltrexone (Bigliardi et al., 2007), in the treatment 
of human pruritic conditions supports a peripheral site of action (Cluny et al., 2010; 
Gomez et al., 2002; Randall et al., 2010; Schlosburg et al., 2011). Consistent with 
this proposal, the findings from the current series of experiments suggest that the 
pruritic response is peripherally-mediated, involving both CB1 and μ- receptors 
(Stander et al., 2005; Yamamoto & Sugimoto, 2010). Future research should 
further assess if the naloxone-induced attenuation of rimonabant 
scratching/grooming is centrally or peripherally mediated, and this could be directly 
investigated using ligands that are unable to cross the BBB.  
In relation to the therapeutic potential of CB1 receptor antagonist/inverse agonists, 
the presence of the pruritic response in newer ‘neutral’ CB1 receptor antagonists 
(Addy et al., 2008; Kirkham, 2008) suggests that the itch response may be 
unavoidable. Therefore, a simple opioid antagonist treatment strategy similar to 
other pruritic conditions should be employed (Ballantyne et al., 1988; Kuraishi et 
al., 2000; Miyamoto et al., 2002). The work presented Chapter 4 demonstrates that 
drug polytherapy can be therapeutically advantageous since co-treatment results 
in the suppression of an unwanted side-effect of one treatment by the other. 
 
8.2.2 Chapter Five; Monoamine and Opioid System Interactions 
In view of a gap in the literature concerning Contrave™, Experiments 4-6 
employed BSS methodology to systematically and comprehensively profile the 
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behavioural effects of bupropion and naltrexone, alone and in combination, within 
a feeding context.  
8.2.2.1 Behavioural Specificity of Bupropion 
The results of the bupropion dose-response study (Experiment 4) confirmed that 
bupropion dose-dependently reduces mash intake (Billes & Cowley, 2007; 
Greenway, Whitehouse, et al., 2009; Stairs & Dworkin, 2008; Zarrindast & 
Hosseininia, 1988), as well as time spent feeding and the duration of feeding bouts 
(statistically significant only at 40mg/kg). However, our findings also question the 
behavioural specificity of bupropion and supports evidence of bupropion-induced 
psychomotor stimulation (Billes & Cowley, 2007; Carrasco et al., 2004; Cooper et 
al., 1980; Gomez et al., 2008; Nielsen et al., 1986; Paterson et al., 2010; Redolat, 
Gomez, et al., 2005; Redolat, Vidal, et al., 2005; Santamaria & Arias, 2010; Soroko 
et al., 1977; Zarrindast et al., 1996; Zarrindast & Hosseininia, 1988).  
The anorectic dose of bupropion (40mg/kg) in Experiment 4 produced significant 
increases in rearing, sniffing and locomotor behaviours. This increased activity 
even extended to a significant increase in feeding frequency, despite reductions in 
feeding duration. Furthermore, although non-significant, sub-anorectic doses of 
bupropion also demonstrated a trend towards this hyperactive behavioural profile. 
It is pertinent to note that the bupropion timecourse profiles both for eat duration 
and other behavioural measures are almost identical (see Figure 5-3). As 
bupropion appears to impact all behaviours from the start of the session, this may 
suggest that the profile is not a result of enhanced satiety, but rather an indirect 
behavioural effect. For example, in a test condition of finite duration major 
increases in locomotor activity would allow less time for feeding behaviour. This 
suggests a possible response competition hypothesis, similar to that suggested for 
rimonabant (Tallett et al., 2007b). Moreover, the psychomotor stimulation induced 
by bupropion produces a BSS profile similar to that seen with the administration of 
amphetamines, d-FEN (Blundell & McArthur, 1981; Halford et al., 1998) and 
cocaine (Cooper & Vanderhoek, 1993), compounds that are known to produce 
behaviourally non-specific reductions in intake. 
Bupropion is a selective dopamine and noradrenaline reuptake inhibitor, the 
psychomotor stimulant effects of which are thought to be mediated via the 
dopamine system. Previous research has demonstrated that dopamine infusions in 
the NAcc produce increased locomotor activity (Barnes et al., 1986), and that 
pharmacological blockade of dopamine receptors blocks amphetamine-induced 
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locomotion (Vaccarino et al., 1986). Furthermore, the locomotor effects of 
bupropion can be blocked by chronic destruction of dopamine neurons (Cooper et 
al., 1980) and by D1 and D2 antagonists (Yamada et al., 2004). Therefore, it would 
seem logical that the bupropion-induced increases in striatal dopamine 
concentrations (however see; Nielsen et al., 1986; Waldmeier, 1982) result in the 
reported psychomotor stimulation.  
Interestingly, despite evidence that both the anorectic and psychostimulant effects 
of bupropion are typically produced at similar dosages, it has been suggested that 
they are actually independent phenomenon (Billes & Cowley, 2007). Billes and 
Cowley (2007) emphasise that increasing doses of bupropion that caused 
incremental increases in activity (0–10 and 20–40 mg/kg) did not also significantly 
decrease food intake to the same extent. Conversely, incremental reductions in 
food intake (seen between 10 and 20 mg/kg) were not correlated with a significant 
increase in activity levels. However, it is pertinent to note that no statistical 
correlations were reported, and the hypothesis would assume equivalent sensitivity 
of the measures of food intake and locomotor activity. This would seem improbable 
considering the major differences in the units of measurement and base rates for 
intake and activity. However, it is acknowledged that enhanced locomotor activity 
is not always found to reduce food intake (Cooper & Vanderhoek, 1993; Hodge et 
al., 2008; Vanrossum & Simons, 1969). Due to the unclear nature of the current 
results, future research should attempt to dissociate the two bupropion-induced 
effects to establish if bupropion is acting specifically on appetite mechanisms to 
reduce food intake (see Section 8.2.2.3). This is especially important within the 
context of its current status as one component of a potential polytherapy for 
obesity. 
8.2.2.2 Behavioural Specificity of Naltrexone 
The results of the naltrexone dose-response study (Experiment 5) confirmed a 
dose-dependent reduction in mash consumption and feeding behaviour (frequency 
and duration) over the one-hour test session. Although only the highest dose used 
(3.0mg/kg) produced a statistically significant suppression, the intermediate dose 
(1.0mg/kg) demonstrated a (non-significant) 22% reduction in intake, and 
significantly reduced the frequency of eating behaviour. This suggests that 
1.0mg/kg may be close to the anorectic threshold for naltrexone. The current 
findings also suggest that naltrexone, while longer-acting, may be less potent than 
naloxone. Findings using similar methodology, within the same laboratory, found a 
threshold dose of 1.0mg/kg for naloxone (Tallett et al., 2008a), compared to 
224 
 
3.0mg/kg for naltrexone as shown in Experiment 5. The present study found no 
significant effects of naltrexone on the additional eating-related parameters; time 
taken to locate the food source, eat latency, eat bout duration and eat rate. This 
would suggest that the initial motivation for food remained unaffected by 
naltrexone. This is consistent with evidence that naltrexone reduces motivation to 
eat post-ingestion (Kirkham & Blundell, 1986) and that naloxone also fails to 
induce changes in these parameters (Glass et al., 2001; Kirkham & Blundell, 1986, 
1987; Tallett et al., 2008a). 
Surprisingly, main effects analysis showed a naltrexone-induced effect on most 
elements of behaviour, potentially questioning the behavioural selectivity of 
naltrexone anorexia. However, further post-hoc analysis revealed that, compared 
with vehicle, naltrexone (3.0mg/kg) only significantly increased rest duration, and 
decreased the frequency of locomotion and sniffing. Furthermore, closer 
examination of the timecourses revealed an effect on intake and feeding 
behaviours during the first half of the session, but an effect on the other 
behavioural parameters during the second half of the session (see Figure 5-7). 
This profile is consistent with a ‘normal’ BSS, with elevated resting and reduced 
general activity towards the end of the session. Although the elevated resting and 
reduced activity may be explained by naltrexone-induced sedation, the fact that 
resting occurred after, but not before, food consumption lends to the satiating 
effect of naltrexone. It is interesting to note that significant increases in resting 
behaviour have also been seen with higher doses of naloxone (Tallett et al., 
2008a). The modest naltrexone-induced acceleration of the eat-to-rest transition (V 
= timebin 6; Ntx3.0 = timebin 4) is further evidence of satiety enhancement and 
appetite suppression rather than a non-specific behavioural disruption.  
Interestingly, the findings of Experiment 5 suggest that naltrexone is less potent 
than naloxone and yet produces a wider behavioural activity. These differences 
may reflect significant variation in pharmacokinetics and pharmacodynamics 
(Goldstein & Naidu, 1989; Magnan et al., 1982; Raynor et al., 1994; Tepperman et 
al., 1983). Despite such differences, however, it is still fair to conclude that the 
inhibition of intake by naltrexone is a consequence of a behaviourally-selective 
anorectic action. 
8.2.2.3 The combination 
8.2.2.3.1 Food intake and Feeding Behaviour 
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Despite the use of ‘sub-anorectic’ doses (based on Experiments 4 and 5), when 
given alone, both bupropion (20mg/kg) and naltrexone (1.0mg/kg) significantly 
reduced food intake. However, it is pertinent to note that the actual % suppression 
is very similar to that seen in the dose response studies (issues regarding drug 
variability across experiments will be discussed later; see Section 8.3.1). The 
doses used in Experiment 6 can therefore be considered threshold or sub-maximal 
doses.  
Experiment 6 demonstrated an additive effect of a bupropion-naltrexone 
combination on food intake (Greenway, Whitehouse, et al., 2009). The 
combination reduced food intake by 38-41%, suppression greater than that seen 
with either of the individual compounds given alone (14-25%). This effect is 
indicative of an additive interaction, in that the reductions seen in response to 
combined treatment (BNL = 38%, BNH = 41%) closely matched those simply 
calculated by the addition of reductions in response to the constituent agents (BV = 
25%, NL = 14%, NH = 24%). This is consistent with previous reports of an additive 
interaction seen in lean animals (Greenway, Whitehouse, et al., 2009). 
Furthermore, this would not be inconsistent with the proposal that co-
administration of an opioid antagonist, such as naltrexone, inhibits the opioid-
mediated negative feedback effect on POMC neurons in the ARC, augmenting the 
effect of bupropion treatment (Greenway, Whitehouse, et al., 2009).  
However, neither combination produced significant reductions in feeding 
behaviours (frequency or duration), demonstrating that objective reductions in food 
intake can be observed without changes in feeding related parameters. However, 
the combination did produce dose-dependent reduction in eat rate (significant only 
at BNH) which, most likely, is the cause of reduced mash consumption. 
8.2.2.3.2 Non-Feeding Behaviour and the Behavioural Satiety Sequence 
The behavioural parameters confirmed some of the findings from Experiments 4 
and 5, notably, the psychomotor stimulation seen with bupropion alone. Most 
surprisingly, co-treatment with naltrexone attenuated bupropion-induced 
psychomotor stimulation. Thus, the significant increases in rear and sniff frequency 
following bupropion administered alone, were significantly reduced by co-
administration of high-dose naltrexone (1.0mg/kg). Moreover, bupropion-induced 
elevated locomotion levels, failed to differ significantly from vehicle plus naltrexone 
co-treatment. This suggests that, similar to recent reports for CB1 receptor 
antagonist/inverse agonists (Tallett et al., 2007a; 2008b; see Chapter 4), co-
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treatment with opioid antagonists, such as naltrexone, counters the unwanted 
effects of bupropion. It may also support reports that bupropion-induced 
psychomotor stimulation and its anorectic effects are independent phenomenon 
(Billes & Cowley, 2007). For example, naltrexone co-administration dose-
dependently restored the structural integrity of the BSS by attenuating the 
psychomotor response and yet did not restore the bupropion-induced suppressed 
peak feeding response. 
It is important to note that, opioid agonists (e.g. morphine) are known to increase 
locomotor activity in rodents (Iwamoto, 1981) when infused into the region of the 
dopamine cell bodies of the VTA and NAcc (Broekkamp et al., 1979; Kalivas et al., 
1983; Stinus et al., 1980; Vezina et al., 1987), an effect blocked either by opioid 
antagonism (Iwamoto, 1981) or dopamine depletion (Churchill et al., 1995). The 
crossover between opioid and dopaminergic action in the regulation of locomotion 
in these areas may therefore suggest a reciprocal relationship whereby opioid 
blockade (via naltrexone) may act to suppress dopaminergic action and ultimately 
attenuate this psychomotor activity.  
8.2.2.4 Conclusions, Implications and Future Research 
In conclusion, findings reported in Chapter 4 support an additive interaction for the 
combination of bupropion and naltrexone (constituent elements in Contrave™). 
Experiments 4 and 5 have shown that bupropion produces a psychomotor 
stimulation that is attenuated by co-treatment with naltrexone. It is important to 
emphasise that this attenuation is seen concurrently with additive effects on food 
intake, suggesting that bupropion-induced anorexia and psychomotor stimulation 
are independent phenomena (Billes & Cowley, 2007). 
Future research should investigate the bupropion-induced locomotor activity in 
more detail to confirm that this effect is truly independent of its anorectic 
properties. Although co-treatment with naltrexone appears to negate such 
behavioural effects, it is concerning, given the current status of Contrave™, that 
basic preclinical work such as this is only now being completed. In this context, it is 
emphasised that a thorough preclinical assessment of all novel treatments should 
be completed before such therapies progress to human testing. 
Additionally, evidence suggests that the strength of interaction between naltrexone 
and bupropion varies dependent upon the obesity model used. For example, 
Greenway, et al. (2009) observed an additive bupropion-naltrexone interaction in 
lean mice, yet reported a stronger (possibly synergistic) interaction in obese mice. 
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The reason for this discrepancy is not immediately clear, but the greater effect of 
the combination in obese mice is certainly consistent with effects reported by the 
same authors for weight loss in obese humans. Therefore, the use of a rodent 
obesity model with a BSS methodology may help to provide further detail about the 
behavioural effects of this particular anorectic combination. 
 
8.2.3 Chapter Six; Serotonin and Opioid System Interactions 
Despite the current literature on the behavioural effects of the preferential 5-HT1B/2C 
receptor agonist mCPP within a feeding context, Experiment 7 assessed the 
behavioural specificity of its acute anorectic response under local laboratory 
conditions in order to select an appropriate dose for the proceeding combination 
study. Experiment 8 then employed BSS methodology to assess the anorectic 
efficacy and behavioural specificity of combined low-dose treatment with mCPP 
and naltrexone, with the intention of targeting both homeostatic satiety and 
hedonic mechanisms.  
8.2.3.1 Behavioural specificity of mCPP 
The results of the mCPP dose-response study (Experiment 7) are consistent with 
evidence (Clifton et al., 1993; Dalton et al., 2006; Hikiji, 2004; Kennett & Curzon, 
1988, 1991; Kennett et al., 1987; Samanin et al., 1979; Vickers et al., 2000; 
Vickers, Easton, et al., 2003; Ward et al., 2008) that acute mCPP dose-
dependently reduces food intake up to circa. 57% (3.0mg/kg; significant at 1.0-
3.0mg/kg). Current results also support previous research (Kitchener & Dourish, 
1994; Simansky & Vaidya, 1990) in that mCPP appears to dose-dependently 
reduce the frequency (but not the duration) of eating bouts (significant at 3.0mg/kg) 
and the rate of eating (significant at 1.0-3.0mg/kg). This type of feeding 
suppression is also seen with other 5-HT compounds, such as the indirect agonist 
sibutramine (Stricker-Krongrad et al., 1995; Tallett et al., 2009c).  
mCPP significantly increased the time taken to locate the food source and, at the 
highest dose (3.0mg/kg), almost significantly increased eat latency. This is 
consistent with previous reports that mCPP increases the latency to feed at 
2.5mg/kg (Clifton et al., 1993) and that it produces a dose-dependent increase in 
latency to initiate lever pressing in operant studies (Wallis & Lal, 1998). 
Furthermore, research suggests that other 5-HT-related compounds, such as 
sibutramine, increase the latency to the first meal in baboons (Foltin, 2006). 
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Unsurprisingly, mCPP was also found to decrease the frequency of sniffing and 
locomotor behaviour. This reduction in active behaviours is indicative of 
hypoactvity, as widely reported for a wide range of 5-HT2C receptor agonists 
including mCPP (Clifton et al., 2000; Halford et al., 1997; Hewitt et al., 2002; 
Higgins et al., 2012; Kennett & Curzon, 1988; Kennett et al., 1997; Kitchener & 
Dourish, 1994; Simansky & Vaidya, 1990; Somerville et al., 2007; Stiedl et al., 
2007; Vickers et al., 2000; see Chapter 6). Interestingly, the timecourse analyses 
both for the eating parameters and other behavioural measures are almost 
identical. In other words, mCPP is impacting all behaviours from the start of the 
session (see Figure 6-5), suggesting that the profile may not be a result of 
enhanced satiety, but rather an indirect behavioural effect. Furthermore, at a clear 
anorectic dose of 3.0mg/kg, mCPP did not demonste an acceleration in the BSS, 
which would be indicative of enhanced satiety. In fact, if anything, there is a shift to 
the right, typically indicative of delayed satiety and seen with orexigenic agents. 
Experiment 7 found that, alongside the reduction in active behaviours, mCPP 
increased grooming levels (however see: Hewitt et al., 2002; Kitchener & Dourish, 
1994). This finding is consistent with evidence that serotonergic agents induce 
scratching in both rats (Berendsen & Broekkamp, 1991; Eison et al., 1992; 
Kuraishi et al., 2008) and humans (Fjellner & Hägermark, 1979; Weisshaar et al., 
1997; however see: Ständer et al., 2009). It is possible the increased grooming 
levels are a result of the ability of 5-HT2C receptor agonists to increase 
thermogenesis (Hayashi, Suzuki, et al., 2004). Furthermore, it is interesting to note 
that there is a species-specific difference regarding the impact of mCPP on 
grooming behaviour. In rats, mCPP increases grooming (Bagdy et al., 1992; Bagdy 
& Makara, 1995; Kitchener & Dourish, 1994), whereas, in mice, it reduces 
grooming (Hewitt et al., 2002; Lee et al., 2004; Ständer et al., 2009) 
Compared to Chapter 5, there is an asymmetry of findings regarding this grooming 
effect, whereby bupropion was found to increase locomotion and decrease 
grooming while, in Experiment 7, mCPP was found to decrease locomotion and 
increase grooming. This may be explained by response competition. For example, 
within a test session of finite duration, any enhancement of active behaviours 
leaves a limited amount of time for other behaviours such as grooming. In contrast, 
when active behaviours are suppressed, more sedentary behaviours (such as 
grooming) may be elevated.  
Worryingly, despite some differences (lithium increases the duration of feeding 
time and maintains the structural integrity of the BSS, whereas mCPP decreases 
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the frequency of feeding bouts and disrupts the BSS), the behavioural profile of 
mCPP holds some similarity to that of LiCl (Ishii et al., 2004). For example, both 
agents reduce intake by 40-50%, reduce eating rate and reduce active behaviours 
such as locomotion and sniffing. This is potentially unsurprising considering the 
links between the 5-HT2C receptor and nausea (Cowen et al., 1995; O'Neil et al., 
2012; Sargent et al., 1997). Additionally, the periodic bouts of eating seen with 
mCPP are reminiscent of the profile following quinine-adulterated diet, which is 
characterised by digging and repeated sampling over the test session (Ishii, 
Blundell, Halford, & Rodgers, 2003; Ishii et al., 2004). Current findings therefore 
suggest that mCPP may reduce food intake via the induction of mild nausea and/or 
altered taste perception.  
8.2.3.2 The combination 
8.2.3.2.1 Food Intake and Feeding Behaviour 
As the results of Experiment 7 suggested that mCPP may have produced a non-
specific anorectic effect at the high dose, the lowest dose was chosen for the 
interaction study (Experiment 8). As with Experiment 7, mCPP (0.1mg/kg) alone 
failed to significantly impact any feeding or non-feeding behavioural measures 
compared to vehicle. However, it is important to emphasise the significant main 
effects of the currently-used dose on food intake and the rate of eating. These 
(larger sample) effects would suggest that 0.1 mg/kg was close to the anorectic 
threshold for mCPP (Kennett & Curzon, 1988; Ward et al., 2008), and a good 
choice for a sub-anorectic/threshold dose. However, it should be noted that the 
doses of naltrexone used (0.1 and 1.0mg/kg) both produced a significant reduction 
in mash consumption and a dose-dependent reduction in eat duration (significant 
at 1.0mg/kg). The variation of naltrexone sensitivity across experiments will be 
specifically discussed later (see Section 8.1.3). 
The combination of mCPP with both doses of naltrexone significantly reduced one-
hour food intake compared to vehicle. However, the co-treatment failed to provide 
evidence of an additive effect (mV = -40.71% vs. a calculated -45.35%; mN = -
34.50% vs. a calculated -76.42%). Previous research has found that serotonin 
release increases opioid receptor density in hypothalamic regions associated with 
appetite regulation, as a potential compensatory mechanism against a serotonin-
mediated reduction in opioidergic tone (Churruca et al., 2004). This would suggest 
that co-treatment with naltrexone (an opioid antagonist) should prevent the 
stimulation of opioid neurons and this negative feedback system, thereby 
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intensifying the appetite suppressant effects of mCPP alone. However, the present 
data on food intake and feeding parameters (eat duration and frequency) are 
inconsistent with this view, and provide little evidence of either dose combination 
producing an effect beyond that of naltrexone alone. One could go so far as to say 
that the results can be largely, if not totally, understood in terms of the naltrexone 
component.  
8.2.3.2.2 Non-feeding Behaviour and the Behavioural Satiety Sequence 
In Experiment 8, the increase in grooming seen with mCPP (significant at 
3.0mg/kg in Experiment 7) appears to be attenuated by co-treatment with 
naltrexone. This is consistent with evidence that serotonin-induced biting and itch-
related behaviour is inhibited by subcutaneous and intracisternal naloxone 
administration (Kuraishi et al., 2008). However, since the elevation of grooming by 
mCPP was not significant in this study, the extent to which it could be suppressed 
is limited; therefore, this may be spurious finding. Nevertheless, it may also 
suggest that, similar to recent reports for CB1 receptor antagonist/inverse agonists 
(Tallett et al. 2008b, 2009a; see Chapter 4) and bupropion (see Chapter 5), 
naltrexone co-treatment may counter at least some of the unwanted effects of 
higher doses of mCPP.  
Furthermore, the decreased sniff frequency and locomotion frequency, in addition 
to the increased rest duration, seen with the combination treatments are patterns 
similar to that seen in earlier work with naltrexone (Experiment 5), albeit at higher 
doses. This further emphasises the point that the effects of the drug combination 
are primarily due to naltrexone action. It is important to note at this point that 
variations in these parameters can be seen at different periods during the 
timecourse (feeding at the beginning and decreased active behaviours towards the 
end). Therefore, the profile for naltrexone, alone and in combination, remains 
indicative of a ‘normal’ BSS profile. 
It is noteworthy that the BSS profile of mCPP (0.1mg/kg), given alone, appears to 
shift to the right, suggesting a delay in the onset of satiety, which is a similar 
pattern to that seen in Experiment 7 with the highest dose of mCPP (3.0mg/kg). 
However, this is not the case for the combination treatments, where, as with the 
other parameters, the eat-to-rest transition and BSS profiles mimic those seen with 
naltrexone given alone. 
231 
 
8.2.3.3 Conclusions, Implications and Future Research 
Although Experiment 7 confirmed the anorectic efficacy of mCPP, it brought into 
question the behavioural specificity of the compound. In light of the hypoactivity 
seen at the highest dose (3.0mg/kg), further study would be needed to confirm if 
mCPP is a selective anorectic agent, or if it is producing reductions in food intake 
as an indirect consequence of hypoactivity and/or increased grooming. 
Furthermore, at the highest dose used, the BSS profiles were not accelerated, 
thereby suggesting that satiety may not have been enhanced.  
In summary, the combination of a sub-anorectic dose of the preferential 5-HT1B/2C 
receptor agonist mCPP and threshold/sub-maximal doses of the opioid antagonist 
naltrexone produced an infra-additive (less than additive) effect on food intake and 
feeding measures. Any suppression of food intake and feeding duration appeared 
to be purely a result of a naltrexone-induced anorexia, which largely remained 
unaltered by co-treatment with mCPP. This negative outcome is supported by the 
lack of a positive anorectic interaction between naloxone and sibutramine (Tallett 
et al., 2010b). However, it is pertinent to note that sibutramine is a dual (serotonin- 
and noradrenaline-) reuptake inhibitor, whereas combinations of naloxone with 
fluoxetine (Hagan et al., 1997) and 5-HTP (Fernandez-Tome, 1988), agents that 
specifically increase overall 5-HT levels, have been reported to produce an 
additive/synergistic interaction. It may be that the preferential 5-HT1B/2C receptor 
agonist mCPP could not activate the same targets. It would therefore be 
interesting to assess the generality of present findings using a more specific 5-
HT2C receptor agonist (such as lorcaserin) in combination with an opioid 
antagonist. 
 
8.2.4 Chapter Seven; Peptide and Opioid System Interactions 
Experiments 9 and 10 were designed to (i) assess the anorectic efficacy and 
behavioural specificity of GLP-1 agonist, exendin-4, with a focus on locomotor and 
non-ingestive behaviours and (ii) assess the combination of a compound thought 
to primarily influence satiety signalling, exendin-4 with one believed to primarily 
impact reward mechanisms, naltrexone. 
8.2.4.1 Behavioural specificity of Exendin-4 
The findings of Experiment 9 confirmed previous reports (Aziz & Anderson, 2002, 
2003; Bojanowska & Nowak, 2007; Bojanowska & Radziszewska, 2011; Chan et 
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al., 2013; Hayes, Kanoski, et al., 2011; Kanoski et al., 2011; Kanoski et al., 2012; 
Mack, Moore, et al., 2006; Perez-Tilve et al., 2007; Szayna et al., 2000; Talsania et 
al., 2005) that exendin-4 (0.25 and 2.5μg/kg) potently and dose-dependently 
reduces intake. The intermediate dose (0.25μg/kg) reduced intake by 26% and the 
high dose (2.5μg/kg) reduced intake by 76%. Although current results appear to 
demonstrate more potent effects than previously reported (see review: Nielsen et 
al., 2004), this may be accounted for by differences in the palatability of the test 
diet (Dickson et al., 2012) and/or the duration of the observation period (Kanoski et 
al., 2012; Talsania et al., 2005). 
The lowest dose used (0.025μg/kg) failed to produce any significant effects on 
mash consumption, eating-related parameters or any non-ingestive behavioural 
measures. In contrast, there was a significant suppression of food intake and 
feeding behaviour by 0.25 and 2.5μg/kg, suggesting a threshold between 0.025 
and 0.25μg/kg. This is consistent with literature suggesting an ED50 for exendin-4 
of 0.15 - 0.25μg/kg (Nielsen et al., 2004; Young et al., 1999). At the anorectic 
doses, exendin-4 significantly increased eat bout duration, and reduced eat rate. 
The highest dose also produced a near significant paradoxical reduction in eat 
latency. The impact of exendin-4 on these eating-related parameters may indicate 
some disruption to basic perceptual or motivational mechanisms, such as the 
induction of malaise or nausea. This is consistent with reports of emesis and 
nausea following exenatide treatment in human trials (e.g. Buse et al., 2004). 
Dramatically, exendin-4 dose-dependently reduced both the frequency and 
duration of locomotion, rearing, sniffing, and grooming near to the point of 
elimination. Furthermore, frequency and duration measures for resting were 
profoundly increased, with the highest dose of exendin-4 producing resting levels 
>7 times greater than control. This could be interpreted as the profile of a strong 
satiety signal; indeed, a suppression of peak feeding following some food 
consumption and the acceleration of the BSS can be seen in Figure 7-5. However, 
whilst the suppression of the active behaviours could be perceived as the 
enhancement of satiety, timecourse assessments reveal that all ingestive and non-
ingestive behaviours were reduced from the beginning to the end of the test 
session. The present ‘hypoactive’ exendin-4 profile is consistent with research 
(Erreger et al., 2012; Talsania et al., 2005) showing a suppression of general 
activity at very high doses (30 or 120μg/kg). Moreover, there is evidence of 
locomotor suppression at doses as low as 0.5μg/kg (Mack, Moore, et al., 2006). 
Additionally, exendin-4 (3μg/kg) has been reported to suppress water intake 
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independent of food intake (McKay et al., 2011). Such findings are consistent with 
behavioural non-specificity even at relatively low dose levels. 
Taken together, the behavioural signature of exendin-4 seen in Experiment 9 is 
reminiscent of that seen following administration of LiCl, a common emetic (Ishii et 
al., 2004). Previous research, using a similar methodology, within the same 
laboratory, found that administration of LiCl reduced intake of palatable mash by 
42%, whilst reducing eat rate and suppressing the frequency and duration of 
locomotion, rearing, sniffing, and grooming. Although not dissimilar to the current 
exendin-4 profile, LiCl increased the duration of time spent feeding (with no impact 
on frequency measures), whereas exendin-4 decreased the frequency of eating 
bouts (with no impact on duration measures). It should also be noted that LiCl 
produced no effects on resting behaviour, unlike the notable effects seen with 
exendin-4. However, these profile differences could be at least partly misleading 
as LiCl doses of equi-anorectic strength to that of 2.5μg/kg exendin-4 may well 
exert a more intense behavioural profile.  
Current behavioural observations are consistent with the literature (discussed 
earlier, see Section 7.2) suggesting the overlap in neuronal activation following 
LiCl and GLP-1 administration. For example, systemic administration of LiCl is 
found to activate GLP-1 neurons in the caudal brainstem including those projecting 
to the PVN and other areas of the forebrain associated with appetite regulation 
(Parkinson et al., 2009; Rinaman, 1999a; Thiele et al., 1998). Further research has 
found that both the neuro-excitatory and aversive behavioural effects of LiCl can 
be significantly attenuated by GLP-1 receptor blockade (Rinaman, 1999a; Seeley 
et al., 2000; Thiele et al., 1998). Together with the current findings, the data 
suggest that the anorectic effects of GLP-1R agonist exendin-4 are at least 
partially due to visceral illness and potentially transmitted via a nausea circuitry in 
common with LiCl. However, it should be noted that some work has demonstrated 
that anorectic doses of exendin-4 fails to induce kaolin consumption (a measure of 
malaise; Mack, et al., 2006), suggesting that the two effects may be independent 
of one another, and/or occur at different doses.  
8.2.4.2 The combination 
8.2.4.2.1 Food Intake and Feeding Behaviour 
Consistent with Experiment 9, the results of Experiment 10 demonstrated that, 
when given alone, the lower dose of exendin-4 (0.025 µg/kg) produced no 
significant effects on food consumption, whereas the higher dose (0.25 µg/kg), 
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given alone significantly reduced consumption by 41% (vs. vehicle), and reduced 
both the frequency and duration of eating. Naltrexone (0.1mg/kg) also significantly 
reduced mash consumption (by 36% relative to control), as well as the frequency 
and duration of feeding behaviour. These results conflict with the findings in 
Chapter 5, but are consistent with the effects obtained against a similar basal 
intake in Chapter 6 (see also Section 8.3.1.2). 
Despite the intrinsic efficacy of the high dose of exendin-4 (0.25µg/kg) and of 
naltrexone (0.1 mg/kg) on intake and behaviour, the combination treatments failed 
to evidence any signs of a positive interaction. The near-identical effects of 
individual vs. combined treatment on food intake is most clearly seen with the high 
dose of exendin-4 and naltrexone (VN = 34.9%, EHN = 34.4% vs. a predicted 
75.7%). The effects on mash consumption mirror those seen on the measures of 
feeding behaviour. This is consistent with previous work that failed to demonstrate 
an additive effect on food intake when administering GLP-1 and naloxone to 
neonatal chicks (Bungo et al., 1999). However, the lack of additive interaction with 
these compounds stands in contrast to evidence of additive and/or synergistic 
anorectic and/or weight loss interactions reported for GLP-1 agonists in 
combination with other agents such as glucagon (Day et al., 2009), PYY3-36 (Paulik 
et al., 2011; Reidelberger et al., 2011b; Talsania et al., 2005), leptin (Bojanowska 
& Nowak, 2007), calcitonin (Bello et al., 2010), and AM-251 (Bojanowska & 
Radziszewska, 2011). 
8.2.4.2.2 Non-feeding Behaviour and the Behavioural Satiety Sequence 
Consistent with Experiment 9, exendin-4 was found to reduce the frequency of 
sniffing, while less potently (seen only in main effects analysis) increasing resting 
and reducing locomotor activity. Interestingly, naltrexone also exerted weak (again, 
main effects analysis only) inhibitory effects on grooming and locomotion. 
Consistent with effects on intake, although the high dose of exendin-4 and 
naltrexone individually produced a modest acceleration in the BSS, their 
combination failed to produce any further acceleration in this measure of 
behavioural satiety. The BSS profiles thus did not provide any evidence that co-
treatment with these agents led to an additive interaction. 
8.2.4.2.3 Evidence of an Additive Anorectic Interaction 
It is pertinent to note that, as Experiment 10 neared completion, a report was 
published demonstrating an additive anorectic interaction between exendin-4 and 
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naltrexone in rats (Liang et al., 2013). Consistent with the present findings, the 
authors found significant dose-dependent anorectic effects with exendin-4 (1 - 
10μg/kg) and naltrexone (0.32 – 3.2μg/kg), when given alone. Interestingly, 
however, the effects were much less potent than those found in the present study. 
However, in contrast to the current work, significant additive anorectic effects were 
observed, over 10-fold dose ranges, when these agents were given in 
combination. It is also interesting to note that, in a second experiment on CTA, 
Liang et al. (2013) not only confirmed the aversive effects of low doses of exendin-
4 (1.0 & 3.2 µg/kg) but also showed that these effects were not countered (may 
have even been exacerbated) by the addition of naltrexone 
The reason for the significant discrepancy in the combination efficacy are not 
immediately clear, especially since the two studies differed on so many 
methodological dimensions (see Table 8-1). Many factors can influence drug 
effects on behaviour, including age (Tirelli et al., 2003), strain (Porsolt et al., 1978) 
and housing conditions (Hughes & Syme, 1972). Therefore, any one or 
combination of these factors may have been responsible for the differential 
outcome. However, attention is specifically drawn to the potential significance of 
between-study differences in the method of drug co-administration. Consistent 
throughout the present thesis, including dose-ranging studies on exendin-4 
(Experiment 9) and naltrexone (Experiment 5), animals in the current interaction 
experiment (Experiment 10) received two individual injections separated by a 15 
minute interval, with the start of testing delayed by a further 15min (see Chapter 3). 
In contrast, Liang et al. (2013) dissolved the two drugs together for a single 
injection 10-15minutes prior to testing. This difference in co-administration 
(sequential versus simultaneous) becomes of interest when considering that, in 
Experiment 10, exendin-4 was administered well before naltrexone. The data from 
the current experiment demonstrates that the effects of the combined treatment 
are statistically indistinguishable from those seen with either agent given alone. 
Given this evidence, it would seem parsimonious to conclude that the effect of one 
of the compounds (exendin-4?) was ‘dominating’ that of the other. Although it is 
theoretically possible that the two drugs interfered with one another’s 
pharmacokinetics and/or pharmacodynamics, this would not easily account for the 
additive anorectic profile reported by Liang et al. (2013). Instead, it is suggested 
that the effects of the agent administered first (exendin-4) may dominate those of 
the agent administered second (naltrexone). This hypothesis may be further 
supported, in this case, by the aversive effects of exendin-4-induced malaise, and 
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Table 8-1: Summary of methodological differences that may explain the 
discrepancies in findings between to Liang et al. (2013) and Experiment 10 
Highlighting methodological differences such as genetic strain, nutritional status, test diet, 
environment & duration, dose ranges, number of treatment conditions, and inter-test interval. 
 Liang et al. (2013) Experiment 10 
Subjects Sprague Dawley Lister Hooded 
Number of subjects 8 10 
Weight 250-275g 215–518g 
Regular Food Prolab RMH 1000 
BK No.1 Rodent Breeder and Grower 
(Pellet Diet) 
Test Food Prolab RMH 1000 
BK No.1 Rodent Breeder and Grower 
(Mash) 
# Treatment Conditions 18 6 
Naltrexone doses 0, 0.32, 1.0, 3.2 mg/kg
-1
 0, 0.01, 0.1 mg/kg 
Exendin-4 doses 0, 1.0, 3.2, 10 µg/kg
-1
 0, 0.025, 0.25, 2.5 µg/kg 
Combination Dissolved together in saline 15minute injection interval 
Injection-Testing-Interval 10-15minutes 30min and 15min 
Time of Day Dark Phase Light Phase 
Pre-feeding 4hour food restriction Free feeding 
Test Duration 1h, 4h and 20h 1h 
Wash-out period 2 days 7 days 
 
especially when also considering that naltrexone is presumed to influence 
reinforcement mechanisms after the ingestion of food. In other words, the profile 
seen with the exenin-4 high dose combination treatment may predominantly reflect 
the influence of exendin-4, thereby explaining the lack of difference versus the 
peptide given alone. 
8.2.4.3 Conclusions, Implications and Future Research 
In conclusion, present results confirm that exendin-4 and naltrexone have 
individually intrinsic anorectic effects but that co-administration of these 
compounds does not produce an additive effect. This pattern differs from another 
recent study (Liang et al., 2013), although this discrepancy may be explained by 
differences in the method of drug co-administration. Interestingly, the two studies 
agreed on the ultimate conclusion, that exendin-4 induces a lithium-like 
behavioural profile in tests of food intake and that co-treatment with naltrexone 
does not counteract this, but may in fact worsen the aversive effects (Liang et al., 
2013). Neither study supports the role of an exendin-4 plus naltrexone combination 
for the treatment of obesity, yet both illustrate the value of assessing the 
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behavioural selectivity of novel treatments/treatment combinations at an early 
stage in the drug development process.  
Future research should assess if polytherapy could benefit the side-effect profile of 
exendin-4. For example, co-treatment of GLP-1 agonists with glucagon (Day, 
2009), PYY3-36 (Paulik et al., 2011; Reidelberger et al., 2011b; Talsania et al., 
2005), leptin (Bojanowska & Nowak, 2007; Reidelberger et al., 2011a), the amylin 
analogue calcitonin (Bello et al., 2010), and the cannabinoid CB1 receptor 
antagonist/inverse agonist AM-251 (Bojanowska & Radziszewska, 2011) has 
previously been shown to produce an additive/synergistic effect on food 
intake/weight gain. However, none of these studies has involved in-depth 
behavioural analysis such as that employed in the current thesis.   
 
8.3 Issues Arising 
8.3.1 Drug Variability/Sensitivity 
The experiments of the present thesis have identified some sensitivity differences 
to particular compounds. Despite no obvious differences in the experimental 
subjects, the laboratory, the methodologies, or the researcher, potency variations 
have been identified both for the opioid antagonist naltrexone, and the dopamine 
and noradrenaline reuptake inhibitor bupropion.  
8.3.1.1 Variability in Vehicle Control Profile 
Some variation in baseline control group intake was seen across experiments (see 
Figure 8-1). This could be readily explained by batch differences in appetite and 
feeding patterns. Interestingly, seasonal effects on laboratory rodent behaviour 
(Ferguson & Maier, 2013) may have influenced between-study variation in intake 
and general activity levels. However, neither the variation in food intake (Figure 8-
1) nor seasonal changes appear to map onto variations in other non-ingestive 
behaviours such as locomotion and/or resting. Nevertheless, the between-study 
variation in intake may help to, at least partially, account for the variation in drug 
sensitivity. For example, significant reductions in mash consumption are more 
likely to be detected when control levels of intake are high. 
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Figure 8-1: Effects of baseline control treatment on mash intake by non-deprived 
male rats during a 1-h test with palatable mash, across all 10 Experiments  
Data are mean values (± S.E.M). Minimum and Maximum mean values are reported. V = 
vehicle (distilled water or saline). Green = Dose-response studies (aka. single injection 
studies), Blue = Interaction studies (aka. double injection studies). See text for full details 
8.3.1.2 Variability of Naltrexone Sensitivity 
Throughout the current thesis, the highest variability of drug sensitivity has been 
seen with naltrexone. Data from Experiment 5 showed that the suppressant effects 
of naltrexone on food intake and feeding duration were statistically significant at 
the highest dose (3.0mg/kg) only. In contrast, Experiment 6 demonstrated that a 
lower dose (1.0mg/kg) significantly reduced mash consumption and time spent 
feeding. Although it should be noted that this dose actually reduced intake by 
21.68% (and significantly decreased the frequency of eating episodes) in 
Experiment 5, a reduction similar to that seen in Experiment 6 (25.98%). This 
suggests that the variability in drug response is most likely due to the influence of 
variation in baseline intake on the statistical threshold. This explanation may also 
explain the statistical reduction in mash intake with naltrexone 1.0mg/kg in 
Experiment 8 and 10. The baseline control in Experiment 8 was one of the higher 
intake values seen in the thesis (as seen in Figure 8-1; 21.07g ±1.47) whereas the 
baseline control of Experiment 5 was atypically low (14.91g ± 0.90). Therefore, 
Experiment 5 produced a seemingly larger naltrexone suppression of intake 
(39.78%), yet all three experiments (5, 6 and 8) produced similar absolute mash 
intakes (11.68 ± 1.05, 14.28 ± 1.36, and 13.63 ± 1.20, respectively). 
Most dramatically, the low dose naltrexone (0.1mg/kg) which produced only a 
4.89% reduction in mash intake in Experiment 5 and a non-significant 14.12% 
14.91 
22.63 
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 10
M
as
h
 In
ta
ke
 (
g)
 
Experiment 
239 
 
reduction in Experiment 6, produced significant 25.69% and 35.71% reductions in 
Experiments 8 and 10, respectively. Again, however, the absolute mash intakes 
were quite similar (Exp5, 14.19 ± 0.92; Exp6, 16.57 ± 1.46; Exp8, 16.81 ± 1.80; 
Exp10, 12.98 ±0.80), suggesting that variability in baseline intake is the root cause 
of the inconsistency in dose-sensitivity.  
It is also important to note that the interaction drug studies involved a double 
injection procedure which may have altered the stress background and therefore 
the drug response. However, it is pertinent to note that the mean baseline control 
intake across dose-response studies (18.75g) is almost identical to that seen in the 
interaction studies (18.28g).  
8.3.1.3 Variability of Bupropion Sensitivity 
In contrast, it is unclear as to why bupropion (20mg/kg) failed to significantly 
suppress intake in Experiment 4, and yet produced a significant reduction in 
consumption in Experiment 6. Both Experiments (4 and 6) were characterised by a 
mid-range baseline control intake (17.89 ± 1.08 and 19.30 ± 1.24, respectively). 
Furthermore, there is no evidence of a floor effect; in fact, Experiment 4 shows that 
bupropion (20mg/kg) marginally increased intake from vehicle to 18.85g (± 0.81), 
whereas Experiment 6 actually showed a significant reduction from vehicle to 
14.84g (± 1.42).  
Overall, the observed differences in drug sensitivity across studies indicate that 
previous research is not a fool-proof guarantee of the behavioural outcome for a 
specific drug dose. This could be a consequence of batch differences, baseline 
levels of behaviour, strain of rat, and the exact methodologies employed. 
Therefore, caution must always be exercised when using previous research to 
guide dose selection and/or when comparing drug effects across 
papers/laboratories. 
8.3.2 The Implications for the Interpretation of the Behavioural 
Satiety Sequence and Behavioural Specificity 
A key theme that runs through the current thesis is the interpretation of the BSS in 
the context of behavioural specificity. BSS methodology is typically used to provide 
behavioural profiles to confirm whether a treatment-induced reduction in food 
intake is reached directly by an action on the normal physiological regulation of 
appetite or indirectly via a host of non-specific mechanisms (Halford et al., 1998; 
Rodgers et al., 2010). Interestingly, the current work has highlighted that a non-
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specific behavioural profile does not necessarily allow for conclusions to be drawn 
regarding the causation of the anorexia.  
For example, in Chapter 4 (Experiment 1-3), the induction of compulsive 
scratching and grooming by rimonabant may be an unwanted drug effect but it 
does not appear to account for the concurrent suppression of appetite (see Figure 
4-13). The naloxone-induced blockade of rimonabant-induced scratching and 
grooming, but not of rimonabant anorexia, demonstrates that a non-selective drug 
effect is not automatically the cause of anorexia. Similarly, in Chapter 5 
(Experiment 6), the induction of hyperlocomotion by bupropion could lead to the 
conclusion that the anorectic response to this drug is mediated by some non-
specific mechanism, such as increased locomotion (see Figure 5-4). In contrast, 
current data suggest that bupropion independently produces anorexia in addition 
to psychomotor stimulation. Thus, the hyperlocomotive effects of bupropion were 
attenuated by naltrexone co-treatment without impacting the bupropion-induced 
suppression of peak feeding (see Figure 5-11).  
The findings of Chapters 4 and 5 therefore imply that while providing 
comprehensive behavioural profiles, BSS methodology should not be the only tool 
used when assessing the behavioural specificity of drug effects on food intake. 
The need for additional testing should also be considered following the 
interpretation of “selective” anorectic profiles, such as that seen with exendin-4 in 
Chapter 7. As discussed earlier, the BSS profile for exendin-4 (2.5μg/kg) could be 
interpreted as the profile of a strong satiety signal (see Figure 7-5). However, an 
assessment of the timecourse reveals that all ingestive and non-ingestive 
behaviours were reduced from the beginning to the end of the test session, which 
may alternatively suggest that exendin-4 is producing a sedative action. Further 
research is therefore required to assess the causation of this exendin-4 
behavioural profile. 
8.4 Future directions  
In addition to the directions discussed in individual chapters, future research in this 
field should focus on clarification of current findings through the application of 
additional research methodologies Furthermore, the agents used in this thesis 
have not exhausted the anorectic compounds (see Chapter 2) that could 
potentially be assessed, alone and in combination, for their therapeutic potential as 
anti-obesity agents. 
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8.4.1 Additional methodologies 
It is important to emphasise that the methodology used in the current thesis is but 
one approach designed to play a part in a broader battery of tests needed to 
provide a comprehensive understanding of drug effects on food intake. Ideally, 
BSS analysis should be conducted initially on all new treatments and/or 
combinations with the most promising approaches then subject to multiple 
behavioural assessments such as meal patterning analysis (e.g. Clifton, 2000), 
macronutrient preference (e.g. Berthoud et al., 2012), dietary-induced hyperphagia 
(e.g. Hariri & Thibault, 2010) and genetic obesity models (e.g. Kurtz et al., 1989). 
Additional studies, investigating hedonics and motivation, can also be conducted. 
BSS methodology employs measures of eating-related parameters, such as the 
ability to seek food, the initial motivation for food, and the rate of food 
consumption, effects on which may provide evidence relevant to basic perceptual 
or motivational mechanisms. However, it can be argued that a non-significant 
effect on food intake does not negate a possible treatment effect on food 
motivation, as assessed for example by breakpoint analysis (e.g. Somerville et al., 
2007). Therefore, further assessment of these motivational mechanisms may 
enhance our understanding of appetite suppressing agents. 
Although the eat-to-rest transition, used to assess the acceleration/delay of satiety, 
is not mathematically or statistically derived, other tests would allow for a more 
mathematical assessment of drug interaction, e.g. isobolographic or dose-addition 
analysis. Isobolographic analysis (Loewe & Muischnek, 1926; cited in Tallett, 
2009) assesses the efficacy of a drug combination on food intake by graphically 
representing the data. The ED50 for the individual drugs (calculated by regression 
analysis) is plotted on a graph, and these values are then connected and 
surrounded by their 95% confidence limits to outline the “dose-additive” region. 
The ED50 is then calculated and plotted for the combination. If this falls within that 
region, it is defined as additive. If it is above the region, it is considered infra-
additive and, if below, it is considered supra-additive (see: Roth et al., 2010). 
Dose-addition analysis, however, is a less formal approach of that taken by 
isobolographic analysis (see: Liang et al., 2013; Ward et al., 2008) 
Although this methodology would not be suitable for the large range of behavioural 
measures employed in the current thesis, they could be exploited to confirm the 
nature of any drug interactions identified with BSS analysis. The same point would 
apply to chronic testing and the use of rodent models of obesity.  
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In conclusion, more thorough preclinical work, starting initially with BSS analysis, 
should result in a greater understanding of how agents actually produce the 
endpoints outlined by the FDA and EMEA (Rodgers et al., 2010). This should 
ultimately help to avoid ‘after-the-fact’ withdrawals of compounds, seen most 
recently with rimonabant and sibutramine. 
8.4.2 Methodological Limitations 
8.4.2.1 Metabolic Assessment 
The BSS is not a suitable methodology for assessing metabolic effects of anorectic 
agents. However, throughout the thesis, in all experimental conditions, none was 
associated with a reduction in total post-treatment weight gain, the principle 
measure used to account for this short-coming. Experiments 1-10 also failed to 
reveal any significant main effects of treatment or significant interactions on daily 
percent body weight gain. This is undoubtedly due to the acute nature of the 
treatment, the relatively low dosages involved (sub-anorectic, threshold and sub-
maximal) and the relatively short biological half-lives of the compounds used. It is 
also possible that the animals may have compensated for the reduction in food 
intake during testing by increasing consumption throughout the rest of the day. 
This would readily explain why there was no significant suppression of bodyweight 
gain even 24hours after testing. It is therefore proposed that BSS methodology 
should be accompanied by post-treatment weight gain analysis and the 
measurement of home cage intake at regular intervals (e.g. 1h, 4h, 12h, and 24h) 
over the same period.  
8.4.2.2 Alternative methods of co-treatment 
The method of drug co-treatment used throughout the present thesis, whereby the 
individual agents were administered i.p. individually 15minutes apart, has 
limitations. Although, this technique accounts for the pharmacokinetic and 
pharmacodynamics differences in the compounds used, the dual injection method 
causes increased stress to the animals and may result in increased arousal and 
“independent” effects on food intake (as in Chapter 5 and 7). It may also cause 
problems with drugs competing for the same receptor site, as discussed in Chapter 
7. It is proposed that future studies should assess the impact of administration 
method on food intake to inform the further use of BSS analysis. For example, a 
follow up study based on the design of Experiment 10; a within-subjects design 
whereby each subject receives six experimental conditions according to a Latin 
Square (with a 7-day wash out period): Vehicle (Saline; V); Naltrexone (0.1mg/kg) 
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in saline (N); Exendin-4 (0.025µg/kg) in saline (EL); Exendin-4 (0.025µg/kg) + 
Naltrexone (0.1mg/kg) in the same saline solution (ELN); Exendin-4 (0.25µg/kg) in 
saline (EHV); and Exendin-4 (0.25µg/kg) + Naltrexone (0.1mg/kg) in the same 
saline solution (EHN). Comparing the results of an exendin-4/naltrexone co-
treatment with the use of combined injection to the results of Experiment 10 should 
provide a better understanding of the co-treatment effects. 
8.4.3 Potential Neurobiological Targets for Future Research 
As a number of recent reviews have stressed the lack of true detail on the 
behavioural effects of novel anti-obesity agents (see Table 2-3), alone or in 
combination (Adan, 2013; Chugh & Sharma, 2012; Colon-Gonzalez et al., 2013; 
Rodgers et al., 2012), it is important that future research behaviourally profiles 
these treatments using BSS and related methodologies. Given the huge variety of 
polytherapies currently in early-stage development (see Table 2-5), four 
polytherapy strategies (outlined in Chapter 2) should serve to guide further work: 
(1) satiety peptide plus satiety peptide, (2) adiposity signal plus satiety peptide, (3) 
small molecule agent plus adiposity signal or satiety peptide, and (4) small 
molecule agent plus small molecule agent. Specific attention should be given as 
soon as possible to those agents and/or combinations that have recently been 
licensed, or are likely to be licensed soon, for example Qsymia® (topiramate and 
phentermine) and Empatic™ (bupropion and zonisamide). 
It is also important to note the recent focus in drug development towards agents 
that reduce the severity of metabolic disorders rather than having a sole focus on 
appetite and/or bodyweight reduction. Therefore, while BSS analysis may be a 
good starting point for the assessment of preclinical agents, future research should 
also profile the effects of novel agents on cardiovascular function as well as 
metabolic parameters such as cholesterol, insulin resistance and circulating 
triglycerides. 
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8.5 Overall Conclusions 
In light of the limitations of lifestyle and surgical options for the treatment of 
obesity, the search for safe novel drugs for weight loss is of utmost importance. 
Disappointingly, previous and current anti-obesity drugs are limited in terms of 
maximal weight loss, adverse side-effects and/or long-term resistance (see 
Chapter 2). Although we do not yet fully understood the neurobiology of appetite, 
there is a huge array of interacting systems that regulate intake and bodyweight 
and which could be potential targets for an anti-obesity agent (see Chapter 1). 
However, given the industry track-record, it is paramount that these 
pharmacological actions are not only effective but also selective.  
The current thesis has furthered our understanding of the acute effect of individual 
treatment with the general opioid receptor antagonist naltrexone (Experiment 5), 
the noradrenaline and dopamine reuptake inhibitor bupropion (Experiment 4), the 
serotonin 5-HT1B/2C receptor agonist mCPP (Experiment 7), and the naturally-
occurring GLP-1R mimetic exendin-4 (Experiment 9), on food intake, behaviour 
and bodyweight gain. Furthermore, the assessment of the acute anorectic 
response to co-treatment with sub-maximal doses of these compounds and an 
opioid antagonist (naloxone; Experiments 1-3 / naltrexone Experiments 6, 8 and 
10) has emphasised some of the benefits of polytherapy; the use of lower drug 
doses, possible synergistic but at least additive reductions in food intake, and 
importantly the reduction/elimination of side-effects normally associated with 
higher doses of the constituent agents. Finally, the current thesis has once again 
emphasised the value of detailed behavioural analysis of drug effects on appetite. 
 
